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Abstract 
 
The present thesis is mainly dedicated to heterocyclic and organofluorine compounds as 
well as C-nucleosides. Within the study new synthetic approaches to above-mentioned substances 
have been developed. In addition, the reactivity of newly synthesized products was investigated. A 
wide range of novel 2-(β-D-ribofuranosyl)pyrimidines including perfluoroalkyl-containing 
derivatives was synthesized by 3+3 cyclocondensation between 1-(β-D-ribofuranosyl)formamidine 
and various dielectrophiles, such as 3-(di)alkoxy- and 3-chloro-1-(polyfluoroalkyl)propen-1-ones, 
3-nitro- and 3-(phenylethynyl)chromones and (het)aryl acetylenic ketones. Reaction of 6-
arylamino-1,3-dialkyluracils with perfluorinated carboxylic acid anhydrides or chloroanhydrides in 
the presence of pyridine and subsequent cyclization in concentrated sulphuric acid gave the 
corresponding 1,3-dialkyl-5-(polyfluoroalkyl)-5-deazaalloxazines. The reactivity of these 
compounds towards nucleophilic and reducing reagents, such as acetophenone, nitromethane, 
potassium cyanide, indole, p-thiocresol, sodium cyanoborohydride and Hantzsch dihydropyridine, 
was studied. The nucleophilic addition, which takes place at position 5 of the 5-deazaalloxazine 
system, is in most cases irreversible and leads to 5,10-dihydro derivatives in good to excellent 
yields. An unexpected recyclization in the series of spiro[indole-3,5'-pyrimido[4,5-b]quinoline]-
2,2',4'-trione derivatives, carried out via a three-component reaction of (thio)barbituric acids, isatins 
and electron-rich aromatic amines, was observed. 
 
 
Kurzzusammenfassung 
 
Die vorliegende Arbeit ist vor allem den heterocyclischen und fluororganischen 
Verbindungen sowie C-Nukleosiden gewidmet. Im Rahmen der Studie wurden neue synthetische 
Zugänge zu oben erwähnten Substanzen entwickelt. Zusätzlich wurde die Reaktivität der neu 
synthetisierten Produkte untersucht. Eine breite Palette von neuen 2-(β-D-
ribofuranosyl)pyrimidinen einschließlich perfluoralkylhaltigen Derivaten wurde durch [3+3]-
Cyclokondensation zwischen 1-(β-D-Ribofuranosyl)formamidin und verschiedenen 
Dielektrophilen, wie 3-(Di)alkoxy- und 3-Chlor-1-(polyfluoralkyl)propen-1-onen, 3-Nitro- und 3-
(Phenylethinyl)chromonen und acetylenischen (Het)arylketonen, synthetisiert. Die Reaktion von 6-
Arylamino-1,3-dialkyluracilen mit perfluorierten Carbonsäureanhydriden oder chlorhaltigen 
Anhydriden in Gegenwart von Pyridin und nachfolgende Cyclisierung in konzentrierter 
Schwefelsäure ergibt die entsprechenden 1,3-Dialkyl-5-polyfluoralkyl-5-deazaalloxazine. Die 
Reaktivität dieser Verbindungen gegen nucleophile und reduzierende Reagenzien, wie 
Acetophenon, Nitromethan, Kaliumcyanid, Indol, p-Thiokresol, Natriumcyanoborhydrid und das 
vi 
Hantzsche Dihydropyridin, wurde untersucht. Die nukleophile Addition, die an der 5-Position des 
5-Deazaalloxazinsystems stattfindet und in den meisten Fällen irreversibel ist, führt zu 5,10-
Dihydro-Derivaten in guten bis sehr guten Ausbeuten. Eine unerwartete Recyclisierung konnte bei 
der Dreikomponentenreaktion zwischen (Thio)barbitursäuren, Isatinen und elektronenreichen 
aromatischen Aminen beobachtet werden, durch die die Reihe der Spiro[indol-3,5'-pyrimido[4,5-
b]chinolin]-2,2',4'-trion-Derivate gebildet wurde. 
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General Introduction 
 
Nowadays organic chemistry is probably one of the most rapidly developing fields of natural 
science. Advances in supramolecular chemistry, stereoselective organocatalysis, oxidative coupling 
and C-H activation, decarboxylative coupling, as well as achievements in artificial photosynthesis 
and water photolysis together with other fascinating discoveries become hot research topics over the 
last few decades. 
Science exerts influence on life, and life in turn has an impact on science. For instance, 
organic chemistry is closely related with biology; understanding of intracellular processes enables, 
on the on hand, a treatment of various diseases, and on the other hand, serves as a source of 
inspiration for new synthetic methods. 
Since in 1964 George H. Heilmeier achieved the switching of colors by electric-field-
induced realignment of dichroic dyes, organic liquid crystals have been successfully used in LCD 
(Liquid Crystals Displays). The last ones tend to be replaced by monitors based on OLED (Organic 
Light-Emitting Diode) technology. Synthetic chemistry relationship to other branches of industry 
and science can be continued. 
A great number of organic compounds being of importance to mankind belong to the 
heterocyclic class, which forms by far the largest division of classical organic chemistry. 
Approximately 20 million chemical compounds had been identified by the end of the second 
millennium; about one half of them contain heterocyclic systems. Heterocycles occur in many 
natural products, such as alkaloids, vitamins, hormones, antibiotics, as well as pharmaceuticals, 
herbicides, dyes, and other products of technical importance (advanced materials, corrosion 
inhibitors, sensitizers, stabilizing agents, etc.).1 The majority of pharmaceutical products that mimic 
biologically active natural products are heterocycles as well. More than 90% of new drugs contain a 
heterocyclic moiety, and the interface between chemistry and biology is crossed by heterocyclic 
compounds.2 
Other important aspect of our research work is organofluorine chemistry. Thus, more than 
two thirds of newly synthesized compounds described within the present thesis contain fluorine. 
The last one is the most electronegative element with very tight bound valence electrons, which in 
turn results in low atomic polarizability and small size (van der Waals radius = 1.47 Å). The C-F 
binding energy ranges as high as 130 kcal/mol.3 
Fluorine can be highly favourable in pharmaceutical and agrochemical compounds. One or 
just a few atoms in an organic molecule can dramatically change its chemical and biological nature, 
including its stability, lipophilicity, and bioactivity. 
Manfred Schlosser, professor of chemistry at the Swiss Federal Institute of Technology, 
Lausanne, says: "Smuggling fluorine into a lead structure enhances the probability of landing a hit 
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almost 10-fold". Fluorinated drugs have made up approximately 5-15% of the total number of 
launched drugs worldwide over the past 50 years with a noticeable increase in the past decade.4 The 
trifluoroethylamine moiety, CF3CH(R)NHR', is known to be an amide isostere, while substituent 
fluorine itself is an analog of hydrogen. On the other hand, according to Grimm's Hydride 
Displacement Law, fluorine can be considered as a bioisostere of OH, NH2 and CH3-group.5 
Despite organofluorine compounds are rare in nature, fluorinase enzymes have been discovered in 
living organisms.6 
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1 Design and Synthesis of Novel Pyrimidine C-Nucleosides 
from 1-(β-D-Ribofuranosyl)formamidine 
1.1 Introduction 
1.1.1 Natural and synthetic C-nucleosides. Biological role 
 
C-Nucleosides are generally considered as compounds containing a heterocyclic aglycone 
and a carbohydrate moiety linked together by a carbon-carbon bond. However, C-nucleosides 
considerably differ from the most common nucleosides, in which sugar and heterocyclic aglycone 
are connected by a C–N bond. First of all, the C–C bond is responsible for the resistance of C-
nucleosides to hydrolytic and enzymatic cleavage. 
C-Nucleosides are suitable candidates for extension of the genetic alphabet, and 
consequently, for usage as building blocks of DNA. In contrast to naturally occurring nucleosides, 
they are able to form artificial base-pairs based not only on hydrogen bonding, but also on 
hydrophobic interactions and metal bridges.7 
Natural C-nucleosides, having C1 of their sugar moieties linked to nitrogen-containing 
heterocycles through a carbon-carbon bond, have been known since 1957, when pseudouridine 1 
(Figure 1), the first member of this class of compounds, was isolated from yeast RNA. The 
elucidation of its structure was accomplished two years later. Since then other members of this 
important class of natural compounds have been isolated.8 
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a) X = S    Tiazofurin;
b) X = Se  Selenazofurin.  
Figure 1. Natural (1, 2) and synthetic (3a,b) C-nucleosides. 
C-Nucleosides (as well as standard N-nucleosides) can in principle target various enzymes 
involved in nucleic acid metabolism. The major advantage of C-nucleosides is the stability toward 
hydrolytic and enzymatic cleavage of the nucleosidic bond, due to the replacement of the 
nucleosidic C-N bond by the nonhydrolyzable C-C bond.7 
Aryl C-glycoside antibiotics constitute an emerging class of biologically active natural 
products. Ravidomycin, the congener of the gilvocarcin-class antitumor antibiotics possessing an 
amino sugar, shows an enhanced antitumor activity.9 
Tiazofurin 3a and selenazofurin 3b are two widely studied synthetic C-nucleosides. The 
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biological effects of these nucleosides appear to be due to inhibition of inosine monophosphate 
dehydrogenase (IMPDH), which induces the shutdown of guanine nucleotide synthesis. IMP 
dehydrogenase is associated with cell proliferation and is a possible target for cancer 
chemotherapy.10 Selenazofurin 3b the selenium analog of 3a, shows effective antitumor and 
antiviral activity, as well as efficacy as a maturation-inducing agent.11 
However, pyrimidine C-nucleosides bearing a carbohydrate moiety at the C-2 atom have not 
received much attention despite the fact that some of them are useful in treating a wide variety of 
diseases including infections, infestations, neoplasms, and autoimmune diseases.12 
 
1.1.2 Fluorinated pyrimidine nucleosides 
 
Some special position among all classes of pharmacologically active nucleosides has been 
occupied by fluoro-containing congeners with fluorine functionality at the heterocyclic part (Figure 
2). Fluorinated nucleosides and their analogues represent the class of organofluorine compounds, 
which in the last three decades have found an extensive application in biological chemistry, life-
science and medicine branches.13, 14 
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n-C5H11
OH
O
N
NH
O
F3C
O
OH
4
Capecitabine
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5
Trifluridine
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Figure 2. Fluorinated pyrimidine nucleosides clinically used as antimetabolites. 
 
1.1.3 Cytidine deaminase as a potential biological target 
 
We consider desired C-nucleosides first of all as potential cytidine deaminase inhibitors. 
Cytidine deaminase (CDA, EC 3.5.4.5) is a homotetrameric zinc-protein belonging to the 
pyrimidine salvage pathway, which catalyzes the deamination of cytidine and deoxycytidine. 
Furthermore, CDA deaminates also several cytosine nucleoside based drugs used as antineoplastic 
and antiviral agents causing the loss of their therapeutic efficiency.15 
Deamination by an apolipoprotein B mRNA editing enzyme (APOBEC) called activation-
induced cytidine deaminase (AID) is critical for generating high-affinity antibodies, and 
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deamination by APOBEC-3 proteins can inhibit retrotransposons and the replication of retroviruses 
such as human immunodeficiency virus and hepatitis B virus.16 The absolute dependence of 
antibodies somatic hypermutation on cytidine residues was also established.17 Hence 2-(β-D-
ribofuranosyl)pyrimidines may be potential immunosuppressive agents, which are very useful for 
transplantology and therapy of autoimmune diseases. 
Despite of the structural differences between the amino acid sequences (e.g. between the E. 
coli and human CDA there is only about 30% of identity), catalytic mechanism of all above 
mentioned cytidine deaminases must be similar. It is proved by numerous chemical,18, 19 structural15, 
16 and computational20, 21 studies. 
In recent years cytidine deaminases attract more and more attention of scientists. Articles 
devoted to CDA have been published in high-impact journals such as Nature16 and Science17. 
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Scheme 1. Catalytic pathway for the conversion of cytidine by CDA.18, 19 Only the minima are displayed. Compare with 
desired mimetics 8! 
 
1.1.4 Task setting and motivation 
 
Inspired by the relevance of C-nucleosides as well as fluorinated pyrimidine nucleosides, we 
have undertaken the current study to develop a new type of pyrimidine C-ribosides furnished with 
polyfluoralkyl-substituents at position 4 or 6. At the same time, taking into account our interest in 
CDA inhibition, design and synthesis of various non-fluorinated C-nucleosides was the second 
important task within the present work. 
 
1.2 Synthetical approach: 1,3-binucleophile + 1,3-bielectrophile 
 
There are different applicable approaches to the synthesis of a variety of C-nucleosides. 
They can be classified into four categories based on the strategies they use:7 
1) Construction of an aglycone unit upon a carbohydrate moiety; 
2) Construction of a carbohydrate moiety upon an aglycone unit; 
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3) Direct coupling of a carbohydrate moiety with a preformed aglycone unit; 
4) Modification of the existing C-nucleosides. 
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Scheme 2. The key stage of the synthesis of pyrimidine C-nucleosides according to the chosen strategy. 
Our synthetic approach is based on the initial functionalization of β-D-ribofuranose, 
followed by formation of the aglycone via 3+3 cyclocondensation: the 1,3-binucleophile, namely 1-
(β-D-ribofuranosyl)formamidine, reacts with different 1,3-bielectrophiles to form the desired 
pyrimidine ring (Scheme 2). Afterwards, some of the obtained C-nucleosides were further modified. 
Thus, the first and fourth strategies were applied during this study. 
Taking into account that we have to deal with unprotected sugars, the synthetic manipulations 
should be conducted preferably in mild reaction conditions; otherwise the carbohydrate moiety can be 
damaged. 
 
1.3 Synthesis of 1-(β-D-ribofuranosyl)formamidine hydrochloride, the starting 
material 
 
The key synthetic building block 14 was synthesized in three steps from 1,2,3,5-tetra-O-
acetyl-β-D-ribofuranose 11 using known procedures (Scheme 3). 
The synthesis of 2,3,5-tri-O-acetyl-β-D-ribofuranosyl cyanide 12,23 the key step in the 1-(β-
D-ribofuranosyl)formamidine preparation, is referred to the Lewis acid-mediated electrophilic 
substitution. The first Lewis acid-catalyzed glycosylation for the synthesis of aryl C-glycosides was 
reported in 1945.28 The same principle can be applied for another type of C-nucleosides. Usually 
the reaction occurs with high α/β-selectivity. The general principle of glycosylation with Lewis 
acids is shown in Scheme 4. The selectivity of this reaction with different sugars, substrates and 
catalysts has been studied.29, 30 The best result in our hands showed the method using tin 
tetrachloride as a Lewis acid, developed by M. T. Reetz and coworkers, which hereby showed an 
extremely high stereospecificity (no α-anomer has been detected). 
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Me Si Cl
Me
Me
Me Si
Me
Me
N
OHOH
O
OH NH OMe
OHOH
O
OH NH2
+
NH2
OAcOAc
O
AcO
N
Cl
OAcOAc
O OAc
AcO
i ii iii
iv
73% 71% 100%
48%
9 10
11
12
13 14  
Scheme 3. Synthesis of 1-(β-D-ribofuranosyl)formamidine hydrochloride. 
Reagents and conditions: i: KCN, KI, NMP, r.t., 48 h;22 ii: SnCl4, DCM, 24 h at r.t., then 6 h reflux;23, 24 iii: MeOH, 
NaOMe, 72 h;25, 26 iv: NH3 in MeOH, NH4Cl, 72 h.27 
O
O
O
O
R2
O
R1
O
O
O
R1
H H
O
O O
R1
Nu
H(RO)n (RO)n
+
Lewis acid
- R2COO
NuX
(RO)n
- X+
X = H, Si(Me)3
Nu = (Het)Ar, CN, Allyl, Propargyl, etc.   
Scheme 4. General mechanism of glycosylation under Lewis acid catalysis, which explains the high stereoselectivity of 
the reaction. 
Next, the obtained nitrile 12 was treated with a catalytic amount of sodium methoxide in 
methanol to give the deprotected β-D-ribofuranosyl-1-carboximidic acid methyl ester, which 
afforded 1-(β-D-ribofuranosyl)formamidine hydrochloride after treatment with a methanolic 
solution of ammonia and ammonium chloride. 
 
1.4 Syntheses of various 2-(β-D-ribofuranosyl)pyrimidines 
1.4.1 Syntheses of 2-(β-D-ribofuranosyl)-4-(perfluoroalkyl)pyrimidines 
 
Condensation with β-ethoxy-α,β-unsaturated perfluoroalkyl ketones affords corresponding 
4-(perfluoroalkyl)pyrimidine C-nucleosides. In fact, ethoxymethylene group constitutes a hidden 
aldehyde function. 
Previously reported condensation of 4-ethoxy-1,1,1-trifluorobut-3-en-2-one with amidines 
gave a mixture of the corresponding tetrahydropyrimidines and pyrimidines.31 After some 
optimization we found that treatment of amidine 14 with 4-ethoxy-1,1,1-trifluorobut-3-en-2-one 
15a in DMF at 80 °C in the presence of MeONa and DBU resulted in the formation of 2-(β-D-
ribofuranosyl)-4-(trifluoromethyl)pyrimidine 16a. Using potassium carbonate with molecular sieves 
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4Å at 60 °C, perfluoroethylated analogue 16b was prepared in even better yield. The current 
method constitutes a convenient approach to 5,6-unsubstituted pyrimidines. 
OHOH
O
OH N N
Rf
Rf
O
EtO14
15a,b
+
a: Rf = CF3, 33%;
b: Rf = C2F5, 59%. 16a,b  
Scheme 5. Syntheses of 2-(β-D-ribofuranosyl)-4-(perfluoroalkyl)pyrimidines. 
Reagents and conditions: a: NaOMe, DBU, DMF, 80 °C, 3 h; b: K2CO3, molecular sieves 4Å, DMF, 60 °C, 5 h, under 
argon.31, 32 
The steric configuration of the anomeric center is confirmed by X-ray analysis of the 
nucleoside 16a, which crystallizes from EtOAc/CHCl3 solution in monoclinic system (space group 
P21) with one equivalent of chloroform. Thus, we can conclude the same configuration for the 
whole C-nucleoside range synthesized from 1-(β-D-ribofuranosyl)formamidine 14. 
4-Ethoxy-1,1,1-trifluoro-3-buten-2-one and 1-ethoxy-4,4,5,5,5-pentafluoro-1-penten-3-one 
were synthesized by the known method33 from ethyl vinyl ether and corresponding trifluoroacetic or 
pentafluoropropionic acid anhydride respectively in the presence of 4-N,N-dimethylaminopyridine 
as a catalyst. 
 
Figure 3. Ortep plot of 2-(β-D-ribofuranosyl)-4-(trifluoromethyl)pyrimidine 16a (40% probability level). Crystal 
solvate with 1 eq of chloroform. 
 
1.4.2 Synthesis of C-nucleosides from 1,3-diketones 
 
Next, we decided to involve 1,3-diketones in this study to obtain the corresponding 4,6-
substituted 2-(β-D-ribofuranosyl)pyrimidines, and to our great disappointment, we were confronted 
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with significant difficulties. As opposed to benzamidine, used in the trial experiments, 
ribosylamidine 14 turned out to be insufficiently reactive under the same conditions and seems to 
decompose before the reaction starts (see Chapter 1.4). So after several unsuccessful attempts we 
decided to substitute the enolic OH-group for a more easily replaceable chlorine atom, which is a 
weaker π-electron-donating group, and therefore, less deactivates the conjugated double bond 
(Michael acceptor) towards nucleophiles in the initial addition reaction, which is the rate-limiting 
stage of the current cyclocondensation.34 Moreover, β-chloro-α,β-unsaturated ketones proved to be 
so reactive that the reaction with 2-(β-D-ribofuranosyl)formamidine shows a marked exothermic 
effect and should be conducted under cooling to suppress undesirable side processes (Scheme 6). 
Finally, in order to establish the generality of this cyclization, a variety of nucleosides 19 was 
successfully obtained (Table 1). These results clearly show that despite some limitations (see 
Chapter 1.4, Table 2, product 19m) the present reaction can be applicable to different β-chloro-α,β-
unsaturated ketones 18, providing a reliable route to the synthesis of a wide range of the 4,6-
disubstituted pyrimidine C-nucleosides 19. 
ii
Cl O
R1 R2
O O
R1 R2
OHOH
O
OH NN
R1 R2
i (A or B)
17a-k 18a-k
19a-k
14
Mixture of isomers
 
Scheme 6. Synthesis of C-nucleosides from 1,3-diketones. 
Reagents and conditions: i(A): SOCl2, CHCl3, boiling under reflux, 3 h;35 i(B): oxalyl chloride, DMF, DCM, –78 to 
r.t.;36 ii: K2CO3, molecular sieves 4Å, DMF, 0 °C, 2 h.37 
Table 1. Synthesis of C-nucleosides 19 from activated 1,3-diketones. 
Entry R1 R2 
Yield, %c
18 19 
a Ph CF3 92a 71 
b 
S *  
CF3 81a 73 
c Ph n-C3F7 93a 55 
d 
Et
*
 
CF3 99a 42 
e Me CF3 52b 57 
f Ph COOMe 97b 33 
g 
O *  
CF3 88b 67 
h i-Pr CF3 63b 55 
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Entry R1 R2 
Yield, %c
18 19 
i 2-Naphthyl CF3 57a 38 
j 
S *  
COOMe 86b 42 
k 
*
F  
n-C3F7 74a 49 
a – α,β-unsaturated β-chloroketone was prepared according to the method A (with SOCl2); 
b – α,β-unsaturated β-chloroketone was prepared according to the method B (with (COCl)2); 
c – yields refer to pure isolated products. 
At the 1,3-diketone activation stage an application of thionyl chloride in boiled chloroform 
is possible only in case of perfluorosubstituted diketones and if they are not sensitive to acids (e.g. 
diketones containing furan ring cannot be used). In other cases, either no reaction or decomposition 
was observed. Next, the products were distilled in a high vacuum to afford a yellow or green liquid 
consisting of a mixture of structural and cis/trans isomers 18, which were not separated and used 
without additional purification. The synthesis of β-ethoxy-α,β-unsaturated ketones from the 
corresponding 1,3-diketones was particularly studied and considered by K. I. Pashkevich35 (method 
with thionyl chloride) and R. E. Mewshaw36 (method with oxalyl chloride). 
Diketones 17d, f, h and k were synthesized via classical Claisen condensation in the 
presence of sodium methylate, while others were purchased from chemical supply companies. 
 
1.4.3 Aminolysis and hydrazinolysis of methyl 2-(β-D-ribofuranosyl)-6-(2-
thienyl)pyrimidine-4-carboxylate 
 
OHOH
O
OH NN
S
NH2
O
OHOH
O
OH NN
S
N2H3
O
iii
20 21
19j
83%100%
 
Scheme 7. Aminolysis and hydrazinolysis of methyl 2-(β-D-ribofuranosyl)-6-(2-thienyl)pyrimidine-4-carboxylate. 
Reagents and conditions: i: 7N ammonia in MeOH, r.t., overnight; ii: N2H4, MeOH, r.t., overnight. 
One congener (19j), obtained from α,β-unsaturated β-chloroketone and bearing an ester 
group, was employed for the synthesis of other non-fluorinated nucleoside derivatives. When this 
compound was dissolved in methanolic ammonia and allowed to stir at room temperature overnight, 
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nucleoside 20 possessing a carboxamide function at the 2-position was obtained in quantitative 
yield. Treatment of 19j with hydrazine hydrate in methanol at room temperature afforded the 
corresponding hydrazide 21 in 83% yield (Scheme 7). 
As we see, these simple reactions proceed under mild conditions and in high yields. In 
addition, no labour-intensive work up of the reaction mixture is required. 
1.4.4 Synthesis of 2-(β-D-ribofuranosyl)-4-(2-hydroxyphenyl)-5-nitropyrimidines and 
catalytic reduction of nitro group 
We continued to search for applicable 1,3-dinucleophiles. It is known that 3-nitrochromone 
22a reacts with amidines to give the corresponding 5-nitropyrimidines.38 Thus, we decided to test 
the reaction on our 2-(β-D-ribofuranosyl)formamidine 14. As a result, 5-nitropyrimidine C-
nucleosides were successfully synthesized from the corresponding 3-nitrochromones (Scheme 8). 
The 2-position of the chromone is activated by the nitro group, and hence easily participates in the 
Michael addition, followed by a chromone ring-opening reaction and subsequent cyclocondensation 
to give the 5-nitropyrimidine. 
The cyclization took place in the presence of sodium methoxide, acetic acid and 
triethylamine in methanol yielding 5-nitropyrimidine 23a in 36% yield. A buffer solution is 
required to provide the optimal pH. On the one hand, the initial amidine 14 is inactive in its 
protonated form. On the other hand, basic media can destroy the product (especially at the air; an 
easily oxidized phenolate anion forms) as well as the 3-nitrochromone. So the optimal pH level was 
found to be neutral. A similar result was obtained with 2-methyl- and 2-butyl-3-nitrochromones in 
DMF instead of methanol, which gave compounds 23b and c in 35% and 48% yields, respectively. 
N N OH
NO2
R
OHOH
O
OH N N OH
NH2
R
OHOH
O
OH
O
O
NO2
R
a: 36%; 
b: 35%;
c: 48%.
14 +
i ii
100%
 a: R = H; b: R = Me; c: R = n-Bu.
22a-c
23a-c 24a-c
Scheme 8. Synthesis of 2-(β-D-ribofuranosyl)-4-(2-hydroxyphenyl)-5-nitropyrimidines and catalytic reduction of nitro 
group. 
Reagents and conditions: i(a): NaOMe, AcOH, NEt3, MeOH, 80 °C, 1,5 h; i(b,c): NaOMe, AcOH, NEt3, DMF, 50 °C, 
5 h, under argon;38 ii: H2, Pd (10 % on charcoal), MeOH, r.t., 2 days. 
The obtained 5-nitropyrimidine C-nucleosides 23a-c were catalytically reduced using 10 wt. 
% Pd/C as the catalyst under a hydrogen pressure of 1 atm to give the corresponding 5-amino 
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compounds 24a-c. The latter are especially interesting for us because of their ability to mimic the 
substrate or its transition state (see Introduction, Scheme 1). 5-Amino-substituted 2-(β-D-
ribofuranosyl)pyrimidines are remarkably similar to cytidine and are expected to be able to form 
stable chelate complexes with a zinc cation and hereby to inhibit cytidine deaminase (compare with 
6). 
It is worth to say a few words about the 3-nitrocromone synthesis, which has been 
significantly improved (Scheme 9). The nitration of 4-hydroxycoumarin 25 was carried out under 
mild conditions in the presence of a catalytic amount of sodium nitrite. In this case the reaction runs 
smoothly and without spontaneous overheating. The reaction conditions of the hydrolysis of 4-
hydroxy-3-nitrocoumarin 26 and of the subsequent neutralization were also optimized and led to 
increasing of the yield up to 90%. The reaction was carried out at 55 °C for 90 min. Then the 
reaction mixture was neutralised in an ice bath with 1.3 eq of acetic acid (calculated on taken alkali) 
and then carefully acidified with 0.5 eq of hydrochloric acid. Also a novel approach is to apply 
orthoesters in the presence of sulphuric acid (instead of previously used carboxylic acid 
anhydrides)39 in order to obtain 3-nitrocromones from 2-nitro-2'-hydroxyacetophenone 27. This 
advantage is especially essential in case of 2-unsubstituted product because the preparation and use 
of unstable acetic formic anhydride can be avoided.40 
O O
OH
O O
OH
NO2
O
OH
NO2
O
O
NO2
R
R C(OMe)3
i ii
iii
%09%78
25 7262
a: R = H, 82%;
a: R = Me, 84%;
b: R = n-Bu, 67%. 22a-c  
Scheme 9. Synthesis of 3-nitrocromone. 
Reagents and conditions: i: HNO3, AcOH (glacial), NaNO2 (cat.) 40 °C, 2 h; ii: KOH in H2O, 55 °C, 1,5 h;41 iii: 
H2SO4(cat.), boiling 8 h.39 
 
1.4.5 Synthesis of C-nucleosides from conjugated ketoalkynes and β,β-dimethoxy-α,β-
unsaturated ketones 
 
In order to increase the variety of C-nucleosides, we tested different binucleophiles such as 
conjugated ketoalkynes and β,β–dimethoxyketoalkenes, which, as it has turned out, show a good 
reactivity towards ribosylamidine 14 (Scheme 10). In fact, β,β–dimethoxyketoalkenes have been 
relatively poorly investigated so far as convenient precursors of pyrimidines with alkoxy group at 
position 4 or 6 (depending on the opposite substituent). The application of α,β-ynones is essential 
for pyridyl-substituted pyrimidines because they cannot be obtained neither from 1,3-diketones nor 
β-ethoxy-α,β-unsaturated ketones (see Chapter 1.2.2 and 1.4). 
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OHOH
O
OH NN
RfMeO
N
N
*
Cl
Me
Ph
OHOH
O
OH NN
Ph R
Rf
OOMe
MeO
R
O
Ph
28a, 29a: R = 3-Py, 68%;
28b, 29b: R =                     , 52%.
14
28a,b
29a,b
30a,b
31a,b
ii
30a, 31a: Rf = CF3, 72%;
30b, 31b; Rf = CHF2, 75%.
i
 
Scheme 10. Synthesis of C-nucleosides from various precursors. 
Reagents and conditions: i: K2CO3, molecular sieves 4Å, DMF, 70 °C, 4 h, under argon;42 ii: K2CO3, molecular sieves 
4Å, DMF, 60 °C, 5½ h, under argon.43 
4,4-Dimethoxy-1,1,1-trifluoro-3-buten-2-one 30a and 4,4-dimethoxy-1,1-difluoro-3-buten-
2-one 30b were prepared by a reported procedure from 1,1-dimethoxyethylene and the 
corresponding anhydride in the presence of pyridine as a base.44 
N
N O
Me
Ph
N
N Cl
Me
Ph
CHO
N
N Cl
Me
Ph
COOH
N
N Cl
Me
Ph
COCl
i ii iii
32 33 34 35b
31% 92%91%
 
Scheme 11. Synthesis of 5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carboxylic acid chloroanhydride 35b. 
Reagents and conditions: i: DMF, POCl3, 70 °C, 2 h; ii: KMnO4, acetone, r.t., 12 h; iii: SOCl2, reflux, 3 h.45, 46
 
Next, the acyl chlorides were coupled with phenylacetylene 36a by standard methods to give 
the desired α,β unsaturated ynones (Scheme 12). 
R Cl
O
N
N
*
Cl
Me
Ph
R
O
PhPhH
35a,b
35a, 28a: R = 3-Py*HCl, 68%;
35b, 28b: R =                     , 80%.
28a,b
+
36a
 
Scheme 12. Sonogashira coupling with acyl chlorides. 
Reagents and conditions: Pd(PPh3)2Cl2, CuI, NEt3, dioxane, r.t. (a) or 70 °C (b), 2 h, under argon.46, 47
 
 
1.4.6 Synthesis of C-nucleosides from 3-(phenylethynyl)-4H-chromen-4-one 
 
Finally, 3-phenylacetylenylcromone appears to react with ribofuranosyl formamidine in the 
presence of K2CO3 and molecular sieves in DMF giving the desired product 38a in a high yield 
(Scheme 13). This unusual type of reaction was first described by Dewen Li, Shudong Duan and 
Youhong Hu as a convenient tool for combinatorial chemistry. The authors unambiguously 
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confirmed the Z-configuration of the obtained products by 1D-NOE difference experiments and X-
ray crystal structure analyses as well.48 The reaction runs smoothly. The product 38a does not need 
a complicated purification and can be isolated in pure state by simple recrystallization from 
methanol. 
OHOH
O
OH N N
O
Ph
O
O Ph
83%
14
37a
38a
+
 
Scheme 13. Synthesis of C-nucleoside from 3-(phenylethynyl)-4H-chromen-4-one. 
Reagents and conditions: K2CO3, molecular sieves 4Å, DMF, 60 °C, 6 h, under argon.48
 
The initial 3-phenylacetylenylcromone was synthesized in three steps from 2'-
hydroxyacetophenone 39 using known procedures (Scheme 14). The condensation product with 
DMFDMA49 40 was treated with the iodine-pyridine complex in chloroform giving 3-
iodochromone 41.50-52 The latter underwent the Sonogashira coupling with phenylacetylene to 
afford the desired 3-(phenylethynyl)chromone 37a.53, 54 
O
O Ph
OH
Me
O
OH
O
NMe2
O
O
I
37
i
80%
39 40
ii iii
41
94% 81%
 
Scheme 14. Synthesis of 3-(phenylethynyl)-4H-chromen-4-one. 
Reagents and conditions: i: DMFDMA, 90 °C, reflux, 2 h;49 ii: I2, pyridine, CHCl3, 0 °C, 1 h;50-52 iii: phenylacetylene, 
Pd(PPh3)2Cl2, CuI, NEt3, DMF, r.t., 2 days, under argon.53, 54
 
 
1.5 Spectral considerations 
 
The structures of all C-nucleosides were characterized by IR, 1H, 13C NMR spectral data as 
well as MS and HRMS analysis. 
All NMR signals of the β-D-ribofuranosyl moiety were easily assigned since they have been 
already described in the literature.55 In addition, HSQC correlation spectrum of compound 19k was 
measured and vicinity of corresponding C and H atoms was additionally confirmed. The coupling 
between neighbouring OH and CH protons is clearly observed in the spectra acquired in DMSO-d6, 
unlike chloroform-d. In case when RF = C2F5 or n-C3F7, the polyfluoroalkyl groups appear as 
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undecipherable multiplets. In addition, the presence of fluorinated alkyl groups was confirmed by 
19F NMR. 
 
1.6 Negative results 
 
To our great disappointment, we have not succeeded in synthesizing the majority of 
predesigned C-nucleosides. Many of them are unstable against nucleophiles because of the high 
number of electron withdrawing groups present in the pyrimidine ring (19l, 53 and 55) and have not 
been isolated in pure state, or the 1-(β-D-ribofuranosyl)formamidine decomposes during the 
reaction (48, 56a and b). The negative results and the corresponding reaction conditions with 
comments are briefly summarized in Table 2. 
Table 2. Negative results. 
Starting material Product Reaction condition Comments 
O O
Ph CF317a  
 
N N
CF3Ph
R
19a  
NaOAc, AcOH (cat.), 
dioxane, 115 °C, 12 h. 
Despite, for example, 
benzamidine ready react 
with 4,4,4-trifluoro-1-
phenylbutane-1,3-dione in 
dioxane at 115 °C in the 
presence of a catalytic 
amount of acetic acid, 1-
(β-D-ribofuranosyl)form-
amidinedoes 
notenterintothisreaction. 
Only the following 
product was isolated: 
CF3
O NH2
42  
The problem is based on 
the solubility of starting 
material. 
NaOAc, AcOH (cat.), 
methanol, 80 °C, 3 h. 
No reaction was observed. 
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Starting material Product Reaction condition Comments 
 
 
 
O O
Ph CF317a  
 
 
N N
CF3Ph
R
19a  
NaOAc, AcOH (cat.), 
methanol, 110 °C, 20 
h. 
Only the initial diketone 
and some products of 
decompositions were 
detected by TLC. 
DBU, DMF, heating. Desired product was not 
observed. 
TMSCl, NEt3, DBU, 
heating. 
–ʺ– 
O
O
CF3
OH OH
43
 
N N
CF3
O
OH
R
44  
 
 
 
NaOAc, DMF, hea-
ting 110 °C, 9 h. 
Products are difficult to 
separate. The main 
supposed by-product is 
shown below: 
N NH
O
OH O
F3C
R
45 31 
DBU, DMF, heating. 
 
O
N
+
OH
ONa
O O
46  
N N
N
+O O
R
47  
MeOH, 60 °C, 1 h. No desired product was 
isolated. Product decom-
poses on TLC. Only a 
mixture of by-products 
was isolated. 
MeOH, r.t., 3 h. No reaction was observed. 
O
O
NMe2
48  
N N
O
R
49  
MeONa, DBU, DMF, 
heating under argon. 
No reaction was observed. 
N
O Cl
CF3MeO
50  
N N
N
H
CF3O
R
51  
DMF, NEt3, heating. Unclear TLC. High 
polarity of the expected 
product and consequently 
high binding affinity to 
silica gel. 
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Starting material Product Reaction condition Comments 
O O
CF3
OCl
52
 
N N
OO
F3C
R
53  
K2CO3, DMF. 4-Chloro-3-(trifluoro-
acetyl)coumarin is un-
stable in basic media. The 
product also seems to be 
unstable because of elec-
tron withdrawing groups 
in the pyrimidine ring. 
TMSCl, NEt3, DMF. 
TMSCl, NEt3, DMF, 
pressure tube, 120 °C 
O
CF3
O
OEt
Ph
54  
N N
CF3
OPh
R
55  
NaOMe, DBU, DMF, 
r.t., 1 d. 
The reaction was observed 
on TLC but the product 
decomposes on silica gel. 
Purification is im-
possible.56 
DBU, DMF, r.t., 1 d. 
K2CO3, DMF, 80 °C, 
4 h. 
F
F
F
F
F
CHO
56a  
N N
F
F
F
F
R
57a  
K2CO3, molecular 
sieves 4Å, DMF, 110 
°C, 6 h. 
The aldehyde probably 
reacts, but cyclization does 
not occur at this tem-
perature. Low reactivity of 
o-fluorine and decom-
position of the sugar 
moiety at high temp-
erature. 
CHO
ClO2N 56b  N N
NO2
R
57b  
K2CO3, KF, molecular 
sieves 4Å, DMF, 90 
°C, 3 h. –ʺ– 
F3C CF3
Cl O
18l  
N N
CF3F3C
R
19l  
NaOAc, molecular 
sieves 4Å, DMF, 0 
°C, 2 h. 
α,β-Unsaturated β-chloro-
ketone decomposes before 
the reaction started. 
K2CO3, molecular 
sieves 4Å, DMF, 0 
°C, 2 h. 
The product decomposes 
on silica gel because of 
electron withdrawing 
groups in the pyrimidine 
ring. 
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Starting material Product Reaction condition Comments 
N
H
O
Cl
O
* HCl
58  
N N
N
H
O
R
59  
K2CO3, molecular 
sieves 4Å, DMF, 60 
°C, 2 h. 
Unclear TLC. High 
polarity of the expected 
product and consequently 
high binding affinity to 
silica gel. 
C2F5
R
MeO
OOMe
n-Pr
30c  
N N
C2F5
R
MeO
R
n-Pr
31c  
K2CO3, molecular 
sieves 4Å, DMF, 60 
°C, 5 h, under argon. 
The problem lies in the 
starting material. Despite 
the 1H NMR spectrum 
seems to correspond to the 
desired α,β-unsaturated 
β,β-dimethoxyketone, the 
substance has an extre-
mely low boiling point and 
cannot be the right pro-
duct. 
F3C
O O
OEt
60  
NH N
O CF3
R
61  
K2CO3, molecular 
sieves 4Å, DMF, 60 
°C, 4 h, under argon. 
The β-ketoester decom-
poses in basic media. 1-(β-
D-Ribofuranosyl)formami-
dine trifluoroacetate was 
isolated. 
O
O Ph
CF3
37b
 
N N
O
Ph
F3C
R
38b  
–– 
The problem lies in the 
starting material. Reaction 
of 3-bromo-2-trifluoro-
methyl-chromen-4-one 
with phenylacetylene is 
not clean. A lot of side 
products are formed. 
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Starting material Product Reaction condition Comments 
n-C3F7
N
O
Cl
18m  
N
N
n-C3F7
N
R
19m  
 
 
–– 
The problem lies in the 
starting material. It cannot 
be synthesized at r.t. 
because it reacts with 
itself. See reaction below: 
N
n-C3F7
Cl O
N
+
n-C3F7
Cl O
n-C3F7O
N
polymerization
18m
OHOH
O
OH
*
R = 
 
As we have already mentioned in the report, cyclization of amidine 1 with 3-(2,2,2-trifluoro-
1,1-dihydroxy-ethyl)chromen-4-one failed. We suppose that four side-products (it follows from 19F 
NMR spectrum) are a mixture of tricyclic stereoisomers 45 (Table 2).31 
 
1.7 Conclusions 
 
A wide range of pyrimidine C-nucleosides have been synthesized starting from 1,2,3,5-tetra-
O-acetyl-β-D-ribofuranose. Among them are many fluoro-containing compounds. We developed 
useful methods for 3+3 cyclocondensations between 1-(β-D-ribofuranosyl)formamidine and a 
variety of 1,3-bielectrophiles as well as for further transformations, such as reduction of the nitro 
group, aminolysis and hydrazinolysis of the ester group. However, since the last stages involve 
unprotected carbohydrate derivatives, harsh reaction conditions should be avoided. Thus, 1,3-
diketones were replaced by more reactive β,β-dimetoxy-α,β-unsaturated ketones. While potassium 
carbonate was found to be an appropriate base (except reaction with 3-nitrochromones), DMF is the 
most suitable solvent for the 3+3 cyclocondensation. The applicable reaction temperature lies in the 
range 0 to 70 °C depending on the 1,3-bielectrophile. 
Examples 16a, 19a,b, 23a and 24a have been sent to be tested. The pharmacological 
evaluation is performed by Dr. M. Lalk (University of Greifswald). 
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2 Synthesis and Reactivity of Polyfluoroalkyl-5-deazaalloxazines 
2.1 Introduction 
2.1.1 Flavin, alloxazine and their derivatives. Structure of heterocyclic cores and 
definitions 
 
Flavin 62a (or benzo[g]pteridine-2,4(3H,10H)-dione) and alloxazine 62b (or 
benzo[g]pteridine-2,4(1H,3H)-dione) are closely related structures and constitute two different 
tautomers with the same skeleton (Figure 4). The 5,10-dihydro derivative 63 can be considered both 
as reduced form of 62a and 62b. The same is also valid for the corresponding 5-deaza compounds 
64a, b and 65. Substituents at position 1 and 10 are decisive to assign the compounds to flavins or 
alloxazines. 
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Figure 4. Flavin 62a, alloxazine 62b and dihydro form 63. Below are shown their 5-deaza derivatives 64a, b and 65. 
According to IUPAC nomenclature, the parent 5-deazaalloxazin structure 64b is referred to 
as pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione. 
 
2.1.2 Natural flavins and 5-deazaflavins: biological role and pharmacological relevance 
 
Flavins are versatile and, in many aspects, essential redox-active natural compounds, which 
play important roles as enzyme cofactors in numerous biochemical processes.57 Thus, riboflavin 67, 
also known as vitamin B2, plays a key role in energy metabolism (Figure 5). Reduced flavin 
mononucleotide is a source of 5,6-dimethylbenzimidazole, the lower ligand of vitamin B12.58 
8-Hydroxy-5-deazariboflavin plays an impotent role in the repair of cyclobutane DNA 
lesions 66 caused by 200-400 nm light irradiation (Scheme 15).59 These intrastrand cis,syn-
thymidine dimmers, the predominant UV-induced DNA damage, are cancerogenic, mutagenic and 
lethal for cells in a variety of organisms.60 8-Hydroxy-5-deazariboflavin takes part in the absorption 
of light, which is one of the critical steps in the light-driven repair reaction.59 Afterwards, energy is 
transferred from the excited molecule to flavin adenine dinucleotide (FADH−). The following 
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cyclobutane DNA lesion cleavage is based on the radical mechanism promoted by electron transfer 
from excited FADH−. Unstable Pyr<>Pyr∙− species undergo spontaneous splitting followed by a 
back electron transfer to the FADH∙.60 Moreover, as was shown by experiments in vitro, 
photoexcited 8-hydroxy-5-deazariboflavin is able to repair the cyclobutane lesions directly.61, 62 
As we see, stability of flavin/5-deazariboflavin radicals is of crucial importance to the 
photosensitized cleavage of thymine dimer. In this context, it should be noted that perfluoroalkyl 
groups cannot be classified as radical stabilizing or destabilizing in an absolute sense. Instead, RF 
groups enhance the radical stabilizing ability of electron donor groups conjugated with a radical 
center (so called captodative effect), and decreases the radical stabilizing ability of electron 
withdrawing groups.63 
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66  
Scheme 15. Splitting cyclobutane DNA lesion with the participation of flavin adenine dinucleotide and light-harvesting 
8-hydroxy-5-deazariboflavin. 
The 5-deazaflavin moiety is a part of a unique coenzyme known as Factor 420 (F420) 68 
from anaerobic thermophilic methanogenic bacteria (Figure 5), Methanobacterium (strain 
M.o.H.).64 
Later deazaflavins were also found in streptomycetes65 and in halobacteria.66, 67 
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Figure 5. Natural compounds containing flavin (67) and deazaflavin moiety (68). 
CO2 + 4H2 → CH4 + 2H2O 
Scheme 16. Bacterial methanogenesis. 
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2.1.3 Pharmacological relevance and other applications 
 
5-Deazaflavins are of considerable pharmacological relevance and attract significant 
attention of scientists. Thus, the synthesis of cytochrome P450 3A4 inhibitor containing 5-
deazaflavin residue as well as the synthesis and photophysical properties of a deazaflavin-bridged 
porphyrinatoiron(III), which mimics the interaction of the above mentioned deazaflavin inhibitor 
with the Heme-Thiolate Cofactor of Cytochrome P450 3A4, has been reported.68 RNA molecules 
that specifically bind riboflavin have been isolated.69 In addition, 5-deazaflavins attract attention as 
perspective antitumor agents.70, 71 Thus, one can expect some interesting biological activities in the 
range of desired bioisosteric compounds within the current project. 
To our surprise, 5-deazaalloxazines have not received much attention despite the close 
similarity to above discussed 5-deazaflavins. Of particular interest is the development of fluorescent 
nucleosides based on 5-deazaalloxazine that maintain the hydrogen-bonding properties of natural 
nucleoside bases.72 
As mentioned in chapters 2.3 and 2.7, we dealt with 5-disubstituted 5,10-dihydro-5-
deazaalloxazines, which can be considered as a product of addition of a nucleophile to position 5 of 
the corresponding 5-deazaalloxazine or 10-substituted 5-deazaalloxazin-10-ium cation. In this sense 
these compounds are very similar to 9-alkoxyacridanes 69. The last ones have been depicted by W. 
Abraham and coworkers as the main part of photoswitchable rotaxanes and calixarene-based 
photoswitchable ionophores.73-77 The effect is based on reversible photo-driven dissociation of the 
9-methoxy group (Scheme 17). 
N
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R1O-
hv
69a 69b  
Scheme 17. Photoheterolysis of 9-alkoxyacridane and the corresponding thermal back reaction.73-77 
 
2.1.4 Task setting and motivation 
 
Our interest to 5-polyfluoroalkyl-5-deazaalloxazines can be summed up in the following 
bullet points: 
 Close similarity to biologically relevant natural compounds; 
 Target structures contain fluorine with all the resulting consequences; 
 Redox properties; 
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 Fluorescent properties. 
The combination of these attributes presents intriguing possibilities for biological and 
pharmacological properties. Moreover, during the current study there were found other remarkable 
properties of 5-deazaalloxazines, such as distorted structures, due to intramolecular interaction, 
molecular shape and tendency to add various nucleophiles to position 5. At the same time, fluoro-
containing 5-deazaalloxazines have not received much attention despite their potential interest as 
highly reactive substrates in organic synthesis and biologically active compounds with useful 
physicochemical applications. Therefore, we have undertaken the current study in order to develop 
a convenient synthetic approach to 5-polyfluoroalkyl-5-deazaalloxazines and at least partially 
investigate their striking chemical properties. 
 
2.2 Syntheses of 5-polyfluoroalkyl-5-deazaalloxazines 
2.2.1 Existing methods 
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Scheme 18. Existing synthetic approaches to 5-deazaalloxazines overview.78-84 
5-Deazaalloxazines have previously been synthesized by cyclization of 6-(arylamino)uracils 
with one-carbon reagents (triethyl orthoformate, dimethylformamide dimethylacetal,78 carbon 
disulfide,79 N,N-dimethyldichloromethyleniminium chloride80 and the Vilsmeier reagent81). 
Similarly, treatment of 6-arylamino-1,3-dimethyluracils 70 with aromatic aldehydes provided 5-
aryl-1,3-imethylpyrimido[4,5-b]quinoline-2,4(1H,3H,5H,10H)-diones 71, followed by 
dehydrogenation with thionyl chloride to give 5-aryl-1,3-dimethylpyrimido[4,5-b]quinoline-
2,4(1H,3H)-diones.78 5-Deazaalloxazines can be obtained via cyclocondensation of urea with 2-
chloroquinoline-3-carboxamide82 or 2-chloroquinoline-3-carbonitrile 72.83 Friedländer reaction 
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between o-aminobenzaldehydes and barbituric acid has been successfully applied as well84 (Scheme 
18). 
 
2.2.2 Prehistory and first trials 
 
Before the work on 5-polyfluoroalkyl-5-deazaalloxazines was started, we had synthesized 
structurally similar compounds 77a and b (Scheme 19). Thus, each of them constitutes a doubly 
annelated pyridine bearing a trifluoromethyl group at the 4-position. 
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Scheme 19. One-pot synthesis of 3-acyl-4-chlorocoumarines 74a-c and subsequent cyclocondensation with 
aminoheterocycles. 
Reagents and conditions: i: 1) TMSCl, pyridine, dioxane, r.t., 1 h;85 2) corresponding anhydride or chloroanhydride was 
added, 90 °C, 2 h (a, b) or ½ h (c); 3) POCl3, 60 °C, 2 h; ii: DMF, TMSCl, 80 °C, 4 h. 
 
Figure 6. Ortep plot of 3-trifluoroacetyl-4-chlorocoumarine 74a (35% probability level). 
This approach seemed to be most convenient for the synthesis of 5-deazaalloxazines. 
Initially we tried to synthesize 6-chloro-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-
2,4(1H,3H)-dione 80 from 1,3-dimethylbarbituric acid 79a in the same manner as 4-chloro-3-
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(trifluoroacetyl)-2H-chromen-2-one from 4-hydroxycoumarin.86 After these attempts have been 
failed, we tried to convert an amino group of 6-amino-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-
2,4(1H,3H)-dione 78 into chlorine through diazotation (Scheme 20). 
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Scheme 20. Unsuccessful attempts to synthesize 6-chloro-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-dione, 
which was expected to be a convenient precursor of 5-trifluoromethyl-5-deazaalloxazines. 
Reagents and conditions: i: pyridine, dioxane, TMSCl, r.t., 2 h; ii: TFAA, 90 °C; iii: POCl3, 60 °C; iv: HCl, NaNO2, 
water, 0 °C; v: CuCl, CuCl2, 60 °C. 
In both cases only the starting materials were isolated after the reactions; no diazotation was 
observed under employed reaction conditions. 
Even attempts to synthesize 1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4,6(1H,3H,5H)-
trione 81 experienced failure, despite the simple acetic anhydride reacted with 1,3-
dimethylbarbituric acid smoothly and in 95% yield (Scheme 21). 
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Scheme 21. Unsuccessful attempts to synthesize 1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4,6(1H,3H,5H)-trione 
which represents the possible precursor to 6-chloro-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-dione. 
Reagents and conditions: i: DMAP, dioxane, TFAA, reflux, 2 h. 
In this case also only the starting material was isolated. 
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2.2.3 Attempts to synthesize pyrimido[5,4-c]quinoline-2,4(1H,3H)-diones, the 
structural isomers of 5-deazaalloxaziness. Negative results. 
 
The pyrimido[5,4-c]quinoline-2,4(1H,3H)-dione core (84) is structurally isomeric to the 5-
deazaalloxazine core. It can be easily constructed from 4-aminoquinoline-3-carboxylic acid amide 
or ester.87 Nevertheless, convenient synthetic methods for 5-polyfluorsubstituted derivatives have 
not been developed so far. Taking on this task, we attached special importance to the combinatorial 
aspect. According to our plan, 1,3-dimethyl-6-piperidin-1-yl-5-(trifluoroacetyl)uracil 78b is 
activated by phosphorus pentachloride or triflic anhydride, followed by cyclocondensation with 
aniline (Scheme 22). In fact, we considered compound 82 as a building block similar to 80, but with 
inversed order of reacting centers. 
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Scheme 22. Unsuccessful attempts to synthesize 1,3-dimethyl-5-(trifluoromethyl)pyrimido[5,4-c]quinoline-2,4(1H,3H)-
dione. 
Reagents and conditions: i: PCl5 in CHCl3 or Tf2O in DCM, r.t., 1 d; ii: aniline, r.t., 1 d; iii: H2SO4, r.t., 1 d. 
To our great disappointment, this chosen strategy has not been successful in our hands. All 
the stages were carried out in one-pot protocols and always resulted to unidentifiable mixture. 
 
2.2.4 Three-step synthesis of 5-polyfluoroalkyl-5-deazaalloxazines from 6-
chlorouracils, anilines and polyfluoroacyl chlorides/anhydrides 
 
5-Polyfluoroalkyl-5-deazaalloxazines were synthesized from 6-chloro-1,3-dialkylyluracils in 
three steps using a 2+3+1 strategy (Scheme 23). 
6-Chloro-1,3-dipropyluracil, the starting material for 1,3-dipropyl-5-deazaalloxazines, was 
prepared from N,N'-dipropyl urea and malonic acid in 2 steps and 54% overall yield.88, 89 N,N'-
Dimetyl- and N,N'-dipropylbarbituric acids were converted into 85a and 85b, respectively, using the 
method with water and phosphorus oxychloride developed by W. Pfleiderer and K.-H. 
Schündehütte.89 
On the first stage, the chlorine atom is substituted by the aniline. Three different procedures 
have been used depending on the initial amine reactivity. Coupling of 6-chloro-1,3-dialkylyluracils 
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with anilines was carried out mostly at 180 °C under argon,78 where the excess of anilines plays a 
role as a base. When dibasic anilines were used, contrariwise, a 20% excess of 85a was employed in 
combination with 1 equivalent of quinoline (calculated on chlorouracil 85a). Only in case of 
inactive anilines, such as 5-amino-3-methyl-1-phenylpyrazole or α-naphthylamine, application of n-
butyllithium as a base was necessary. 
Then the 5-position of obtained 6-aminouracil is acylated by perfluorinated carboxylic acid 
anhydride or chloroanhydride, and afterwards 5-deazaalloxazines 88 form by cyclization under 
acidic conditions. 
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Scheme 23. Syntheses of 5-polyfluoroalkyl-pyrimido[4,5-b]quinoline-2,4-diones. 
Reagents and conditions: i: aniline (2.2 eq), 180 °C, 3 h, under argon (Method A),78 or aniline (0.8 eq), quinoline, 180 
°C, 3 h, under argon (Method B), or aniline (2.2 eq), n-BuLi, THF, –78 to °C, under argon (Method C);90 ii: anhydride 
of polyfluorinated carbonic acid (or cloroanhydride), pyridine, dioxane, r.t., overnight;91 iii: H2SO4, (conc.), r.t., 3 h. 
Taking into account that compounds are slowly hydrolyzed, their contact with water during 
the isolation should be minimized and carried out at ~0 °C, but firstly the solvent should be 
evaporated and the residue needs to be dried in high vacuum on a boiling water bath. 
5-Polyfluoroalkyl-5-deazaalloxazines 88 are yellow colored compounds mostly good 
soluble in chloroform and less soluble in DMSO and methanol. They are also soluble in sulphuric 
and trifluoroacetic acid. Addition of TFA increases their solubility in chloroform. 
Table 3. Two-step synthesis of 1,3-dimethyl-5-poly-fluoroalkyl-pyrimido[4,5-b]quinoline-2,4-diones 88. 
Entry R1 R2 R3 
Yield, %a 
87 88 
a CH3 H CF3 93 89 
b CH3 H n-C3F7 96 73 
c CH3 7,9-diMe CF3 90 84 
d CH3 7,9-diMe C2F5 88 84 
e CH3 7,9-diMe n-C3F7 87 92 
f CH3 7-Et CF3 88 50 
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Entry R1 R2 R3 
Yield, %a 
87 88 
g CH3 7-Et CClF2 97 57 
h CH3 7-Et C2F5 94 81 
i CH3 9-MeO CF3 90 49 
j CH3 9-MeO CClF2 92 67 
k CH3 8-MeO CF3 12b 
l CH3 8-MeO CClF2 40b 
m CH3 8-MeO n-C3F7 94 32 
n CH3 8-CF3 CF3 99 51 
o CH3 7-NO2 CF3 79 82 
p CH3 7-Br CF3 94 84 
q CH3 7-EtO CF3 82 73 
r CH3 7-EtO CHF2 99 80 
s n-Pr 7-MeO CHF2 86b 
t n-Pr 7-MeO C2F5 86 81 
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a – yields refer to pure isolated products; b – yield after 2 stages (the product of acylation was introduced into 
the reaction without purification); c – after acylation the already cyclized product was isolated. 
As the target molecules bear a polyfluoroalkyl group at position 5, the C-F coupling of C-5, 
C-6 and the polyfluoroalkyl residue itself was observed by 13C NMR spectra. In case when RF = 
C2F5 or n-C3F7, the polyfluoroalkyl group appears as undecipherable multiplets merging with noise. 
In addition, the presence of fluorinated alkyl groups was confirmed by 19F NMR. Example 88f was 
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additionally measured by 2D COSY, HSQC and HMBC. These data were used to assign H and C 
signals of 88f as well as other examples by similarity of their chemical shift. 
 
Figure 7. Ortep plot of 7-ethoxy-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 88n 
(35% probability level). 
 
Figure 8. Ortep plot of 5-[chloro(difluoro)methyl]-9-methoxy-1,3-dimethylpyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
88j (35% probability level). 
As seen from Figures 7, 8, 9 and 12, the pyrido-pyrimidine part of the molecules is slightly 
twisted (Table 4, entry 2 and 3). Despite the aromaticity, they are not planar due to repulsion 
between the polyfluoroalkyl group and the neighboring oxygen (Entry 1). The distance between the 
oxygen and the nearest fluorine atom lies in the range between 2.50 and 2.48 Å (Entry 5), which is 
significantly less than the sum of van der Waals radii according to Bondi (the expected value should 
be 2.99 Å).92 Moreover, short intramolecular contacts were observed between the nearest F and H 
atoms (Entry 9). Thus, the rotation angle of the polyfluoroalkyl group (Entry 4) is dictated mainly 
by Van der Waals repulsion from the neighboring H and O atoms. 
We also believe that the reason for the repulsion is not only due to close intramolecular 
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contacts, but also due to a strong electrostatic dipole-dipole interaction between CO and C-CF3. 
Thus, the longest O∙∙∙F distance (Entry 5) is observed in case of the less bulky (as compared with n-
C3F7 and CClF2), but more electronegative CF3-group in examples 88n and 92a. 
 
Figure 9. Ortep plot of 5-(heptafluoropropyl)-8-methoxy-1,3-dimethylpyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 88m 
(25% probability level). Crystal solvate with 1 eq of chloroform. 
As we see in Figure 9, a short intramolecular F3∙∙∙H7 contact of 2.434 Å is also observed in 
structure 88m, which is a little bit beyond the normal van der Waals contact distance (~2.65 Å92). 
Table 4. Torsion angles φ and interatomic distances r (atom numeration according to Ortep plot). 
 Entry 88n 88j 88m 92a 
φABCD, ° 
1 
C10C3C5O2, 
−32.18 
C14C9C11O2, 
−27.28 
C15C9C11O3, 
−25.97 
C12C3C1O1, 
35.47 
2 
C3N1N2C5, 
−6.99 
C9N1N2C11, 
−5.94 
C9N2N1C11, 
−4.57 
C3N1N2C1, 
11.62 
3 
C10N1N2O2, 
−15.40 
C14N1N2O2, 
−13.24 
C15N2N1O3, 
−11.71 
C12N1N2O1, 
19.76 
4 
C2C3C10F2, 
−89.07 
C8C9C14Cl1, 
−87.89 
C8C9C15C16, 
−85.22 
C4C3C12F3, 
84.10 
rAB, Å 
5 F3O2, 2.548 F2O2, 2.510 F2O3, 2.500 F1O1, 2.548 
6 F2O2, 2.974 Cl1O2, 3.148 O3F4, 2.706 F3O1, 3.109 
7 C10O2, 2.902 C14O2, 2.878 C15O3, 2.887 C12O1, 2.965 
8 C3C5, 2.531 C9C11, 2.531 C9C11, 2.542 C3C1, 2.541 
 9 F1H11, 2.204 F1H7, 2.246 F1H7, 2.253 F2H5, 2.208 
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In cases of meta-substituted anilines, the formation of two regioisomers is possible. Isolation 
of the pure isomer required thorough recrystallization; therefore, yields are lower than for other 
anilines (Table 2). 
Table 5. The selectivity of the cyclization in the case of meta-substituted anilines. 
 8/6-Substituted isomers ratioa
R1 MeO MeO MeO CF3 
R2 CF3 n-C3F7 CClF2 CF3 
 87 / 13 50 / 50 92 / 8 86 / 14 
a – determined by 1H NMR. 
Electrophilic attack of the less sterically hindered position leads to predomination of the 8-
substituted isomer. On the other hand, hydrophobic interaction can take place between the 
substituent attached to the aniline ring and the polyfluoroalkyl group. This balance between 
attraction and repulsion is supposed to be decisive for the observed regioisomeric ratio. 
Isomers were assigned using 1H NMR data. Thus, the spectra of 8-substituted isomers 
contain a doublet with coupling constant 4J = 2.65-2.83 Hz or narrow multiple in case of 88o (due 
to through space interaction between H-6 and CF3 groups). 
 
2.3 Syntheses of 5-hydroxy-5,10-dihydro-5-deazaalloxazines and their conversion into 
5-deazaalloxazines 
 
Next, we were interested, what the product will be in case of N,N-disubstituted 6-
aminouracil. After acylation and cyclization in sulfuric acid, compounds 90, which contain a 
tertiary amino group, give the corresponding 5-hydroxy-5,10-dihydro-5-deazaalloxazines 91 
(Scheme 24, 25). As we estimated, under strong acidic conditions the compounds 90a-c form 5-
deazaalloxazine-10-ium cation 95. The latter undergoes reaction with an hydroxyl anion 
immediately after dilution with water. 
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Scheme 24. Syntheses of 5-hydroxy-1,3,10-trimethyl-5-trifluoromethyl-5,10-dihydro-5-deazaalloxazine. 
Reagents and conditions: i: N-methylaniline, 180 °C, 3 h;78 ii: trifluoroacetic anhydride, pyridine, dioxane, r.t., 
overnight;91 ii: H2SO4, (conc.), r.t.. 
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Treatment of 5-hydroxy-5,10-dihydro-5-deazaalloxazines 91 with thionyl chloride resulted 
in cleavage of the C-N bond. In this way we obtained 5-deazaalloxazines 92 bearing a ω-
chloroalkyl group at position 9. This result can be explained by the higher chloride anion 
nucleophilicity in contrast to hydrogensulfate. Other expected but not obtained products are 
represented in Figure 10. 
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Scheme 25. Syntheses of 5-hydroxy-5,10-dihydro-5-deazaalloxazines and their conversion into5-deazaalloxazines. 
Reagents and conditions: i: anhydride of polyfluorinated carbonic acid (or cloroanhydride), pyridine, r.t., overnight;91 ii: 
H2SO4, (conc.), r.t., 3 h; iii: SOCl2, CHCl3, boiling under reflux, 3 h. 
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Figure 10. Alternative products (not obtained). 
 
Figure 11. Ortep plot of 6-hydroxy-8,10-dimethyl-6-(trifluoromethyl)-1,2-dihydro-6H-pyrimido[4,5-b]pyrrolo[3,2,1-
ij]quinoline-7,9(8H,10H)-dione 91a (35% probability level). 
Besides other methods, the structure of 91a was confirmed by X-ray crystallographic 
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analysis. As we see in Figure 11, a strong intramolecular hydrogen bond of 1.765 Å length is 
present there. 
 
Figure 12. Ortep plot of 9-(2-Chloroethyl)-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-
dione 92a (35% probability level). 
The structure of 92a was confirmed by X-ray analysis as well (see discussion in Chapter 
2.2.4) 
 
2.3.1 Mechanistic pathway consideration 
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Scheme 26. 7-Ethyl-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione doesn't undergo 
alkylation. 
Reagents and conditions: xylene, methyl iodide or dimethyl sulphate, heating up to 150 °C. 
5-Deazaalloxazines do not undergo alkylation, but existence of 5-deazaalloxazines 
containing a quaternized nitrogen 95 was proved by 1H and 13C NMR. For this purpose, 6-hydroxy-
8,10-dimethyl-6-(trifluoromethyl)-1,2-dihydro-6H-pyrimido[4,5-b]pyrrolo[3,2,1-ij]quinoline-
7,9(8H,10H)-dione 91a was dissolved in deuterochloroform, followed by addition of triflic 
anhydride (Scheme 27). 
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Scheme 27. Formation of 5-deazaalloxazine-10-ium cation 95a. 
The CH2-protons appears as two triplets. It indicates equivalence of protons within each 
methylene group and consequently the molecular symmetry (the methylene groups lie in the mirror 
plane). In the opposite case, the pattern of the signals would be more complicated, namely four 
doublets of doublets of doublets. In addition, the MS(GC) and HRMS spectra of 92a contain strong 
peaks corresponding to the above mentioned cation 95a, namely [M-Cl]+. The same is valid for 9-
(3-chloropropyl)-5-(heptafluoropropyl)-1,3-dimethylpyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
92b. 
All this facts together with the successful synthesis of 5-hydroxy-1,3,10-trimethyl-5-
(trifluoromethyl)-5,10-dihydropyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 91c suggest Pathway A 
to be right; no C-N bond cleavage takes place (Scheme 28). 
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Scheme 28. Mechanistic pathways. 
 
2.4 Suzuki and Sonogashira coupling with 7-bromo-5-trifluoromethyl-5-
deazaalloxazine 
 
The 8-bromo derivative 88p undergoes Suzuki and Sonogashira reaction in high yields. 
Thereby, the conjugated π-electron system is extended that exerts a significant influence on the 
photophysical properties. 
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Scheme 29. Suzuki and Sonogashira coupling with 7-bromo-5-trifluoromethyl-pyrimido[4,5-b]quinoline-2,4-dione. 
Reagents and conditions: i: Pd(PPh3)4, K2CO3, dioxane, H2O, 100 °C, ½ h, under argon;93 ii: Pd(PPh3)2Cl2, CuI, DIPA, 
THF, r.t., 48 h, under argon.94 
 
2.5 Reduction of 5-deazaalloxazines 
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Scheme 30. Reduction of 5-deazaalloxazines. 
Reagents and conditions: i: diethyl 1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate (6 eq), xylene, TsOH, 155 °C, 5 
h, under argon; ii: NaBH3CN, THF, AcOH, 4 days.95 
 
Figure 13. Ortep plot of 1,3,7,9-Tetramethyl-5-(trifluoromethyl)-5,10-dihydropyrimido[4,5-b]quinoline-2,4(1H,3H)-
dione 98a (40% probability level). 
5-Deazaalloxazines are reduced by Hantzsch dihydropyridine or sodium cyanoborohydride 
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to the corresponding 5,10-dihydro-5-deazaalloxazines 98a and b. The reduction of compounds 88c 
and f with sodium cyanoborohydride95 was carried out in excellent yield and under milder 
conditions as compared to the primarily used 1,4-dihydropyridinedicarboxylate. 
Sodium cyanoborohydride is known as a selective and stable reducing agent which is used 
in slightly acidic media. Moreover, it is cheaper than diethyl 1,4-dihydropyridinedicarboxylate and 
easy to handle. 
The structure of product 98a was unambiguously confirmed by X-ray analysis. 
 
2.6 Alkylation of 1,3,7,9-tetramethyl-5-(trifluoromethyl)-5,10-dihydropyrimido[4,5-
b]quinoline-2,4(1H,3H)-dione 
 
Theoretically two main positions for alkylation were expected: N-10 and C-4a. As we 
estimated, alkylation took place at the carbon atom. From the 2D NOESY spectrum of 100 it is 
clearly seen that benzylic methylene group is located in the neighbourhood of H-5 (corresponding 
cross-peak at 3.12 and 4.00 ppm). In fact, this is in agreement with a result obtained by H. Fenner 
and W. Bauch. The authors reported about alkylation at position 4a of 1,3-dimethyl-5,10-dihydro-5-
deazaalloxazine, carried out with methyl iodide.96 
N
H
N
N
Me
O
Me
OCF3
Me
Me
N N
N
Me
O
Me
O
Me
Me
F3C
Ph
Bn-Br+
i
82%
98a
99
100  
Scheme 31. Benzylation of 5,10-dihydro-5-deazaalloxazine 98a. 
Reagents and conditions: i: K2CO3, DMF, r.t., overnight, under argon. 
 
Figure 14. Ortep plot of 1,3,7,9-tetramethyl-5-(trifluoromethyl)-5,10-dihydropyrimido[4,5-b]quinoline-2,4(1H,3H)-
dione 100 (35% probability level). 
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In our case, the reaction proceeded with high diastereoselectivity. Therefore, it raises the 
question concerning the relative configuration at C-4 and C-5. In order to accomplish the structure 
elucidation, a single crystal was grown. Thus, according to X-ray data (Figure 14), the obtained 
substance constitutes a diastereomeric mixture of 4aR,5R- and 4aS,5S-enantiomers. As expected, 
benzyl bromide attacks the substrate from the less sterically hindered side. 
 
2.7 Reaction of 5-deazaalloxazines with C- and N-nucleophiles 
 
Another remarkable feature of 5-polyfluoroalkyl-5-deazaalloxazines has been found during 
the study, namely the ability to react with some nucleophiles, such as acetophenone, nitromethane 
and hydrogen cyanide, under basic conditions in excellent yields (Scheme 32). A similar reaction 
has been previously reported for 10-substituted 5-deasaflavines, since H.-J. Duchstein, H. Fenner 
and W. Bauch published their results in the year 1989,97, 98 but not for 5-deazaalloxazines. 
N N
N
O
O
Me
Me
CF3
Et
N
H
N
N
O
O
Me
Me
F3C
N
Et
N
H
N
N
O
O
Me
Me
F3C
Et
NO2
N
H
N
N
O
O
Me
Me
F3C
Et
O
Ph
N N
N
O
O
Me
Me
F3C
N
N N
N
O
O
Me
Me
F3C
NO2
N N
N
O
O
Me
F3C
O
Ph
N N
N
O
O
Me
Me
CF3
Cl 70%94%
93%81%
86% 92%
i
ii
iii
i
ii
iii
88f
92a
101a
101b
101c
102a
102b
102c  
Scheme 32. Interaction of 5-trifluoromethyl-5-deazaalloxazines with C-nucleophiles. 
Reagents and conditions: i: acetophenone, NaH (60% in mineral oil), THF, r.t., overnight; ii: MeNO2, NaOMe, THF, 
MeOH, r.t., overnight; iii: KCN, DMSO, r.t., overnight. 
In case of 9-(2-chloroethyl)-5-deazaalloxazine 92a, a further cyclization takes place. Taking 
into account that 5-deazaalloxazines do not undergo alkylation, this reaction can be rationalized by 
a cascade mechanism (Scheme 33). 
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Scheme 33. Proposed mechanism. 
Especially interesting in this context is a reaction with indole, which rapidly couples 5-
deazaalloxazine 88f in the presence of a strong base (Scheme 34). The resulting σ-complex 
undergoes rearrangement at 80 °C in 5 hours to form a thermodynamically more stable C-isomer. 
N-Adduct 101d can be decomposed by heating and to form hereby the initial materials 88f and 103, 
especially in the presence of traces of bases. Addition of a small amount of acetic acid stabilizes the 
product. Both isomers were isolated. 
The direction of the nucleophilic addition was confirmed by 13C NMR spectroscopy. The 
quaternary carbon atom C-5 of 101a-e and 102a-c appears as a quadruplet (2J(C-F) = 25.7-33.0 Hz) 
in the aliphatic region at 46.2-50.2 and 65.3 ppm (the outstanding value refers to the 5-(indol-1-yl) 
derivative 101d). 
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Scheme 34. Indole as N- and C-nucleophile. Reaction with 5-deazaalloxazines. 
Reagents and conditions: i: NaH (60% in mineral oil), THF, r.t., 3 min; ii: NaH (60% in mineral oil), DMF, 80 °C, 5 h, 
under argon. 
In some cases, a simple substitution of chlorine for the nucleophile was observed instead of 
addition to the 5-position. In other cases, 5-deazaalloxazine 92a does not enter into the reaction at 
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all (Scheme 35). 
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Scheme 35. Reaction of 9-(2-cloroethyl)-1,3-dimethyl-5-trifluoromethyl-pyrimido[4,5-b]quinoline-2,4-dione 24a with 
N- and S-nucleophiles. 
Reagents and conditions: i: DMSO, r.t., overnight; ii: DMSO, NaOMe, r.t., overnight. 
5-Deazaalloxazine 88f reacts reversibly with p-thiocresol 105 to form 101f (Scheme 36). 
The reaction requires base catalysis. In this case, the equilibrium is shifted almost completely 
toward the product. While the starting materials disappeared, the product was observed on TLC, 
but, unfortunately, has never been isolated in a pure state, because most of it decomposes during the 
isolation. The additional evidence of the chemical transformation is bleaching of the mixture during 
the reaction. 5,10-Dihydro-5-deazaalloxazines, in contrast to yellow 5-deazaalloxazines, are 
colourless. 
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Scheme 36. Reversible reaction of 5-deazaalloxazine 88f with p-thiocresol 105. 
Reagents and conditions: NaOMe, DMF, r.t., overnight. 
A product of the reaction of 88f with morpholine 106 was not observed, even when sodium 
hydride was used as a base (Scheme 37). In contrast to the previous case with p-thiocresol, even 
bleaching of the mixture was not noticed. According to the poor literature data, addition of amines 
to fused pyridines may take place, but the equilibrium is strongly shifted towards the starting 
material.99, 100 
It should be mentioned here that nucleophilic addition is more characteristic for pyridinium 
salts (this reaction is closely associated with the name of Fritz Kröhnke101) rather than non-
quaternized pyridines.102 
The easiness with which 5-polyfluoroalkyl-5-deazaalloxazines react with nucleophiles 
requires some consideration. First of all, the pyridine core is fused with two other aromatic rings; 
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this circumstance substantially reduces aromaticity of the central cycles. Secondly, we should take 
into account the influence of substituents, especially at the reacting center. Thus, the perfluoroalkyl 
group causes a strong negative inductive effect. Moreover, according to the charge-alternation rules, 
the mesomeric effect distributed from pyrimidin-2,4-dione ring appears to be electron-withdrawing 
at the 5-position. Thirdly, the 5-polyfluoroalkyl-5-deazaalloxazine ring system is slightly twisted 
(see X-ray structures 88n, 88j, 88m and 92a) and consequently has decreased aromaticity compared 
to its planar state. 
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Scheme 37. No reaction between 5-deazaalloxazine 88f and morpholine 106. 
Reagents and conditions: NaH (60% in mineral oil), THF, r.t., overnight. 
 
2.8 Cyclization of 6-(Benzylamino)-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-
2,4(1H,3H)-dione under basic conditions 
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Scheme 38. Cyclization of 6-(Benzylamino)-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-dione under basic 
conditions. 
Reagents and conditions: i: TFAA, pyridine, dioxane, r.t., overnight;91 ii: NEt3, DMF, 125 °C, 10 h, under argon. 
Next, we tried to do the cyclization in case of N-benzyl-6-aminouracil where the methylene 
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group between the nitrogen atom and the phenyl group should prevent aromatization of the new 
ring. Unfortunately, it was not possible to isolate any clear product when sulfuric acid was applied. 
But another interesting reaction took place when the reaction was catalyzed by triethylamine. 
Thereby, a six-member ring is formed (Scheme 38). 
The obtained product 108, contrary to the expected structure 109, shows a quadruplet in the 
13C DEPT spectrum with a significant coupling constant 2J(C-F) = 31.9 Hz, which was surprising. 
Therefore, the product was confirmed by X-ray analysis (Figure 15). 
 
Figure 15. 6,8-Dimethyl-2-phenyl-4-(trifluoromethyl)-4,8-dihydro-2H-pyrimido[4,5-d][1,3]oxazine-5,7(1H,6H)-dione 
108 (40% probability level). 
 
2.8.1 Discussion of the mechanistic pathway 
 
According to literature data, this type of cyclization is rationalized by a 1,5-hydrogen shift, 
followed by an usual nucleophilic addition of the hydroxyl group to the imine (Scheme 39, 
Pathway A).103-106 The [1,5]-H migration was confirmed by an experiment with 
deuterotrifluoroacetic acid as a reaction medium; no deuterium was found in the product.107 
But our example somewhat differs from the already described reactions in the literature. To 
the best of our knowledge, no similar reactions with secondary amines have been reported hitherto. 
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Only reactions involving tertiary amines were reported. This phenomenon is strongly associated 
with the so-called tert-amino effect. Secondly, these reactions proceed mostly either under acidic 
catalysis (TFA,103, 107 silica gel,106 Sc(OTf)3105) or at high temperature,104 and never in basic media. 
Taking into account the NH-acidic properties of 78c, other possible pathways have to be 
considered, too. 
We propose the following alternative mechanism of this reaction (Scheme 39, Pathway B): 
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Scheme 39. Proposed mechanisms. 
As the reaction runs in the presence of triethylamine, deprotonation is supposed to be the 
first step. The negative charge is delocalized over several atoms, particularly over the deprotonated 
nitrogen and oxygen of the trifluoroacetyl group. Then two synchronous transformations take place: 
a 1,2-hydrogen shift and a bond formation between carbon and oxygen atoms. Now the negative 
charge is delocalized over C-6 and the carbon atom adjacent to the CF3 group. Finally, protonation 
leads to the obtained product 108. 
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2.9 Photophysical properties of 5-polyfluoroalkyl-5-deazaalloxazines 
 
Molar absorption coefficients, absorption maxima, fluorescence band maxima and Stokes 
shifts for 6 compounds were determined within the study (Figure 16, 17; Table 6). As expected, the 
synthesized 5-deazaalloxazines have pronounced fluorescence properties. 
Table 6. Photophysical properties of 5-deazaalloxazines in chloroform: molar absorption coefficients ε at absorption 
maxima λa, fluorescence band maxima λf, and Stokes shift ΔνSt. 
Compd λa, nm ε, M-1·cm-1 λf, nm ΔνSt, cm-1
88w 405 9500 460 2950 
88x 353 12400 516 8950 
88f 397 5200 468 3820 
88u 410 17500 480 3560 
97a 417 9800 494 3740 
92b 395 5400 466 3860 
As seen from Table 6, compound 97a exhibits the most pronounced bathochromic shift 
among all other examples. The absorption coefficient values lie within 5200-17500 M-1·cm-1, which 
is too high to be explained by a n – π* electronic transition. Hereby one can assume that this 
maxima correspond to π – π* transition. The structure of 88x has an outstanding value of Stokes 
shift that can be rationalized by vibrational energy relaxation. The highest absorption coefficient is 
observed for 88u, the structure having the longest conjugated π-electron system. 
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Figure 16. Normalized absorption and uncorrected emission spectra of compounds 92b, 88x and 88u in chloroform. 
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Figure 17. Normalized absorption and uncorrected emission spectra of compounds 88w, 97a and 88f in chloroform. 
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2.10 Conclusions 
 
In conclusion, we have developed a convenient and inexpensive approach for the synthesis 
of 5-polyfluoroalkyl-5-deazaalloxazines. These compounds are not readily available by other 
methods. 
5-Acyl-6-aminouracils containing a tertiary amino group cyclize in sulfuric acid to the 
corresponding 5-hydroxy-5,10-dihydro-5-deazaalloxazines. The latter can be converted into 5-
deazaalloxazines via C-N bond cleavage promoted by thionyl chloride. 
In case of 5-acyl-N-benzyl-6-aminouracil an unusual cyclization leading to a six-membered 
ring was observed. 
Unlike Hantzsch dihydropyridine, sodium cyanoborohydride was found to be an excellent 
reductant for 5-polyfluoroalkyl-5-deazaalloxazines to convert them into the corresponding 5,10-
dihidro derivatives. The obtained product undergoes highly regio- and diastereoselective alkylation 
with benzyl bromide. The possibility to reduce the pyridine fragment of 5-polyfluoroalkyl-5-
deazaalloxazines is a crucial feature important for development of artificial FAD/FADH2 system 
analogues with tunable redox potential. 
Suzuki and Sonogashira couplings with 8-bromo-5-deazaalloxazine derivative were carried 
out successfully and in high yields. 
Another remarkable feature of 5-deazaalloxazines has been found during the study, namely 
the ability to react with a variety of nucleophiles at position 5. In case of 9-(2-chloroethyl)-5-
deazaalloxazines, a further cyclization leads to 7,9-dioxo-1,2,7,8,9,10-hexahydro-6H-pyrimido[4,5-
b]pyrrolo[3,2,1-ij]quinolines. 
As expected, the synthesized 5-deazaalloxazines have pronounced fluorescence properties. 
Examples 77a, 77b, 88b, 88h, 88j, 88n and 88q have been sent to be tested. The 
pharmacological evaluation is performed by Dr. M. Lalk (University of Greifswald). 
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3 Synthesis of Spiro[pyrimido[4,5-b]quinoline-3',5-indoline-2'-one]-3,10-
dihydro-2,4-diones via Three-Component Reaction 
and Unexpected Recyclization 
3.1 Introduction 
3.1.1 Biological relevance of similar structures 
 
This chapter is devoted to spiro[pyrimido[4,5-b]quinoline-3',5-indoline-2'-one]-3,10-
dihydro-2,4-diones. The target scaffold can be mentally divided into several biologically relevant 
moieties. First of all, it is the heterocyclic oxindole system containing one carbon atom common to 
two rings. Presence of the chiral spiro carbon leads to the sterically constrained spiro structure and 
is one of the important factors of the biological activities. Spirooxindole and spiroindoline ring 
systems are widely distributed among natural alkaloids, including anesthetics (horsfiline 112),108 
mammalian cell cycle inhibitors, antibiotics, antitumor agents (spirotryprostatin B),109 and in 
synthetic drugs (for instance, ibutamoren 111, the orally active growth hormone secretagogue).110 
On the other hand, the target scaffold includes so important motifs, such as 6-aminouracil 
and 1,4-dihydropyridine. The last moiety occurs in a large number of pharmaceutical products 
known as L-type calcium channel blockers (almodipine 114)111 and calcium agonists (CGP-
28392).112 AEAC, which refers to 6-aminouracils, is a thymidine phosphorylase inhibitor and 
exhibits antitumor activity.113 Thus, the combination of these moieties presents intriguing 
possibilities for pharmacological studies and drug design (Figure 18). 
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Figure 18. Representatives of closely related heterocycles and their biological activities.108-113 
Chapter	3: Spiro[pyrimido[4,5-b]quinoline-3',5-indoline-2'-one]-3,10-dihydro-2,4-diones 
47 
3.1.2 Multicomponent reactions as a powerful synthetic method 
 
Multicomponent reactions (MCRs) are very advantageous in many aspects. For instance, 
such reactions that provide maximum diversity are especially desirable in combinatorial chemistry 
and perfectly amenable to automation.114 On the other hand, MCRs usually lead to minimization of 
energy consumption and waste production due to their atom economy and facile execution. 
Because of their high productivity, the multicomponent reactions have attracted considerable 
attention as a source of a colossal number of substances to bioscreening and medicinal chemistry 
research, and are particularly useful for the preparation of spiroheterocyclic systems. 
 
3.2 Results and discussion 
3.2.1 Synthetic strategy based on Hantzsch- and Biginelli-type reactions 
 
The 3+2+1 strategy, where 1,3-binucleophiles, such as -CCN-, -CCO- and -NCN-, 1-C-
nucleophile-2-C-electrophile and 1,1-C-bielectrophile form a heterocyclic ring by one-pot 
cyclocondensation, is one of the most important approaches toward the synthesis of 1,4-
dihydropyridines (DHPs),115, 126 4H-pyranes114, 127 and Biginelli compounds.128 The following 
starting materials have been successfully used in the synthesis of DHP: 
 1,3-CCN-Binucleophiles 
5-Aminopyrazoles,115, 117, 119, 122, 123 6-aminouracils,124 β-naphthylamine,116, 118, 121 5-amino-
isooxazoles120 and 6-amino-2-(methylthio)pyrimidin-4(1H)-one.126 
 1-C-Nucleophile-2-C-electrophiles 
Barbituric115, 117-121, 123, 125 and thiobarbituric120 acids, simple ketones,126 1,3-diketones,116, 119, 
124, 126 cyanomethyl ketones,122 etc.119 
 1,1-C-Bielectrophiles 
Isatin,115-117, 119, 120, 122 aromatic aldehydes.118, 121, 123-126 
The first component (1,3-binucleophile) can be generated in situ, for example, from a ketone 
that contains an active methylene group in α-position and from an amine125 or ammonia itself as in 
the classical Hantzsch dihydropyridine synthesis. Another variation is the two-component 
condensation, where one of them plays a double role: namely as 1,3-binucleophile and 1-
nucleophile-2-electrophile (Scheme 40).129, 130 
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3.2.2 Synthesis of spiro[pyrimido[4,5-b]quinoline-3',5-indoline-2'-one]-3,10-dihydro-
2,4-diones and unexpected recyclization 
 
In recent year (2012) a significant attention has been paid to multicomponent DHPs 
synthesis involving isatin as a carbonyl component and 1,1-C-bielectrophile.115, 117, 120 But in the 
light of our study, the possibility of the formation of the opposite isomer in such reactions with the 
similar spectral and analytical data has not received adequate attention. 
We developed an efficient one-pot three-component synthesis of compounds 118/119 a-w 
(Scheme 40). As the first component, derivatives of barbituric or thiobarbituric acid 79 were used. 
The second component is an electron-rich aniline, and the third one is isatin. 
This reaction occurs in normal atmosphere and usually gives moderate to high yields mostly 
depending on the initial aniline. Initially we tested briefly various solvents and catalysts and found 
conditions proposed by X.-S. Wang and coworkers (EtOH, I2, r.t.) to be the best. It is worth to 
mention here that the reaction runs successfully at r.t. even without iodine, but, however, in little bit 
lower yields. The progress of the reaction was monitored by TLC, and in most cases the synthesis 
was complete after 24 h. The results are summarized in Table 7. A completely unexpected result 
was observed, namely that the expected structure of some products proved to be wrong. As shown 
in Scheme 40, two products are possible: the normal one 118 and isomeric one 119. 
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Scheme 40. Synthesis of spiro[pyrimido[4,5-b]quinoline-3',5-indoline-2'-one]-3,10-dihydro-2,4-diones. 
Reagents and conditions: i: EtOH, I2 (cat.), r.t., 24 h.118 
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Figure 19. Variety of anilines 
Table 7. Syntheses of spiro[pyrimido[4,5-b]quinoline-3',5-indoline-2'-one]-3,10-dihydro-2,4-diones 118 and 119 via 
three-component condensation. 
Entry 
Barbituric acid Aniline 116 Isatin Product 
R1 X № R2 R3 R4 Isomerc Yield, %a
a Pr O a 3,5-diMeO- H H 119 79 
b Pr O b 3,4,5-triMeO- H H 119 26 
c Pr O c 2-anthracenamine H H 119 91 
d H O a 3,5-diMeO- H H 119 51 
e Me O a 3,5-diMeO- H H 119 57 
f Me O a 3,5-diMeO- Cl H 119 72 
g Me O a 3,5-diMeO- H Et 118 82 
h Me O b 3,4,5-triMeO- H Et 118 55 
i Me O a 3,5-diMeO- F H 119 75 
j Me O a 3,5-diMeO- H Me 118 86 
k Me O b 3,4,5-triMeO- H Me 118 52 
l Me O b 3,4,5-triMeO- NO2 H 118(85), 119(15) 67 / 23b
m Et S a 3,5-diMeO- H H 119 81 
n Et S b 3,4,5-triMeO- H H 119 53 
o Et S a 3,5-diMeO- H Et 118 72 
p Et S a 3,5-diMeO- Cl H 119 68 
q Et S b 3,4,5-triMeO- H Et 118 47 
r Et S a 3,5-diMeO- F H 119 59 
s Et S b 3,4,5-triMeO- F H 119 36 
t Et S a 3,5-diMeO- H Me 118 56 
u Et S a 3,4,5-triMeO- H Me 118 47 
v Et S a 3,5-diMeO- NO2 H 118(25), 119(75) 63 / 19 b 
w Et S c 2-anthracenamine H Et 118 73b
a – yields refer to pure isolated products; b – yield of isolated mixture / yield of the major isomer isolated in a 
pure state; c – in brackets are given isomers ratio. 
After first trials, four commercially available barbituric acid derivatives 79a-d, three 
aromatic amines 116, and six isatins 117 were chosen for the library extension and validation of the 
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observed results. Let us consider what the product distribution depends on. In case of N-substituted 
isatins exclusively the normal product 118 was isolated. For R4 = H only the opposite isomer 119 
forms. And only in case of 5-nitroisatin both isomers were detected. As we see, the product depends 
entirely on the type of isatin. 
The isomers were identified by X-ray analysis or NOESY. The decisive correlations are 
shown in Figure 20. The peak of the amine proton can be assigned by the first correlation. Another 
NH-signal belongs to the amide. The second and third cross-peaks indicate the position of each 
aromatic ring being in neighborhood to the corresponding acidic protons. In case of N-alkyl 
structures, the algorithm of explanation is the same except that the 1-ethyl or methyl protons are 
taken into consideration instead of the NH. 
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Figure 20. Determination of regioisomer by NOESY. Arrows show the decisive correlations. 
The structures of products 118 and 119 were characterized by IR, 1H, 13C NMR spectral data 
as well as MS and HRMS analysis. For examples 119f, 118g, 119c and 118u were measured COSY 
and HSQC correlations. In addition, HMBC spectra of 118g and 118u were obtained. The 
regiochemistry of 119b and 119e is confirmed by X-ray analysis. Isomeric structures of 119c, 119f, 
118g, 118l, 118u, 119v were determined using 2D NOESY-methods. In those cases, when N-
alkylisatins were employed in the reaction, isomers can be easily assigned by the signal of the NH-
proton, which are in the range of 9.14 (118g) to 9.40 ppm (118w) in DMSO. The dihydropyridine 
NH proton appears at 9.14 to 9.98 ppm, whereas the NH of the indolin-2-one fragment comes out at 
10.32 to 11.05 ppm. Therefore, we draw the conclusion that N-alkylisatins give the expected 
isomer. The isomeric structure of other substances was determined by comparing the most decisive 
carbon and proton chemical shifts related to the di- and trimethoxyaniline moieties with the 
examples confirmed for sure by X-ray or NOESY. The NMR data are summarized in Tables 8-11. 
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Table 8. The 1H and 13C NMR data for isomers 119 from 3,5-dimethoxyaniline. 
 1H NMR 13C NMR 
Compd MeO-4 MeO-6 H-5 H-7 MeO-4 MeO-6 CH-5 CH-7 
4e 3.50 3.76 6.04 6.12 –– –– –– –– 
4a 3.49 3.75 6.03 6.11 56.4 56.1 92.9 90.1 
4f 3.53 3.77 6.07 6.14 56.5 56.2 93.1 90.2 
4i 3.52 3.77 6.07 6.13 56.5 56.2 93.1 90.2 
4m 3.51 3.76 6.05 6.13 56.5 56.2 93.1 90.2 
4p 3.54 3.77 6.09 6.15 56.6 56.2 93.2 90.3 
4r 3.53 3.77 6.08 6.15 56.5 56.2 93.2 90.3 
4v 3.54 3.78 6.10 6.20 56.6 56.2 93.3 90.4 
 
Table 9. The 1H and 13C NMR data for isomers 118 from 3,5-dimethoxyaniline. 
 1H NMR 13C NMR 
Compd MeO-6' MeO-8' H-7' H-9' MeO-6' MeO-8' CH-7' CH-9' 
4g 3.32 3.77 6.13 6.67 56.2 56.1 95.5 95.0 
4j 3.36 3.77 6.12 6.67 56.8 56.1 95.5 95.0 
4o 3.34 3.79 6.16 6.80 –– –– –– –– 
4t 3.38 3.78 6.15 6.79 56.9 56.2 96.0 95.2 
 
Table 10. The 1H and 13C NMR data for isomers 119 from 3,5-3,4,5-trimethoxyaniline. 
 1H NMR 13C NMR 
Compd MeO MeO MeO H-7 MeO MeO MeO CH-7 
4b 3.29 3.59 3.83 6.36 56.8 60.8 61.3 92.0 
4n 3.28 3.59 3.83 6.38 56.9 60.8 61.4 92.1 
4s 3.33 3.61 3.84 6.40 56.9 60.9 61.4 92.2 
 
Table 11. The 1H and 13C NMR data for isomers 118 from 3,5-3,4,5-trimethoxyaniline. 
 1H NMR 13C NMR 
Compd MeO-6' MeO-7' MeO-8' H-9' MeO-6' MeO-7' MeO-8' CH-9' 
4h 3.03 3.60 3.83 6.92 60.1 61.1 56.6 97.2 
4k 3.12 3.60 3.83 6.93 60.4 61.2 56.6 97.2 
4l 3.27 3.62 3.85 6.96 60.4 61.2 56.7 97.3 
4q 3.04 3.61 3.80 7.05 60.2 61.1 56.7 97.5 
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Figure 21. Ortep plot of 5,7-dimethoxy-1',3'-dimethyl-1'H-spiro[indole-3,5'-pyrimido[4,5-b]quinoline]-
2,2',4'(1H,3'H,10'H)-trione 119e (30% probability level). Crystal solvate with 3 eq of trifluoroacetic acid. 
 
Figure 22. Ortep plot of 4,5,6-trimethoxy-1',3'-dipropyl-1'H-spiro[indole-3,5'-pyrimido[4,5-b]quinoline]-
2,2',4'(1H,3'H,10'H)-trione 119b (25% probability level). Crystal solvate with 1 eq of methanol. 
As seen from crystallographic data, configuration of the spiro carbon atom is near to 
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tetrahedral: The angle values appear within the range of 100° to 115° (in tetrahedron ~109.47°). 
Indolin-2-one and 5,10-dihydropyrimido[4,5-b]quinoline-2,4-dione moieties lie in orthogonal 
planes. Torsion angles C19C1N1C6 (119e) and C24C3N1C8 (119b) make up −90.00° and 94.05° 
respectively. 
All synthesized spiro compounds are novel, but nevertheless, similar to previously described 
derivatives. Remarkably, despite a substantial number of publications dedicated to three-component 
spiroindolinone synthesis via Hantzsch-like reaction,115-117, 119, 120, 122 the possible recyclization has 
not been considered yet. The isomers have similar analytical data and, therefore, without additional 
X-ray crystallographic investigation or NOESY experiment could be wrongly assigned. The only 
similar transformation was described by A. Bazgir and coworkers for a two-component reaction, 
where 6-aminouracil 120 plays double role (Scheme 41).129, 130 The authors concluded the structure 
of one congener (R1 = R2 = R3 = CH3, R4 = H) using X-ray analysis, but the regiochemistry of the 
other products 121, particularly the one obtained from N-methylisatin, was not confirmed. 
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Scheme 41. Two-component condensation accomplished by reamidation reported by A. Bazgir and coworkers.129, 130 
 
3.2.3 Reactions of other carbonyl compounds instead of isatins 
 
The study of the three-component condensation between barbituric acids, anilines and 
carbonyl compounds was continued (Scheme 42). The reaction was carried out successfully only 
with electron-rich anilines and relatively active carbonyl compounds. 
Next, we tried to replace isatins by other active carbonyl compounds, such as chloral hydrate 
and ethyl pyruvate. When chloral hydrate was introduced into analogous reaction, unexpected 
product 123 with hydrolyzed trichloromethyl group was obtained under the same conditions in 17% 
yield. Fused 1,4-dihydropyridine 125, prepared from ethyl pyruvate in 25% yield, is unstable and 
rearranges slowly at room temperature under the action of atmospheric moisture affording 
quantitatively indolinone 126 (Scheme 42). The structures of compounds 123 and 125 were 
characterized by IR, 1H, 13C NMR spectral data as well as MS, HRMS and elemental analysis. The 
structure of 126 was additionally confirmed by X-ray diffraction analysis (Figure 23). 
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Scheme 42. Three-component condensation leading to 5,10-dihydro-5-deazaalloxazines and its following 
rearrangement. 
Reagents and conditions: i: I2, EtOH, r.t., 5 days; ii: I2, EtOH, r.t., overnight; iii: slowly conversion during storage at r.t. 
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Scheme 43. Using of 3-benzylamino-5,5-dimethyl-cyclohex-2-enone leads to formation of quinoline derivative. 
Reagents and conditions: i: I2, EtOH, r.t., overnight. 
 
Figure 23. Ortep plot of 5-(4,6-Dimethoxy-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl)-1,3-dimethyl-pyrimidine-2,4,6-
trione 126 (35% probability level). 
If 3-benzylamino-5,5-dimethyl-cyclohex-2-enone 127 is used instead of polymethoxy-
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anilines 116a-c, 1,3-dimethylbarbituric acid 79a does not enter into the reaction (Scheme 43). As a 
result, the quinoline derivative 128 was obtained in 43% yield. Very recently, this reaction has been 
described by H. Kefayati and coworkers for the three-component condensation of isatin, dimedone 
and various amines.131 
 
3.2.4 Interpretation of the results 
 
The formation of the normal isomer can be rationalized by the mechanism analogous to the 
one proposed for the case of aromatic aldehydes instead of isatins (Scheme 44).121 We believe that 
intermediate 129a is unstable because no convincing examples of the synthesis and unambiguous 
characterization of Knoevenagel products synthesized from barbituric acids and isatins have been 
published so far.132 
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Scheme 44. Proposed reaction mechanism of formation of 118. 
The formation of isomeric products 119 needs individual consideration. We have not 
established the exact mechanism, however, a reasonable suggestion is offered in Scheme 45. In fact, 
the alkyl group on the nitrogen protects isatin from the ring opening reaction. This in turn suggests 
that the amide carbonyl of isatin is activated during the reaction by attachment of an electron 
withdrawing group to the nitrogen atom. Then reamidation takes place and subsequent 
cyclocondensation leads to the final product 119e. Normally, isatin and barbituric acid form the 
corresponding dibarbiturates 133,132 but we suppose the existence of an equilibrium between 
starting materials and intermediate 131. The latter, being activated by a conjugated CO group, 
reacts rapidly with aniline. Normally, the isatin ring opens not easily, but N-acylderivatives133-139 as 
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well as N-carbamides140 (activated by isocyanates) and N-substituted isatins,141 conjugated with a 
CO group via a double bond, react readily with amines and other nucleophiles with ring opening. It 
is interesting that the reamidation takes place also in the presence of other 1,3-dicarbonyl 
compounds131 and substances similar to barbituric acid (Scheme 41 and 43).129, 130 The first step 
definitely is deprotonation of the initial isatin. It is obvious that 5-nitroisatin forms an anion more 
easily than other isatins used in the current study. But on the other hand, delocalization of negative 
charge on the NO2 group leads to significantly decreased nucleophilicity of the anion. Thus, it 
partially prevents formation of isomeric product 119l or v. 
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Scheme 45. Proposed reaction mechanism of formation of 119 and possible intermediate 133. 
We also found that product 119e can be obtained from dibarbiturate 133 under the same 
conditions. But the question still remains, whether compound 133 loses one or two molecules of 
barbituric acid 79a, before deprotonation and subsequent alkylation of the amide nitrogen takes 
place. Of course, we cannot exclude the possibility that an adduct of one molecule of barbituric acid 
to isatin (Scheme 46) is the key intermediate. 
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Scheme 46. Product of Knoevenagel condensation between isatin and N,N-dimethylbarbituric acid (considered to be 
unstable132) as intermediate. 
In any case, the exact mechanism of this transformation is still open to question. 
 
3.3 Conclusions 
 
A novel and efficient synthesis of spiroindolinones via three-component reaction between 
(thio)barbituric acids, electron-rich anilines and isatins has been developed. The described reactions 
proceed in ethanolic media in the presence of iodine and constitute a simple, practical, and 
environmentally friendly method for obtaining heterocyclic compounds containing a spiroindole-
3,5'-pyrimido[4,5-b]quinoline system. During the study, an unexpected recyclization related to the 
isatin ring opening was observed. A possible mechanistic pathway has been proposed. 
In addition, the combinatorial aspect of the developed synthetical approach can be useful in 
biologically-orientated syntheses and drug-discovery. 
Examples 119a, 119b, 119c and 119e have been sent to be tested. The pharmacological 
evaluation is performed by Dr. M. Lalk (University of Greifswald). 
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Scheme 47. To Chapter 1. Pyrimidine C-nucleosides. 
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Scheme 48. To Chapter 2. 5-Polyfluoroalkyl-5-deazaalloxazines. 
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Scheme 49. To Chapter 3. Spiro[pyrimido[4,5-b]quinoline-3',5-indoline-2'-one]-3,10-dihydro-2,4-diones. 
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4 Experimental Part 
4.1 General: analytical equipment, chemicals and work technique 
 
NMR Spectroscopy: 1H NMR spectra (250.13, 300.13 and 500.13 MHz) and 13C NMR 
spectra (62.90, 75.47 and 125.77 MHz) were recorded on Bruker instruments AVANCE 250, ARX 
300, and AVANCE 500 respectively using CDCl3, DMSO-d6 and CF3COOD as solvents. The 
spectra were calibrated according to the solvent signals (CDCl3: 1H = 7.26, 13C = 77.36; DMSO-d6: 
1H = 2.54, 13C = 40.45; CF3COOD: 1H = 11.50, 13C = 116.60 (q, 1J(C-F) = 283.19 Hz) and 164.20 (q, 
2J(C-F) = 43.99 Hz)). 19F-NMR spectra were recorded at 235.33 or 282.38 MHz on AVANCE 250 
and ARX 300 respectively considering CFCl3-signal as a zero point of the scale. All chemical shifts 
are given in ppm. All coupling constants J are indicated in Hz. 
Multiplicities are given as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br = broad signal. More complex coupling patterns are represented by combinations of 
the respective symbols. For example, td indicates a triplet of doublets with the larger coupling 
constant associated with the first symbol (here: triplet). 
The 1H and 13C NMR signals were assigned by DEPT and two-dimensional 1H-1H COSY, 
1H-1H NOESY and 1H-13C correlation spectra (HMBC and HSQC). 
 
Mass spectrometry (MS): 
a) Finnigan MAT 95 XP (Thermo Electron Corporation), EI, 70 eV; 
b) GC 6890/ MS D 5973 (Agilent Technologies), MS(GC), 70 eV. 
 
High resolution MS (HRMS): 
a) Finnigan MAT 95 XP (Thermo Electron Corporation), EI, 70 eV; 
b) 6210 Time-of-Flight LC/MS (Agilent Technologies), ESI. 
Only the measurements with an average deviation from the theoretical mass of ± 2 μDa were 
accounted as correct. 
 
Infrared spectroscopy (IR): Nicolet 380 FT-IR spectrometer with ATR sampling 
technique for solids as well as liquids. Signal characterization: (w) = weak, (m) = medium, (s) = 
strong. 
 
Elemental analysis (EA): Flash EA 1112 (Thermoquest). 
 
X-ray crystallography: Bruker Apex Kappa-II diffraktometer with CCD camera (Mo-Kα 
radiation and graphite monochromator, λ = 0.71073 Å). The space group is determined by the 
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XPREP program and the structures were solved via the SHELX-97 program package. Refinements 
were carried out according to the minimum square error method. 
 
UV/Vis spectroscopy: Lambda 2 (Perkin Elmer). Cuvette length l = 1 cm. 
 
Fluorescence spectroscopy: HITACHI F-4010. Cuvette length l = 1 cm, cuvette width w = 
= 1 cm. 
 
Thin layer chromatography (TLC): Merck HPTLC silica gel 60 F254 (aluminium sheets 
20x20 cm). Detection with UV light at 254 and 366 nm; afterwards development with vanillin-
sulfuric acid solution (1 g of vanillin, 14 mL of acetic acid and 1 mL of conc. sulfuric acid in 85 mL 
of methanol). 
 
Melting Points: All the measurements were carried out on the FP900 Thermosystem 
(Mettler) using a polarized light microscope Laborlux 12 POL S (Leitz). The melting points are 
uncorrected. 
 
Column chromatography: Separation on Acros or Merck silica gel 60 Å (0.060-0.200 mm, 
70-230 mesh). Eluents were distilled before use. 
 
All chemicals were purchased from the standard chemical suppliers, such as Sigma-
Aldrich®, Arcos®, Merck® and others. 
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4.2 General procedures and product characterisations 
4.2.1 Synthesis of pyrimidine C-nucleosides 
 
2-(β-D-Ribofuranosyl)-4-(trifluoromethyl)pyrimidine (16a) 
 
Into a 25-mL flask were placed 0.3 g of 1-(β-D-ribofuranosyl)form-
amidine (1.41 mmol, 1 eq), 0.069 g of MeONa (1.27 mmol, 0.9 eq), 0.043 g of 
1,8-diazabicyclo[5.4.0]undec-7-ene (0.282 mmol, 0.2 eq) and DMF (3 mL). 
Then 0.474 g of 4-ethoxy-1,1,1-trifluoro-3-buten-2-one (2.82 mmol, 2 eq) was 
added and the reaction mixture was stirred at 80 °C for 3 hours under argon. After cooling to room 
temperature the inorganic precipitate was filtered off and the filtrate was evaporated under reduced 
pressure. The crude product was purified by column chromatography: silica gel (120 g) / EtOAc (Rf 
= 0.08–0.14). 
Yield 0.130 g (33%), white solid, mp 93-95 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.50-3.60 (m, 1H, H-5a'), 3.61-3.71 (m, 1H, H-5b'), 
3.93-4.01 (m, 1H, H-4'), 4.02-4.11 (m, 1H, H-3'), 4.22-4.30 (m, 1H, H-2'), 4.70 (dd, 1H, 3J1 = 6.61 
Hz, 3J2 = 4.72 Hz, OH-5'), 4.92 (d, 1H, 3J = 4.72 Hz, H-1'), 5.04 (d, 1H, 3J = 5.85 Hz, OH-3'), 5.28 
(d, 1H, 3J = 5.67 Hz, OH-2'), 8.02 (d, 1H, 3J = 5.10 Hz, H-5), 9.25 (d, 1H, 3J = 5.10 Hz, H-6). 
13C NMR (62.90 MHz, DMSO-d6): δ = 63.0 (CH2OH), 72.3 (CH-3'), 76.8 (CH-2'), 86.1 
(CH-4'), 86.5 (CH-1'), 117.3 (CH-5), 121.5 (q, 1J(C-F) = 275.2 Hz, CF3), 154.9 (q, 2J(C-F) = 35.6 Hz, 
C-4), 162.1 (CH-6), 170.3 (C-2). 
19F NMR (282.38 MHz, DMSO-d6): δ = –68.6 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 280 ([M]+, 0.36), 203 ([M–CF3]+, 11), 191 (100), 189 (18), 178 
(17), 177 (33). 
HRMS (ESI): Calcd. for C10H12F3N2O4 [M+H]+: 281.07437, found: 281.07441. 
Anal. Calcd for C10H11F3N2O4: C, 42.86; H, 3.96; N, 10.00. Found: C, 41.00; H, 3.68; N, 
8.41. 
IR (ATR, cm–1): ṽ = 3390 (m), 3153 (m), 2979 (w), 2929 (w), 2817 (w), 1588 (w), 1576 
(m), 1462 (w), 1449 (w), 1418 (m), 1337 (s), 1320 (w), 1307 (m), 1295 (w), 1250 (w), 1225 (w), 
1202 (m), 1171 (s), 1150 (s), 1119 (s), 1100 (m), 1079 (s), 1042 (m), 1002 (w), 975 (w), 909 (m), 
887 (m), 851 (m), 800 (w), 761 (m), 719 (m), 703 (m), 677 (s), 649 (s), 586 (w), 542 (m), 528 (m). 
 
2-(β-D-Ribofuranosyl)-4-(pentafluoroethyl)pyrimidine (16b) 
 
Into a 25-mL flask were placed 0.2 g of 1-(β-D-ribofuranosyl)formamidine (0.94 mmol, 1 
eq), 0.26 g of K2CO3 (1.88 mmol, 2 eq), molecular sieves 4Å (0.3 g) and DMF (4 mL). Then  
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0.205 g of 1-etoxy-4,4,5,5,5-pentafluoro-1-penten-3-one (0.94 mmol, 1 
eq) was added at 0 °C and the reaction mixture was stirred at 60 °C for 4 hours 
under argon.  After cooling to room temperature the inorganic precipitate was 
filtered off and the filtrate was evaporated under reduced pressure. The crude 
product was purified by column chromatography: silica gel (75 g) / EtOAc (Rf = 0.09–0.21). 
Yield 0.185 g (59%), white solid, mp 72 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.48-3.59 (m, 1H, H-5a'), 3.60-3.69 (m, 1H, H-5b'), 
3.93-4.01 (m, 1H, H-4'), 4.03-4.10 (m, 1H, H-3'), 4.22-4.29 (m, 1H, H-2'), 4.67 (dd, 1H, 3J1 = 6.42 
Hz, 3J2 = 4.91 Hz, OH-5'), 4.91 (d, 1H, 3J = 4.53 Hz, H-1'), 5.04 (d, 1H, 3J = 5.86 Hz, OH-3'), 5.28 
(d, 1H, 3J = 5.66 Hz, OH-2'), 8.07 (d, 1H, 3J = 5.10 Hz, H-5), 9.26 (d, 1H, 3J = 5.10 Hz, H-6). 
13C NMR (62.90 MHz, DMSO-d6): δ = 63.1 (CH2OH), 72.5 (CH-3'), 76.8 (CH-2'), 86.1 
(CH-4'), 86.5 (CH-1'), 118.8 (CH-5), 154.9 (t, 2J(C-F) = 26.4 Hz), 161.9 (CH-6), 170.2 (C-2). 
19F NMR (282.38 MHz, DMSO-d6): δ = –118.0 (q, J = 2.1 Hz, CF2), –82.2 (t, J = 2.1 Hz, 
CF3). 
MS (GC, 70 eV): m/z (%) = 330 ([M]+, 0.73), 253 (12), 241 (100), 239 (17), 228 (15), 227 
(33). 
HRMS (EI): Calcd. for C11H11F5N2O4 [M]+: 330.06335, found: 330.06274. 
IR (ATR, cm–1): ṽ = 3419 (w), 3263 (m), 2945 (w), 2883 (w), 1574 (s), 1456 (m), 1435 (w), 
1429 (w), 1423 (w), 1404 (m), 1385 (w), 1362 (w), 1335 (m), 1302 (m), 1277 (w), 1205 (s), 1159 
(s), 1130 (s), 1107 (s), 1093 (s), 1051 (s), 1030 (s), 1014 (s), 999 (s), 984 (m), 947 (m), 933 (m), 
895 (m), 874 (m), 847 (m), 833 (m), 797 (m), 770 (m), 735 (s), 690 (m), 681 (m), 667 (s), 635 (m), 
615 (s), 534 (s). 
 
2-(β-D-Ribofuranosyl)-4-phenyl-6-(trifluoromethyl)pyrimidine (19a) 
 
Initial diketone was previously activated via conversion into 
corresponding α,β-unsaturated β-chloroketone: 
To a solution of 4,4,4-trifluoro-1-phenylbutane-1,3-dione (2 g, 9.25 
mmol, 1 eq) in chloroform (6 mL) was added 2.258 g of SOCl2 (27.8 mmol, 3 
eq), followed by the addition of DMF (0.034 g, 0.46 mmol, 0.05 eq). The mixture was refluxed for 
3 hours. After that the solvent with an excess of SOCl2 was evaporated, and the residue was 
distilled in a high vacuum to afford a green liquid consisting of mixture of isomers (1.994 g, 92%). 
Into a 25-mL flask were placed 0.15 g of 1-(β-D-ribofuranosyl)formamidine (0.71 mmol, 1 
eq), 0.39 g of K2CO3 (2.82 mmol, 4 eq) and DMF (3 mL). Then 0.182 g of the previously prepared 
α,β-unsaturated β-chloroketone (0.78 mmol, 1.1 eq) was added at 0 °C and the reaction was stirred 
at this temperature for the next 1½ hours. After that the mixture was allowed to stand at r.t. 
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overnight. The next day the inorganic precipitate was filtered off and the filtrate was evaporated 
under reduced pressure. The crude product was purified by column chromatography: silica gel (40 
g) / EtOAc (Rf = 0.30–0.39). 
Yield 0.178 g (71%), light green solid, mp 77-78 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 4.73 (dd, 1H, 2J = 12.28 Hz, 3J = 1.32 Hz, H-5a'), 3.93 
(br s, 3H, OH), 4.04 (dd, 1H, 2J = 12.28 Hz, 3J = 2.46 Hz, H-5b'), 4.28 (s 1H, H-4'), 4.41-4.50 (m, 
2H, H-2', H-3'), 5.27 (d, 1H, 3J = 2.65 Hz, H-1'), 7.45-7.60 (m, 3H, CHPh), 7.84 (s 1H, H-5), 7.99-
8.08 (m 2H, CHPh). 
13C NMR (62.90 MHz, CDCl3): δ = 62.2 (CH2OH), 71.6 (CH-3'), 78.0 (CH-2'), 85.2 (CH-
4'), 85.9 (CH-1'), 111.9 (CH-5), 120.7 (q, 1J(C-F) = 275.6 Hz, CF3), 127.9 (CHAr), 129.6 (CHAr), 
132.7 (CHAr), 135.2, 156.5 (q, 2J(C-F) = 36.0 Hz, C-6), 167.8, 170.6. 
19F NMR (282.38 MHz, CDCl3): δ = –69.8 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 356 ([M]+, 1.8), 268 (15), 267 (100), 253 (32). 
HRMS (ESI): Calcd. for C16H16F3N2O4 [M+H]+: 357.10567, found: 357.10634. 
Anal. Calcd for C16H15F3N2O4: C, 53.94; H, 4.24; N, 7.86. Found: C, 54.70; H, 4.30; N, 
7.10. 
IR (ATR, cm–1): ṽ = 3354 (s), 3078 (w), 2925 (m), 2854 (w), 1595 (s), 1548 (s), 1501 (w), 
1479 (w), 1454 (w), 1427 (w), 1388 (s), 1333 (w), 1282 (w), 1261 (s), 1207 (m), 1179 (s), 1136 (s), 
1100 (s), 1078 (s), 1051 (s), 1025 (s), 1001 (m), 990 (m), 943 (m), 929 (m), 880 (m), 833 (m), 802 
(w), 770 (s), 750 (m), 711 (m), 687 (s), 666 (m), 633 (s), 596 (m), 573 (m), 548 (s). 
 
2-(β-D-Ribofuranosyl)-4-(2-thienyl)-6-(trifluoromethyl)pyrimidine (19b) 
 
Initial diketone was previously activated via conversion into 
corresponding α,β-unsaturated β-chloroketone: 
To a solution of  4,4,4-trifluoro-1-(2-thienyl)butane-1,3-dione (2 g, 9.00 
mmol, 1 eq) in chloroform (6 mL) was added 3.213 g of SOCl2 (27.0 mmol, 3 
eq), followed by the addition of DMF (0.033 g, 0.4 mmol, 0.05 eq). The mixture was refluxed for 3 
hours. After that the solvent with an excess of SOCl2 was evaporated, and the residue was distilled 
in a high vacuum to afford a yellow-green liquid consisting of mixture of isomers (1.772 g, 81%). 
The product partially crystallized at r.t.. 
Into a 25-mL flask were placed 0.15 g of 1-(β-D-ribofuranosyl)formamidine (0.71 mmol, 1 
eq), 0.39 g of K2CO3 (2.82 mmol, 4 eq) and DMF (3 mL). Then 0.187 g of the previously prepared 
α,β-unsaturated β-chloroketone (0.78 mmol, 1.1 eq) was added at 0 °C and the reaction was stirred 
at this temperature for the next 2 hours. After that the mixture was allowed to stand at r.t. overnight. 
The next day the inorganic precipitate was filtered off and the filtrate was evaporated under reduced 
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pressure. The crude product was purified by column chromatography: silica gel (65 g) / EtOAc (Rf 
= 0.31–0.36). 
Yield 0.187 g (73%), white solid, mp 165-167 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.57-3.67 (m, 1H, H-5a'), 3.67-3.77 (m, 1H, H-5b'), 
3.95-4.04 (m, 1H, H-4'), 4.09-4.18 (m, 1H, H-3'), 4.24-4.32 (m, 1H, H-2'), 4.66 (dd, 1H, 3J1 = 6.52 
Hz, 3J2 = 5.01 Hz, OH-5'), 4.89 (d, 1H, 3J = 3.96 Hz, H-1'), 5.03 (d, 1H, 3J = 6.04 Hz, OH-3'), 5.32 
(d, 1H, 3J = 5.47 Hz, OH-2'), 7.36 (dd, 1H, 3J1 = 4.91 Hz, 3J2 = 3.78 Hz, H-4''), 8.02 (dd, 1H, 3J = 
4.91 Hz, 4J = 1.13 Hz, H-3''), 8.41 (dd, 1H, 3J = 3.78 Hz, 4J = 1.13 Hz, H-5''), 8.47 (s, 1H, H-5). 
13C NMR (62.90 MHz, DMSO-d6): δ = 63.4 (CH2OH), 72.6 (CH-3'), 76.7 (CH-2'), 85.9 
(CH-4'), 86.7 (CH-1'), 111.2 (CH-5), 121.7 (q, 1J(C-F) = 275.4 Hz, CF3), 130.3 (CHAr), 132.4 (CHAr), 
134.4 (CHAr), 141.5, 155.6 (q, 2J(C-F) = 35.2 Hz, C-6), 162.6, 170.6. 
19F NMR (282.38 MHz, DMSO-d6): δ = –68.5 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 362 ([M]+, 0.51), 274 (15), 273 (100), 271 (12), 259 (29). 
HRMS (ESI): Calcd. for C14H14F3N2O4S [M+H]+: 363.06209, found: 363.06229. 
IR (ATR, cm–1): ṽ = 3511 (w), 3251 (s), 3114 (w), 2930 (w), 2878 (w), 1603 (s), 1575 (w), 
1547 (m), 1529 (m), 1504 (w), 1494 (w), 1463 (w), 1455 (w), 1418 (s), 1396 (m), 1382 (m), 1347 
(w), 1316 (w), 1290 (m), 1270 (s), 1229 (m), 1210 (m), 1168 (s), 1149 (s), 1137 (s), 1103 (s), 1092 
(s), 1074 (s), 1067 (s), 1049 (s), 1038 (s), 1020 (s), 994 (m), 984 (m), 941 (m), 930 (m), 879 (m), 
864 (m), 855 (m), 802 (m), 793 (m), 767 (m), 752 (s), 743 (m), 731 (s), 701 (s), 684 (s), 667 (m), 
631 (s), 592 (m), 568 (m), 544 (m). 
 
2-(β-D-Ribofuranosyl)-4-(heptafluoropropyl)-6-phenylpyrimidine (19c) 
 
Initial diketone was previously activated via conversion into 
corresponding α,β-unsaturated β-chloroketone: 
To a solution of 4,4,5,5,6,6,6-heptafluoro-1-phenylhexane-1,3-dione 
(2 g, 6.33 mmol, 1 eq) in chloroform (6 mL) was added 2.258 g of SOCl2 
(19.0 mmol, 3 eq), followed by the addition of DMF (0.023 g, 0.32 mmol, 
0.05 eq). The mixture was refluxed for 3 hours. After that the solvent with an excess of SOCl2 was 
evaporated, and the residue was distilled in a high vacuum to afford a green liquid consisting of 
single isomer (1.973 g, 93%). 
Into a 25-mL flask were placed 0.15 g of 1-(β-D-ribofuranosyl)formamidine (0.71 mmol, 1 
eq), 0.39 g of K2CO3 (2.82 mmol, 4 eq) and DMF (3 mL). Then 0.260 g of the previously prepared 
α,β-unsaturated β-chloroketone (0.78 mmol, 1.1 eq) was added at 0 °C and the reaction was stirred 
at this temperature for the next 2 hours. After that the mixture was allowed to stand at r.t. overnight. 
The next day the inorganic precipitate was filtered off and the filtrate was evaporated under reduced 
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pressure. The crude product was purified by column chromatography: silica gel (50 g) / EtOAc : 
CHCl3 = 1:2, then pure EtOAc (Rf = 0.38–0.48). 
Yield 0.176 g (55%), white solid, mp 124 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.39 (br s, 3H, OH), 3.74 (d, 1H, 2J = 12.27 Hz, H-5a'), 
4.04 (d, 1H, 2J = 12.27 Hz, H-5b'), 4.30 (s, 1H, H-4'), 4.42-4.52 (m, 2H, H-2', H-3'), 5.29 (d 1H, 3J 
= 2.83 Hz, H-1'), 7.48-7.62 (m, 3H, CHPh), 7.89 (s, 1H, H-5), 8.03-8.12 (m, 2H, CHPh). 
13C NMR (62.90 MHz, CDCl3): δ = 62.4 (CH2OH), 72.0 (CH-3'), 78.3 (CH-2'), 85.6 (CH-
4'), 85.9 (CH-1'), 113.9 (CH-5), 128.0 (CHAr), 129.7 (CHAr), 132.8 (CHAr), 135.3, 156.8 (t, 2J(C-F) = 
26.4 Hz, C-4), 167.6, 170.6. 
19F NMR (282.38 MHz, CDCl3): δ = –126.1 (m, CF2), –116.9 (m, CF2), –80.0 (t, J = 9.20 
Hz, CF3). 
MS (EI, 70 eV): m/z (%) = 456 ([M]+, 14), 425 (16), 407 (14), 383 (10), 379 (27), 368 (69), 
367 (100), 366 (16), 365 (46), 355 (11), 354 (45), 353 (79), 351 (16), 339 (14), 338 (31), 325 (15), 
206 (16), 128 (18), 103 (29). 
HRMS (ESI): Calcd. for C18H16F7N2O4 [M+H]+: 457.09928, found: 457.09909. 
IR (ATR, cm–1): ṽ = 3457 (s), 3409 (m), 3099 (w), 2942 (w), 1587 (s), 1542 (m), 1498 (w), 
1452 (w), 1411 (w), 1392 (w), 1376 (m), 1349 (m), 1338 (m), 1302 (w), 1278 (m), 1233 (s), 1204 
(s), 1181 (s), 1160 (m), 1127 (m), 1108 (s), 1084 (s), 1074 (s), 1055 (m), 1040 (m), 1027 (m), 1001 
(m), 983 (w), 974 (w), 961 (m), 929 (w), 917 (s), 890 (m), 874 (s), 797 (m), 776 (m), 767 (m), 744 
(s), 734 (s), 692 (s), 665 (m), 637 (s), 613 (m), 601 (m), 580 (m), 557 (m), 543 (s). 
 
2-(β-D-Ribofuranosyl)-4-(4-ethylphenyl)-6-(trifluoromethyl)pyrimidine (19d) 
 
Initial diketone was previously activated via conversion into 
corresponding α,β-unsaturated β-chloroketone: 
To a solution of 1-(4-ethylphenyl)-4,4,4-trifluorobutane-1,3-dione 
(2 g, 8.19 mmol, 1 eq) in chloroform (6 mL) was added 2.923 g of SOCl2 
(24.6 mmol, 3 eq), followed by the addition of DMF (0.03 g, 0.4 mmol, 0.05 eq). The mixture was 
refluxed for 3 hours. After that the solvent with an excess of SOCl2 was evaporated, and the residue 
was distilled in a high vacuum to afford a green liquid consisting of mixture of isomers (2.120 g, 
99%). 
Into a 25-mL flask were placed 0.2 g of 1-(β-D-ribofuranosyl)formamidine (0.94 mmol, 1 
eq), 0.26 g of K2CO3 (3.76 mmol, 4 eq), molecular sieves 4Å (0.3 g) and DMF (4 mL). Then 0.272 
g of the previously prepared α,β-unsaturated β-chloroketone (1.03 mmol, 1.1 eq) was added at 0 °C 
and the reaction was stirred at this temperature for the next 2 hours. After that the mixture was 
allowed to stand at r.t. overnight. The next day the inorganic precipitate was filtered off and the 
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filtrate was evaporated under reduced pressure. The crude product was purified by column 
chromatography: silica gel (50 g) / EtOAc : CHCl3 = 1:1 (Rf = 0.09–0.14). 
Yield 0.152 g (42%), white solid, mp 89 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.27 (t, 3H, 3J = 7.56 Hz, Et), 2.75 (q, 2H, 3J = 7.56 
Hz, Et), 3.61 (dd, 1H, 2J = 11.52 Hz, 3J = 4.53 Hz, H-5a'), 3.72 (dd, 1H, 2J = 11.52 Hz, 3J = 4.06 
Hz, H-5b'), 3.97-4.05 (m, 1H, H-4'), 4.12-4.21 (m, 1H, H-3'), 4.31-4.38 (m, 1H, H-2'), 4.71 (s, 1H, 
OH-5'), 4.97 (d, 1H, 3J = 4.34 Hz, H-1'), 5.04 (s, 1H, OH-3'), 5.31 (s, 1H, OH-2'), 7.48 (d, 2H, 3J = 
8.40 Hz, H-3'', H-5''), 8.32 (d, 2H, 3J = 8.40 Hz, H-2'', H-6''), 8.48 (s, 1H, H-5). 
13C NMR (62.90 MHz, DMSO-d6): δ = 16.2 (CH3), 29.0 (CH2), 63.1 (CH2OH), 72.5 (CH-
3'), 76.7 (CH-2'), 85.9 (CH-4'), 86.8 (CH-1'), 112.5 (CH-5), 121.7 (q, 1J(C-F) = 275.7 Hz, CF3), 128.8 
(CHAr), 129.6 (CHAr), 133.4, 149.7, 155.9 (q, 2J(C-F) = 35.1 Hz, C-6), 167.4, 170.5. 
19F NMR (282.38 MHz, DMSO-d6): δ = –68.3 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 349 (15), 348 (89), 347 (14), 332 (22), 331 (32), 329 (11), 320 
(21), 319 (100), 291 (32), 252 (27). 
HRMS (ESI): Calcd. for C18H20F3N2O4 [M+H]+: 385.1370, found: 385.1374. 
IR (ATR, cm–1): ṽ = 3313 (m), 2964 (w), 2931 (w), 2874 (w), 1595 (s), 1543 (m), 1514 (w), 
1495 (w), 1460 (w), 1435 (m), 1390 (s), 1286 (m), 1263 (s), 1209 (m), 1178 (s), 1147 (s), 1099 (s), 
1078 (s), 1049 (s), 1026 (s), 991 (s), 943 (m), 930 (m), 881 (m), 874 (m), 862 (m), 839 (s), 800 (m), 
777 (m), 762 (m), 741 (m), 706 (s), 683 (s), 658 (m), 636 (s), 581 (s), 550 (s). 
 
2-(β-D-Ribofuranosyl)-4-methyl-6-(trifluoromethyl)pyrimidine (19e) 
 
Initial diketone was previously activated via conversion into 
corresponding α,β-unsaturated β-chloroketone: 
In 15 mL of DCM were dissolved 2 g of 1,1,1-trifluoropentane-2,4-dione 
(13.0 mmol, 1 eq) and 1.233 g of DMF (16.9 mmol, 1.3 eq). Then the solution 
was cooled to –78 °C and oxalyl chloride (1.977 g, 15.6 mmol, 1.2 eq) was added. After that the 
mixture was carefully heated to r.t. (gas evaluation!) and allowed to stand at this temperature for 2 
hours. Afterwards the reaction mixture was diluted with ice water. The organic layer was separated 
and water phase was extracted twice with DCM. Combined organic layers were dried over sodium 
sulfate and evaporated. The residue was distilled in vacuum to afford a colorless liquid consisting of 
mixture of isomers (1.155 g, 52%). 
Into a 25-mL flask were placed 0.2 g of 1-(β-D-ribofuranosyl)formamidine (0.94 mmol, 1 
eq), 0.26 g of K2CO3 (3.76 mmol, 4 eq), molecular sieves 4Å (0.3 g) and DMF (4 mL). Then 0.179 
g of the previously prepared α,β-unsaturated β-chloroketone (1.03 mmol, 1.1 eq) was added at 0 °C 
and the reaction was stirred at this temperature for the next 2 hours. After that the mixture was 
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allowed to stand at r.t. overnight. The next day the inorganic precipitate was filtered off and the 
filtrate was evaporated under reduced pressure. The crude product was purified by column 
chromatography: silica gel (50 g) / EtOAc (Rf = 0.16–0.22). 
Yield 0.158 g (57%), white solid, mp 138-139 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 2.66 (s, 3H, CH3), 3.51-3.62 (m, 1H, H-5a'), 3.65-
3.74 (m, 1H, H-5b'), 3.94-4.02 (m, 1H, H-4'), 4.04-4.12 (m, 1H, H-3'), 4.19-4.26 (m, 1H, H-2'), 4.77 
(dd, 1H, 3J1 = 7.18 Hz, 3J2 = 4.16 Hz, OH-5'), 4.88 (d, 1H, 3J = 4.15 Hz, H-1'), 5.02 (d, 1H, 3J = 
5.85 Hz, OH-3'), 5.29 (d, 1H, 3J = 5.66 Hz, OH-2'), 7.94 (s, 1H, H-5). 
13C NMR (75.47 MHz, DMSO-d6): δ = 25.0 (CH3), 62.8 (CH2OH), 72.0 (CH-3'), 76.7 (CH-
2'), 85.8 (CH-4'), 86.5 (CH-1'), 116.8 (CH-5), 121.6 (q, 1J(C-F) = 275.1 Hz, CF3), 154.5 (q, 2J(C-F) = 
35.1 Hz, C-6), 170.0, 172.3. 
19F NMR (282.38 MHz, DMSO-d6): δ = –68.6 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 294 ([M]+, 0.46), 206 (11), 205 (100), 203 (17), 192 (11), 191 
(37). 
HRMS (ESI): Calcd. for C11H13F3N2NaO4 [M+Na]+: 317.07196, found: 317.07175. 
IR (ATR, cm–1): ṽ = 3321 (m), 3207 (m), 2912 (w), 1601 (m), 1564 (m), 1433 (m), 1398 (s), 
1377 (m), 1321 (m), 1308 (m), 1284 (m), 1242 (s), 1203 (m), 1171 (s), 1149 (s), 1130 (s), 1119 (s), 
1097 (s), 1084 (s), 1049 (s), 1028 (s), 1001 (m), 982 (m), 962 (m), 933 (m), 885 (s), 876 (s), 866 
(s), 804 (m), 777 (m), 750 (m), 717 (m), 696 (m), 683 (m), 644 (m), 554 (s). 
 
Methyl 2-(β-D-ribofuranosyl)-6-phenylpyrimidine-4-carboxylate (19f) 
 
Initial diketone was previously activated via conversion into 
corresponding α,β-unsaturated β-chloroketone: 
In 15 mL of DCM were dissolved 1 g of methyl 2,4-dioxo-4-
phenylbutanoate (4.84 mmol, 1 eq) and 0.745 g of DMF (10.2 mmol, 2.1 eq). 
Then the solution was cooled to –78 °C and oxalyl chloride (0.739 g, 5.82 mmol, 1.2 eq) was 
added. After that the mixture was carefully heated to r.t. (gas evaluation!) and allowed to stand at 
this temperature for 2 hours. Afterwards the reaction mixture was diluted with ice water. The 
organic layer was separated and water phase was extracted twice with DCM. Combined organic 
layers were dried over sodium sulfate and evaporated. The residue was distilled in high vacuum to 
afford a yellow liquid consisting of mixture of isomers (1.056 g, 97%). 
Into a 25-mL flask were placed 0.2 g of 1-(β-D-ribofuranosyl)formamidine (0.94 mmol, 1 
eq), 0.520 g of K2CO3 (3.76 mmol, 4 eq), molecular sieves 4Å (0.3 g) and DMF (4 mL). Then 0.232 
g of the previously prepared α,β-unsaturated β-chloroketone (1.03 mmol, 1.1 eq) was added at 0 °C 
and the reaction was stirred at this temperature for the next 2 hours. After that the mixture was 
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allowed to stand at r.t. overnight. The next day the inorganic precipitate was filtered off and the 
filtrate was evaporated under reduced pressure. The crude product was purified by column 
chromatography: silica gel (30 g) / EtOAc (Rf = 0.06–0.13). 
Yield 0.108 g (33%), white solid, mp 132-134 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.57-3.68 (m, 1H, H-5a'), 3.71-3.80 (m, 1H, H-5b'), 
4.00 (s, 3H, MeO), 4.00-4.06 (m, 1H, H-4'), 4.14-4.22 (m, 1H, H-3'), 4.30-4.37 (m, 1H, H-2'), 4.80 
(dd, 1H, 3J1 = 7.37 Hz, 3J2 = 4.35 Hz, OH-5'), 5.00 (d, 1H, 3J = 4.16 Hz, H-1'), 5.02 (d, 1H, 3J = 
6.04 Hz, OH-3'), 5.31 (d, 1H, 3J = 5.67 Hz, OH-2'), 7.59-7.70 (m, 3H, HPh), 8.28-8.35 (m, 2H, HPh), 
8.45 (s, 1H, H-5). 
13C NMR (75.47 MHz, DMSO-d6): δ = 54.0 (OMe), 63.0 (CH2OH), 72.2 (CH-3'), 76.9 (CH-
2'), 85.8 (CH-4'), 87.0 (CH-1'), 115.9 (CH-5), 128.4 (CHPh), 130.1 (CHPh), 132.8 (CHPh), 136.3, 
156.6, 165.2, 166.6, 170.3. 
MS (EI, 70 eV): m/z (%) = 245 (11), 234 (21), 233 (89), 231 (25), 220 (17), 219 (100), 217 
(14). 
HRMS (ESI): Calcd. for C17H19N2O6 [M+H]+: 347.12376, found: 347.12335. 
IR (ATR, cm–1): ṽ = 3257 (m), 2937 (w), 1732 (s), 1589 (s), 1539 (s), 1504 (w), 1497 (w), 
1452 (m), 1441 (m), 1416 (m), 1373 (s), 1336 (m), 1281 (m), 1255 (s), 1198 (s), 1149 (m), 1105 (s), 
1086 (s), 1074 (s), 1049 (s), 1028 (s), 1003 (s), 991 (m), 980 (m), 947 (s), 935 (m), 914 (m), 903 
(m), 895 (m), 868 (m), 849 (m), 802 (m), 777 (m), 768 (m), 754 (s), 721 (s), 687 (s), 633 (s), 548 
(s). 
 
2-(β-D-Ribofuranosyl)-4-(2-furyl)-6-(trifluoromethyl)pyrimidine (19g) 
 
Initial diketone was previously activated via conversion into 
corresponding α,β-unsaturated β-chloroketone: 
In 15 mL of DCM were dissolved 1 g of 4,4,4-trifluoro-1-(2-
furyl)butane-1,3-dione (4.85 mmol, 1 eq) and 0.745 g of DMF (10.2 mmol, 2.1 
eq). Then the solution was cooled to –78 °C and oxalyl chloride (0.739 g, 5.82 mmol, 1.2 eq) was 
added. After that the mixture was carefully heated to r.t. (gas evaluation!) and allowed to stand at 
this temperature for 2 hours. Afterwards the reaction mixture was diluted with ice water. The 
organic layer was separated and water phase was extracted twice with DCM. Combined organic 
layers were dried over sodium sulfate and evaporated. The residue was distilled in vacuum to afford 
a brownish liquid consisting of mixture of isomers (0.962 g, 88%). The product partially 
crystallized at r.t.. 
Into a 25-mL flask were placed 0.2 g of 1-(β-D-ribofuranosyl)formamidine (0.94 mmol, 1 
eq), 0.26 g of K2CO3 (3.76 mmol, 4 eq), molecular sieves 4Å (0.3 g) and DMF (4 mL). Then 0.232 
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g of the previously prepared α,β-unsaturated β-chloroketone (1.03 mmol, 1.1 eq) was added at 0 °C 
and the reaction was stirred at this temperature for the next 2 hours. After that the mixture was 
allowed to stand at r.t. overnight. The next day the inorganic precipitate was filtered off and the 
filtrate was evaporated under reduced pressure. The crude product was purified by column 
chromatography: silica gel (50 g) / EtOAc (Rf = 0.26–0.34). 
Yield 0.220 g (67%), white solid, mp 102-103 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.56-3.67 (m, 1H, H-5a'), 3.69-3.79 (m, 1H, H-5b'), 
3.98-4.06 (m, 1H, H-4'), 4.09-4.18 (m, 1H, H-3'), 4.24-4.32 (m, 1H, H-2'), 4.75 (dd, 1H, 3J1 = 7.18 
Hz, 3J2 = 4.35 Hz, OH-5'), 4.94 (d, 1H, 3J = 3.97 Hz, H-1'), 5.03 (d, 1H, 3J = 6.04 Hz, OH-3'), 5.36 
(d, 1H, 3J = 5.47 Hz, OH-2'), 6.87 (dd, 1H, 3J1 = 3.59 Hz, 3J2 = 1.70 Hz, H-4''), 7.72 (dd, 1H, 3J = 
3.50 Hz, 4J = 0.67 Hz, H-3''), 8.12-8.16 (m, 2H, H-5, H-5''). 
13C NMR (75.47 MHz, DMSO-d6): δ = 62.9 (CH2OH), 72.1 (CH-3'), 76.8 (CH-2'), 85.8 
(CH-4'), 86.7 (CH-1'), 110.6 (CHAr), 114.4 (CH-5), 116.9 (CHAr), 121.5 (q, 1J(C-F) = 275.3 Hz, CF3), 
148.8 (CHAr), 150.8, 155.7 (q, 2J(C-F) = 35.3 Hz, C-6), 158.2, 170.9. 
19F NMR (282.38 MHz, DMSO-d6): δ = –68.7 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 346 ([M]+, 1.14), 258 (18), 257 (100), 255 (16), 243 (50). 
HRMS (ESI): Calcd. for C14H14F3N2O5 [M+H]+: 347.08493, found: 347.08476. 
IR (ATR, cm–1): ṽ = 3356 (m), 3103 (w), 1606 (s), 1599 (s), 1543 (m), 1479 (s), 1435 (m), 
1423 (w), 1396 (m), 1371 (s), 1335 (w), 1317 (m), 1298 (m), 1267 (s), 1228 (m), 1215 (m), 1190 
(m), 1178 (s), 1153 (s), 1138 (s), 1107 (s), 1076 (s), 1057 (s), 1026 (s), 991 (s), 932 (m), 918 (w), 
891 (s), 885 (s), 874 (m), 851 (m), 808 (s), 795 (m), 768 (s), 760 (s), 743 (s), 704 (s), 687 (s), 648 
(s), 608 (s), 592 (s), 548 (s). 
 
2-(β-D-Ribofuranosyl)-4-isopropyl-6-(trifluoromethyl)pyrimidine (19h) 
 
Initial diketone was previously activated via conversion into 
corresponding α,β-unsaturated β-chloroketone: 
In 15 mL of DCM were dissolved 2 g of 1,1,1-trifluoro-5-methylhexane-
2,4-dione (10.9 mmol, 1 eq) and 1.043 g of DMF (14.3 mmol, 1.3 eq). Then the 
solution was cooled to –78 °C and oxalyl chloride (1.673 g, 13.2 mmol, 1.2 eq) was added. After 
that the mixture was carefully heated to r.t. (gas evaluation!) and allowed to stand at this 
temperature for 2 hours. Afterwards the reaction mixture was diluted with ice water. The organic 
layer was separated and water phase was extracted twice with DCM. Combined organic layers were 
dried over sodium sulfate and evaporated. The residue was distilled in vacuum to afford a colorless 
liquid consisting of mixture of isomers (1.396 g, 63%). 
Into a 25-mL flask were placed 0.2 g of 1-(β-D-ribofuranosyl)formamidine (0.94 mmol, 1 
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eq), 0.26 g of K2CO3 (3.76 mmol, 4 eq), molecular sieves 4Å (0.3 g) and DMF (4 mL). Then 0.218 
g of the previously prepared α,β-unsaturated β-chloroketone (1.03 mmol, 1.1 eq) was added at 0 °C 
and the reaction was stirred at this temperature for the next 2 hours. After that the mixture was 
allowed to stand at r.t. overnight. The next day the inorganic precipitate was filtered off and the 
filtrate was evaporated under reduced pressure. The crude product was purified by column 
chromatography: silica gel (50 g) / EtOAc (Rf = 0.31–0.39). 
Yield 0.167 g (55%), white solid, mp 65-67 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.30 (s, 3H, CH3), 1.33 (s, 3H, CH3), 3.21 (sept, 1H, 
i-Pr), 3.51-3.62 (m, 1H, H-5a'), 3.65-3.74 (m, 1H, H-5b'), 3.95-4.02 (m, 1H, H-4'), 4.07-4.15 (m, 
1H, H-3'), 4.21-4.28 (m, 1H, H-2'), 4.72 (dd, 1H, 3J1 = 7.09 Hz, 3J2 = 4.44 Hz, OH-5'), 4.90 (d, 1H, 
3J = 3.97 Hz, H-1'), 5.02 (d, 1H, 3J = 6.04 Hz, OH-3'), 5.29 (d, 1H, 3J = 5.67 Hz, OH-2'), 7.93 (s, 
1H, H-5). 
19F NMR (282.38 MHz, DMSO-d6): δ = –68.4 (s, CF3). 
13C NMR (62.90 MHz, DMSO-d6): δ = 22.2 (CH3), 22.2 (CH3), 36.5 (CHPr), 63.0 (CH2OH), 
72.3 (CH-3'), 76.9 (CH-2'), 85.8 (CH-4'), 86.8 (CH-1'), 114.8 (CH-5), 121.7 (q, 1J(C-F) = 275.3 Hz, 
CF3), 155.0 (q, 2J(C-F) = 35.1 Hz, C-6), 170.2, 180.3. 
MS (EI, 70 eV): m/z (%) = 322 ([M]+, 2.47), 245 (11), 234 (21), 233 (89), 231 (25), 220 
(18), 219 (100), 217 (14). 
HRMS (ESI): Calcd. for C13H18F3N2O4 [M+H]+: 323.12132, found: 323.12123. 
IR (ATR, cm–1): ṽ = 3317 (m), 2962 (w), 2918 (m), 2881 (w), 1601 (m), 1585 (m), 1558 (s), 
1470 (w), 1456 (w), 1431 (m), 1398 (m), 1379 (m), 1333 (s), 1302 (m), 1242 (s), 1223 (m), 1194 
(m), 1176 (s), 1138 (s), 1119 (s), 1097 (s), 1049 (s), 1028 (s), 987 (m), 953 (m), 935 (m), 903 (m), 
887 (s), 874 (s), 843 (m), 831 (m), 808 (m), 771 (s), 748 (m), 716 (s), 687 (s), 667 (s), 642 (s), 550 
(m). 
 
2-(β-D-Ribofuranosyl)-4-(2-naphthyl)-6-(trifluoromethyl)pyrimidine (19i) 
 
Initial diketone was previously activated via conversion into 
corresponding α,β-unsaturated β-chloroketone: 
To a solution of 4,4,4-trifluoro-1-(2-naphthyl)butane-1,3-dione (1 g, 
3.76 mmol, 1 eq) in chloroform (3 mL) was added 1.341 g of SOCl2 (11.3 
mmol, 3 eq), followed by the addition of DMF (0.014 g, 0.18 mmol, 0.05 eq). The mixture was 
refluxed for 3 hours. After that the solvent with an excess of SOCl2 was evaporated, and the residue 
was distilled in a high vacuum to afford a yellow liquid consisting of mixture of isomers (0.611 g, 
57%). 
Into a 25-mL flask were placed 0.2 g of 1-(β-D-ribofuranosyl)formamidine (0.94 mmol, 1 
O
OH OH
OH N N
F
F
F
Experimental	Part	
72 
eq), 0.52 g of K2CO3 (3.76 mmol, 4 eq), molecular sieves 4Å (0.3 g) and DMF (4 mL). Then 0.295 
g of the previously prepared α,β-unsaturated β-chloroketone (1.03 mmol, 1.1 eq) was added at 0 °C 
and the reaction was stirred at this temperature for the next 2 hours. After that the mixture was 
allowed to stand at r.t. overnight. The next day the inorganic precipitate was filtered off and the 
filtrate was evaporated under reduced pressure. The crude product was purified by column 
chromatography: silica gel (50 g) / CHCl3, mixture EtOAc : CHCl3 = 1:1. Rf = 0.28–0.35 (in 
EtOAc). 
Yield 0.144 g (38%), white solid, mp 192-193 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.61-3.72 (m, 1H, H-5a'), 3.72-3.82 (m, 1H, H-5b'), 
4.02-4.09 (m, 1H, H-4'), 4.18-4.25 (m, 1H, H-3'), 4.37-4.45 (m, 1H, H-2'), 4.76 (dd, 1H, 3J1 = 6.52 
Hz, 3J2 = 4.52 Hz, OH-5'), 5.04 (d, 1H, 3J = 4.34 Hz, H-1'), 5.08 (d, 1H, 3J = 6.04 Hz, OH-3'), 5.36 
(d, 1H, 3J = 5.67 Hz, OH-2'), 7.63-7.74 (m, 2H, HNaph), 8.03-8.09 (s, 1H, HNaph), 8.12-8.19 (m, 2H, 
HNaph), 8.47 (dd, 2H, 3J = 8.78 Hz, 4J = 1.79 Hz, HNaph), 8.69 (s, 1H, H-5), 9.06 (d, 1H, 4J = 1.51 Hz, 
HNaph). 
13C NMR (125.77 MHz, DMSO-d6): δ = 63.1 (CH2OH), 72.5 (CH-3'), 76.7 (CH-2'), 86.0 
(CH-4'), 86.8 (CH-1'), 113.1 (CH-5), 121.8 (q, 1J(C-F) = 275.6 Hz, CF3), 124.8 (CHAr), 128.0 (CHAr), 
128.6 (CHAr), 129.2 (CHAr), 129.7 (CHAr), 129.7 (CHAr), 130.1 (CHAr), 133.2, 133.6, 135.6, 156.0 
(q, 2J(C-F) = 35.2 Hz, C-6), 167.3, 170.6. 
19F NMR (282.38 MHz, CDCl3): δ = –68.26 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 406 ([M]+, 1.71), 371 (10), 370 (44), 341 (41), 340 (17), 318 
(17), 317 (100), 313 (11), 303 (25), 274 (14), 153 (13), 152 (13). 
HRMS (ESI): Calcd. for C20H18F3N2O4 [M+H]+: 407.12132, found: 407.12157. 
IR (ATR, cm–1): ṽ = 3479 (w), 3207 (w), 2920 (w), 1595 (m), 1585 (m), 1552 (s), 1471 (w), 
1444 (w), 1429 (m), 1390 (s), 1346 (m), 1306 (m), 1279 (m), 1265 (s), 1234 (m), 1200 (m), 1174 
(s), 1153 (s), 1138 (s), 1124 (s), 1099 (s), 1051 (s), 1034 (s), 984 (m), 962 (m), 945 (m), 930 (m), 
885 (m), 870 (s), 827 (m), 804 (m), 791 (m), 760 (s), 752 (s), 723 (m), 710 (s), 683 (s), 621 (m), 
602 (m), 569 (m), 559 (m). 
 
Methyl 2-(β-D-ribofuranosyl)-6-(2-thienyl)pyrimidine-4-carboxylate (19j) 
 
Initial diketone was previously activated via conversion into 
corresponding α,β-unsaturated β-chloroketone: 
In 15 mL of DCM were dissolved 2 g of methyl 2,4-dioxo-4-(2-
thienyl)butanoate (9.42 mmol, 1 eq) and 1.447 g of DMF (19.8 mmol, 2.1 eq). 
Then the solution was cooled to –78 °C and oxalyl chloride (1.435 g, 11.3 mmol, 1.2 eq) was 
added. After that the mixture was carefully heated to r.t. (gas evaluation!) and allowed to stand at 
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this temperature for 2 hours. Afterwards the reaction mixture was diluted with ice water. The 
organic layer was separated and water phase was extracted twice with DCM. Combined organic 
layers were dried over sodium sulfate and evaporated. The crude residue was purified via short-path 
column chromatography: silica gel (14 g) / DCM (140 mL) to give a greyish-green solid consisting 
of mixture of isomers (1.876 g, 86%). 
Into a 50-mL flask were placed 0.7 g of 1-(β-D-ribofuranosyl)formamidine (3.29 mmol, 1 
eq), 0.835 g of K2CO3 (13.2 mmol, 4 eq), molecular sieves 4Å (1.05 g) and DMF (14 mL). Then 
0.835 g of the previously prepared α,β-unsaturated β-chloroketone (3.62 mmol, 1.1 eq) was added at 
0 °C and the reaction was stirred at this temperature for the next 2 hours. After that the mixture was 
allowed to stand at r.t. overnight. The next day the inorganic precipitate was filtered off and the 
filtrate was evaporated under reduced pressure. The crude product was purified by column 
chromatography: silica gel (100 g) / EtOAc (Rf = 0.05–0.09). 
Yield 0.483 g (42%), white solid, mp 136-138 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.59-3.70 (m, 1H, H-5a'), 3.71-3.80 (m, 1H, H-5b'), 
3.97-4.05 (m, 1H, H-4'), 3.98 (s, 3H, MeO), 4.11-4.19 (m, 1H, H-3'), 4.23-4.31 (m, 1H, H-2'), 4.75 
(dd, 1H, 3J1 = 7.18 Hz, 3J2 = 4.54 Hz, OH-5'), 4.91 (d, 1H, 3J = 3.78 Hz, H-1'), 5.01 (d, 1H, 3J = 
6.04 Hz, OH-3'), 5.32 (d, 1H, 3J = 5.29 Hz, OH-2'), 7.32 (dd, 1H, 3J1 = 4.91 Hz, 3J2 = 3.78 Hz, H-
4''), 7.97 (dd, 1H, 3J = 4.91 Hz, 4J = 1.13 Hz, H-3''), 8.32 (dd, 1H, 3J = 3.78 Hz, 4J = 1.13 Hz, H-5''), 
8.38 (s, 1H, H-5). 
13C NMR (62.90 MHz, DMSO-d6): δ = 54.0 (MeO), 63.2 (CH2OH), 72.3 (CH-3'), 76.9 (CH-
2'), 85.8 (CH-4'), 86.9 (CH-1'), 114.3 (CH-5), 130.2 (CHAr), 131.5 (CHAr), 133.6 (CHAr), 141.8, 
156.2, 161.8, 165.2, 170.4. 
MS (EI, 70 eV): m/z (%) = 352 ([M]+, 0.29), 264 (11), 263 (100), 249 (19), 134 (36). 
HRMS (ESI): Calcd. for C15H17N2O6S [M+H]+: 353.08018, found: 353.08025. 
IR (ATR, cm–1): ṽ = 3225 (m), 3105 (m), 2941 (w), 1745 (w), 1716 (s), 1587 (s), 1537 (s), 
1444 (s), 1435 (s), 1410 (m), 1377 (s), 1344 (m), 1325 (m), 1300 (m), 1269 (s), 1236 (s), 1200 (s), 
1142 (m), 1101 (s), 1086 (s), 1051 (s), 1039 (s), 1022 (s), 997 (s), 989 (s), 978 (m), 932 (s), 903 
(m), 883 (m), 856 (s), 831 (m), 798 (w), 779 (m), 762 (s), 746 (s), 729 (s), 716 (s), 671 (m), 631 (s), 
611 (s), 544 (s). 
 
2-(β-D-Ribofuranosyl)-4-(4-fluorophenyl)-6-(heptafluoropropyl)pyrimidine (19k) 
 
Initial diketone was previously activated via conversion into corresponding α,β-unsaturated 
β-chloroketone: 
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To a solution of 4,4,5,5,6,6,6-heptafluoro-1-(4-
fluorophenyl)hexane-1,3-dione (1.17 g, 3.50 mmol, 1 eq) in chloroform 
(3.5 mL) was added 1.25 g of SOCl2 (10.5 mmol, 3 eq), followed by the 
addition of DMF (0.013 g, 0.18 mmol, 0.05 eq). The mixture was refluxed 
for 3 hours. After that the solvent with an excess of SOCl2 was evaporated, 
and the residue was distilled in a high vacuum to afford a yellow liquid consisting of mixture of 
isomers (0.911 g, 74%). 
Into a 25-mL flask were placed 0.2 g of 1-(β-D-ribofuranosyl)formamidine (0.94 mmol, 1 
eq), 0.52 g of K2CO3 (3.76 mmol, 4 eq) , molecular sieves 4Å (0.3 g)  and DMF (4 mL). Then 0.365 
g of the previously prepared α,β-unsaturated β-chloroketone (1.22 mmol, 1.1 eq) was added at 0 °C 
and the reaction was stirred at this temperature for the next 2 hours. After that the mixture was 
allowed to stand at r.t. overnight. The next day the inorganic precipitate was filtered off and the 
filtrate was evaporated under reduced pressure. The crude product was purified by column 
chromatography: silica gel (50 g) / EtOAc : CHCl3 = 1:2, then pure EtOAc (Rf = 0.44–0.51). 
Yield 0.219 g (49%), white solid, mp 117-118 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.54-3.64 (m, 1H, H-5a'), 3.65-3.74 (m, 1H, H-5b'), 
3.97-4.05 (m, 1H, H-4'), 4.11-4.19 (m, 1H, H-3'), 4.29-4.37 (m, 1H, H-2'), 4.68 (dd, 1H, 3J1 = 6.42 
Hz, 3J2 = 5.10 Hz, OH-5'), 4.98 (d, 1H, 3J = 4,34 Hz, H-1'), 5.06 (d, 1H, 3J = 6.04 Hz, OH-3'), 5.32 
(d, 1H, 3J = 5.48 Hz, OH-2'), 7.43-7.53 (m, 2H, H-3'', H-5''), 8.46-8.54 (m, 2H, H-2'', H-6''), 8.57 (s, 
1H, H-5). 
13C NMR (62.90 MHz, DMSO-d6): δ = 63.2 (CH2OH), 72.7 (CH-3'), 76.7 (CH-2'), 86.0 
(CH-4'), 86.8 (CH-1'), 114.3 (CH-5), 117.2 (d, 2J(C-F) = 21.9 Hz, CH-3''), 131.5 (d, 3J(C-F) = 9.2 Hz, 
CH-2''), 132.3 (d, 4J(C-F) = 2.9 Hz, C-1''), 156.2 (t, 2J(C-F) = 26.5 Hz, C-6), 165.7 (d, 1J(C-F) = 251.0 
Hz, CH-4''), 166.2, 170.4. 
19F NMR (282.38 MHz, CDCl3): δ = –125.7 (s, CF2), –115.4 (m, CF2), –107.7 (s, CFAr) –
79.7 (t, J = 9.20 Hz, CF3). 
MS (EI, 70 eV): m/z (%) = 474 ([M]+, 2.1), 386 (13), 385 (100), 371 (34), 78 (31), 63 (36). 
HRMS (ESI): Calcd. for C18H15F8N2O4 [M+H]+: 475.08986, found: 475.08976. 
IR (ATR, cm–1): ṽ = 3491 (m), 3460 (m), 3406 (m), 2947 (w), 2904 (w), 1605 (m), 1587 (s), 
1545 (m), 1512 (m), 1417 (m), 1389 (m), 1377 (m), 1348 (m), 1336 (m), 1300 (m), 1279 (m), 1230 
(s), 1203 (s), 1182 (s), 1161 (s), 1126 (s), 1109 (s), 1095 (s), 1086 (s), 1072 (s), 1053 (s), 1038 (s), 
1009 (m), 997 (m), 962 (m), 918 (s), 891 (s), 878 (m), 868 (m), 849 (s), 825 (s), 806 (m), 779 (m), 
743 (s), 725 (m), 694 (m), 662 (m), 625 (m), 611 (m), 573 (s), 559 (s), 544 (m). 
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2-(β-D-Ribofuranosyl)-6-(2-thienyl)pyrimidine-4-carboxamide (20) 
 
Methyl 2-(β-D-ribofuranosyl)-6-(2-thienyl)pyrimidine-4-carboxylate 
(0.1 g, 0.28 mmol, 1 eq) was dissolved in 0.81 mL of 7M ammonia solution in 
methanol (5.7 mmol, 20 eq) and stirred at room temperature overnight. The 
next day the solvent was evaporated under reduced pressure and the residue 
was properly dried in high vacuum to give a pure product. 
Yield 0.096 g (100%), white amorphous solid foam. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.57-3.67 (m, 1H, H-5a'), 3.67-3.77 (m, 1H, H-5b'), 
3.94-4.01 (m, 1H, H-4'), 4.15-4.23 (m, 1H, H-3'), 4.32-4.39 (m, 1H, H-2'), 4.74 (dd, 1H, 3J1 = 6.23 
Hz, 3J2 = 5.29 Hz, OH-5'), 4.90 (d, 1H, 3J = 4,54 Hz, H-1'), 4.98 (d, 1H, 3J = 5.86 Hz, OH-3'), 5.24 
(d, 1H, 3J = 5.48 Hz, OH-2'), 7.31 (dd, 1H, 3J1 = 4.91 Hz, 3J2 = 3.78 Hz, H-4''), 7.94 (dd, 1H, 3J = 
4.91 Hz, 4J = 1.13 Hz, H-3''), 8.06 (br s, 1H, NH-a), 8.26 (br s, 1H, NH-b), 8.28 (dd, 1H, 3J = 3.78 
Hz, 4J = 1.13 Hz, H-5''), 8.33 (s, 1H, H-5). 
13C NMR (75.47 MHz, DMSO-d6): δ = 63.3 (CH2OH), 72.7 (CH-3'), 76.4 (CH-2'), 85.9 
(CH-4'), 86.7 (CH-1'), 111.7 (CH-5), 130.2 (CHAr), 131.0 (CHAr), 133.1 (CHAr), 142.2, 159.1, 
161.6, 165.7, 169.2. 
MS (EI, 70 eV): m/z (%) = 337 ([M]+, 078), 301 (16), 292 (10), 249 (12), 248 (100), 234 
(27), 161 (11), 134 (52), 108 (11). 
HRMS (ESI): Calcd. for C14H16N3O5S [M+H]+: 338.08052, found: 338.08071. 
IR (ATR, cm–1): ṽ = 3306 (s), 3093 (m), 2928 (m), 2874 (m), 1682 (s), 1574 (s), 1525 (s), 
1429 (s), 1394 (s), 1344 (s), 1317 (s), 1228 (m), 1200 (m), 1095 (s), 1078 (s), 1034 (s), 991 (s), 947 
(m), 889 (s), 858 (s), 812 (m), 779 (m), 714 (s), 665 (s), 617 (s), 534 (s). 
 
2-(β-D-Ribofuranosyl)-6-(2-thienyl)pyrimidine-4-carbohydrazide (21) 
 
Methyl 2-(β-D-ribofuranosyl)-6-(2-thienyl)pyrimidine-4-carboxylate 
(0.1 g, 0.28 mmol, 1 eq) was dissolved in 2 mL of methanol. Then hydrazine 
hydrate (0.178 g, 2.84 mmol, 10 eq) was added. After few minutes a white 
precipitate begins to appear. The next day it was filtered off, washed with 
methanol and dried in high vacuum to give a pure product. 
Yield 0.083 g (83%), white solid, mp 226-228 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.56-3.66 (m, 1H, H-5a'), 3.67-3.76 (m, 1H, H-5b'), 
3.93-4.00 (m, 1H, H-4'), 4.14-4.22 (m, 1H, H-3'), 4.34-4.42 (m, 1H, H-2'), 4.74 (dd, 1H, 3J1 = 6.24 
Hz, 3J2 = 5.28 Hz, OH-5'), 4.79 (br s, 2H, NH2), 4.88 (d, 1H, 3J = 4,72 Hz, H-1'), 4.97 (d, 1H, 3J = 
5.66 Hz, OH-3'), 5.23 (d, 1H, 3J = 5.67 Hz, OH-2'), 7.31 (dd, 1H, 3J1 = 4.91 Hz, 3J2 = 3.77 Hz, H-
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4''), 7.94 (dd, 1H, 3J = 4.91 Hz, 4J = 1.13 Hz, H-3''), 8.28 (dd, 1H, 3J = 3.77 Hz, 4J = 1.13 Hz, H-5''), 
8.28 (s, 1H, H-5), 10.14 (br s, 1H, NH). 
13C NMR (75.47 MHz, DMSO-d6): δ = 63.2 (CH2OH), 72.7 (CH-3'), 76.2 (CH-2'), 86.0 
(CH-4'), 86.6 (CH-1'), 111.5 (CH-5), 130.2 (CHAr), 131.0 (CHAr), 133.2 (CHAr), 142.2, 158.6, 
161.5, 161.9, 169.0. 
MS (EI, 70 eV): m/z (%) = 452 ([M]+, 1.81), 129 (34), 115 (15), 101 (15), 98 (18), 97 (14), 
87 (23), 85 (20), 84 (19), 83 (23), 81 (11), 74 (13), 73 (87), 71 (34), 70 (15), 69 (32), 67 (13), 61 
(15), 60 (100), 59 (10), 57 (46), 56 (20), 55 (53), 45 (53), 44 (38), 43 (92), 42 (19), 41 (56), 39 (17). 
HRMS (ESI): Calcd. for C14H17N4O5S [M+H]+: 353.09142, found: 353.09165. 
IR (ATR, cm–1): ṽ = 3340 (m), 3269 (m), 3103 (m), 2922 (m), 1713 (s), 1587 (s), 1525 (s), 
1516 (s), 1464 (m), 1435 (s), 1377 (s), 1346 (m), 1302 (m), 1267 (m), 1246 (w), 1213 (m), 1194 
(m), 1178 (m), 1126 (s), 1113 (s), 1099 (m), 1088 (s), 1051 (s), 1028 (s), 987 (s), 939 (s), 920 (m), 
899 (m), 870 (m), 851 (m), 802 (w), 779 (w), 764 (s), 750 (s), 723 (s), 640 (s), 619 (s), 582 (s), 532 
(s). 
 
2-(β-D-Ribofuranosyl)-4-(2-hydroxyphenyl)-5-nitropyrimidine (23a) 
 
A sealed ACE pressure tube was charged with 0.3 g of 1-(β-D-
ribofuranosyl)formamidine (1.41 mmol, 1 eq), 0.080 g of NaOMe (1.48 mmol, 
1.05 eq), 0.008 g of AcOH (0.14 mmol, 0.1 eq), 0.143 g of NEt3 (1.41 mmol, 1 
eq) and MeOH (4.5 mL). After 3-nitro-4H-chromen-4-one (0.493 g, 1.41 
mmol, 1 eq) was added, the reaction mixture was stirred at 80 °C for 1½ hours under argon. After 
cooling to room temperature the inorganic precipitate was filtered off and the filtrate was 
evaporated under reduced pressure. The crude product was purified by column chromatography: 
silica gel (110 g) / EtOAc (Rf = 0.11–0.19). 
Yield 0.176 g (36%), yellow amorphous solid foam. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.52-3.62 (m, 1H, H-5a'), 3.62-3.72 (m, 1H, H-5b'), 
3.95-4.04 (m, 1H, H-4'), 4.07-4.16 (m, 1H, H-3'), 4.28-4.37 (m, 1H, H-2'), 4.71 (dd, 1H, 3J1 = 6.42 
Hz, 3J2 = 4.91 Hz, OH-5'), 4.97 (d, 1H, 3J = 4.72 Hz, H-1'), 5.05 (d, 1H, 3J = 5.86 Hz, OH-3'), 5.34 
(d, 1H, 3J = 5.67 Hz, OH-2'), 6.94 (dd, 1H, 3J1 = 8.12 Hz, 4J = 0.95 Hz, H-3''), 7.07 (ddd, 1H, 3J1 = 
7.65 Hz, 3J2 = 7.37 Hz, 4J = 0.95 Hz, H-5''), 7.45 (ddd, 1H, 3J1 = 8.12 Hz, 3J2 = 7.37 Hz, 4J = 1.7 
Hz, H-4''), 7.71 (dd, 1H, 3J1 = 7.65 Hz, 4J = 1.7 Hz, H-6''), 9.37 (s, 1H, H-6), 10.52 (s, 1H, OH-2''). 
13C NMR (62.90 MHz, DMSO-d6): δ = 63.0 (CH2OH), 72.5 (CH-3'), 76.9 (CH-2'), 86.1 
(CH-4'), 86.5 (CH-1'), 116.4 (CHAr), 120.7 (CHAr), 122.7, 131.5 (CHAr), 133.8 (CHAr), 144.4, 154.2 
(CHAr), 156.4, 158.2, 171.7. 
MS (EI, 70 eV): m/z (%) = 349 ([M]+, 59), 313 (16), 303 (39), 267 (10), 260 (100), 258 (12), 
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249 (14), 246 (66), 230 (13), 217 (11), 216 (10), 214 (17), 213 (46), 201 (13), 200 (30), 199 (25), 
197 (13), 186 (26), 185 (14), 173 (12), 172 (19), 171 (42), 170 (31), 169 (20), 144 (13), 116 (11), 
115 (13), 102 (11), 91 (12), 89 (24), 63 (11), 43 (15). 
HRMS (EI): Calcd. for C15H15N3O7 [M]+: 349.09045, found: 349,09066. 
IR (ATR, cm–1): ṽ = 3242 (s), 2932 (w), 2879 (w), 1606 (w), 1581 (s), 1545 (s), 1524 (m), 
1504 (w), 1453 (m), 1427 (m), 1355 (s), 1303 (m), 1265 (m), 1210 (w), 1159 (w), 1070 (s), 1080 
(s), 1047 (s), 984 (w), 943 (w), 910 (w), 888 (w), 850 (s), 807 (w), 756 (s), 706 (m), 687 (m), 665 
(m), 624 (s), 579 (m), 542 (s). 
 
2-(β-D-Ribofuranosyl)-4-(2-hydroxyphenyl)-6-methyl-5-nitropyrimidine (23b) 
 
Into a 50-mL flask were placed 0.7 g of 1-(β-D-ribofuranosyl)form-
amidine (3.29 mmol, 1 eq), 0.187 g of NaOMe (3.46 mmol, 1.05 eq), 0.018 g 
of AcOH (0.33 mmol, 0.1 eq), 0.333 g of NEt3 (3.29 mmol, 1 eq), molecular 
sieves 4Å (1.05 g) and DMF (10.5 mL). After 2-methyl-3-nitro-4H-chromen-4-
one (0.675 g, 3.29 mmol, 1 eq) was added, the reaction mixture was stirred at 70 °C for 2 hours 
under argon. After cooling to room temperature the inorganic precipitate was filtered off and the 
filtrate was evaporated under reduced pressure. The crude product was purified by column 
chromatography: silica gel (100 g) / EtOAc (Rf = 0.16–0.25). 
Yield 0.416 g (35%), yellow amorphous solid foam. 
1H NMR (300.13 MHz, DMSO-d6): δ = 2.68 (s, 3H, Me-6), 3.51-3.63 (m, 1H, H-5a'), 3.63-
3.74 (m, 1H, H-5b'), 3.96-4.04 (m, 1H, H-4'), 4.08-4.17 (m, 1H, H-3'), 4.26-4.34 (m, 1H, H-2'), 4.75 
(dd 1H, 3J1 = 4.34 Hz, 3J2 = 6.99 Hz, OH-5'), 4.92 (d 1H, 3J = 4.15 Hz, H-1'), 5.02 (d 1H, 3J = 5.86 
Hz, OH-3'), 5.34 (d 1H, 3J = 5.48 Hz, OH-2'), 6.89-6.96 (m, 1H, H-3''), 6.98-7.07 (m, 1H, H-5''), 
7.36-7.45 (m, 1H, H-4''), 7.51-7.58 (m, 1H, H-6''), 10.40 (s, 1H, OH-2''). 
13C NMR (62.90 MHz, DMSO-d6): δ = 22.7 (CH3), 62.9 (CH2OH), 72.2 (CH-3'), 76.9 (CH-
2'), 85.9 (CH-4'), 86.5 (CH-1'), 116.4 (CHAr), 120.5 (CHAr), 122.7, 131.6 (CHAr), 133.3 (CHAr), 
144.8, 156.3, 158.8, 161.4, 169.7. 
MS (EI, 70 eV): m/z (%) = 364 ([M+H]+, 14), 363 ([M]+, 78), 318 (15), 317 (83), 274 (100), 
272 (12), 260 (50), 244 (10), 228 (19), 227 (75), 215 (12), 214 (27), 213 (24), 211 (12), 200 (36), 
199 (18), 198 (11), 185 (14), 57 (10), 44 (16), 43 (11). 
HRMS (EI): Calcd. for C16H17N3O7 [M]+: 363.10610, found: 363.10664. 
IR (ATR, cm–1): ṽ = 3252 (s), 2930 (m), 1699 (w), 1606 (w), 1573 (s), 15 27 (s), 1455 (m), 
1435 (m), 1386 (w), 1354 (s), 1294 (m), 1265 (w), 1227 (w), 1153 (w), 1094 (s), 1046 (m), 972 (w), 
941 (w), 884 (m), 847 (s), 828 (w), 807 (w), 756 (s), 675 (m), 667 (m), 641 (m), 610 (m), 575 (m), 
576 (m). 
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2-(β-D-Ribofuranosyl)-4-(2-hydroxyphenyl)-6-butyl-5-nitropyrimidine (23c) 
 
Into a 50-mL flask were placed 0.65 g of 1-(β-D-ribofuranosyl)form-
amidine (3.06 mmol, 1 eq), 0.173 g of NaOMe (3.21 mmol, 1.05 eq), 0.018 
g of AcOH (0.31 mmol, 0.1 eq), 0.309 g of NEt3 (3.06 mmol, 1 eq), 
molecular sieves 4Å (0.975 g) and DMF (10 mL). After 2-butyl-3-nitro-4H-
chromen-4-one (0.756 g, 3.06 mmol, 1 eq) was added, the reaction mixture was stirred at 50 °C for 
5 hours under argon. After cooling to room temperature the inorganic precipitate was filtered off 
and the filtrate was evaporated under reduced pressure. The crude product was purified by column 
chromatography: silica gel (100 g) / EtOAc (Rf = 0.21–0.35). 
Yield 0.600 g (48%), light beige solid, mp 167-169 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 0.95 (t, 3H, 3J = 7.37 Hz, Me), 1.34-1.48 (m, 2H, 
CH2-c), 1.70-1.83 (m, 2H, CH2-b), 2.90 (t, 2H, 3J = 7.55 Hz, CH2-a), 3.51-3.62 (m, 1H, H-5a'), 
3.63-3.73 (m, 1H, H-5b'), 3.96-4.03 (m, 1H, H-4'), 4.09-4.16 (m, 1H, H-3'), 4.27-4.34 (m, 1H, H-
2'), 4.71 (dd 1H, 3J1 = 6.99 Hz, 3J2 = 4.54 Hz, OH-5'), 4.93 (d 1H, 3J = 4.16 Hz, H-1'), 5.02 (d 1H, 
3J = 6.05 Hz, OH-3'), 5.33 (d 1H, 3J = 5.47 Hz, OH-2'), 6.90-6.95 (m, 1H, H-3''), 6.98-7.05 (m, 1H, 
H-5''), 7.36-7.44 (m, 1H, H-4''), 7.49-7.54 (m, 1H, H-6''), 10.36 (s, 1H, OH-2''). 
13C NMR (62.90 MHz, DMSO-d6): δ = 14.6 (CH3), 22.8 (CH2-c), 30.7 (CH2-b), 34.1 (CH2-
a), 63.0 (CH2OH), 72.4 (CH-3'), 76.9 (CH-2'), 85.8 (CH-4'), 86.7 (CH-1'), 116.4 (CHAr), 120.5 
(CHAr), 122.6, 131.7 (CHAr), 133.2 (CHAr), 144.8, 156.2, 159.0, 164.1, 169.8. 
MS (EI, 70 eV): m/z (%) = 406 ([M+H]+, 11), 405 ([M]+, 51), 360 (15), 359 (79), 317 (16), 
316 (100), 302 (19), 269 (37), 228 (14), 214 (14). 
HRMS (EI): Calcd. for C19H23N3O7 [M]+: 405.15305, found: 405.15371. 
IR (ATR, cm–1): ṽ = 3512 (w), 3331 (m), 2956 (w), 2929 (w), 2874 (w), 2860 (w), 1614 (m), 
1595 (m), 1576 (s), 1525 (s), 1452 (s), 1417 (m), 1381 (m), 1360 (s), 1321 (m), 1294 (m), 1269 (m), 
1232 (m), 1211 (m), 1180 (w), 1155 (w), 1105 (s), 1095 (s), 1074 (s), 1047 (s), 1028 (m), 1012 (m), 
980 (m), 939 (m), 905 (w), 887 (m), 876 (m), 858 (m), 845 (s), 824 (m), 814 (m), 797 (w), 754 (s), 
737 (m), 704 (m), 692 (m), 636 (s), 602 (s), 586 (m), 555 (s), 544 (s). 
 
2-(β-D-Ribofuranosyl)-5-amino-4-(2-hydroxyphenyl)-pyrimidine (24a) 
 
Into a 25-mL flask were placed 0.118 g of 2-(β-D-ribofuranosyl)-4-(2-
hydroxyphenyl)-5-nitropyrimidine (0.34 mmol), 0.012 g of Pd/C (10 wt. %) 
and MeOH (3.5 mL). The system was washed three times with argon and 
afterwards three times with hydrogen. The reaction mixture was stirred for 2 
days at r.t. and under atmospheric pressure. As the reduction was complete (monitoring by TLC), 
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the mixture was filtered through a Celite pad (2-3 cm). The Celite was washed three times with 
MeOH. The filtrate was evaporated under reduced pressure and the residue was properly dried in 
high vacuum to give a pure product. 
Yield 0.108 g (100%), pale yellow amorphous solid foam. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.50 (dd, 1H, 2J = 11.71 Hz, 3J = 3.77 Hz, H-5a'), 
3.65 (dd, 1H, 2J = 11.71 Hz, 3J = 3.69 Hz, H-5b'), 3.88-3.97 (m, 1H, 4H'), 4.05-4.13 (m, 1H, H-3'), 
4.18-4.27 (m, 1H, H-2'), 4.76 (d, 1H, 3J = 4.54 Hz, H-1'), 4.78-5.86 (br m, 5H, OH, NH2), 6.94-7.06 
(m, 2H, CHAr), 7.31-7.79 (m, 1H, CHAr), 7.45 (dd, 1H, 3J = 7.74 Hz, 4J = 1.51 Hz, CHAr), 8.29 (s, 
1H, H-6), 10.44 (br s, 1H, OH-2''). 
13C NMR (62.90 MHz, DMSO-d6): δ = 62.9 (CH2OH), 72.2 (CH-3'), 76.6 (CH-2'), 85.4 
(CH-4'), 86.4 (CH-1'), 117.3 (CHAr), 120.3 (CHAr), 124.3, 131.4 (CHAr), 131.6 (CHAr), 140.1, 144.7 
(CHAr), 149.2, 156.0, 157.2. 
MS (EI, 70 eV): m/z (%) = 319 ([M]+, 54), 230 (100), 217 (12), 216 (83), 214 (14), 201 (10). 
HRMS (EI): Calcd. for C15H17N3O5 [M]+: 319.11627, found: 319.11684. 
IR (ATR, cm–1): ṽ = 3324 (s), 3207 (s), 2928 (m), 2873 (m), 1633 (w), 1608 (w), 1568 (m), 
1558 (m), 1549 (w), 1504 (w), 1495 (w), 1488 (w), 1447 (s), 1418 (m), 1398 (m), 1327 (m), 1295 
(m), 1249 (m), 1206 (m), 1158 (w), 1097 (s), 1082 (s), 1047 (s), 985 (m), 911 (m), 889 (m), 857 
(m), 831 (m), 799 (m), 756 (s), 700 (s), 667 (s), 633 (s), 596 (s), 534 (s). 
 
2-(β-D-Ribofuranosyl)-5-amino-6-methyl-4-(2-hydroxyphenyl)-pyrimidine (24b) 
 
Into a 50-mL flask were placed 0.25 g of 2-(β-D-ribofuranosyl)-4-(2-
hydroxyphenyl)-6-methyl-5-nitropyrimidine (0.69 mmol), 0.025 g of Pd/C (10 
wt. %) and MeOH (7.5 mL). The system was washed three times with argon 
and afterwards three times with hydrogen. The reaction mixture was stirred for 
2 days at r.t. and under atmospheric pressure. As the reduction was complete (monitoring by TLC), 
the mixture was filtered through a Celite pad (2-3 cm). The Celite was washed three times with 
MeOH. The filtrate was evaporated under reduced pressure and the residue was properly dried in 
high vacuum to give a pure product. 
Yield 0.229 g (100%), yellow amorphous solid foam. 
1H NMR (250.13 MHz, DMSO-d6): δ = 2.42 (s, 3H, CH3), 3.51 (dd, 1H, 2J = 11.62 Hz, 3J = 
3.08 Hz, H-5a'), 3.69 (dd, 1H, 2J = 11.62 Hz, 3J = 3.31 Hz, H-5b'), 3.89-3.98 (m, 1H, 4H'), 4.09-
4.16 (m, 1H, H-3'), 4.16-4.22 (m, 1H, H-2'), 4.74 (d, 1H, 3J = 3.62 Hz, H-1'), 4.40-5.80 (br m, 5H, 
OH, NH2), 6.92-7.00 (m, 1H, CHAr), 7.02 (d, 1H, 3J = 8.04 Hz, CHAr), 7.29-7.39 (m, 2H, CHAr), 
10.28 (br s, 1H, OH-2''). 
13C NMR (62.90 MHz, DMSO-d6): δ = 21.4 (CH3), 62.7 (CH2OH), 71.7 (CH-3'), 76.9 (CH-
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2'), 85.1 (CH-4'), 86.5 (CH-1'), 117.2 (CHAr), 120.2 (CHAr), 124.6, 131.2 (CHAr), 131.8 (CHAr), 
137.8, 148.3, 152.0, 155.8, 156.6. 
MS (EI, 70 eV): m/z (%) = 334 ([M+H]+, 10), 333 ([M]+, 52), 332 (17), 305 (14), 289 (21), 
265 (15), 245 (14), 244 (100), 243 (12), 242 (25), 231 (13), 230 (84), 228 (23), 225 (25), 215 (11), 
177 (11), 164 (15), 57 (57), 41 (16). 
HRMS (ESI): Calcd. for C16H20N3O5 [M+H]+: 334.13975, found: 334.13978. 
IR (ATR, cm–1): ṽ = 3334 (m), 3232 (m), 2962 (m), 2918 (m), 2872 (m), 1633 (m), 1622 
(m), 1608 (m), 1591 (m), 1564 (s), 1558 (s), 1539 (m), 1504 (m), 1495 (m), 1487 (m), 1470 (m), 
1446 (s), 1435 (s), 1429 (s), 1392 (s), 1385 (s), 1362 (s), 1344 (m), 1338 (m), 1294 (s), 1250 (m), 
1223 (s), 1194 (m), 1157 (m), 1097 (s), 1080 (s), 1047 (s), 1038 (s), 989 (m), 972 (s), 939 (s), 870 
(s), 841 (s), 816 (m), 800 (m), 756 (s), 716 (s), 673 (s), 665 (s), 621 (s), 598 (s), 540 (s). 
 
2-(β-D-Ribofuranosyl)-5-amino-6-butyl-4-(2-hydroxyphenyl)-pyrimidine (24c) 
 
Into a 50-mL flask were placed 0.2 g of 2-(β-D-ribofuranosyl)-4-(2-
hydroxyphenyl)-6-butyl-5-nitropyrimidine (0.49 mmol), 0.02 g of Pd/C (10 
wt. %) and MeOH (6 mL). The system was washed three times with argon 
and afterwards three times with hydrogen. The reaction mixture was stirred 
for 2 days at r.t. and under atmospheric pressure. As the reduction was complete (monitoring by 
TLC), the mixture was filtered through a Celite pad (2-3 cm). The Celite was washed three times 
with MeOH. The filtrate was evaporated under reduced pressure and the residue was properly dried 
in high vacuum to give a pure product. 
Yield 0.185 g (100%), pale green amorphous solid foam. 
1H NMR (250.13 MHz, DMSO-d6): δ = 0.97 (t, 3H, 3J = 7.37 Hz, Me), 1.37-1.51 (m, 2H, 
CH2-c), 1.64-1.77 (m, 2H, CH2-b), 2.75 (t, 2H, 3J = 7.46 Hz, CH2-a), 3.51 (dd, 1H, 2J = 11.43 Hz, 3J 
= 4.67 Hz, H-5a'), 3.68 (dd, 1H, 2J = 11.43 Hz, 3J = 2.93 Hz, H-5b'), 3.89-3.98 (m, 1H, 4H'), 4.09-
4.17 (m, 1H, H-3'), 4.17-4.25 (m, 1H, H-2'), 4.75 (d, 1H, 3J = 3.78 Hz, H-1'), 4.77-4.95 (br m, 3H, 
OH, NH2), 5.04-5.19 (br m, 2H, OH), 6.93-7.01 (m, 1H, CHAr), 7.03 (d, 1H, 3J = 7.55 Hz, CHAr), 
7.29-7.39 (m, 2H, CHAr), 10.27 (br s, 1H, OH-2''). 
13C NMR (75.47 MHz, DMSO-d6): δ = 14.8 (CH3), 23.0 (CH2-c), 29.3 (CH2-b), 33.0 (CH2-
a), 62.8 (CH2OH), 72.0 (CH-3'), 76.9 (CH-2'), 85.1 (CH-4'), 86.7 (CH-1'), 117.1 (CHAr), 120.3 
(CHAr), 124.7, 131.1 (CHAr), 131.8 (CHAr), 137.2, 148.7, 155.2, 155.5, 156.7. 
MS (EI, 70 eV): m/z (%) = 376 ([M+H]+, 11), 375 ([M]+, 50), 374 (13), 346 (20), 333 (100), 
287 (12), 286 (73), 284 (14), 273 (11), 272 (63), 256 (16), 243 (12), 242 (14). 
HRMS (EI): Calcd. for C19H25N3O5 [M]+: 375.17887, found: 375.17847. 
IR (ATR, cm–1): ṽ = 3342 (m), 3226 (m), 2953 (m), 2928 (m), 2866 (m), 1622 (m), 1608 
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(m), 1593 (w), 1558 (s), 1539 (m), 1504 (w), 1495 (w), 1487 (w), 1450 (s), 1429 (s), 1392 (m), 
1377 (m), 1344 (m), 1338 (m), 1294 (m), 1223 (m), 1155 (m), 1097 (s), 1080 (s), 1047 (s), 976 (m), 
937 (m), 866 (m), 845 (m), 820 (m), 806 (m), 797 (m), 756 (s), 696 (s), 673 (s), 665 (s), 621 (s), 
584 (s), 571 (s), 542 (s). 
 
2-(β-D-Ribofuranosyl)-4-phenyl-6-pyridin-3-ylpyrimidine (29a) 
 
Into a 25-mL flask were placed 0.2 g of 1-(β-D-ribofuranosyl)form-
amidine (0.94 mmol, 1 eq), 0.195 g of 1-(5-chloro-3-methyl-1-phenyl-1H-
pyrazol-4-yl)-3-phenylprop-2-yn-1-one (0.94 mmol, 1 eq), 0.26 g of K2CO3 
(1.88 mmol, 2 eq), molecular sieves 4Å (0.3 g) and DMF (4 mL). Then the 
reaction mixture was stirred at 70 °C for 4 hours under argon. After cooling to room temperature 
the inorganic precipitate was filtered off and the filtrate was evaporated under reduced pressure. 
The crude residue was purified via short-path column chromatography: silica gel (12 g) / CHCl3 (1 
L), than 1.5 L of EtOAc (Rf = 0.03–0.09). The fraction of EtOAc was evaporated to give the desired 
product. 
Yield 0.156 g (68%), yellow amorphous solid foam. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.60-3.71 (m, 1H, H-5a'), 3.72-3.81 (m, 1H, H-5b'), 
4.01-4.08 (m, 1H, H-4'), 4.21-4.29 (m, 1H, H-3'), 4.39-4.47 (m, 1H, H-2'), 4.86 (dd, 1H, 3J1 = 6.23 
Hz, 3J2 = 4.91 Hz, OH-5'), 5.02 (d, 1H, 3J = 4.15 Hz, H-1'), 5.03 (d, 1H, 3J = 5.85 Hz, OH-3'), 5.28 
(d, 1H, 3J = 5.47 Hz, OH-2'), 7.60-7.71 (m, 4H, CHPh), 8.37-8.45 (m, 2H, CHAr), 8.65 (s, 1H, H-5), 
8.69-8.75 (m, 1H, CHAr), 8.78-8.85 (m, 1H, CHAr), 9.55 (s, 1H, CHAr). 
13C NMR (62.90 MHz, DMSO-d6): δ = 63.2 (CH2OH), 72.7 (CH-3'), 76.8 (CH-2'), 85.7 
(CH-4'), 87.4 (CH-1'), 112.8 (CH-5), 124.9 (CHAr), 128.4 (CHAr), 129.9 (CHAr), 132.3 (CHAr), 
132.9, 135.8 (CHAr), 137.1, 149.6 (CHAr), 152.7 (CHAr), 163.3, 165.4, 169.9. 
IR (ATR, cm–1): ṽ = 3271 (m), 3063 (m), 2918 (m), 2872 (m), 1585 (s), 1574 (s), 1556 (m), 
1531 (s), 1504 (m), 1485 (m), 1471 (m), 1452 (m), 1427 (m), 1417 (m), 1410 (m), 1365 (s), 1331 
(m), 1294 (m), 1244 (m), 1192 (m), 1101 (s), 1078 (s), 1043 (s), 1026 (s), 1001 (s), 991 (s), 941 
(m), 876 (m), 827 (m), 818 (m), 768 (s), 743 (s), 690 (s), 665 (s), 633 (s), 540 (s). 
MS (EI, 70 eV): m/z (%) = 365 ([M]+, 9.1), 277 (29), 276 (100), 274 (14), 263 (20), 262 
(75), 248 (10), 247 (16), 234 (14), 233 (13), 105 (12), 104 (12). 
HRMS (ESI): Calcd. for C20H20N3O4 [M+H]+: 366.14483, found: 366.14506. 
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2-(β-D-Ribofuranosyl)-4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6-
phenylpyrimidine (29b) 
 
Into a 25-mL flask were placed 0.15 g of 1-(β-D-ribofuranosyl)-
formamidine (0.71 mmol, 1 eq), 0.226 g of 1-(5-chloro-3-methyl-1-
phenyl-1H-pyrazol-4-yl)-3-phenylprop-2-yn-1-one (0.71 mmol, 1 eq), 
0.215 g of K2CO3 (1.55 mmol, 2.2 eq), molecular sieves 4Å (0.225 g) 
and DMF (3 mL). Then the reaction mixture was stirred at 70 °C for 4 hours under argon. After 
cooling to room temperature the inorganic precipitate was filtered off and the filtrate was 
evaporated under reduced pressure. The crude product was purified by column chromatography: 
silica gel (50 g) / EtOAc (Rf = 0.20–0.31). 
Yield 0.175 g (52%), beige amorphous solid foam. 
1H NMR (300.13 MHz, DMSO-d6): δ = 2.59 (s, 3H, CH3), 3.55-3.66 (m, 1H, H-5a'), 3.67-
3.77 (m, 1H, H-5b'), 3.99-4.06 (m, 1H, H-4'), 4.16-4.24 (m, 1H, H-3'), 4.41-4.48 (m, 1H, H-2'), 4.83 
(dd, 1H, 3J1 = 6.71 Hz, 3J2 = 4.82 Hz, OH-5'), 4.98 (d, 1H, 3J = 4.72 Hz, H-1'), 5.02 (d, 1H, 3J = 
5.67 Hz, OH-3'), 5.24 (d, 1H, 3J = 5.66 Hz, OH-2'), 7.54-7.72 (m, 8H, CHPh), 8.20 (s, 1H, H-5), 
8.22-8.30 (m, 2H, CHp-Ph). 
13C NMR (75.47 MHz, DMSO-d6): δ = 15.1 (CH3), 63.3 (CH2OH), 72.8 (CH-3'), 76.7 (CH-
2'), 85.9 (CH-4'), 87.3 (CH-1'), 114.6 (CH-5), 116.8, 126.4 (CHAr), 127.9, 128.1 (CHAr), 129.9 
(CHAr), 130.1 (CHAr), 130.3 (CHAr), 132.2 (CHAr), 137.2, 138.3, 150.2, 160.0, 164.6, 169.6. 
MS (EI, 70 eV): m/z (%) = 478 ([M, 35Cl]+, 16), 442 (20), 413 (10), 391 (33), 390 (26), 389 
(100), 387 (16), 377 (24), 376 (24), 375 (63), 373 (17), 361 (10), 360 (15), 129 (14), 104 (10), 97 
(12), 85 (13), 84 (13), 83 (16), 77 (21), 73 (39), 71 (14), 70 (11), 69 (34), 67 (10), 60 (50), 57 (25), 
56 (14), 55 (31), 46 (12), 45 (23), 44 (72), 43 (56), 41 (29). 
HRMS (ESI): Calcd. for C25H24ClN4O4 [M+H, 35Cl]+: 479.1481, found: 479.1485; calcd. for 
C15H12ClF2N3O3 [M+H, 37Cl]+: 481.1463, found: 481.1469. 
IR (ATR, cm–1): ṽ = 3317 (m), 3130 (w), 3064 (w), 2924 (m), 1574 (s), 1547 (m), 1525 (s), 
1498 (s), 1479 (m), 1471 (m), 1462 (m), 1454 (m), 1404 (s), 1379 (m), 1346 (s), 1317 (m), 1292 
(m), 1248 (m), 1223 (m), 1190 (m), 1159 (w), 1097 (s), 1074 (s), 1047 (s), 1030 (s), 993 (m), 941 
(m), 922 (m), 876 (m), 837 (m), 822 (m), 804 (w), 762 (s), 717 (m), 690 (s), 673 (s), 654 (s), 635 
(s), 608 (m), 596 (m), 544 (m), 528 (m). 
 
2-(β-D-Ribofuranosyl)-4-methoxy-6-(trifluoromethyl)pyrimidine (31a) 
 
Into a 25-mL flask were placed 0.2 g of 1-(β-D-ribofuranosyl)formamidine (0.94 mmol, 1 
eq), 0.190 g of 4,4-dimethoxy-1,1,1-trifluoro-3-buten-2-one (1.03 mmol, 1.1 eq), 0.26 g of K2CO3 
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(1.88 mmol, 2 eq), molecular sieves 4Å (0.3 g) and DMF (4 mL). Then the 
reaction mixture was stirred at 60 °C for 5½ hours under argon. After cooling to 
room temperature the inorganic precipitate was filtered off and the filtrate was 
evaporated under reduced pressure. The crude residue was purified via short-path 
column chromatography: silica gel (10 g) / CHCl3 (400 mL), than EtOAc (Rf = 0.19–0.29). The 
fraction of EtOAc was evaporated to give the desired product. 
Yield 0.209 g (72%), white solid, mp 129 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.52-3.63 (m, 1H, H-5a'), 3.63-3.72 (m, 1H, H-5b'), 
3.92-4.00 (m, 1H, H-4'), 4.06 (s, 3H, MeO), 4.06-4.14 (m, 1H, H-3'), 4.20-4.27 (m, 1H, H-2'), 4.65 
(dd, 1H, 3J1 = 6.80 Hz, 3J2 = 4.72 Hz, OH-5'), 4.80 (d, 1H, 3J = 3.96 Hz, H-1'), 5.00 (d, 1H, 3J = 
6.04 Hz, OH-3'), 5.28 (d, 1H, 3J = 5.66 Hz, OH-2'), 7.45 (s, 1H, H-5). 
13C NMR (62.90 MHz, DMSO-d6): δ = 55.7 (MeO), 63.0 (CH2OH), 72.4 (CH-3'), 76.6 (CH-
2'), 85.7 (CH-4'), 86.6 (CH-1'), 105.3 (CH-5), 121.5 (q, 1J(C-F) = 274.6 Hz, CF3), 155.3 (q, 2J(C-F) = 
35.0 Hz), 171.0, 171.7. 
19F NMR (282.38 MHz, DMSO-d6): δ = –68.7 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 311 ([M+H]+, 1.74), 310 ([M]+, 1.25), 233 (12), 222 (16), 221 
(100), 219 (27), 208 (16), 207 (90), 205 (19), 68 (11). 
HRMS (ESI): Calcd. for C11H14F3N2O5 [M+H]+: 311.08493, found: 311.08440. 
IR (ATR, cm–1): ṽ = 3346 (m), 3159 (m), 3118 (w), 2966 (w), 2937 (w), 2908 (w), 2889 (w), 
1606 (m), 1585 (w), 1558 (m), 1504 (w), 1479 (s), 1456 (w), 1435 (m), 1383 (s), 1348 (m), 1331 
(m), 1304 (m), 1267 (m), 1225 (m), 1201 (s), 1186 (m), 1176 (m), 1151 (s), 1140 (s), 1099 (s), 1057 
(s), 1034 (s), 1026 (s), 986 (s), 957 (s), 899 (m), 879 (s), 870 (s), 839 (m), 800 (m), 768 (s), 756 (s), 
723 (m), 687 (s), 631 (s), 586 (m), 561 (m). 
 
2-(β-D-Ribofuranosyl)-4-(difluoromethyl)-6-methoxypyrimidine (31b) 
 
Into a 25-mL flask were placed 0.2 g of 1-(β-D-ribofuranosyl)form-
amidine (0.94 mmol, 1 eq), 0.188 g of 4,4-dimethoxy-1,1-difluoro-3-buten-2-one 
(1.13 mmol, 1.2 eq), 0.26 g of K2CO3 (1.88 mmol, 2 eq), molecular sieves 4Å 
(0.3 g) and DMF (4 mL). Then the reaction mixture was stirred at 60 °C for 5½ 
hours under argon. After cooling to room temperature the inorganic precipitate was filtered off and 
the filtrate was evaporated under reduced pressure. The crude residue was purified via short-path 
column chromatography: silica gel (30 g) / CHCl3 (1.2 L), than EtOAc (Rf = 0.14–0.17). The 
fraction of EtOAc was evaporated to give the desired product. 
Yield 0.205 g (75%), white solid, mp 114-115 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.52-3.63 (m, 1H, H-5a'), 3.64-3.73 (m, 1H, H-5b'), 
O
OH OH
OH N N
O
F
F
F
O
OH OH
OH N N
O
F
F
Experimental	Part	
84 
3.92-3.99 (m, 1H, H-4'), 4.02 (s, 3H, MeO), 4.07-4.14 (m, 1H, H-3'), 4.20-4.27 (m, 1H, H-2'), 4.71 
(dd, 1H, 3J1 = 6.90 Hz, 3J2 = 4.63 Hz, OH-5'), 4.78 (d, 1H, 3J = 3.96 Hz, H-1'), 4.99 (d, 1H, 3J = 
6.04 Hz, OH-3'), 5.25 (d, 1H, 3J = 5.67 Hz, OH-2'), 6.95 (t, 1H, 2J(H-F) = 54.11 Hz, CHF2), 7.15 (s, 
1H, H-5). 
13C NMR (62.90 MHz, DMSO-d6): δ = 55.3 (MeO), 63.0 (CH2OH), 72.4 (CH-3'), 76.6 (CH-
2'), 85.7 (CH-4'), 86.7 (CH-1'), 104.6 (t, 3J(C-F) = 4.6 Hz, CH-5), 113.0 (t, 1J(C-F) = 239.7 Hz, CHF2), 
161.1 (t, 2J(C-F) = 24.7 Hz, C-4), 170.4, 171.4. 
19F NMR (282.38 MHz, DMSO-d6): δ = –120.2 (s, CHF2). 
IR (ATR, cm–1): ṽ = 3340 (m), 3271 (m), 2953 (w), 2910 (m), 1606 (s), 1564 (s), 1485 (m), 
1471 (s), 1435 (m), 1381 (s), 1360 (m), 1338 (m), 1321 (m), 1296 (m), 1282 (m), 1228 (w), 1200 
(m), 1184 (m), 1171 (m), 1122 (s), 1099 (s), 1088 (s), 1076 (s), 1045 (s), 1026 (s), 991 (s), 982 (s), 
964 (s), 943 (m), 933 (s), 903 (m), 879 (m), 864 (s), 824 (m), 808 (m), 791 (m), 768 (m), 752 (m), 
727 (m), 700 (s), 675 (m), 627 (m), 598 (m), 577 (s), 559 (s). 
MS (GC, 70 eV): m/z (%) = 203 (100), 201 (15), 189 (51), 187 (12), 31 (13). 
HRMS (EI): Calcd. for C11H14N2O5F2 [M]+: 292.08653, found: 292.08698. 
 
2-(β-D-Ribofuranosyl)-(5Z)-5-benzylidene-5H-chromeno[4,3-d]pyrimidine (38a) 
 
Into a 25-mL flask were placed 0.15 g of 1-(β-D-ribofuranosyl)form-
amidine (0.71 mmol, 1 eq), 0.174 g of 3-(phenylethynyl)-4H-chromen-4-one 
(0.71 mmol, 1 eq), 0.293 g of K2CO3 (2.1 mmol, 3 eq), molecular sieves 4Å 
(0.225 g) and DMF (3 mL). Then the reaction mixture was stirred at 60 °C for 
6 hours under argon. After cooling to room temperature the inorganic 
precipitate was filtered off and the filtrate was evaporated under reduced 
pressure. The crude product was recrystallized from MeOH to afford a pure substance. 
Yield 0.237 g (83%), yellow solid, mp 204-206 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.56-3.69 (m, 1H, H-5a'), 3.70-3.81 (m, 1H, H-5b'), 
3.97-4.06 (m, 1H, H-4'), 4.12-4.22 (m, 1H, H-3'), 4.28-4.37 (m, 1H, H-2'), 4.84-4.95 (m, 2H, H-1', 
OH-5'), 5.03 (d, 1H, 3J = 6.05 Hz, OH-3'), 5.29 (d, 1H, 3J = 5.67 Hz, OH-2'), 6.77 (s, 1H, =CH–Ph), 
7.23-7.38 (m, 3H, CHAr), 7.41-7.51 (m, 2H, CHAr), 7.56-7.65 (m, 1H, CHAr), 7.89 (d 1H, 3J = 7.55 
Hz, CHAr), 8.20-8.27 (m, 1H, CHAr), 9.34 (s, 1H, H-6). 
13C NMR (62.90 MHz, DMSO-d6): δ = 63.1 (CH2OH), 72.4 (CH-3'), 76.8 (CH-2'), 85.7 
(CH-4'), 86.9 (CH-1'), 106.5 (CH), 117.5 (CH), 118.9, 120.3, 124.6 (CHAr), 125.2 (CHAr), 127.9 
(CHAr), 129.5 (CHAr), 129.8 (CHAr), 135.1 (CHAr), 135.4, 144.2, 152.4, 154.3 (CHAr), 155.5, 169.2. 
MS (EI, 70 eV): m/z (%) = 405 ([M+H]+, 64), 404 ([M]+, 100), 368 (20), 316 (56), 315 (99), 
314 (51), 313 (30), 302 (50), 301 (88), 300 (15), 299 (12), 286 (23), 285 (32), 273 (13), 272 (11), 
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271 (32), 256 (11), 247 (16)m 246 (78), 206 (15), 189 (12), 128 (12), 73 (11), 44 (16), 43 (14). 
HRMS (ESI): Calcd. for C23H21N2O5 [M+H]+: 405.14450, found: 405.14481. 
IR (ATR, cm–1): ṽ = 3273 (s), 3064 (m), 2916 (m), 2871 (w), 1658 (w), 1644 (w), 1607 (m), 
1595 (m), 1573 (m), 1543 (m), 1494 (w), 1461 (m), 1447 (m), 1424 (m), 1415 (m), 1392 (w), 1331 
(m), 1316 (m), 1281 (m), 1242 (m), 1210 (w), 1189 (w), 1161 (w), 1098 (s), 1052 (s), 1043 (s), 
1019 (m), 985 (m), 942 (w), 908 (m), 865 (m), 837 (w), 825 (w), 813 (w), 792 (w), 759 (s), 746 (s), 
731 (m), 716 (m), 687 (s), 675 (m), 665 (m), 639 (s), 627 (s), 606 (m), 551 (m). 
 
4.2.2 Synthesis of 3-acyl-4-chlorocoumarines 
 
4-Chloro-3-(trifluoroacetyl)coumarin (74a) 
 
Procedure for the synthesis of compound 4a. Synthesis was conducted in 
a pressure tube. To the suspension of 4-hydroxycoumarin (2.5 g, 15.4 mmol) in 
dry dioxane (20 mL) was added 2.56 g (32.4 mmol) of dry pyridine. After a 
brief stirring, when the mixture became completely homogeneous, were added 2.01 g (18.5 mmol) 
of trimethylsilyl chloride. The reaction mixture was stirred for 1 h at room temperature. Then was 
added 4.21 g (20.0 mmol) of trifluoroacetic anhydride and the mixture was stirred for another 2 h at 
80-90 °C. To the cooled reaction mass was added 2.36 g (15.4 mmol) of phosphorus oxychloride 
and the mixture was stirred for 2 h at 60 °C. Then the reaction mass was diluted with ice water and 
extracted with chloroform (50 ml), the chloroform layer was separated, and the water phase was 
extracted two times with chloroform (50 ml). The combined extract was dried under sodium 
sulphate, chloroform was removed and the residue was dried in a high vacuum on a boiling water 
bath. Yield 3.94 g (93%). To obtain product of extra high purity sublimation in vacuum was used. 
In this case, the yield is 3.29 g (77%). 
White solid, mp 115-117 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 7.43 (d, 1H, 3J = 8.31 Hz, H-8), 7.44-7.52 (m, 1H, H-
6), 7.72-7.80 (m, 1H, H-7), 7.98 (d, 1H, 3J = 8.12 Hz, H-5). 
13C NMR (75.47 MHz, CDCl3): δ = 115.2 (q, 1J(C-F) = 290.7, CF3), 117.2, 117.7 (CH-8), 
121.1, 126.1 (CH-6), 127.0 (CH-5), 135.9 (CH-7), 150.6, 153.2, 156.2, 181.2 (q, 2J(C-F) = 40.8, CO). 
19F NMR (282.38 MHz, CDCl3): δ = –75.8 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 276 ([M]+, 35Cl, 11), 209 (34), 208 (11), 207 (100), 135 (20), 
123 (16), 69 (15), 62 (11). 
HRMS (EI): Calcd. for C11H435ClF3O23 [M]+: 275.97956, found: 275.97919. 
IR (ATR, cm–1): ṽ = 3086 (w), 3051 (w), 1728 (s), 1605 (s), 1593 (m), 1566 (m), 1549 (s), 
1539 (s), 1479 (m), 1452 (s), 1333 (m), 1315 (s), 1275 (m), 1236 (m), 1196 (s), 1169 (s), 1155 (s), 
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1134 (s), 1072 (s), 1034 (m), 974 (s), 959 (s), 851 (s), 820 (s), 781 (m), 768 (s), 743 (s), 723 (s), 658 
(s), 625 (m), 606 (m), 600 (m), 582 (s), 573 (s). 
 
4-Chloro-3-[chloro(difluoro)acetyl]coumarin (74b) 
 
The title substance was prepared starting from 0.5 g of 4-
hydroxycoumarin, 0.512 g of pyridine, 0.402 g of TMSCl, 0.974 g of 
chlorodifluoroacetic anhydride, 0.473 g of POCl3 and 4 mL of dioxane, using 
the same procedure as in case of 74a. Yield of crude product and purified by sublimation is 0.781 g 
(86%) and 0.631 g (70%) respectively. White solid, mp 82-84 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 7.44 (d, 1H, 3J = 8.31 Hz, H-8), 7.44-7.51 (m, 1H, H-
6), 7.72-7.79 (m, 1H, H-7), 7.98 (d, 1H, 3J = 8.12 Hz, H-5). 
13C NMR (62.90 MHz, CDCl3): δ = 117.3, 117.7 (CH-8), 119.6 (t, 1J(C-F) = 305.2, CClF2), 
121.5, 126.1 (CH-6), 126.9 (CH-5), 135.7 (CH-7), 150.2, 153.1, 156.2, 181.7 (t, 2J(C-F) = 34.9, CO). 
19F NMR (282.38 MHz, CDCl3): δ = –64.3 (s, CF2Cl). 
MS (GC, 70 eV): m/z (%) = 292 ([M]+, 35Cl2, 2.1), 209 (33), 308 (11), 207 (100), 135 (19), 
123 (19), 99 (10), 87 (10), 85 (11), 62 (11). 
HRMS (EI): Calcd. for C11H435Cl2F2O23 [M]+: 291.95001, found: 291.94975. 
IR (ATR, cm–1): ṽ = 3080 (w), 1747 (s), 1714 (s), 1682 (m), 1599 (s), 1566 (s), 1556 (m), 
1539 (m), 1504 (m), 1481 (m), 1452 (s), 1317 (s), 1294 (m), 1246 (w), 1230 (w), 1198 (s), 1165 (s), 
1132 (s), 1084 (m), 1034 (m), 976 (s), 962 (s), 922 (s), 901 (s), 870 (m), 851 (s), 810 (m), 785 (s), 
771 (s), 758 (s), 714 (s), 648 (s), 633 (s), 611 (m), 581 (s), 571 (s), 544 (m). 
 
4-Chloro-3-(methoxalyl)coumarin (74c) 
 
To a suspension of 4-hydroxycoumarin (15 g, 93 mmol, 1 eq) in 120 
mL of dry dioxane was added dry pyridine (15.366 g, 194 mol, 2.1 eq). After 
a brief stirring, when the solution became completely homogeneous, 
trimethylsilyl chloride (12.06 g, 111 mmol, 1.2 eq) was added. The reaction mixture was stirred for 
1 h at room temperature, followed by addition of methyl oxalyl chloride (14.733 g, 120 mmol, 1.3 
eq). After stirring for ½ h at 80-90 °C the mixture was cooled to r.t. and 14.184 g of phosphorus 
oxychloride (93 mmol, 1 eq) was added. Then the mixture was stirred for 2 h at 60 °C. Afterwards 
the reaction mass was diluted with ice water and the product was extracted with chloroform. The 
combined extract was dried under sodium sulphate, chloroform was evaaporated and the residue 
was recrystallized from benzene to give 17.76 g of the pure product. 
Yield 17.76 g (72%), beige solid, mp 110-112 °C. 
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1H NMR (300.13 MHz, CDCl3): δ = 3.96 (s, 3H, MeO), 7.42 (d, 1H, 3J = 8.31 Hz, H-8), 
7.43-7.50 (m, 1H, H-6), 7.70-7.78 (m, 1H, H-7), 8.04 (d, 1H, 3J = 8.12 Hz, H-5). 
13C NMR (62.90 MHz, CDCl3): δ = 53.8 (MeO), 117.6 (CH-8), 118.1, 121.8, 126.0 (CH-6), 
127.4 (CH-5), 135.6 (CH-7), 151.7, 153.1, 157.9, 161.5, 181.9 (CO). 
MS (GC, 70 eV): m/z (%) = 266 ([M]+, 35Cl, 2.4), 209 (34), 208 (11), 207 (100), 135 (16), 
123 (19). 
HRMS (ESI): Calcd. for C12H835ClO5 [M+H]+: 267.00548, found: 267.00565. 
IR (ATR, cm–1): ṽ = 3091 (w), 1761 (s), 1713 (s), 1699 (s), 1668 (s), 1651 (m), 1633 (m), 
1603 (s), 1587 (s), 1549 (s), 1539 (s), 1520 (s), 1504 (s), 1481 (m), 1450 (s), 1435 (s), 1365 (m), 
1335 (m), 1313 (s), 1294 (s), 1259 (s), 1238 (s), 1205 (s), 1159 (m), 1136 (m), 1105 (m), 1088 (s), 
1036 (s), 1003 (s), 960 (s), 881 (m), 856 (s), 835 (m), 814 (m), 793 (m), 779 (s), 762 (s), 741 (s), 
733 (s), 683 (m), 662 (s), 650 (m), 611 (s), 604 (m), 584 (s), 557 (m). 
 
4.2.3 Synthesis of fused pyridines from 4-chloro-3-(trifluoroacetyl)coumarin 
 
9,11-Dimethyl-7-(trifluoromethyl)-6H-chromeno[3',4':5,6]pyrido[2,3-d]pyrimidine-
6,8,10(9H,11H)-trione (77a) 
 
A sealed ACE pressure tube was charged with 0.3 g of 4-chloro-3-
(trifluoroacetyl)coumarin 74a (1.09 mmol, 1 eq), 0.169 g of 6-amino-1,3-
dimethyluracil, 5 mL of dry DMF and 1 mL of trimethylsilyl chloride. The 
reaction mixture was stirred at 80 °C for 4 h, cooled to r.t. and diluted with 
methanol. The precipitate was filtered off, washed twice with methanol and dried in a high vacuum. 
Yield 0.3 g (73%), white solid, mp 267-269 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.41 (s, 3H, CH3-9), 3.70 (s, 3H, CH3-11), 7.30-7.38 
(m, 1H, H-2), 7.47 (d, 1H, 3J = 8.31 Hz, H-4), 7.70-7.78 (m, 1H, H-3), 8.32 (d, 1H, 3J = 8.12 Hz, H-
1). 
13C NMR (75.47 MHz, 12% TFA-d in CDCl3): δ = 30.3 (CH3), 31.6 (CH3), 105.8, 112.4, 
114.9, 117.8 (CHAr), 120.3 (q, 1J(C-F) = 276.8, CF3), 124.7 (CHAr), 131.3 (CHAr), 136.0 (CHAr), 
151.3, 152.0, 152.5, 153.5, 153.6 (q, 2J(C-F) = 37.9), 157.7, 160.8. 
19F NMR (282.38 MHz, CDCl3): δ = –64.3 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 377 ([M]+, 49), 376 (100). 
HRMS (ESI): Calcd. for C17H11F3N3O4 [M+H]+: 378.06962, found: 378.06916. 
Anal. Calcd for C17H10F3N3O4: C, 54.12; H, 2.67; N, 11.14. Found: C, 54.07; H, 2.59; N, 
10.89. 
IR (ATR, cm–1): ṽ = 2960 (w), 1757 (m), 1714 (s), 1660 (s), 1606 (m), 1589 (s), 1564 (s), 
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1552 (s), 1462 (s), 1412 (m), 1396 (m), 1365 (m), 1323 (w), 1308 (m), 1288 (m), 1244 (s), 1230 (s), 
1215 (s), 1194 (s), 1173 (s), 1155 (s), 1134 (s), 1082 (m), 1059 (m), 1047 (m), 1011 (s), 970 (m), 
935 (m), 891 (m), 872 (w), 833 (w), 824 (m), 775 (s), 760 (m), 748 (m), 733 (s), 692 (m), 685 (m), 
660 (m), 642 (m), 623 (m), 609 (w), 569 (w), 542 (w). 
 
8-methyl-10-phenyl-7-(trifluoromethyl)chromeno[4,3-b]pyrazolo[4,3-e]pyridin-6(10H)-
one (77b) 
 
This product was prepared following the same procedure used for 74a, 
starting from 0.3 g of 4-chloro-3-(trifluoroacetyl)coumarin (1.09 mmol, 1 eq), 
0.188 g of 5-amino-3-methyl-1-phenyl-1H-pyrazol (1.09 mmol, 1 eq) and 1 mL 
of TMSCl in 5 mL of DMF. 
Yield 0.219 g (51%), yellow solid, mp 219 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 1H NMR (300.13 MHz, DMSO-d6): δ = 2.76 (s, 3H, 
6J(H-F) = 3.72 Hz, CH3-8), 7.33 (d, 1H, 3J = 8.31 Hz, H-4), 7.35-7.43 (m, 2H, H-2, CHp-Ph), 7.54-
7.63 (m, 3H, H-3, CHPh), 8.22-8.29 (m, 2H, CHPh), 8.52 (d, 1H, 3J = 8.03 Hz, H-1). 
13C NMR (75.47 MHz, CDCl3): δ = 17.2 (q, 6J(C-F) = 6.89, CH3), 109.9, 115.2, 117.2 (CHAr), 
118.8, 121.8 (CHAr), 122.3 (q, 1J(C-F) = 275.8, CF3), 125.1 (CHAr), 126.0 (CHAr), 127.2 (CHAr), 
129.5 (CHAr), 133.6 (CHAr), 137.0 (q, 2J(C-F) = 36.8), 138.5, 144.3, 152.2, 152.4, 152.9, 157.8. 
19F NMR (282.38 MHz, CDCl3): δ = –55.0 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 396 ([M+H]+, 23), 395 ([M]+, 100), 394 (12). 
HRMS (ESI): Calcd. for C21H13F3N3O2 [M+H]+: 396.09544, found: 396.09499. 
Anal. Calcd for C21H12F3N3O2: C, 63.80; H, 3.06; N, 10.63. Found: C, 63.44; H, 2.98; N, 
10.42. 
IR (ATR, cm–1): ṽ = 3072 (w), 1738 (s), 1614 (w), 1593 (m), 1568 (s), 1516 (w), 1498 (s), 
1466 (m), 1443 (m), 1419 (s), 1390 (m), 1365 (m), 1340 (m), 1323 (w), 1275 (m), 1261 (w), 1242 
(s), 1213 (s), 1174 (s), 1136 (s), 1117 (s), 1097 (m), 1074 (s), 1036 (m), 1020 (m), 1003 (w), 991 
(m), 955 (w), 906 (w), 887 (m), 858 (w), 835 (w), 814 (w), 797 (m), 768 (s), 752 (s), 731 (s), 714 
(m), 687 (s), 677 (m), 656 (s), 648 (m), 631 (m), 598 (w), 584 (m), 546 (w), 536 (m), 528 (w). 
 
4.2.4 Synthesis of 6-amino-1,3-dialkylpyrimidine-2,4(1H,3H)-diones 
 
General procedure for the synthesis of 6-amino-1,3-dialkylpyrimidine-2,4(1H,3H)-
diones 70. 
Method A (for simple anilines): 
In a Schlenk tube were placed 1 eq of 6-chloro-1,3-dialkyluracil and 2,2 eq of amine. Then 
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the reaction mass was heated under argon at 180 °C for 3 hours. After cooling to 100 °C the mixture 
was treated by hot water, cooled to r.t. and triturated with diethyl ether. The formed solid was 
filtered off by suction, washed twice with water and diethyl ether and dried in a high vacuum. 
Method B (for anilines with two amino groups): 
In a Schlenk tube were placed 1 eq of amine and 1.2 eq of 6-chloro-1,3-dimethyluracil 
(molar ratio = 1 : 2.4). Then 1 eq of quinoline was added and the reaction mass was heated under 
argon at 180 °C for 3 hours. After cooling to 70 °C the mixture was treated by hot ethanol and 
boiled few minutes under reflux. The precipitate was filtered off by suction, washed twice with 
ethanol and dried in a high vacuum. 
Method C (for inactive amines): 
In a Schlenk flask was prepared solution of amine (2.2 eq) in dry THF. Then 2.2 eq of n-
butyl lithium (2.5 M solution in hexane) was added at –78 °C under argon. To obtained lithium salt 
previously prepared solution of 6-chloro-1,3-dialkyluracil (1 eq) in THF was added dropwise and 
afterwards the reaction mixture was allowed to warm to r.t.. The next day the solution was acidified 
with acetic acid and the solvent was evaporated. The solid rest was triturated with water and diethyl 
ether, filtered off by suction, washed twice and dried in a high vacuum. 
 
6-[(4-Methoxyphenyl)amino]-1,3-dipropylpyrimidine-2,4(1H,3H)-dione (70a) 
 
The product was prepared according to the Method A, starting from 1.2 
g of 6-chloro-1,3-dipropyluracil and 1.409 g of p-anisidine. 
Yield 1.133 g (69%), pinkish solid, mp 109-111 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 0.86 (t, 3H, 3J = 6.99 Hz), 0.95 (t, 
3H, 3J = 7.09 Hz), 1.46-1.82 (m, 4H, CH2), 3.68-3.88 (m, 5H, CH2, MeO), 3.96 (t, 1H, 3J = 6.99 
Hz), 4.66 (s, 1H, H-5), 6.78 (br s, 1H, NH), 6.84 (d, 2H, 3J = 6.84 Hz, CHPh), 7.01 (d, 2H, 3J = 6.84 
Hz, CHPh). 
13C NMR (75.48 MHz, CDCl3): δ = 11.4 (CH3), 11.6 (CH3), 21.4 (CH2), 21.9 (CH2), 42.9 
(CH2), 44.2 (CH2), 55.8 (MeO), 78.1 (CH-5), 115.1 (CHAr), 128.0 (CHAr), 129.8, 151.9, 153.8, 
158.7, 163.3. 
MS (GC, 70 eV): m/z (%) = 318 ([M+H]+, 19), 317 ([M]+, 99), 275 (46), 274 (49), 260 (12), 
233 (20), 190 (31), 189 (20), 175 (17), 174 (20), 162 (22), 153 (10), 149 (18), 148 (25), 147 (27), 
146 (15), 134 (13), 133 (18), 132 (18), 123 (100), 121 (13), 108 (16), 77 (11), 68 (15), 43 (15), 41 
(19). 
HRMS (ESI): Calcd. for C17H24N3O3 [M+H]+: 318.18122, found: 318.18072. 
IR (ATR, cm–1): ṽ = 3273 (w), 2958 (m), 2875 (w), 2837 (w), 1687 (s), 1606 (s), 1587 (s), 
1531 (s), 1506 (s), 1479 (s), 1456 (s), 1437 (s), 1412 (s), 1392 (s), 1379 (s), 1360 (s), 1335 (m), 
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1319 (m), 1286 (s), 1267 (m), 1242 (s), 1205 (m), 1178 (s), 1165 (s), 1105 (m), 1049 (m), 1032 (s), 
1011 (m), 937 (m), 895 (m), 878 (m), 831 (m), 777 (s), 764 (s), 750 (s), 737 (s), 712 (m), 673 (m), 
644 (m), 629 (s), 552 (s). 
 
6-(2,3-Dihydro-1H-indol-1-yl)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (70b) 
 
The product was prepared according to the Method A, starting from 0.7 g of 
6-chloro-1,3-dimethyluracil and 1.051 g of indoline. 
Yield 0.714 g (69%), white solid, mp 148-149 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.15 (t, 2H, 3J = 7.93 Hz, CH2-3'), 3.36 
(s, 3H, CH3), 3.40 (s, 3H, CH3), 3.77 (t, 2H, 3J = 7.93 Hz, CH2-2'), 5.56 (s, 1H, H-5), 6.67 (d, 1H, 3J 
= 7.93 Hz, H-7'), 6.89-6.98 (m, 1H, H-5'), 7.09-7.18 (m, 1H, H-6'), 7.23 (d, 1H, 3J = 7.37 Hz, H-4'). 
13C NMR (75.48 MHz, CDCl3): δ = 28.2 (CH3), 29.1 (CH2-3'), 33.6 (CH3), 54.3 (CH2-2'), 
89.7 (CH-5), 112.8 (CHAr), 122.6 (CHAr), 125.7 (CHAr), 127.8 (CHAr), 131.9, 145.6, 153.2, 154.5, 
163.6. 
MS (GC, 70 eV): m/z (%) = 258 ([M+H]+, 15), 257 ([M]+, 100), 256 (19), 119 (50), 118 
(31), 117 (10), 82 (47). 
HRMS (EI): Calcd. for C14H15N3O2 [M]+: 257.11588, found: 257.11583. 
IR (ATR, cm–1): ṽ = 3049 (w), 2949 (w), 2860 (w), 1695 (s), 1651 (s), 1635 (s), 1614 (s), 
1605 (s), 1591 (s), 1504 (w), 1485 (s), 1435 (s), 1381 (m), 1362 (m), 1354 (m), 1336 (m), 1302 (m), 
1292 (m), 1265 (s), 1230 (m), 1217 (m), 1169 (m), 1159 (w), 1149 (w), 1093 (w), 1065 (w), 1047 
(w), 1024 (w), 989 (m), 937 (w), 924 (w), 879 (w), 868 (w), 827 (w), 806 (w), 797 (s), 756 (s), 748 
(s), 725 (m), 716 (m), 694 (m), 683 (m), 671 (m), 604 (w), 554 (m), 538 (m). 
 
6-(3,4-Dihydroquinolin-1(2H)-yl)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (70c) 
 
The product was prepared according to the Method C, using a solution of 1,2,3,4-
tetrahydroquinoline (1.846 g) in dry THF (22 mL), 5.5 mL of n-butyl lithium (2.5 M solution in 
hexane) and a solution of 6-chloro-1,3-dimethyluracil (1.1 g) in dry THF (22 mL). 
Yield 1.494 g (87%), brownish oil. 
1H NMR (300.13 MHz, CDCl3): δ = 2.00-2.13 (m, 2H, CH2-3'), 2.86 (t, 2H, 
3J = 6.71 Hz, CH2-4'), 3.25 (s, 3H, CH3), 3.37 (s, 3H, CH3), 3.46 (t, 2H, 3J = 5.86 
Hz, CH2-2'), 5.51 (s, 1H, H-5), 6.55 (d, 1H, 3J = 8.12 Hz, H-8'), 6.86-6.96 (m, 1H, 
H-6'), 7.01-7.09 (m, 1H, H-7'), 7.11 (d, 1H, 3J = 7.74 Hz, H-5'). 
13C NMR (62.90 MHz, DMSO-d6): δ = 22.5 (CH2), 26.8 (CH2), 28.3 (CH3), 32.5 (CH3), 
49.8 (CH2-2'), 95.3 (CH-5), 117.7 (CHAr), 122.3 (CHAr), 126.5, 127.3 (CHAr), 130.0 (CHAr), 141.3, 
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153.1, 156.3, 163.6. 
MS (GC, 70 eV): m/z (%) = 272 ([M+H]+, 16), 271 ([M]+, 100), 270 (69), 254 (34), 186 
(12), 185 (55), 133 (19), 132 (35), 130 (21), 117 (27), 82 (58), 77 (11). 
HRMS (ESI): Calcd. for C15H18N3O2 [M+H]+: 272.13935, found: 272.13934. 
IR (ATR, cm–1): ṽ = 2932 (m), 2859 (w), 1697 (m), 1644 (s), 1615 (s), 1598 (s), 1587 (s), 
1491 (s), 1425 (s), 1389 (m), 1368 (m), 1296 (m), 1253 (m), 1229 (m), 1192 (m), 1171 (m), 1114 
(w), 1072 (w), 1020 (w), 996 (m), 941 (w), 910 (w), 888 (w), 875 (w), 850 (w), 806 (m), 749 (s), 
716 (m), 700 (m), 690 (m), 654 (w), 645 (w), 596 (w), 547 (m). 
 
1,3-Dimethyl-6-[(3-methyl-1-phenyl-1H-pyrazol-5-yl)amino]pyrimidine-2,4(1H,3H)-
dione (70d) 
 
The product was prepared according to the Method C, using a solution of 
5-amino-3-methyl-1-phenylpyrazole (0.764 g) in dry THF (7 mL), 1.76 mL of n-
butyl lithium (2.5 M solution in hexane) and a solution of 6-chloro-1,3-
dimethyluracil (0.35 g) in dry THF (7 mL). 
Yield 0.51 g (82%), white solid, mp 125-126 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 2.32 (s, 3H, CH3-3'), 3.10 (s, 3H, CH3), 3.39 (s, 3H, 
CH3), 4.38 (s, 1H, H-5), 6.36 (s, 1H, H-4'), 7.34-7.42 (m, 1H, CHp-Ph), 7.46-7.60 (m, 4H, CHPh), 
8.83 (br s, 1H, NH). 
13C NMR (75.48 MHz, DMSO-d6): δ = 14.8 (CH3-3'), 28.2 (CH3), 30.9 (CH3), 78.0 (CH-5), 
105.9, 123.6 (CHPh), 128.1 (CHPh), 130.1 (CHPh), 136.5, 139.2, 149.4, 152.1, 153.8, 162.3. 
MS (GC, 70 eV): m/z (%) = 312 ([M+H]+, 19), 311 ([M]+, 100), 184 (18), 82 (13), 77 (23), 
55 (19). 
HRMS (ESI): Calcd. for C16H18N5O2 [M+H]+: 312.14550, found: 312.14612. 
IR (ATR, cm–1): ṽ = 3452 (w), 3331 (w), 3138 (w), 3030 (w), 2902 (w), 1701 (s), 1651 (s), 
1633 (s), 1605 (s), 1593 (s), 1549 (s), 1497 (s), 1471 (s), 1435 (s), 1417 (s), 1381 (s), 1362 (m), 
1313 (m), 1286 (m), 1230 (m), 1198 (m), 1173 (m), 1144 (m), 1076 (m), 1049 (w), 1022 (m), 1014 
(m), 995 (m), 908 (w), 854 (w), 837 (w), 798 (w), 783 (s), 752 (s), 743 (s), 712 (m), 692 (s), 667 
(m), 650 (m), 619 (s), 602 (s), 575 (s). 
 
1,3-Dimethyl-6-{[3-(trifluoromethyl)phenyl]amino}pyrimidine-2,4(1H,3H)-dione (70e) 
 
The product was prepared according to the Method A, starting from 1.1 g of 6-chloro-1,3-
dimethyluracil and 2.233 g of 3-(trifluoromethyl)aniline. 
Yield 1.587 g (84%), white solid, mp 198-200 °C. 
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1H NMR (300.13 MHz, CDCl3): δ = 3.25 (s, 3H, CH3), 3.53 (s, 3H, CH3), 
4.91 (s, 1H, H-5), 7.25 (br s, 1H, NH), 7.28-7.35 (m, 1H, CHAr), 7.36 (s, 1H, CHAr), 
7.39-7.47 (m, 2H, CHAr). 
13C NMR (62.90 MHz, CDCl3): δ = 28.3 (CH3), 30.1 (CH3), 79.7 (CH-5), 
121.6 (q, 3J(C-F) = 3.8 Hz, CH), 123.1 (q, 3J(C-F) = 3.8 Hz, CH), 123.8 (q, 1J(C-F) = 
272.7 Hz, CF3), 128.0 (CH), 130.5 (CH), 132.5 (q, 2J(C-F) = 32.9 Hz), 138.5, 152.2, 153.1, 163.6. 
19F NMR (282.38 MHz, CDCl3): δ = –62.9 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 300 ([M+H]+, 15), 299 ([M]+, 100), 280 (16), 241 (15), 214 
(18), 213 (67), 212 (11), 200 (33), 199 (33), 186 (20), 185 (35), 172 (20), 145 (69), 127 (46), 126 
(12), 95 (10), 82 (35), 55 (21), 54 (10), 42 (13). 
HRMS (ESI): Calcd. for C13H13F3N3O2 [M+H]+: 300.09544, found: 300.09553. 
IR (ATR, cm–1): ṽ = 3307 (w), 3066 (w), 1699 (m), 1633 (s), 1605 (s), 1591 (m), 1537 (s), 
1493 (s), 1471 (m), 1443 (m), 1421 (m), 1383 (m), 1362 (m), 1331 (s), 1315 (s), 1281 (m), 1265 
(m), 1213 (w), 1171 (s), 1124 (s), 1093 (s), 1066 (s), 1003 (m), 933 (m), 920 (m), 891 (m), 816 (m), 
777 (s), 750 (s), 743 (s), 702 (s), 673 (w), 662 (s), 648 (m), 638 (m), 582 (m). 
 
6,6'-[Methylenebis(4,1-phenyleneimino)]bis(1,3-dimethylpyrimidine-2,4(1H,3H)-dione) 
(70f) 
 
The product was prepared according to the Method B, 
starting from 0.442 g of 6-chloro-1,3-dimethyluracil, 0.209 g of 
4,4'-diaminodiphenylmethane and 0.392 g of quinoline. 
Yield 0.387 g (77%), brownish solid, mp 308-310 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.14 (s, 6H, CH3), 3.46 (s, 6H, CH3), 4.02 (s, 2H, 
CH2), 4.63 (s, 2H, H5, H5'), 7.22 (d, 4H, 3J = 8.50 Hz, CHAr), 7.33 (d, 4H, 3J = 8.50 Hz, CHAr), 
8.50 (s, 2H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.1 (CH3), 30.9 (CH3), 40.8 (CH2), 77.8 (CH-5, 
CH-5'), 126.2 (CH), 130.6 (CH), 137.2, 139.7, 152.5, 154.3, 162.5. 
MS (GC, 70 eV): m/z (%) = 475 ([M+H]+, 20), 474 ([M]+, 72), 473 (100), 334 (13), 229 
(10), 145 (12), 104 (16), 82 (12), 40 (11). 
HRMS (ESI): Calcd. for C25H27N6O4 [M+H]+: 475.20883, found: 475.20938. 
IR (ATR, cm–1): ṽ = 3209 (w), 2953 (w), 1695 (s), 1622 (s), 1589 (s), 1525 (s), 1510 (s), 
1462 (s), 1441 (s), 1431 (s), 1414 (s), 1381 (s), 1360 (s), 1282 (s), 1257 (s), 1192 (m), 1178 (m), 
1107 (m), 1020 (m), 999 (m), 912 (m), 860 (m), 812 (m), 777 (s), 752 (s), 723 (m), 667 (m), 648 
(s), 635 (s), 577 (m), 542 (s). 
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6,6'-[Biphenyl-4,4'-diyldi(imino)]bis(1,3-dimethylpyrimidine-2,4(1H,3H)-dione) (70g) 
 
The product was prepared according to the Method B, 
starting from 0.455 g of 6-chloro-1,3-dimethyluracil, 0.2 g of 
benzidine and 0.404 g of quinoline. 
Yield 0.452 g (91%), grey solid, mp ˃375 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.17 (s, 6H, CH3), 3.50 (s, 6H, CH3), 4.82 (s, 2H, 
H5, H5'), 7.38 (d, 4H, 3J = 8.59 Hz, CHAr), 7.80 (d, 4H, 3J = 8.59 Hz, CHAr), 8.63 (s, 2H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.2 (CH3), 31.1 (CH3), 78.6 (CH-5, CH-5'), 125.8 
(CH), 128.3 (CH), 137.2, 138.8, 152.5, 154.0, 162.5. 
MS (EI, 70 eV): m/z (%) = 461 ([M+H]+, 23), 460 ([M]+, 100), 374 (11). 
HRMS (EI): Calcd. for C24H24O4N6 [M]+: 460.18535, found: 460.185839. 
IR (ATR, cm–1): ṽ = 3219 (m), 3109 (w), 3043 (w), 2958 (w), 2895 (w), 1701 (s), 1624 (s), 
1597 (s), 1581 (s), 1525 (s), 1497 (s), 1466 (s), 1429 (s), 1383 (s), 1363 (s), 1321 (m), 1288 (s), 
1275 (s), 1254 (s), 1192 (m), 1051 (m), 1009 (m), 997 (m), 912 (m), 818 (s), 775 (s), 754 (s), 729 
(m), 698 (m), 669 (m), 654 (m), 642 (m), 602 (s), 538 (m). 
 
4.2.5 Synthesis of 5-(polyfluoroacyl)-6-amino-1,3-dialkyl-pyrimidine-2,4(1H,3H)-diones 
 
General procedure for the synthesis of 5-(polyfluoroacyl)-6-amino-1,3-dialkyl-
pyrimidine-2,4(1H,3H)-diones 87a-w and 90a-c. 
To a solution of 6-amino-1,3-dialkyl-pyrimidine-2,4(1H,3H)-dione 70 (0.4 g) in 4 mL of dry 
dioxane was added dry pyridine (1.2 eq) and corresponding anhydride (or chloroanhydride, if RF = 
n-C3F7) of polyfluorocarboxylic acid (2 eq). Then the solution was allowed to stand at r.t. overnight. 
The next day the solvent was evaporated and the residue was dried in high vacuum at 100 °C. Then 
the crude product was triturated with water, filtered off by suction and dried in a high vacuum. 
 
6-Anilino-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-dione (87a) 
 
The product was prepared according to the general procedure from 0.4 g 
of 6-anilino-1,3-dimethylpyrimidine-2,4(1H,3H)-dione, 0.164 g of pyridine and 
0.727 g of trifluoroacetic anhydride in 4 mL of dry dioxane. 
Yield 0.524 g (93%), white solid, mp 143-145 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.09 (s, 3H, CH3), 3.23 (s, 3H, CH3), 7.22-7.40 (m, 
3H, CHPh), 7.40-7.51 (m, 2H, 3J = 7.27 Hz, CHm-Ph), 11.10 (br s, 1H, NH). 
19F NMR (282.38 MHz, DMSO-d6): δ = –71.4 (s, CF3). 
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13C NMR (75.47 MHz, DMSO-d6): δ = 28.6 (CH3), 36.1 (CH3), 93.3, 117.7 (q, 1J(C-F) = 
288.6 Hz, CF3), 124.2 (CH), 127.1 (CH), 130.5 (CH), 139.4, 151.6, 159.0, 160.7, 179.0 (q, 2J(C-F) = 
35.8 Hz, CO). 
MS (EI, 70 eV): m/z (%) = 328 ([M+H]+, 10), 327 ([M]+, 69), 309 (40), 259 (27), 258 (100), 
230 (11), 201 (64), 197 (53), 133 (11), 92 (12), 77 (20), 69 (11). 
HRMS (ESI): Calcd. for C14H13F3N3O3 [M+H]+: 328.09035, found: 328.09031. 
IR (ATR, cm–1): ṽ = 3057 (w), 2955 (w), 1726 (m), 1668 (s), 1651 (s), 1614 (s), 1585 (s), 
1514 (s), 1495 (s), 1446 (s), 1416 (m), 1387 (m), 1325 (m), 1308 (s), 1284 (m), 1240 (m), 1203 (s), 
1173 (s), 1155 (s), 1084 (s), 1053 (m), 1028 (m), 1014 (m), 995 (s), 926 (m), 872 (w), 860 (w), 845 
(w), 824 (m), 795 (s), 760 (s), 748 (s), 719 (m), 696 (s), 687 (s), 662 (s), 615 (m), 594 (m), 567 (m), 
530 (s). 
 
6-Anilino-5-(2,2,3,3,4,4,4-heptafluorobutanoyl)-1,3-dimethylpyrimidine-2,4(1H,3H)-
dione (87b) 
 
The product was prepared according to the general procedure from 
0.4 g of 6-anilino-1,3-dimethylpyrimidine-2,4(1H,3H)-dione, 0.164 g of 
pyridine and 0.804 g of heptafluorobutyryl chloride in 4 mL of dry dioxane. 
Yield 0.712 g (96%), white solid, mp 127-128 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.08 (s, 3H, CH3), 3.23 (s, 3H, CH3), 7.27 (t, 1H, 3J 
= 7.27 Hz, CHp-Ph), 7.19 (d, 2H, 3J = 7.55 Hz, CHo-Ph), 7.40-7.49 (m, 2H, CHm-Ph), 10.84 (br s, 1H, 
NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.7 (CH3), 36.2 (CH3), 94.7 (С-5), 124.1 (CH), 
127.0 (CH), 130.5 (CH), 139.3, 151.7, 158.5, 160.7, 181.9 (t, 2J(C-F) = 26.6 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –121.2 (s, CF2), –111.0 (q, J = 10.22 Hz, CF2), –
79.9 (t, J = 9.70 Hz, CF3). 
MS (GC, 70 eV): m/z (%) = 427 ([M]+, 7.8), 259 (16), 258 (100), 201 (30), 92 (11), 77 (12). 
HRMS (EI): Calcd. for C16H12O3N3F7 [M]+: 427.07614, found: 427.076505. 
IR (ATR, cm–1): ṽ = 3014 (w), 2956 (w), 1720 (m), 1666 (s), 1624 (s), 1576 (s), 1495 (s), 
1444 (s), 1408 (m), 1379 (m), 1336 (s), 1311 (m), 1282 (s), 1213 (s), 1176 (s), 1147 (s), 1122 (s), 
1088 (m), 1078 (m), 1065 (m), 1028 (m), 1005 (m), 951 (m), 932 (m), 914 (m), 893 (s), 860 (m), 
808 (m), 789 (s), 777 (s), 754 (s), 721 (s), 694 (s), 685 (s), 654 (s), 615 (m), 594 (s), 567 (m), 528 
(s). 
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6-[(2,4-Dimethylphenyl)amino]-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-
dione (87c) 
 
The product was prepared according to the general procedure from 
0.39 g of 6-[(2,4-dimethylphenyl)amino]-1,3-dimethylpyrimidine-
2,4(1H,3H)-dione, 0.143 g of pyridine and 0.632 g of trifluoroacetic 
anhydride in 3.9 mL of dry dioxane. 
Yield 0.481 g (90%), white solid, mp 136-138 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 2.31 (s, 3H, Ar-CH3), 2.32 (s, 3H, Ar-CH3), 2.96 (s, 
3H, N-CH3), 3.22 (s, 3H, N-CH3), 7.10 (d, 1H, 3J = 8.12 Hz, CHAr), 7.17-7.23 (m, 2H, CHAr), 11.43 
(br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 17.5 (Ar-CH3), 20.4 (Ar-CH3), 27.7 (N-CH3), 35.2 
(N-CH3), 91.7 (С-5), 117.0 (q, 1J(C-F) = 287.8 Hz, CF3), 124.9 (CH), 127.4 (CH), 131.7 (CH), 132.0, 
134.0, 136.8, 150.5, 159.1, 159.4, 177.6 (q, 2J(C-F) = 35.8 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –71.1 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 355 ([M]+, 31), 287 (13), 286 (100), 229 (12), 128 (14), 120 (11), 
69 (13). 
HRMS (EI): Calcd. for C16H16O3N3F3 [M]+: 355.11383, found: 355.11345. 
IR (ATR, cm–1): ṽ = 2962 (w), 2359 (w), 1726 (m), 1668 (s), 1645 (m), 1614 (s), 1583 (s), 
1514 (s), 1504 (s), 1454 (s), 1441 (s), 1387 (m), 1379 (m), 1317 (s), 1281 (m), 1246 (m), 1228 (m), 
1213 (s), 1196 (s), 1173 (s), 1155 (s), 1080 (s), 1057 (m), 1036 (m), 995 (s), 947 (m), 893 (m), 883 
(w), 852 (m), 824 (m), 795 (s), 773 (m), 758 (s), 733 (s), 706 (m), 685 (m), 650 (m), 581 (m), 569 
(m), 557 (m), 532 (m). 
 
6-[(2,4-Dimethylphenyl)amino]-1,3-dimethyl-5-(2,2,3,3,3-pentafluoropropanoyl)pyri-
midine-2,4(1H,3H)-dione (87d) 
 
The product was prepared according to the general procedure from 
0.35 g of 6-[(2,4-dimethylphenyl)amino]-1,3-dimethylpyrimidine-
2,4(1H,3H)-dione, 0.128 g of pyridine and 0.837 g of pentafluoropropionic 
anhydride in 3.5 mL of dry dioxane. 
Yield 0.481 g (88%), yellowish solid, mp 193-195 °C. 
1H NMR (250.13 MHz, DMSO-d6): δ = 2.30 (s, 3H, Ar-CH3), 2.32 (s, 3H, Ar-CH3), 2.91 (s, 
3H, N-CH3), 3.23 (s, 3H, N-CH3), 7.10 (d, 1H, 3J = 8.04 Hz, CHAr), 7.18-7.25 (m, 2H, CHAr), 11.42 
(br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 18.5 (CH3), 21.4 (CH3), 28.8 (CH3), 36.4 (CH3), 
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94.1 (С-5), 126.0 (CH), 128.4 (CH), 132.6 (CH), 133.0, 134.8, 137.8, 151.5, 160.2, 160.3, 181.0 (t, 
2J(C-F) = 27.1 Hz, CO). 
19F NMR (235.33 MHz, DMSO-d6): δ = –115.2 (s, CF2), –78.5 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 405 ([M]+, 65), 387 (18), 287 (27), 286 (100), 275 (14), 258 (17), 
229 (24), 120 (11). 
HRMS (ESI): Calcd. for C17H17F5N3O3 [M+H]+: 406.11846, found: 406.11903. 
IR (ATR, cm–1): ṽ = 2962 (w), 2929 (w), 2351 (w), 1724 (s), 1668 (s), 1614 (s), 1583 (s), 
1516 (s), 1504 (s), 1454 (s), 1444 (s), 1385 (m), 1363 (s), 1315 (s), 1279 (m), 1225 (s), 1173 (s), 
1140 (s), 1111 (s), 1061 (m), 1030 (m), 960 (s), 939 (s), 889 (m), 852 (m), 816 (s), 804 (m), 787 (s), 
760 (s), 739 (s), 729 (s), 704 (m), 687 (s), 656 (m), 642 (s), 586 (m), 569 (m), 561 (m), 536 (m). 
 
6-[(2,4-Dimethylphenyl)amino]-5-(2,2,3,3,4,4,4-heptafluorobutanoyl)-1,3-dimethyl-
pyrimidine-2,4(1H,3H)-dione (87e) 
 
The product was prepared according to the general procedure from 
0.35 g of 6-[(2,4-dimethylphenyl)amino]-1,3-dimethylpyrimidine-
2,4(1H,3H)-dione, 0.128 g of pyridine and 0.627 g of heptafluorobutyryl 
chloride in 3.5 mL of dry dioxane. 
Yield 0.535 g (87%), white solid, mp 130 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 2.31 (s, 3H, Ar-CH3), 2.32 (s, 3H, Ar-CH3), 2.95 (s, 
3H, N-CH3), 3.22 (s, 3H, N-CH3), 7.10 (d, 1H, 3J = 8.12 Hz, CHAr), 7.18-7.23 (m, 2H, CHAr), 11.14 
(br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 18.5 (CH3), 21.4 (CH3), 28.7 (CH3), 36.2 (CH3), 
94.0 (С-5), 125.9 (CH), 128.4 (CH), 132.6 (CH), 133.0, 134.9, 137.7, 151.6, 159.7, 160.5, 181.6 (t, 
2J(C-F) = 26.3 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –120.8 (s, CF2), –110.3 (q, J = 169.62 Hz, CF2), –
79.8 (t, J = 9.70 Hz, CF3). 
MS (GC, 70 eV): m/z (%) = 455 ([M]+, 22), 287 (18), 286 (100), 258 (11), 229 (13). 
HRMS (EI): Calcd. for C18H16O3N3F7 [M]+: 455.10744, found: 455.107556. 
IR (ATR, cm–1): ṽ = 2956 (w), 2928 (w), 2145 (w), 1724 (m), 1672 (s), 1606 (s), 1574 (s), 
1502 (s), 1443 (s), 1406 (m), 1387 (m), 1333 (m), 1315 (s), 1282 (m), 1267 (m), 1254 (m), 1221 (s), 
1207 (s), 1198 (s), 1165 (s), 1140 (s), 1120 (s), 1086 (m), 1066 (s), 1055 (s), 1039 (m), 1007 (m), 
959 (m), 951 (m), 933 (s), 924 (s), 893 (m), 856 (m), 816 (s), 802 (m), 787 (s), 758 (s), 743 (s), 725 
(s), 706 (m), 685 (s), 675 (s), 640 (s), 596 (m), 561 (m), 546 (m). 
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6-[(4-Ethylphenyl)amino]-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-dione 
(87f) 
 
The product was prepared according to the general procedure from 0.3 g of 6-[(4-
ethylphenyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-dione, 0.11 g of pyridine and 0.486 g of 
trifluoroacetic anhydride in 3 mL of dry dioxane. 
Yield 0.362 g (88%), grey solid, mp 141-143 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.21 (t, 3H, 3J = 7.55 Hz, 
Et), 2.64 (q, 2H, 3J = 7.55 Hz, Et), 3.06 (s, 3H, CH3), 3.23 (s, 3H, CH3), 7.26 
(d, 2H, 3J = 8.78 Hz, CHAr), 7.29 (d, 2H, 3J = 8.78 Hz, CHAr), 11.22 (br s, 1H, NH). 
19F NMR (282.38 MHz, DMSO-d6): δ = –71.3 (s, CF3). 
13C NMR (75.47 MHz, DMSO-d6): δ = 16.4 (CH3(Et)), 28.5 (CH2), 28.6 (CH3), 36.3 (CH3), 
93.1, 117.8 (q, 1J(C-F) = 288.5 Hz, CF3), 124.4 (CH), 129.8 (CH), 136.8, 143.0, 151.6, 159.2, 160.6, 
178.7 (q, 2J(C-F) = 35.8 Hz, CO). 
MS (EI, 70 eV): m/z (%) = 355 ([M]+, 41), 337 (52), 327 (22), 322 (12), 309 (16), 287 (13), 
286 (100), 272 (13), 259 (15), 258 (90), 229 (13), 225 (36), 201 (23), 197 (17), 128 (15), 91 (11), 
82 (19), 77 (12), 66 (27), 65 (15), 39 (15). 
HRMS (ESI): Calcd. for C16H17F3N3O3 [M+H]+: 356.12165, found: 356.12154. 
IR (ATR, cm–1): ṽ = 3045 (w), 2972 (w), 2879 (w), 1722 (s), 1666 (s), 1622 (s), 1589 (s), 
1558 (m), 1539 (m), 1514 (s), 1506 (s), 1456 (s), 1446 (s), 1435 (s), 1414 (m), 1389 (m), 1373 (m), 
1311 (s), 1282 (m), 1244 (m), 1236 (m), 1211 (s), 1182 (s), 1174 (s), 1155 (s), 1119 (m), 1086 (s), 
1061 (m), 1020 (m), 995 (s), 957 (m), 874 (m), 837 (m), 791 (s), 760 (s), 733 (s), 721 (m), 687 (s), 
654 (m), 633 (m), 584 (m), 554 (m), 542 (m), 532 (m). 
 
5-[Chloro(difluoro)acetyl]-6-[(4-ethylphenyl)amino]-1,3-dimethylpyrimidine-
2,4(1H,3H)-dione (87g) 
 
The product was prepared according to the general procedure from 
0.3 g of 6-[(4-ethylphenyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-
dione, 0.11 g of pyridine and 0.562 g of chlorodifluoroacetic anhydride in 3 
mL of dry dioxane. 
Yield 0.417 g (97%), grey solid, mp 133-135 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.20 (t, 3H, 3J = 7.55 Hz, Et), 2.63 (q, 2H, 3J = 7.55 
Hz, Et), 3.10 (s, 3H, CH3), 3.22 (s, 3H, CH3), 7.22 (d, 2H, 3J = 8.50 Hz, CHAr), 7.28 (d, 2H, 3J = 
8.50 Hz, CHAr), 10.90 (br s, 1H, NH). 
13C NMR (125.77 MHz, DMSO-d6): δ = 16.4 (CH3), 28.5 (CH2), 28.7 (CH3), 35.9 (CH3), 
N
NO O
NH O
F
F
F
N
N
NH
O O
O
F
Cl
F
Experimental	Part	
98 
92.3 (С-5), 121.3 (t, 1J(C-F) = 302.0 Hz, CClF2), 124.2 (CH), 129.8 (CH), 137.0, 142.8, 151.6, 158.9, 
160.3, 180.8 (t, 2J(C-F) = 29.9 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –59.9 (s, CClF2). 
MS (GC, 70 eV): m/z (%) = 371 ([M]+, 35Cl, 5.2), 320 (19), 319 (100), 305 (16), 304 (77), 
247 (10), 207 (38), 192 (10), 82 (13). 
HRMS (ESI): Calcd. for C16H17ClF2N3O3 [M+H, 35Cl]+: 372.09210, found: 372.09257. 
IR (ATR, cm–1): ṽ = 2962 (w), 2931 (w), 2874 (w), 1720 (m), 1660 (s), 1622 (s), 1574 (s), 
1504 (s), 1452 (s), 1441 (s), 1404 (s), 1367 (s), 1311 (m), 1279 (s), 1254 (m), 1174 (s), 1134 (s), 
1095 (m), 1070 (s), 1059 (m), 1005 (s), 953 (m), 930 (s), 914 (s), 870 (s), 841 (m), 825 (s), 804 (s), 
793 (s), 773 (s), 756 (s), 743 (s), 716 (m), 669 (s), 646 (s), 625 (s), 567 (m), 534 (s). 
 
6-[(4-Ethylphenyl)amino]-1,3-dimethyl-5-(2,2,3,3,3-pentafluoropropanoyl)pyrimidine-
2,4(1H,3H)-dione (87h) 
 
The product was prepared according to the general procedure from 
0.35 g of 6-[(4-ethylphenyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-
dione, 0.128 g of pyridine and 0.837 g of pentafluoropropionic anhydride 
in 3.5 mL of dry dioxane. 
Yield 0.516 g (94%), greyish solid, mp 161-163 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.21 (t, 3H, 3J = 7.59 Hz, Et), 2.64 (q, 2H, 3J = 7.59 
Hz, Et), 3.02 (s, 3H, CH3), 3.23 (s, 3H, CH3), 7.29 (s, 4H, CHAr), 11.23 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 16.4 (CH3), 28.5 (CH2), 28.7 (CH3), 36.7 (CH3), 
94.6 (С-5), 124.5 (CH), 129.7 (CH), 136.6, 143.1, 151.7, 159.2, 160.4, 181.1 (t, 2J(C-F) = 27.0 Hz, 
CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –115.6 (s, CF2), –78.7 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 405 ([M]+, 41), 387 (16), 287 (30), 286 (100), 275 (13), 229 (25). 
HRMS (EI): Calcd. for C17H16O3N3F5 [M]+: 405.11063, found: 405.11084. 
IR (ATR, cm–1): ṽ = 2966 (w), 2935 (w), 2874 (w), 1728 (m), 1670 (s), 1591 (s), 1576 (s), 
1504 (s), 1454 (s), 1441 (s), 1408 (m), 1375 (s), 1315 (s), 1281 (s), 1254 (m), 1215 (s), 1176 (s), 
1147 (s), 1117 (s), 1065 (m), 1030 (m), 1020 (m), 959 (s), 933 (s), 874 (m), 839 (m), 820 (m), 810 
(s), 795 (s), 760 (s), 735 (s), 714 (m), 685 (s), 656 (m), 646 (s), 629 (s), 567 (m), 538 (m). 
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6-[(2-Methoxyphenyl)amino]-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-
dione (87i) 
 
The product was prepared according to the general procedure from 0.3 g 
of 6-[(2-methoxyphenyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-dione, 
0.109 g of pyridine and 0.482 g of trifluoroacetic anhydride in 3 mL of dry 
dioxane. 
Yield 0.369 g (90%), greyish solid, mp 174-176 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.97 (s, 3H, CH3), 3.23 (s, 3H, CH3), 3.90 (s, 3H, 
OMe), 7.00-7.10 (m, 1H, CHAr), 7.21 (d, 1H, 3J = 8.69 Hz, CHAr), 7.29-7.38 (m, 2H, CHAr), 11.51 
(br s, 1H, NH). 
19F NMR (282.38 MHz, DMSO-d6): δ = –71.0 (s, CF3). 
13C NMR (75.47 MHz, DMSO-d6): δ = 28.7 (CH3), 36.5 (CH3), 56.9 (OMe), 93.2, 113.2 
(CH), 118.0 (q, 1J(C-F) = 287.6 Hz, CF3), 121.7 (CH), 126.0 (CH), 126.8, 129.2 (CH), 151.5, 152.8, 
159.8, 160.3, 178.3 (q, 2J(C-F) = 35.9 Hz, CO). 
MS (EI, 70 eV): m/z (%) = 358 ([M+H]+, 13), 357 ([M]+, 100), 339 (21), 338 (11), 326 (15), 
289 (13), 288 (96), 274 (11), 273 (86), 128 (12). 
HRMS (ESI): Calcd. for C15H15F3N3O4 [M+H]+: 358.10092, found: 358.10099. 
IR (ATR, cm–1): ṽ = 2976 (w), 2841 (w), 1734 (m), 1714 (m), 1660 (s), 1622 (s), 1585 (s), 
1520 (s), 1498 (s), 1464 (s), 1441 (s), 1417 (m), 1385 (m), 1327 (m), 1296 (s), 1269 (m), 1242 (m), 
1232 (m), 1217 (s), 1207 (s), 1188 (s), 1174 (s), 1144 (s), 1115 (s), 1082 (s), 1049 (m), 1020 (s), 
995 (s), 949 (m), 872 (w), 858 (w), 824 (m), 793 (s), 756 (s), 733 (s), 712 (m), 692 (m), 675 (m), 
660 (s), 598 (m), 577 (m), 550 (m), 527 (s). 
 
5-[Chloro(difluoro)acetyl]-6-[(2-methoxyphenyl)amino]-1,3-dimethylpyrimidine-
2,4(1H,3H)-dione (87j) 
 
The product was prepared according to the general procedure from 0.3 g 
of 6-[(2-methoxyphenyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-dione, 
0.109 g of pyridine and 0.558 g of chlorodifluoroacetic anhydride in 3 mL of 
dry dioxane. 
Yield 0.395 g (92%), greyish solid, mp 163-165 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.00 (s, 3H, CH3), 3.23 (s, 3H, CH3), 3.89 (s, 3H, 
OMe), 7.04 (dd, 1H, 3J1 = 7.57 Hz, 3J2 = 7.55 Hz, CHAr), 7.19 (d, 1H, 3J = 8.67 Hz, CHAr), 7.29-
7.38 (m, 2H, CHAr), 11.26 (br s, 1H, NH). 
13C NMR (125.77 MHz, DMSO-d6): δ = 28.7 (CH3), 36.4 (CH3), 56.9 (CH3), 92.4 (С-5), 
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113.2 (CH), 121.4 (t, 1J(C-F) = 301.3 Hz, CClF2), 121.7 (CH), 125.9 (CH), 126.9, 129.0 (CH), 151.5, 
152.8, 159.6, 160.1, 180.5 (t, 2J(C-F) = 29.8 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –59.7 (s, CClF2). 
MS (GC, 70 eV): m/z (%) = 375 ([M]+, 37Cl, 5.5), 373 ([M]+, 35Cl, 18), 338 (10), 289 (16), 
288 (100), 274 (11), 273 (79), 244 (10), 81 (17). 
HRMS (EI): Calcd. for C15H14O4N3ClF2 [M, 37Cl]+: 373.06354, found: 373.063406. 
IR (ATR, cm–1): ṽ = 3005 (w), 2953 (w), 2845 (w), 1724 (s), 1660 (s), 1628 (s), 1599 (s), 
1576 (s), 1520 (s), 1497 (s), 1454 (s), 1443 (s), 1392 (s), 1362 (s), 1325 (m), 1290 (s), 1267 (s), 
1232 (s), 1194 (m), 1171 (s), 1136 (s), 1115 (s), 1072 (s), 1045 (s), 1030 (s), 1005 (s), 978 (m), 935 
(m), 920 (s), 866 (m), 851 (m), 800 (s), 775 (s), 748 (s), 717 (s), 685 (m), 665 (s), 656 (s), 619 (s), 
590 (m), 571 (m), 552 (m). 
 
5-(2,2,3,3,4,4,4-Heptafluorobutanoyl)-6-[(3-methoxyphenyl)amino]-1,3-dimethylpyri-
midine-2,4(1H,3H)-dione (87m) 
 
The product was prepared according to the general procedure from 
0.4 g of 6-[(3-methoxyphenyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-
dione, 0.145 g of pyridine and 0.712 g of heptafluorobutyryl chloride in 4 
mL of dry dioxane. 
Yield 0.658 g (94%), grey solid, mp 136-138 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.11 (s, 3H, CH3), 3.23 (s, 3H, CH3), 3.78 (s, 3H, 
OMe), 6.84 (d, 1H, 3J = 8.31 Hz, CHAr), 6.89 (d, 1H, 3J = 7.93 Hz, CHAr), 6.98 (s, 1H, H-2'), 7.33 
(dd, 1H, 3J1 = 8.31 Hz, 3J2 = 7.93 Hz, H-5'), 10.78 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.7 (CH3), 36.0 (CH3), 56.2 (CH3), 94.8 (С-5), 
109.5 (CH), 112.9 (CH), 116.1 (CH), 131.2 (CH), 140.5, 151.7, 158.3, 160.7, 161.1, 182.0 (t, 2J(C-F) 
= 26.4 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –121.1 (s, CF2), –110.8 (q, J = 10.22 Hz, CF2), –
80.0 (t, J = 9.70 Hz, CF3). 
MS (GC, 70 eV): m/z (%) = 440 (11), 439 (55), 411 (11), 328 (15), 327 (100), 270 (14). 
HRMS (ESI): Calcd. for C17H15F7N3O4 [M+H]+: 458.0945, found: 458.0943. 
IR (ATR, cm–1): ṽ = 2949 (w), 2847 (w), 2046 (w), 1795 (w), 1716 (m), 1662 (s), 1628 (s), 
1605 (m), 1587 (s), 1564 (s), 1495 (s), 1441 (s), 1408 (m), 1377 (m), 1335 (s), 1317 (m), 1294 (s), 
1259 (m), 1211 (s), 1182 (s), 1144 (s), 1122 (s), 1088 (s), 1051 (s), 1012 (m), 960 (m), 920 (w), 897 
(m), 876 (s), 820 (m), 797 (m), 781 (s), 756 (s), 729 (s), 689 (s), 671 (s), 650 (s), 594 (s), 575 (m), 
548 (m). 
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1,3-Dimethyl-5-(trifluoroacetyl)-6-{[3-(trifluoromethyl)phenyl]amino}pyrimidine-
2,4(1H,3H)-dione (87n) 
 
The product was prepared according to the general procedure from 0.4 g 
of 70e, 0.127 g of pyridine and 0.561 g of trifluoroacetic anhydride in 4 mL of 
dry dioxane. 
Yield 0.523 g (99%), pinkish amorphous solid. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.24 (s, 3H, CH3), 3.27 (s, 3H, 
CH3), 7.50-7.58 (m, 2H, CHAr), 7.61-7.71 (m, 2H, CHAr), 10.40 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.6 (CH3), 34.7 (CH3), 93.3 (С-5), 117.0 (q, 1J(C-F) 
= 289.4 Hz, CF3), 119.7 (CH), 122.7 (CH), 124.7 (q, 1J(C-F) = 272.5 Hz, CF3), 127.5 (CH), 131.2 (q, 
2J(C-F) = 32.1 Hz), 131.7 (CH), 141.2, 151.6, 158.3, 161.0, 179.9 (q, 2J(C-F) = 36.1 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –72.4 (s, CF3), –61.4 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 395 ([M]+, 27), 377 (26), 327 (27), 326 (100), 269 (39), 265 (57), 
201 (32), 145 (15), 128 (12), 82 (12), 69 (11). 
HRMS (EI): Calcd. for C15H11O3N3F6 [M]+: 395.06991, found: 395.07016. 
IR (ATR, cm–1): ṽ = 3078 (w), 2964 (w), 1790 (w), 1722 (m), 1668 (s), 1585 (s), 1514 (m), 
1504 (s), 1495 (s), 1441 (s), 1402 (m), 1371 (m), 1327 (s), 1240 (m), 1159 (s), 1124 (s), 1068 (s), 
995 (s), 976 (s), 924 (m), 906 (m), 887 (m), 858 (w), 822 (m), 795 (s), 756 (s), 733 (m), 725 (s), 698 
(s), 658 (s), 635 (m), 594 (m), 565 (m), 532 (m). 
 
1,3-Dimethyl-6-[(4-nitrophenyl)amino]-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-dione 
(87o) 
 
The product was prepared according to the general procedure from 
0.336 g of 1,3-dimethyl-6-[(4-nitrophenyl)amino]pyrimidine-2,4(1H,3H)-
dione, 0.115 g of pyridine and 0.511 g of trifluoroacetic anhydride in 3.4 mL 
of dry dioxane. 
Yield 0.359 g (79%), brownish solid, mp 256-258 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.25 (s, 3H, CH3), 3.27 (s, 3H, CH3), 7.39 (d, 2H, 3J 
= 9.26 Hz, CH-2', CH-6'), 8.25 (d, 2H, 3J = 9.26 Hz, CH-3', CH-5'), 10.40 (br s, 1H, NH). 
13C NMR (75.48 MHz, DMSO-d6): δ = 28.7 (CH3), 34.6 (CH3), 96.5 (С-5), 116.9 (q, 1J(C-F) 
= 290.1 Hz, CF3), 121.4 (CHAr), 126.3 (CHAr), 143.8, 147.4, 151.6, 157.1, 160.9, 180.3 (q, 2J(C-F) = 
36.3 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –72.3 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 277 (14), 276 (100), 275 (45), 218 (17), 191 (10), 190 (42), 174 
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(30), 163 (16), 162 (23), 149 (12), 147 (26), 145 (11), 144 (18), 131 (12), 127 (62), 116 (10), 90 
(41), 89 (16), 82 (49), 76 (20), 75 (12), 63 (21), 55 (38), 56 (16), 50 (14), 42 (15). 
HRMS (ESI): Calcd. for C14H10F3N4O5 [M+H]+: 371.06123, found: 371.06123. 
IR (ATR, cm–1): ṽ = 3247 (m), 3078 (w), 2913 (w), 1711 (w), 1691 (w), 1660 (w), 1640 (w), 
1633 (m), 1616 (m), 1602 (m), 1578 (m), 1539 (s), 1528 (s), 1520 (s), 1479 (m), 1471 (s), 1434 (m), 
1383 (w), 1371 (w), 1341 (s), 1292 (s), 1265 (m), 1194 (s), 1176 (m), 1143 (m), 1107 (m), 1183 
(w), 1064 (w), 1008 (w), 992 (w), 916 (w), 883 (w), 859 (m), 838 (m), 821 (m), 791 (s), 759 (s), 
736 (s), 716 (s), 645 (s), 667 (m), 632 (s), 578 (m), 537 (s). 
 
6-[(4-Bromophenyl)amino]-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-
dione (87p) 
 
The product was prepared according to the general procedure from 1.2 
g of 6-[(4-bromophenyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-dione, 
0.367 g of pyridine and 1.625 g of trifluoroacetic anhydride in 12 mL of dry 
dioxane. 
Yield 94%, violet solid, mp 186 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.15 (s, 3H, CH3), 3.23 (s, 3H, CH3), 7.27 (d, 2H, 3J 
= 8.88 Hz, CH-2', CH-6'), 7.62 (d, 2H, 3J = 8.88 Hz, CH-3', CH-5'), 10.75 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.6 (CH3), 35.7 (CH3), 93.5 (С-5), 117.4 (q, 1J(C-F) 
= 289.0 Hz, CF3), 119.1, 125.9 (CHAr), 133.3 (CHAr), 139.1, 151.6, 158.6, 160.7, 179.2 (q, 2J(C-F) = 
35.9 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –71.7 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 407 ([M]+, 81Br, 40), 405 ([M]+, 79Br, 40), 389 (33), 387 (40), 
339 (15), 338 (97), 337 (16), 336 (100), 321 (18), 319 (20), 291 (12), 281 (34), 279 (27), 277 (43), 
275 (42), 257 (19), 229 (16), 224 (11), 223 (10), 211 (10), 209 (21), 208 (15), 207 (43), 178 (15), 
172 (23), 171 (13), 170 (16), 157 (12), 155 (13), 145 (15), 128 (32), 127 (13), 91 (12), 82 (25), 81 
(15), 80 (11), 76 (14), 75 (15), 69 (23), 63 (13), 60 (12), 44 (13), 32 (35). 
HRMS (ESI): Calcd. for C14H12BrF3N3O3 [M+H, 79Br]+: 406.00087, found: 406.00136. 
IR (ATR, cm–1): ṽ = 3293 (w), 3191 (w), 3099 (w), 2962 (w), 1766 (w), 1722 (m), 1672 (s), 
1639 (s), 1568 (s), 1503 (s), 1490 (s), 1454 (s), 1443 (s), 1384 (m), 1319 (m), 1301 (m), 1278 (m), 
1244 (m), 1217 (s), 1193 (s), 1176 (s), 1151 (s), 1088 (m), 1071 (s), 1054 (m), 1015 (m), 998 (s), 
960 (m), 941 (m), 871 (m), 825 (s), 814 (s), 796 (s), 783 (s), 755 (s), 733 (s), 718 (s), 681 (s), 671 
(s), 628 (m), 608 (m), 575 (s), 529 (m). 
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6-[(4-Ethoxyphenyl)amino]-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-
dione (87q) 
 
The product was prepared according to the general procedure from 
0.37 g of 6-[(4-ethoxyphenyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-
dione, 0.127 g of pyridine and 0.565 g of trifluoroacetic anhydride in 3.7 
mL of dry dioxane. 
Yield 0.416 g (82%), brownish solid, mp 119-121 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.36 (t, 3H, 3J = 6.99 Hz, EtO), 3.03 (s, 3H, CH3), 
3.22 (s, 3H, CH3), 4.07 (q, 2H, 3J = 6.99 Hz, EtO), 7.00 (d, 2H, 3J = 8.88 Hz, CHAr), 7.29 (d, 2H, 3J 
= 8.88 Hz, CHAr), 11.34 (br s, 1H, NH). 
13C NMR (125.77 MHz, DMSO-d6): δ = 15.4 (CH3(EtO)), 28.6 (CH3), 36.3 (CH3), 64.3 
(CH2(EtO)), 92.7 (С-5), 116.1 (CH), 117.9 (q, 1J(C-F) = 287.9 Hz, CF3), 126.3 (CH), 131.5, 151.7, 
157.9, 159.4, 160.6, 178.4 (q, 2J(C-F) = 35.7 Hz, CO). 
MS (GC, 70 eV): m/z (%) = 371 ([M]+, 11), 353 (10), 276 (21), 275 (100), 274 (19), 247 
(10), 246 (73), 189 (16), 162 (10), 161 (14), 148 (20), 147 (22), 134 (15), 133 (15), 132 (17), 82 
(24). 
HRMS (EI): Calcd. for C16H16O4N3F3 [M]+: 371.10874, found: 371.10840. 
IR (ATR, cm–1): ṽ = 2982 (w), 1722 (m), 1668 (s), 1614 (s), 1576 (s), 1504 (s), 1485 (s), 
1454 (s), 1441 (s), 1408 (m), 1389 (m), 1315 (s), 1304 (m), 1281 (m), 1257 (s), 1242 (s), 1211 (s), 
1188 (s), 1169 (s), 1151 (s), 1113 (s), 1080 (s), 1045 (s), 995 (s), 957 (m), 932 (m), 922 (m), 874 
(m), 833 (s), 824 (m), 795 (s), 758 (s), 737 (s), 721 (m), 689 (s), 656 (s), 633 (m), 586 (m), 567 (s), 
534 (m). 
 
5-(Difluoroacetyl)-6-[(4-ethoxyphenyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-
dione (87r) 
 
The product was prepared according to the general procedure from 
0.04 g of 6-[(4-ethoxyphenyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-
dione, 0.14 g of pyridine and 0.506 g of difluoroacetic anhydride in 4 mL 
of dry dioxane. 
Yield 0.508 g (99%), brownish solid, mp 144-146 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.37 (t, 3H, 3J = 6.90 Hz, EtO), 2.91 (s, 3H, CH3), 
3.24 (s, 3H, CH3), 4.08 (q, 2H, 3J = 6.90 Hz, EtO), 7.03 (d, 2H, 3J = 8.88 Hz, CHAr), 7.17 (t, 1H, 
2J(H-F) = 54.01 Hz, CHF2), 7.35 (d, 2H, 3J = 8.88 Hz, CHAr), 12.54 (br s, 1H, NH). 
13C NMR (75.48 MHz, DMSO-d6): δ = 15.5 (CH3(EtO)), 28.7 (CH3), 37.1 (CH3), 64.3 
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(CH2(EtO)), 94.0 (С-5), 109.2 (t, 1J(C-F) = 242.3 Hz, CHF2), 116.1 (CHAr), 126.6 (CHAr), 131.0, 151.6, 
158.1, 159.8, 162.0, 185.5 (t, 2J(C-F) = 23.8 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –125.7 (s, CHF2). 
MS (EI, 70 eV): m/z (%) = 354 ([M+H]+, 21), 353 ([M]+, 92), 333 (21), 304 (56), 303 (23), 
302 (100), 275 (21), 274 (86), 245 (20), 217 (19), 182 (29), 160 (15), 108 (12), 82 (19), 81 (10). 
HRMS (EI): Calcd. for C16H17F2N3O4 [M]+: 353.11816, found: 353.11822. 
IR (ATR, cm–1): ṽ = 3334 (w), 3080 (w), 2977 (w), 1724 (w), 1651 (m), 1592 (s), 1582 (s), 
1549 (w), 1510 (s), 1445 (s), 1396 (w), 1319 (w), 1319 (w), 1305 (m), 1291 (w), 1240 (s), 1189 
(w), 1176 (w), 1142 (m), 1116 (m), 1080 (m), 1043 (s), 1004 (s), 943 (w), 918 (w), 899 (m), 867 
(m), 844 (m), 818 (m), 807 (s), 777 (s), 769 (s), 760 (s), 751 (s), 712 (w), 694 (m), 666 (m), 628 
(w), 579 (m), 556 (m), 534 (m). 
 
6-[(4-Methoxyphenyl)amino]-5-(2,2,3,3,3-pentafluoropropanoyl)-1,3-
dipropylpyrimidine-2,4(1H,3H)-dione (87t) 
 
The product was prepared according to the general procedure from 
0.35 g of 70a, 0.105 g of pyridine and 0.684 g of pentafluoropropionic 
anhydride in 3.5 mL of dry dioxane. 
Yield 0.439 g (86%), pinkish solid, mp 85-87 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 0.72 (t, 3H, 3J = 7.37 Hz, CH3), 0.91 (t, 3H, 3J = 
7.46 Hz, CH3), 1.42-1.72 (m, 4H, CH2), 3.70-3.89 (m, 7H, CH2, MeO), 7.00 (d, 2H, 3J = 8.87 Hz, 
CHAr), 7.29 (d, 2H, 3J = 8.87 Hz, CHAr), 10.61 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 11.5 (CH3), 12.0 (CH3), 21.3 (CH2), 21.4 (CH2), 
43.3 (CH2), 47.2 (CH2), 56.3 (MeO), 93.3 (С-5), 115.7 (CHAr), 126.4 (CHAr), 131.8, 151.2, 158.0, 
158.8, 160.2, 181.6 (t, 2J(C-F) = 26.8 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –116.0 (s, CF2), –78.7 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 464 ([M+H]+, 15), 463 ([M]+, 85), 445 (15), 403 (18), 345 (20), 
344 (100), 302 (24), 260 (56), 243 (14), 214 (12), 123 (18), 43 (16), 41 (11). 
HRMS (ESI): Calcd. for C20H23F5N3O4 [M+H]+: 464.16032, found: 464.16109. 
IR (ATR, cm–1): ṽ = 2964 (w), 2877 (w), 1716 (m), 1670 (s), 1593 (s), 1504 (s), 1443 (s), 
1416 (s), 1385 (s), 1360 (m), 1329 (m), 1300 (s), 1279 (s), 1246 (s), 1213 (s), 1184 (s), 1171 (s), 
1144 (s), 1109 (s), 1086 (m), 1061 (m), 1032 (s), 962 (s), 953 (s), 932 (s), 910 (m), 870 (m), 845 
(m), 831 (s), 808 (m), 797 (s), 775 (s), 750 (s), 729 (s), 687 (s), 654 (m), 638 (s), 629 (s), 548 (m). 
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6,6'-[Biphenyl-4,4'-diyldi(imino)]bis[1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-
2,4(1H,3H)-dione] (87u) 
 
The product was prepared from 0.25 g of 70g, 0.103 g 
of pyridine and 0.456 g of trifluoroacetic anhydride in 5 mL of 
dry dioxane according to the general procedure, except that the 
synthesis was carried out in a pressure tube at 80 °C for 3 h. 
Yield 0.329 g (93%), beige solid, mp 246 °C (dec.). 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.15 (s, 6H, CH3), 3.24 (s, 6H, CH3), 7.42 (d, 4H, 3J 
= 8.60 Hz, CHAr), 7.79 (d, 4H, 3J = 8.60 Hz, CHAr), 11.07 (br s, 2H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.7 (CH3), 36.2 (CH3), 93.6 (С-5, С-5'), 117.6 (q, 
1J(C-F) = 286.2 Hz, CF3), 124.4 (CH), 128.5 (CH), 137.4, 138.9, 151.7, 158.8, 160.7, 179.0 (q, 2J(C-F) 
= 35.8 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –71.4 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 652 ([M]+, 3.6), 634 (15), 617 (31), 616 (100), 565 (15), 504 
(26), 496 (12). 
HRMS (EI): Calcd. for C28H22O6N6F6 [M]+: 652.14995, found: 652.14898. 
IR (ATR, cm–1): ṽ = 2958 (w), 2359 (w), 1730 (m), 1674 (s), 1605 (s), 1587 (s), 1514 (s), 
1498 (s), 1441 (s), 1404 (m), 1387 (m), 1335 (m), 1298 (m), 1286 (m), 1267 (m), 1238 (m), 1209 
(s), 1194 (s), 1163 (s), 1082 (s), 995 (s), 872 (m), 825 (s), 797 (s), 756 (s), 727 (m), 708 (m), 694 
(m), 667 (m), 640 (m), 594 (m), 571 (m), 534 (m). 
 
6,6'-[Methylenebis(4,1-phenyleneimino)]bis[1,3-dimethyl-5-(trifluoroacetyl)pyrimi-
dine-2,4(1H,3H)-dione] (87v) 
 
The product was prepared according to the general 
procedure from 0.333 g of 70f, 0.133 g of pyridine and 0.59 g 
of trifluoroacetic anhydride in 6.6 mL of dry dioxane. 
Yield 0.458 g (98%), beige solid, mp 129-131 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.07 (s, 6H, CH3), 3.22 (s, 6H, CH3), 3.98 (s, 2H, 
CH2), 7.26 (d, 4H, 3J = 8.69 Hz, CHAr), 7.29 (d, 4H, 3J = 8.69 Hz, CHAr), 11.05 (br s, 2H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.6 (CH3), 36.0 (CH3), 40.7 (CH2), 93.0 (С-5, С-
5'), 120.3 (q, 1J(C-F) = 288.5 Hz, CF3), 124.4 (CH), 130.8 (CH), 137.4, 140.1, 151.6, 159.0, 160.7, 
178.9 (q, 2J(C-F) = 35.5 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –71.4 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 631 (38), 630 (100), 553 (11), 552 (35), 518 (13), 498 (18), 203 
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(12). 
HRMS (ESI): Calcd. for C29H25F6N6O6 [M+H]+: 667.17343, found: 667.17425. 
IR (ATR, cm–1): ṽ = 2962 (w), 1724 (m), 1668 (s), 1593 (s), 1512 (s), 1506 (s), 1454 (s), 
1443 (s), 1435 (s), 1387 (m), 1309 (m), 1284 (s), 1242 (m), 1209 (s), 1186 (s), 1149 (s), 1082 (s), 
1020 (m), 995 (s), 926 (m), 879 (m), 824 (m), 816 (m), 795 (s), 756 (s), 725 (m), 710 (m), 694 (m), 
662 (m), 631 (m), 579 (m), 561 (m), 534 (m). 
 
1,3-Dimethyl-6-(1-naphthylamino)-5-(2,2,3,3,3-pentafluoropropanoyl)pyrimidine-
2,4(1H,3H)-dione (87w) 
 
The product was prepared according to the general procedure from 
0.341 g of 1,3-dimethyl-6-(1-naphthylamino)pyrimidine-2,4(1H,3H)-dione, 
0.105 g of pyridine and 0.413 g of pentafluoropropionic anhydride in 3.4 mL 
of dry dioxane. 
Yield 0.443 g (86%), yellowish solid, mp 156 °C (dec.). 
1H NMR (250.13 MHz, DMSO-d6): δ = 2.90 (s, 3H, CH3), 3.26 (s, 3H, CH3), 7.53-7.63 (m, 
2H, CHAr), 7.64-7.78 (m, 2H, CHAr), 7.93-8.03 (m, 1H, CHAr), 8.08 (d, 1H, 3J = 6.94 Hz, CHAr), 
8.15 (d, 1H, 3J = 8.19 Hz, CHAr), 11.80 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.8 (CH3), 36.2 (CH3), 94.8 (С-5), 123.0 (CH), 
123.4 (CH), 126.6 (CH), 128.0 (CH), 128.4 (CH), 128.5 (CH), 128.5, 129.4 (CH), 134.5, 134.8, 
151.5, 160.3, 160.7, 181.5 (t, 2J(C-F) = 27.1 Hz, CO). 
19F NMR (235.33 MHz, DMSO-d6): δ = –115.2 (s, CF2), –78.5 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 428 ([M+H]+, 13), 427 ([M]+, 77), 409 (49), 309 (18), 308 (100), 
297 (25), 280 (40), 251 (18), 195 (15), 127 (11), 115 (13). 
HRMS (ESI): Calcd. for C19H15F5N3O3 [M+H]+: 428.10281, found: 428.10233. 
IR (ATR, cm–1): ṽ = 3018 (w), 2962 (w), 1728 (m), 1674 (s), 1588 (s), 1574 (s), 1558 (m), 
1538 (m), 1515 (s), 1506 (s), 1455 (s), 1435 (s), 1399 (m), 1385 (m), 1368 (m), 1331 (m), 1305 (m), 
1283 (m), 1232 (s), 1174 (s), 1139 (s), 1112 (s), 1063 (m), 1032 (m), 1013 (w), 984 (w), 959 (s), 
938 (m), 907 (w), 883 (w), 861 (w), 824 (w), 804 (m), 783 (s), 770 (s), 758 (s), 740 (m), 731 (s), 
712 (s), 685 (m), 647 (s), 593 (m), 559 (m), 531 (m). 
 
6-(2,3-Dihydro-1H-indol-1-yl)-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-
dione (90a) 
 
The product was prepared according to the general procedure from 4.085 g of 89a, 1.507 g 
of pyridine and 6.669 g of trifluoroacetic anhydride in 41 mL of dry dioxane. 
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Yield 5.428 g (97%), yellow solid, mp 199 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.07-3.33 (m, 2H, CH2-3'), 3.26 
(s, 3H, CH3), 3.35 (s, 3H, CH3), 3.72-3.84 (m, 1H, CH2-2'a), 3.91-4.04 (m, 1H, 
CH2-2'b), 6.80 (d, 1H, 3J = 7.75 Hz, H-7'), 6.88-6.97 (m, 1H, CHAr), 7.05-7.15 
(m, 1H, CHAr), 7.30 (d, 1H, 3J = 6.99 Hz, H-4'). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.6 (CH3), 29.9 (CH2-3'), 35.0 (CH3), 54.8 (CH2-
2'), 99.3 (С-5), 112.6 (CHAr), 116.2 (q, 1J(C-F) = 290.8 Hz, CF3), 123.4 (CHAr), 126.4 (CHAr), 128.4 
(CHAr), 133.6, 146.0, 152.2, 159.1, 161.6, 181.9 (q, 2J(C-F) = 36.7 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –73.3 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 353 ([M]+, 24), 285 (18), 284 (100), 178 (18), 167 (14), 128 
(31), 118 (31), 110 (11). 
HRMS (ESI): Calcd. for C16H15F3N3O3 [M+H]+: 354.10600, found: 354.10633. 
IR (ATR, cm–1): ṽ = 3057 (w), 2963 (w), 1722 (w), 1696 (m), 1645 (s), 1549 (m), 1483 (s), 
1434 (s), 1401 (s), 1363 (m), 1331 (w), 1303 (w), 1265 (w), 1236 (w), 1229 (w), 1191 (s), 1156 
(m), 1141 (s), 1096 (w), 1082 (w), 1045 (w), 1033 (w), 1017 (w), 986 (m), 968 (s), 940 (w), 873 
(w), 861 (w), 833 (w), 819 (w), 797 (w), 785 (w), 753 (s), 713 (m), 704 (m), 686 (m), 608 (w), 581 
(w), 561 (m), 549 (w), 534 (w). 
 
6-(3,4-Dihydroquinolin-1(2H)-yl)-5-(2,2,3,3,4,4,4-heptafluorobutanoyl)-1,3-
dimethylpyrimidine-2,4(1H,3H)-dione (90b) 
 
The product was prepared according to the general procedure from 
1.444 g of 89b, 0.505 g of pyridine and 1.485 g of heptafluorobutyryl 
chloride in 14 mL of dry dioxane. 
Yield 82%, yellow solid, mp 131-133 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.90-2.19 (m, 2H, CH2-3'), 2.84 (t, 2H, 3J = 6.42 
Hz, CH2-4'), 3.21 (s, 3H, CH3), 3.26 (s, 3H, CH3), 3.36-3.54 (m, 2H, CH2-2'), 6.83 (d, 1H, 3J = 8.12 
Hz, H-8'), 6.84-6.92 (m, 1H, CHAr), 6.99-7.08 (m, 1H, CHAr), 7.30 (d, 1H, 3J = 7.36 Hz, H-5'). 
13C NMR (75.48 MHz, DMSO-d6): δ = 21.8 (CH2), 26.8 (CH2), 28.6 (CH3), 34.1 (CH3), 
50.7 (CH2-2'), 104.2 (С-5), 117.1 (CHAr), 122.3 (CHAr), 125.5, 127.8 (CHAr), 130.7 (CHAr), 140.8, 
152.3, 159.3, 161.6, 185.3 (t, 2J(C-F) = 28.5 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –122.2 (s, CF2), –112.5 (m, CF2), –80.4 (t, J = 9.20 
Hz, CF3). 
MS (GC, 70 eV): m/z (%) = 467 ([M]+, 38), 299 (18), 298 (99), 278 (13), 271 (17), 270 
(100), 185 (40), 169 (11), 132 (22), 130 (18), 128 (11), 117 (12), 86 (14), 82 (11), 81 (15), 69 (14). 
HRMS (ESI): Calcd. for C16H15F3N3O3 [M+H]+: 468.11527, found: 468.11572. 
N
N
N
O O
O
F
F
F
N
N
N
O O
O
F
F
F
F
F
F
F
Experimental	Part	
108 
IR (ATR, cm–1): ṽ = 2953 (w), 2867 (w), 1738 (w), 1705 (m), 1657 (s), 1651 (s), 1602 (w), 
1591 (w), 1574 (m), 1557 (w), 1538 (w), 1494 (m), 1472 (m), 1428 (s), 1396 (m), 1370 (w), 1344 
(m), 1320 (w), 1295 (w), 1275 (w), 1217 (s), 1195 (s), 1179 (s), 1150 (s), 1116 (s), 1079 (m), 1026 
(w), 994 (m), 966 (w), 920 (w), 881 (m), 871 (w), 817 (w), 804 (m), 773 (m), 758 (s), 749 (m), 721 
(m), 687 (m), 652 (m), 624 (w), 596 (w), 555 (m), 540 (w). 
 
1,3-Dimethyl-6-[methyl(phenyl)amino]-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-dione 
(90c) 
 
The product was prepared according to the general procedure from 0.35 
g of ,3-dimethyl-6-[methyl(phenyl)amino]pyrimidine-2,4(1H,3H)-dione, 0.135 
g of pyridine and 0.599 g of trifluoroacetic anhydride in 3.5 mL of dry dioxane. 
Yield 0.484 g (99%), yellow solid, mp 137-139 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.16 (s, 3H, CH3), 3.26 (s, 6H, CH3), 6.95-7.08 (m, 
3H, CHPh), 7.26-7.34 (m, 2H, CHPh). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.6 (CH3), 33.6 (CH3), 39.5 (CH3), 103.9 (С-5), 
115.9 (q, 1J(C-F) = 290.9 Hz, CF3), 117.5 (CH), 122.8 (CH), 130.2 (CH), 145.6, 152.3, 161.4, 161.7, 
182.2 (q, 2J(C-F) = 37.2 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –73.9 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 341 ([M]+, 35), 273 (16), 272 (100), 257 (11), 244 (49), 178 
(12), 159 (53), 132 (13), 128 (27), 106 (20), 77 (28), 69 (15), 60 (10). 
HRMS (ESI): Calcd. for C15H15F3N3O3 [M+H]+: 342.10600, found: 342.10622. 
IR (ATR, cm–1): ṽ = 3051 (w), 3022 (w), 1703 (s), 1651 (s), 1645 (s), 1603 (m), 1587 (m), 
1566 (s), 1487 (s), 1441 (s), 1417 (s), 1394 (s), 1331 (m), 1300 (m), 1240 (m), 1230 (m), 1221 (m), 
1188 (s), 1159 (s), 1142 (s), 1117 (s), 1105 (s), 1080 (s), 1049 (m), 1026 (m), 974 (s), 932 (m), 903 
(m), 825 (s), 812 (m), 787 (m), 754 (s), 710 (s), 698 (s), 650 (s), 617 (m), 582 (m), 548 (s). 
 
1,3-Dimethyl-6-piperidin-1-yl-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-dione (78b) 
 
To a solution of 1,3-dimethyl-6-piperidin-1-ylpyrimidine-2,4(1H,3H)-
dione (2.39 g, 10.7 mmol, 1 eq) in 7.2 mL of dry dioxane was added 
trifluoroacetic anhydride (4.497 g, 21.4 mmol, 2 eq). Next day the starting 
material was still observed on TLC. The solvent was evaporated and the residue 
was dried in a high vacuum at 100 °C. Then a new portion of dry dioxane (3.6 mL) and 
trifluoroacetic anhydride (2.248 g, 10.7 mmol, 1 eq) was added and the mixture was allowed to stay 
at r.t. for 3 days. After evaporation and proper drying at 100 °C in a high vacuum the pure title 
N
N
N
O O
O
F
F
F
N
N
N
OO
O
F
F
F
Experimental	Part	
109 
product was obtained. 
Yield 3.401 g (100%), beige solid, mp 253-255 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.60-1.75 (m, 6H, CH2-3', CH2-4', CH2-5'), 2.83-
2.92 (m, 4H, CH2-2', CH2-6'), 3.19 (s, 3H, CH3), 3.40 (s, 3H, CH3). 
13C NMR (62.90 MHz, DMSO-d6): δ = 24.2 (CH2), 25.7 (CH2), 28.3 (CH3), 35.8 (CH3), 
53.1 (CH2-2', CH2-6'), 97.3 (С-5), 116.6 (q, 1J(C-F) = 290.4 Hz, CF3), 152.4, 161.7, 163.3, 182.5 (q, 
2J(C-F) = 36.4 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –73.1 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 319 ([M]+, 0.31), 251 (14), 250 ([M–CF3]+, 100), 222 (20), 128 
(12), 110 (15), 84 (26), 82 (22), 69 (16). 
HRMS (EI): Calcd. for C13H16F3N3O3 [M]+: 353.11383, found: 319.11437. 
IR (ATR, cm–1): ṽ = 3006 (w), 2947 (m), 2856 (w), 1780 (w), 1716 (w), 1684 (m), 1650 (s), 
1552 (m), 1487 (s), 1436 (s), 1401 (m), 1371 (s), 1336 (w), 1300 (w), 1284 (w), 1259 (w), 1245 
(w), 1235 (w), 1217 (m), 1193 (s), 1158 (m), 1139 (s), 1114 (m), 1079 (m), 1067 (w), 1050 (w), 
1020 (m), 980 (s), 956 (m), 912 (w), 858 (m), 826 (m), 811 (w), 793 (s), 758 (s), 715 (m), 706 (m), 
698 (m), 643 (m), 585 (w), 565 (m). 
 
6-(Benzylamino)-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-2,4(1H,3H)-dione (78c) 
 
To a solution of 6-(benzylamino)-1,3-dimethylpyrimidine-2,4(1H,3H)-
dione (1.825 g, 7.44 mmol, 1 eq) in 9.1 mL of dry dioxane was added 
trifluoroacetic anhydride (3.125 g, 14.9 mmol, 2 eq). Next day the starting 
material was still observed on TLC. The solvent was evaporated and the residue 
was dried in a high vacuum at 100 °C. Then a new portion of dry dioxane (4.5 
mL) and trifluoroacetic anhydride (3.125 g, 14.9 mmol, 2 eq) was added and the mixture was 
allowed to stay at r.t. for one day. After that the formed precipitate was filtered off, washed with 
diethyl ether and dried in a high vacuum. 
Yield 2.441 (96%), white solid, mp 177 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.19 (s, 3H, CH3), 3.53 (s, 3H, CH3), 4.68 (d, 2H, J 
= 5.10 Hz, CH2), 7.34-7.48 (m, 5H, CHPh), 10.30 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.6 (CH3), 36.2 (CH3), 51.3 (CH2), 91.6 (С-5), 
118.1 (q, 1J(C-F) = 288.0 Hz, CF3), 128.7 (CHPh), 129.0 (CHPh), 129.7 (CHPh), 137.4, 151.6, 160.4, 
161.5, 177.4 (q, 2J(C-F) = 35.4 Hz, CO). 
19F NMR (282.38 MHz, DMSO-d6): δ = –70.8 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 341 ([M]+, 6.0), 273 (16), 272 ([M–CF3]+, 100), 243 (16), 242 
(49), 226 (25), 157 (13), 122 (31), 105 (11), 91 (73), 82 (27). 
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HRMS (ESI): Calcd. for C15H15F3N3O3 [M+H]+: 342.10600, found: 342.10562. 
IR (ATR, cm–1): ṽ = 3036 (w), 2142 (w), 2012 (w), 1965 (w), 1720 (w), 1668 (m), 1597 (s), 
1582 (s), 1525 (m), 1496 (w), 1485 (w), 1461 (m), 1447 (m), 1439 (m), 1413 (w), 1383 (w), 1357 
(m), 1328 (w), 1304 (m), 1268 (w), 1239 (w), 1222 (w), 1208 (s), 1164 (s), 1150 (s), 1099 (m), 
1082 (m), 1061 (w), 1033 (w), 1025 (w), 995 (s), 972 (w), 963 (m), 930 (w), 907 (w), 853 (w), 829 
(m), 820 (s), 787 (w), 775 (w), 758 (m), 742 (s), 731 (m), 713 (m), 695 (s), 657 (s), 620 (w), 596 
(w), 584 (m), 538 (w). 
 
4.2.6 Synthesis of 5-polyfluoroalkyl-5-deazaalloxazines 
 
General procedure for the synthesis of 5-polyfluoroalkyl-pyrimido[4,5-b]quinoline-2,4-
diones 88a-x. 
Initial 5-(polyfluoroacyl)-6-amino-1,3-dialkylpyrimidine-2,4(1H,3H)-dione 87 (0.3 g) was 
dissolved in concentrated H2SO4 (1.5 mL) and allowed to stand at r.t. for 3 hours. Then the solution 
was poured into ice water and formed precipitate was filtered off by suction and recrystallized from 
methanol giving the pure product. 
 
1,3-Dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione (88a) 
 
The product was prepared according to the general procedure, starting 
from 0.474 g of 87a and 2.4 mL of H2SO4. 
Yield 0.269 g (89%), yellow solid, mp 195 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.52 (s, 3H, CH3-3), 3.83 (s, 3H, CH3-1), 7.55-7.62 (m, 
1H, H-7), 7.81-7.89 (m, 1H, H-8), 8.01-8.06 (m, 1H, H-9), 8.30-8.36 (m, 1H, H-6). 
13C NMR (62.90 MHz, CDCl3): δ = 29.4 (CH3-3), 30.6 (CH3-1), 110.4 (C-4a), 121.7, 123.3 
(q, 1J(C-F) = 278.7 Hz, CF3), 126.1 (q, 4J(C-F) = 6.1 Hz, CH-6), 127.2, 129.1 (CHAr), 133.4 (CHAr), 
138.7 (q, 2J(C-F) = 33.4 Hz, C-5), 148.2, 150.2, 151.1 (CO-2), 159.3 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –52.5 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 310 ([M+H]+, 13), 309 ([M]+, 77), 197 (100). 
HRMS (ESI): Calcd. for C14H11F3N3O2 [M+H]+: 310.07979, found: 310.07967. 
IR (ATR, cm–1): ṽ = 2956 (w), 1713 (s), 1669 (s), 1614 (w), 1583 (s), 1565 (m), 1494 (m), 
1464 (s), 1419 (m), 1378 (s), 1332 (m), 1286 (m), 1216 (m), 1194 (m), 1156 (s), 1142 (s), 1124 (s), 
1100 (s), 1069 (m), 1030 (m), 989 (s), 929 (w), 877 (w), 856 (w), 812 (m), 775 (s), 756 (s), 745 (s), 
712 (w), 624 (s), 592 (m), 550 (m), 532 (w). 
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5-(Heptafluoropropyl)-1,3-dimethylpyrimido[4,5-b]quinoline-2,4(1H,3H)-dione (88b) 
 
The product was prepared according to the general procedure, starting 
from 0.662 g of 87b and 3.3 mL of H2SO4. 
Yield 0.461 g (73%), yellow solid, mp 183 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.51 (s, 3H, CH3-3), 3.84 (s, 3H, 
CH3-1), 7.54-7.64 (m, 1H, H-7), 7.81-7.90 (m, 1H, H-8), 8.06 (d, 1H, 3J = 8.50 Hz, H-9), 8.32 (m, 
1H, 3J = 8.88 Hz, H-6). 
13C NMR (62.90 MHz, CDCl3): δ = 29.7 (CH3-3), 30.8 (CH3-1), 111.7 (C-4a), 122.7, 127.0 
(CH-6), 127.4 (CHAr), 129.4 (CHAr), 133.3 (CHAr), 140.0 (t, 2J(C-F) = 24.3 Hz, C-5), 148.4, 150.3, 
151.1 (CO-2), 159.1 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –116.6 (s, CF2), –92.0 (br s, CF2), –80.0 (t, J = 9.20 
Hz, CF3). 
MS (GC, 70 eV): m/z (%) = 410 ([M+H]+, 11), 409 ([M]+, 60), 298 (13), 297 (100). 
HRMS (ESI): Calcd. for C16H11F7N3O2 [M+H]+: 410.07340, found: 410.07322. 
IR (ATR, cm–1): ṽ = 3154 (w), 1720 (m), 1615 (s), 1614 (w), 1502 (w), 1463 (m), 1424 (m), 
1392 (m), 1376 (m), 1347 (w), 1329 (m), 1293 (w), 1271 (w), 1251 (w), 1225 (s), 1202 (s), 1190 
(s), 1146 (m), 1128 (m), 1111 (s), 1029 (w), 978 (w), 969 (w), 941 (s), 899 (s), 899 (s), 877 (w), 
825 (m), 769 (s), 748 (s), 726 (s), 691 (m), 621 (m), 599 (w), 539 (m). 
 
1,3,7,9-Tetramethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(88c) 
 
The product was prepared according to the general procedure, starting 
from 0.429 g of 87c and 2.1 mL of H2SO4. 
Yield 0.343 g (84%), yellow solid, mp 192 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 2.52 (s, 3H, CH3), 2.72 (s, 3H, 
CH3), 3.51 (s, 3H, CH3-3), 3.82 (s, 3H, CH3-1), 7.56s1H (s, 1H, H-8), 7.91s1H (s, 1H, H-8). 
13C NMR (62.90 MHz, CDCl3): δ = 18.5 (CH3), 22.4 (CH3), 29.3 (CH3-3), 30.4 (CH3-1), 
109.6 (C-4a), 121.9, 122.4 (q, 4J(C-F) = 5.8 Hz, CH-6), 123.4 (q, 1J(C-F) = 278.2 Hz, CF3), 135.8 (CH-
8), 136.4, 137.2 (q, 2J(C-F) = 33.1 Hz, C-5), 138.4, 146.6, 148.0, 151.2 (CO-2), 159.5 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –52.4 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 338 ([M+H]+, 19), 337 ([M]+, 100), 309 (10), 268 (14), 226 
(10), 225 (83). 
HRMS (EI): Calcd. for C16H14F3N3O2 [M]+: 337.10326, found: 337.10302. 
IR (ATR, cm–1): ṽ = 2962 (w), 1713 (m), 1669 (s), 1625 (w), 1570 (s), 1500 (w), 1468 (s), 
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1435 (m), 1408 (m), 1374 (s), 1348 (m), 1317 (m), 1282 (s), 1239 (s), 1198 (m), 1176 (m), 1150 (s), 
1136 (s), 1112 (m), 1101 (s), 1057 (w), 1041 (m), 996 (m), 974 (m), 962 (m), 921 (w), 860 (m), 847 
(w), 827 (w), 811 (s), 776 (w), 764 (w), 750 (s), 729 (w), 705 (m), 690 (m), 674 (w), 660 (m), 585 
(m), 567 (w), 543 (w). 
 
1,3,7,9-Tetramethyl-5-(pentafluoroethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(88d) 
 
The product was prepared according to the general procedure, starting 
from 0.431 g of 87d and 2.2 mL of H2SO4. 
Yield 0.345 g (84%), yellow solid, mp 225 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 2.52 (s, 3H, CH3), 2.72 (s, 3H, 
CH3), 3.51 (s, 3H, CH3-3), 3.82 (s, 3H, CH3-1), 7.56 (s, 1H, H-8), 7.84 (s, 1H, H-8). 
13C NMR (62.90 MHz, CDCl3): δ = 18.7 (CH3), 22.6 (CH3), 29.5 (CH3-3), 30.6 (CH3-1), 
110.6 (C-4a), 122.81 (CH-6), 122.85, 135.8 (CH-8), 136.7, 137.0, 139.4 (t, 2J(C-F) = 24.1 Hz, C-5), 
146.8, 148.0, 151.2 (CO-2), 159.7 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –91.0 (s, CF2), –74.8 (t, J = 2.0 Hz, CF3). 
MS (GC, 70 eV): m/z (%) = 388 ([M+H]+, 18), 387 ([M]+, 92), 359 (11), 330 (11), 276 (15), 
275 (100), 268 (12). 
HRMS (EI): Calcd. for C17H14F5N3O2 [M]+: 387.10007, found: 387.09992. 
IR (ATR, cm–1): ṽ = 3369 (w), 2919 (w), 1713 (m), 1668 (s), 1625 (w), 1566 (s), 1504 (w), 
1470 (m), 1444 (m), 1435 (m), 1378 (m), 1348 (w), 1292 (m), 1232 (w), 1209 (s), 1192 (s), 1182 
(m), 1162 (s), 1133 (s), 1107 (s), 1062 (s), 1037 (m), 1020 (s), 985 (s), 958 (m), 906 (w), 859 (m), 
816 (m), 763 (w), 737 (w), 762 (w), 742 (s), 727 (s), 691 (m), 658 (m), 599 (w), 586 (m), 567 (m), 
552 (w), 531 (m). 
 
5-(Heptafluoropropyl)-1,3,7,9-tetramethylpyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(88e) 
 
The product was prepared according to the general procedure, starting 
from 0.485 g of 87e and 2.4 mL of H2SO4. 
Yield 0.429 g (92%), yellow solid, mp 198-200 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 2.53 (s, 3H, CH3), 2.73 (s, 3H, 
CH3), 3.51 (s, 3H, CH3-3), 3.84 (s, 3H, CH3-1), 7.58 (s, 1H, H-8), 7.93 (s, 1H, 
H-8). 
13C NMR (62.90 MHz, CDCl3): δ = 18.7 (CH3), 22.6 (CH3), 29.6 (CH3-3), 30.7 (CH3-1), 
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111.0 (C-4a), 123.0, 123.3 (CH-6), 135.8 (CH-8), 136.7, 137.0, 139.0 (t, 2J(C-F) = 23.8 Hz, C-5), 
146.9, 148.1, 151.3 (CO-2), 159.4 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –116.5 (s, CF2), –90.2 (br s, CF2), –80.0 (t, J = 8.7 Hz, 
CF3). 
MS (GC, 70 eV): m/z (%) = 438 ([M+H]+, 20), 437 ([M]+, 100), 409 (10), 380 (11), 326 
(16), 325 (100), 268 (10), 220 (14), 206 (12). 
HRMS (EI): Calcd. for C18H14F3N3O2 [M]+: 437.09688, found: 437.09679. 
IR (ATR, cm–1): ṽ = 2929 (w), 1722 (m), 1678 (s), 1626 (w), 1568 (s), 1494 (w), 1469 (m), 
1444 (m), 1376 (s), 1346 (m), 1313 (w), 1289 (w), 1266 (w), 1255 (w), 1228 (s), 1219 (s), 1198 (s), 
1176 (s), 1130 (m), 1114 (s), 1055 (w), 1035 (w), 1001 (w), 977 (w), 913 (s), 861 (w), 815 (m), 785 
(w), 758 (w), 746 (m), 732 (s), 693 (w), 658 (w), 623 (m), 599 (w), 584 (w), 564 (w), 535 (m). 
 
7-Ethyl-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(88f) 
 
The product was prepared according to the general procedure, 
starting from 0.363 g of 87f and 1.8 mL of H2SO4. 
Yield 0.173 g (50%), yellow solid, mp 164 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 1.30 (t, 3H, 3J = 7.55 Hz, Et), 2.79 (q, 2H, 3J = 7.55 Hz, 
Et), 3.41 (s, 3H, CH3-3), 3.69 (s, 3H, CH3-1), 7.61 (dd, 1H, 3J = 8.69 Hz, 4J = 1,80 Hz, H-8), 7.80 
(d, 1H, 3J = 8.69 Hz, H-9), 7.96 (s, 1H, H-6). 
13C NMR (62.90 MHz, CDCl3): δ = 15.4 (CH3(Et)), 29.4 (CH3-3), 29.6 (CH2(Et)), 30.5 (CH3-
1), 110.2 (C-4a), 121.9 (C-5a), 123.4 (q, 1J(C-F) = 278.7 Hz, CF3), 123.5 (q, 4J(C-F) = 5.9 Hz, CH-6), 
128.9 (CH, C-9), 134.8 (CH, C-8), 137.8 (q, 2J(C-F) = 33.3 Hz, C-5), 143.5 (C-9a), 147.7 (C-10a), 
149.2 (C-7), 151.2 (CO-2), 159.5 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –52.5 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 338 ([M+H]+, 19), 337 ([M]+, 100), 322 (27), 309 (10), 268 
(16), 265 (16), 226 (11), 225 (77), 224 (11), 210 (12). 
HRMS (ESI): Calcd. for C16H15F3N3O2 [M+H]+: 338.11109, found: 338.11193. 
IR (ATR, cm–1): ṽ = 3380 (w), 2970 (w), 1716 (m), 1674 (s), 1620 (w), 1576 (s), 1498 (w), 
1457 (s), 1413 (m), 1376 (s), 1356 (m), 1352 (m), 1286 (m), 1251 (w), 1221 (m), 1196 (m), 1147 
(s), 1130 (s), 1109 (s), 1071 (m), 1056 (m), 989 (m), 944 (w), 883 (w), 860 (w), 843 (s), 823 (w), 
809 (m), 776 (w), 748 (s), 700 (m), 674 (m), 636 (m), 602 (w), 568 (m), 535 (w). 
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5-[Chloro(difluoro)methyl]-7-ethyl-1,3-dimethylpyrimido[4,5-b]quinoline-2,4(1H,3H)-
dione (88g) 
 
The product was prepared according to the general procedure, 
starting from 0.369 g of 87g and 1.8 mL of H2SO4. 
Yield 0.199 g (57%), yellow solid, mp 188 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 1.36 (t, 3H, 3J = 7.56 Hz, Et), 
2.87 (q, 2H, 3J = 7.56 Hz, Et), 3.51 (s, 3H, CH3-3), 3.81 (s, 3H, CH3-1), 7.71 (d, 1H, 3J = 8.68 Hz, 
H-8), 7.94 (d, 1H, 3J = 8.68 Hz, H-9), 8.08 (s, 1H, H-6). 
13C NMR (62.90 MHz, CDCl3): δ = 15.4 (CH3(Et)), 29.4 (CH3-3), 29.6 (CH2(Et)), 30.6 (CH3-
1), 108.3 (C-4a), 120.7 (C-5a), 123.7 (t, 4J(C-F) = 7.8 Hz, CH-6), 123.9 (t, 1J(C-F) = 290.6 Hz, CClF2), 
128.8 (CH, C-9), 134.6 (CH, C-8), 143.1 (C-9a), 143.3 (t, 2J(C-F) = 27.4 Hz, C-5), 147.6 (C-10a), 
149.1 (C-7), 151.2 (CO-2), 159.6 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –40.7 (br s, CClF2). 
MS (GC, 70 eV): m/z (%) = 355 ([M+H]+, 37Cl, 35), 354 ([M+H]+, 35Cl, 20), 353 ([M]+, 
35Cl, 100), 338 (22), 319 (17), 318 (83), 303 (13), 268 (18), 243 (20), 241 (59). 
HRMS (ESI): Calcd. for C16H15ClF2N3O2 [M+H, 35Cl]+: 354.08154, found: 354.08121. 
IR (ATR, cm–1): ṽ = 3370 (w), 2966 (w), 1715 (m), 1667 (s), 1622 (w), 1573 (s), 1503 (w), 
1470 (m), 1454 (s), 1414 (m), 1378 (s), 1358 (m), 1322 (m), 1291 (m), 1274 (m), 1253 (w), 1204 
(w), 1192m 1152 (m), 1140 (m), 1115 (s), 1095 (m), 1069 (m), 1005 (s), 994 (m), 552 (s), 927 (s), 
881 (w), 845 (s), 832 (w), 817 (m), 796 (s), 770 (w), 793 (s), 689 (w), 675 (w), 661 (m), 632 (w), 
621 (w), 580 (w), 560 (m). 
 
7-Ethyl-1,3-dimethyl-5-(pentafluoroethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(88h) 
 
The product was prepared according to the general procedure, 
starting from 0.466 g of 87h and 2.3 mL of H2SO4. 
Yield 0.359 g (81%), yellow solid, mp 235 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 1.35 (t, 3H, 3J = 7.55 Hz, Et), 
2.86 (q, 2H, 3J = 7.55 Hz, Et), 3.51 (s, 3H, CH3-3), 3.82 (s, 3H, CH3-1), 7.72 (d, 1H, 3J = 8.88 Hz, 
H-8), 7.97 (d, 1H, 3J = 8.88 Hz, H-9), 8.01 (s, 1H, H-6). 
13C NMR (62.90 MHz, CDCl3): δ = 15.3 (CH3(Et)), 29.6 (CH3-3), 29.6 (CH2(Et)), 30.7 (CH3-
1), 111.1 (C-4a), 122.7 (C-5a), 123.9 (CH-6), 129.1 (CH, C-9), 134.9 (CH, C-8), 139.4 (t, 2J(C-F) = 
24.0 Hz, C-5), 143.4 (C-9a), 147.9 (C-10a), 149.1 (C-7), 151.2 (CO-2), 159.5 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –91.4 (s, CF2), –75.0 (t, J = 2.0 Hz, CF3). 
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MS (GC, 70 eV): m/z (%) = 388 ([M+H]+, 18), 387 ([M]+, 91), 372 (24), 359 (11), 315 (19), 
276 (14), 275 (100), 268 (12), 260 (12). 
HRMS (EI): Calcd. for C17H14F5N3O2 [M]+: 387.10007, found: 387.09992. 
IR (ATR, cm–1): ṽ = 3381 (w), 2973 (w), 1719 (m), 1675 (s), 1621 (w), 1568 (s), 1504 (w), 
1494 (w), 1454 (s), 1410 (m), 1376 (m), 1339 (w), 1313 (w), 1294 (s), 1229 (m), 1176 (s), 1146 (s), 
1128 (s), 1107 (s), 1069 (m), 1036 (s), 1006 (w), 969 (s), 939 (m), 895 (w), 846 (s), 822 (w), 805 
(m), 758 (w), 746 (s), 736 (m), 725 (s), 683 (m), 672 (m), 635 (w), 598 (w), 578 (w), 557 (m). 
 
9-Methoxy-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(88i) 
 
The product was prepared according to the general procedure, starting 
from 0.319 g of 87i and 1.6 mL of H2SO4. 
Yield 0.147 g (49%), yellow solid, mp 220 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.52 (s, 3H, CH3-3), 3.87 (s, 3H, 
CH3-1), 4.08 (s, 3H, MeO), 7.19 (d, 1H, 3J = 7.74 Hz, H-8), 7.49 (dd, 1H, 3J1 = 9.06 Hz, 3J2 = 7.74 
Hz, H-7), 7.84-7.92 (m, 1H, H-6). 
13C NMR (62.90 MHz, CDCl3): δ = 29.4 (CH3-3), 30.7 (CH3-1), 56.7 (MeO), 110.6 (C-4a), 
111.3 (CHAr), 117.6 (q, 4J(C-F) = 6.1 Hz, CH-6), 122.9, 123.2 (q, 1J(C-F) = 278.7 Hz, CF3), 127.3 
(CHAr), 138.5 (q, 2J(C-F) = 33.5 Hz, C-5), 142.5, 147.4, 151.2 (CO-2), 154.8 (C-9), 159.4 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –52.6 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 340 ([M+H]+, 17), 339 ([M]+, 100), 310 (37), 309 (12), 281 
(20), 267 (13), 253 (26), 252 (12), 227 (24). 
HRMS (EI): Calcd. for C15H12F3N3O3 [M+H]+: 339.08253, found: 339.08253. 
IR (ATR, cm–1): ṽ = 2953 (w), 2848 (w), 1714 (m), 1667 (s), 1611 (w), 1566 (m), 1504 (w), 
1485 (m), 1465 (m), 1444 (w), 1421 (m), 1393 (w), 1376 (m), 1353 (w), 1318 (w), 1287 (s), 1256 
(w), 1233 (s), 1207 (m), 1197 (m), 1161 (s), 1147 (s), 1122 (s), 1099 (m), 1059 (m), 1004 (s), 976 
(m), 877 (w), 862 (w), 838 (w), 822 (w), 788 (s), 778 (m), 757 (m), 747 (s), 714 (m), 700 (s), 688 
(m), 674 (w), 615 (m), 595 (w), 586 (w), 538 (w). 
 
5-[Chloro(difluoro)methyl]-9-methoxy-1,3-dimethylpyrimido[4,5-b]quinoline-
2,4(1H,3H)-dione (88j) 
 
The product was prepared according to the general procedure, starting 
from 0.344 g of 87j and 1.7 mL of H2SO4. 
Yield 0.218 g (67%), yellow solid, mp 210 °C. 
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1H NMR (300.13 MHz, CDCl3): δ = 3.52 (s, 3H, CH3-3), 3.87 (s, 3H, CH3-1), 4.08 (s, 3H, 
MeO), 7.18 (d, 1H, 3J = 7.74 Hz, H-8), 7.50 (dd, 1H, 3J1 = 9.07 Hz, 3J2 = 7.74 Hz, H-7), 7.86-7.93 
(m, 1H, H-6). 
13C NMR (62.90 MHz, CDCl3): δ = 29.5 (CH3-3), 30.7 (CH3-1), 56.7 (MeO), 108.7 (C-4a), 
111.2 (CHAr), 117.9 (t, 4J(C-F) = 7.9 Hz, CH-6), 121.8, 123.9 (t, 1J(C-F) = 291.2 Hz, CF3), 127.0 
(CHAr), 142.4, 144.0 (t, 2J(C-F) = 27.5 Hz, C-5), 147.3, 151.2 (CO-2), 154.8 (C-9), 159.5 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –40.1 (br s, CClF2). 
MS (GC, 70 eV): m/z (%) = 357 ([M]+, 37Cl, 34), 356 ([M+H]+, 35Cl, 28), 355 ([M]+, 35Cl, 
100), 354 (37), 328 (12), 327 (10), 326 (33), 325 (11), 320 (33), 297 (12), 269 (15), 263 (15), 243 
(21). 
HRMS (EI): Calcd. for C15H12ClF2N3O3 [M, 35Cl]+: 355.05298, found: 355.05262; calcd. for 
C15H12ClF2N3O3 [M, 37Cl]+: 357.05003, found: 357.05014. 
Anal. Calcd for C15H12ClF2N3O3: C, 50.65; H, 3.40; N, 11.81. Found: C, 50.87; H, 3.30; N, 
11.96. 
IR (ATR, cm–1): ṽ = 3377 (w), 2963 (w), 1717 (s), 1667 (s), 1611 (w), 1578 (s), 1564 (s), 
1504 (m), 1485 (m), 1463 (m), 1454 (m), 1421 (s), 1392 (m), 1371 (m), 1350 (m), 1317 (w), 1277 
(s), 1249 (m), 1214 (s), 1186 (m), 1126 (s), 1101 (m), 1092 (s), 1059 (m), 1013 (s), 980 (m), 952 
(s), 926 (s), 880 (m), 862 (w), 825 (w), 782 (s), 773 (s), 756 (m), 746 (s), 706 (w), 680 (m), 662 
(m), 629 (w), 610 (m), 587 (w), 563 (w), 534 (w). 
 
8-Methoxy-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(88k) 
 
The product was prepared according to the general procedures for the 
synthesis of 87 and 88, starting from 0.4 g of 6-[(3-methoxyphenyl)amino]-
1,3-dimethylpyrimidine-2,4(1H,3H)-dione 70f, 0.145 g of pyridine and 
0.643 g of trifluoroacetic anhydride in 4 mL of dioxane; than to isolated 
crude product were added 2.5 mL of H2SO4. 
Yield 0.062 g (12% after two steps; calculated on 70f), yellow solid, mp 232-235 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.49 (s, 3H, CH3-3), 3.80 (s, 3H, CH3-1), 4.01 (s, 3H, 
MeO), 7.20 (dd, 1H, 3J = 9.63 Hz, 4J = 2.65 Hz, H-7), 7.28 (d, 1H, 4J = 2.65 Hz, H-9), 8.20 (dq, 1H, 
3J = 9.63 Hz, 5J(H-F) = 2.08 Hz, H-6). 
13C NMR (62.90 MHz, CDCl3): δ = 29.4 (CH3-3), 30.6 (CH3-1), 56.2 (MeO), 106.7 (CHAr), 
107.6 (C-4a), 117.3, 121.3 (CHAr), 123.4 (q, 1J(C-F) = 278.5 Hz, CF3), 127.5 (q, 4J(C-F) = 6.3 Hz, CH-
6), 138.3 (q, 2J(C-F) = 33.8 Hz, C-5), 149.0, 151.3 (CO-2), 153.0, 159.5 (CO-4), 163.8 (CH-8). 
19F NMR (282.38 MHz, CDCl3): δ = –52.4 (s, CF3). 
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MS (GC, 70 eV): m/z (%) = 340 ([M+H]+, 11), 339 ([M]+, 66), 311 (12), 270 (21), 228 (13), 
227 (100). 
HRMS (EI): Calcd. for C15H12F3N3O3 [M+H]+: 339.08253, found: 339.08256. 
IR (ATR, cm–1): ṽ = 3373 (w), 2953 (w), 1716 (m), 1669 (s), 1620 (m), 1569 (m), 1504 (w), 
1480 (m), 1471 (m), 1451 (m), 1412 (m), 1381 (m), 1352 (m), 1329 (w), 1289 (m), 1273 (w), 1233 
(s), 1215 (s), 1157 (s), 1132 (s), 1019 (m), 992 (m), 976 (m), 959 (w), 895 (w), 853 (s), 832 (m), 
803 (s), 749 (s), 733 (w), 698 (m), 673 (w), 639 (s), 571 (w), 544 (w). 
 
5-[Chloro(difluoro)methyl]-8-methoxy-1,3-dimethylpyrimido[4,5-b]quinoline-
2,4(1H,3H)-dione (88l) 
 
The product was prepared according to the general procedures for the 
synthesis of 87 and 88, starting from 0.4 g of 6-[(3-methoxyphenyl)amino]-
1,3-dimethylpyrimidine-2,4(1H,3H)-dione 70f, 0.145 g of pyridine and 
0.744 g of chlorodifluoroacetic anhydride in 4 mL of dioxane; than to 
isolated crude product were added 2.7 mL of H2SO4. 
Yield 0.218 g (40% after two steps; calculated on 70f), yellow solid, mp 272-274 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.51 (s, 3H, CH3-3), 3.81 (s, 3H, CH3-1), 4.01 (s, 3H, 
MeO), 7.22 (dd, 1H, 3J = 9.63 Hz, 4J = 2.83 Hz, H-7), 7.29 (d, 1H, 4J = 2.83 Hz, H-9), 8.22 (dt, 1H, 
3J = 9.63 Hz, 5J(H-F) = 2.90 Hz, H-6). 
13C NMR (75.47 MHz, 12% TFA-d in CDCl3): δ = 30.2 (CH3), 31.7 (CH3), 56.9 (OMe), 
103.3 (CH), 105.8 (C-4a), 116.3, 122.6 (CH), 123.0 (t, 1J(C-F) = 292.1 Hz, CClF2), 129.0 (t, 4J(C-F) = 
8.2 Hz, CH-6), 147.9, 148.1, 148.2 (t, 2J(C-F) = 28.6 Hz), 150.7 (CO-2), 158.7 (CO-4), 166.7. 
19F NMR (282.38 MHz, CDCl3): δ = –40.4 (br s, CClF2). 
MS (GC, 70 eV): m/z (%) = 357 ([M]+, 37Cl, 29), 356 ([M+H]+, 35Cl, 14), 355 ([M]+, 35Cl, 
83), 327 (11), 321 (16), 320 (41), 270 (36), 245 (33), 244 (14), 243 (100), 209 (10). 
HRMS (EI): Calcd. for C15H12ClF2N3O3 [M, 35Cl]+: 355.05298, found: 355.05401. 
IR (ATR, cm–1): ṽ = 3366 (w), 2952 (w), 1713 (s), 1668 (s), 1619 (m), 1566 (s), 1503 (m), 
1482 (s), 1470 (m), 1449 (s), 1411 (m), 1380 (s), 1348 (m), 1326 (w), 1288 (m), 1269 (w), 1232 (s), 
1190 (m), 1136 (s), 1114 (s), 1020 (m), 1003 (s), 975 (w), 959 (m), 946 (s), 851 (s), 826 (m), 804 
(m), 791 (s), 767 (m), 749 (s), 742 (m), 729 (w), 702 (w), 679 (w), 664 (m), 634 (s), 606 (w), 557 
(m), 528 (m). 
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5-(Heptafluoropropyl)-8-methoxy-1,3-dimethylpyrimido[4,5-b]quinoline-2,4(1H,3H)-
dione (88m) 
 
The product was prepared according to the general procedure, 
starting from 0.658 g of 87m and 3.3 mL of H2SO4. 
Yield 0.204 g (32%), yellow solid, mp 214-216 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.50 (s, 3H, CH3-3), 3.82 (s, 3H, 
CH3-1), 4.02 (s, 3H, MeO), 7.21 (dd, 1H, 3J = 9.82 Hz, 4J = 2.79 Hz), H-7, 7.31 (d, 1H, 4J = 2.79 
Hz, H-9), 8.20 (d, 1H, 3J = 9.82 Hz, H-6). 
13C NMR (62.90 MHz, CDCl3): δ = 29.6 (CH3-3), 30.7 (CH3-1), 56.2 (MeO), 106.8 (CHAr), 
108.9 (C-4a), 118.3, 121.3 (CHAr), 128.4 (CH-6), 139.4 (t, 2J(C-F) = 23.5 Hz, C-5), 149.2, 151.3 
(CO-2), 153.0, 159.2 (CO-4), 163.7 (CH-8). 
19F NMR (282.38 MHz, CDCl3): δ = –116.8 (s, CF2), –90.4 (br s, CF2), –80.0 (t, J = 8.7 Hz, 
CF3). 
MS (GC, 70 eV): m/z (%) = 440 ([M+H]+, 12), 439 ([M]+, 64), 411 (12), 328 (14), 327 
(100), 270 (11). 
HRMS (ESI): Calcd. for C17H13F7N3O3 [M+H]+: 440.08397, found: 440.08478. 
Anal. Calcd for C17H12F7N3O3: C, 46.48; H, 2.75; N, 9.57. Found: C, 46.65; H, 2.55; N, 
10.06. 
IR (ATR, cm–1): ṽ = 3151 (w), 2953 (w), 2848 (w), 1715 (m), 1682 (s), 1620 (m), 1565 (s), 
1504 (m), 1485 (s), 1446 (m), 1410 (m), 1380 (s), 1348 (m), 1288 (m), 1271 (w), 1233 (s), 1200 (s), 
1185 (s), 1172 (s), 1141 (s), 1132 (s), 1112 (s), 1069 (w), 1041 (w), 1017 (m), 1002 (m), 975 (w), 
961 (w), 931 (s), 854 (s), 824 (m), 804 (m), 790 (m), 770 (w), 752 (s), 734 (m), 723 (m), 703 (w), 
692 (w), 654 (w), 641 (m), 620 (m), 597 (w), 558 (m), 537 (w). 
 
1,3-Dimethyl-5,8-bis(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione (88n) 
 
The product was prepared according to the general procedure, 
starting from 0.475 g of 87n and 2.4 mL of H2SO4. 
Yield 0.233 g (51%), yellow solid, mp 199-201 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.53 (s, 3H, CH3-3), 3.84 (s, 3H, 
CH3-1), 7.75 (dd, 1H, 3J = 9.16 Hz, 4J = 1.98 Hz, H-7), 8.33-8.36 (m, 1H, H-9), 8.42-8.50 (dm, 1H, 
3J = 9.16 Hz, H-6). 
13C NMR (62.90 MHz, CDCl3): δ = 29.6 (CH3-3), 30.9 (CH3-1), 112.2 (C-4a), 122.7 (CHAr), 
122.9 (q, 1J(C-F) = 278.4 Hz, CF3), 123.0, 123.5 (q, 1J(C-F) = 273.0 Hz, CF3), 126.8 (q, 4J(C-F) = 4.4 
Hz, CHAr), 127.8 (q, 4J(C-F) = 6.2 Hz, CHAr), 134.7 (q, 2J(C-F) = 33.4 Hz), 139.1 (q, 2J(C-F) = 33.9 Hz), 
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149.3, 149.4, 150.9 (CO-2), 158.9 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –63.7 (s, CF3-8), –52.7 (s, CF3-5). 
MS (GC, 70 eV): m/z (%) = 377 ([M]+, 52), 265 (100). 
HRMS (EI): Calcd. for C15H9F6N3O2 [M]+: 377.05935, found: 377.05920. 
IR (ATR, cm–1): ṽ = 3388 (w), 3107 (w), 2966 (w), 1722 (m), 1668 (s), 1585 (m), 1565 (m), 
1511 (w), 1464 (m), 1422 (m), 1393 (w), 1378 (m), 1361 (m), 1336 (m), 1300 (m), 1272 (m), 1222 
(w), 1172 (s), 1122 (s), 1104 (s), 1072 (s), 966 (m), 945 (m), 910 (s), 885 (m), 831 (m), 804 (s), 780 
(w), 760 (w), 745 (s), 710 (m), 700 (s), 679 (m), 673 (m), 657 (w), 630 (m), 581 (w), 553 (w). 
 
1,3-Dimethyl-7-nitro-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(88o) 
 
The product was prepared according to the general procedure, 
starting from 0.309 g of 87o and 1.5 mL of H2SO4. 
Yield 0.242 g (82%), yellow solid, mp 232-234 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.53 (s, 3H, CH3-3), 3.85 (s, 3H, 
CH3-1), 8.17 (d, 1H, 3J = 9.54 Hz, H-9), 8.61 (d, 1H, 3J = 9.54 Hz, H-8), 9.32 (s, 1H, H-6). 
13C NMR (62.90 MHz, CDCl3): δ = 29.8 (CH3-3), 31.1 (CH3-1), 112.5 (C-4a), 120.2, 122.7 
(q, 1J(C-F) = 278.6 Hz, CF3), 123.6 (q, 4J(C-F) = 6.7 Hz, CH-6), 126.7 (CHAr), 130.8 (CHAr), 141.0 (q, 
2J(C-F) = 34.1 Hz, C-5), 145.8, 150.7, 150.8, 152.0 (CO-2), 158.5 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –52.6 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 354 ([M]+, 49), 243 (12), 242 (100), 196 (13). 
HRMS (EI): Calcd. for C14H9F3N4O4 [M]+: 354.05704, found: 354.05725. 
IR (ATR, cm–1): ṽ = 3392 (w), 3133 (w), 2965 (w), 1725 (m), 1680 (s), 1623 (w), 1586 (m), 
1574 (s), 1532 (m), 1496 (m), 1471 (s), 1417 (w), 1373 (m), 1363 (w), 1340 (w), 1294 (m), 1280 
(s), 1230 (w), 1203 (m), 1180 (m), 1155 (s), 1136 (s), 1110 (s), 1070 (w), 993 (m), 986 (m), 972 
(w), 948 (w), 907 (m), 868 (m), 844 (s), 810 (w), 793 (w), 723 (w), 760 (w), 748 (s), 740 (s), 713 
(w), 703 (m), 675 (w), 647 (m), 633 (m), 565 (m), 539 (w), 527 (w). 
 
7-Bromo-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(88p) 
 
The product was prepared according to the general procedure, starting 
from 1.401 g of 87p and 7 mL of H2SO4. 
Yield 1.121 g (84%), yellow solid, mp 200 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.49 (s, 3H, CH3-3), 3.78 (s, 3H, 
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CH3-1), 7.86 (s, 2H, H-8, H-9), 8.41 (s, 1H, H-6). 
13C NMR (75.48 MHz, CDCl3): δ = 29.5 (CH3-3), 30.7 (CH3-1), 111.1 (C-4a), 121.5, 122.5, 
123.0 (q, 1J(C-F) = 278.3 Hz, CF3), 128.2 (q, 4J(C-F) = 6.6 Hz, CH-6), 130.6 (CHAr), 136.8 (CHAr), 
137.8 (q, 2J(C-F) = 33.8 Hz, C-5), 148.5, 148.8, 151.0 (CO-2), 159.0 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –52.7 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 390 ([M+H]+, 81Br, 13), 389 ([M]+, 81Br, 81), 388 ([M+H]+, 
79Br, 15), 387 ([M]+, 79Br, 84), 291 (15), 289 (16), 278 (11), 277 (97), 276 (15), 275 (100), 263 
(11), 261 (11), 182 (11), 176 (11). 
HRMS (EI): Calcd. for C14H9BrF3N3O2 [M, 79Br]+: 386.98248, found: 386.9826; calcd. for 
C14H11F3N3O2 [M, 81Br]+: 388.98043, found: 388.98055. 
IR (ATR, cm–1): ṽ = 3380 (w), 3116 (w), 2962 (w), 2849 (w), 1719 (m), 1668 (s), 1581 (s), 
1564 (s), 1556 (m), 1463 (s), 1447 (s), 1410 (m), 1384 (m), 1372 (s), 1358 (m), 1320 (m), 1295 (m), 
1281 (s), 1228 (w), 1205 (m), 1162 (s), 1129 (s), 1103 (s), 1075 (s), 986 (s), 969 (m), 936 (m), 875 
(w), 858 (w), 831 (s), 808 (m), 797 (w), 772 (w), 757 (w), 748 (s), 713 (w), 702 (s), 672 (m), 639 
(s), 630 (m), 559 (m), 552 (m), 532 (m). 
 
7-Ethoxy-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(88q) 
 
The product was prepared according to the general procedure, 
starting from 0.397 g of 87q and 2 mL of H2SO4. 
Yield 0.276 g (73%), yellow solid, mp 210-212 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 1.44 (t, 3H, 3J = 7.55 Hz, 
EtO), 3.44 (s, 3H, CH3-3), 3.74 (s, 3H, CH3-1), 4.11 (q, 2H, 3J = 7.55 Hz, EtO), 7.41-7.48 (m, 2H, 
H-6, H-8), 7.85 (d, 1H, 3J = 10,01 Hz, H-9). 
13C NMR (62.90 MHz, CDCl3): δ = 14.9 (CH3(EtO)), 29.5 (CH3-3), 30.6 (CH3-1), 64.4 
(CH2(EtO)), 103.9 (q, 4J(C-F) = 6.3 Hz, CH-6), 110.3 (C-4a), 123.1, 123.6 (q, 1J(C-F) = 277.29 Hz, 
CF3), 127.5 (CHAr), 130.5 (CHAr), 136.2 (q, 2J(C-F) = 33.1 Hz, C-5), 146.8, 146.9, 151.2 (CO-2), 
157.6 (C-7), 159.6 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –53.1 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 354 ([M+H]+, 17), 353 ([M]+, 100), 325 (20), 268 (14), 267 
(15), 241 (11), 213 (41). 
HRMS (EI): Calcd. for C16H14F3N3O3 [M]+: 353.09818, found: 353.09811. 
IR (ATR, cm–1): ṽ = 2991 (w), 1742 (s), 1675 (s), 1623 (m), 1583 (s), 1504 (w), 1471 (m), 
1455 (m), 1425 (m), 1414 (s), 1386 (s), 1372 (s), 1324 (w), 1288 (s), 1232 (s), 1209 (s), 1171 (s), 
1159 (s), 1123 (s), 1066 (w), 1040 (s), 988 (m), 953 (w), 916 (w), 861 (w), 845 (s), 830 (m), 806 
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(m), 773 (w), 764 (w), 748 (s), 709 (w), 698 (s), 679 (m), 667 (w), 653 (w), 578 (s), 559 (w), 537 
(w). 
 
5-(Difluoromethyl)-7-ethoxy-1,3-dimethylpyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(88r) 
 
The product was prepared according to the general procedure, 
starting from 0.469 g of 87r and 2.3 mL of H2SO4. 
Yield 0.354 g (80%), yellow solid, mp 238 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 1.50 (t, 3H, 3J = 6.99 Hz, EtO), 3.51 (s, 3H, CH3-3), 
3.81 (s, 3H, CH3-1), 4.19 (q, 2H, 3J = 6.99 Hz, EtO), 7.50 (dd, 1H, 3J = 9.26 Hz, 4J = 2.64 Hz, H-8), 
7.76 (d, 1H, 4J = 2.64 Hz, H-6), 7.89 (d, 1H, 3J = 9.26 Hz, H-9), 8.86 (t, 1H, 2J(H-F) = 53.92 Hz, 
CH2F). 
13C NMR (62.90 MHz, CDCl3): δ = 14.9 (CH3(EtO)), 29.3 (CH3-3), 30.6 (CH3-1), 64.3 
(CH2(EtO)), 105.2 (t, 4J(C-F) = 6.0 Hz, CH-6), 108.6 (C-4a), 112.1 (t, 1J(C-F) = 239.6 Hz, CHF2), 123.0, 
127.6 (CHAr), 130.3 (CHAr), 141.9 (t, 2J(C-F) = 23.7 Hz, C-5), 146.5, 146.5, 151.0 (CO-2), 157.2, 
161.9. 
19F NMR (282.38 MHz, CDCl3): δ = –112.5 (s, CHF2). 
MS (GC, 70 eV): m/z (%) = 336 ([M+H]+, 18), 335 ([M]+, 100), 307 (46), 306 (13), 279 
(14), 256 (13), 195 (43). 
HRMS (EI): Calcd. for C16H15F2N3O3 [M]+: 335.10760, found: 335.10773. 
IR (ATR, cm–1): ṽ = 3353 (w), 3139 (w), 3078 (w), 2989 (w), 2942 (w), 2918 (w), 2849 (w), 
1705 (s), 1659 (s), 1621 (m), 1583 (m), 1538 (w), 1499 (w), 1477 (m), 1462 (m), 1450 (m), 1422 
(m), 1412 (m), 1384 (m), 1321 (w), 1290 (m), 1271 (w), 1251 (w), 1223 (m), 1185 (m), 1148 (m), 
1116 (m), 1095 (m), 1029 (s), 992 (m), 978 (m), 955 (w), 936 (m), 900 (w), 843 (s), 827 (m), 806 
(s), 767 (w), 759 (w), 747 (s), 719 (m), 682 (m), 581 (s), 555 (m). 
 
5-(Difluoromethyl)-7-methoxy-1,3-dipropylpyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(88s) 
 
The product was prepared according to the general procedures for 
the synthesis of 87 and 88, starting from 0.3 g of 6-[(4-
methoxyphenyl)amino]-1,3-dipropylpyrimidine-2,4(1H,3H)-dione 70a, 
0.09 g of pyridine and 0.329 g of difluoroacetic anhydride in 3 mL of 
dioxane; than to isolated crude product were added 2 mL of H2SO4. 
Yield 0.307 g (86% after two steps; calculated on 70a), yellow solid, mp 167-168 °C. 
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1H NMR (300.13 MHz, CDCl3): δ = 0.94-1.11 (m, 6H, CH3(Pr-1), CH3(Pr-3)), 1.66-1.89 (m, 
4H, CH2(Pr-1), CH2(Pr-3)), 3.95 (s, 3H, MeO), 4.06 (t, 2H, 3J = 7.55 Hz, NCH2-3), 4.41 (t, 2H, 3J = 
7.46 Hz, NCH2-1), 7.48 (d, 1H, H-8), 7.77 (s, 1H, H-6), 7.88 (d, 1H, 3J = 9.15 Hz, H-9), 8.86 (t, 1H, 
2J(H-F) = 54.01 Hz, CH2F). 
13C NMR (75.48 MHz, CDCl3): δ = 11.6 (CH3(Pr)), 11.7 (CH3(Pr)), 21.3 (CH2(Pr)), 21.4 
(CH2(Pr)), 44.3 (CH2(Pr)), 45.0 (CH2(Pr)), 55.9 (MeO), 104.5 (t, 4J(C-F) = 6.0 Hz, CH-6), 108.8 (C-4a), 
112.2 (t, 1J(C-F) = 239.11 Hz, CHF2), 122.9, 127.2 (CHAr), 130.4 (CHAr), 142.0 (t, 2J(C-F) = 23.7 Hz, 
C-5), 146.3, 146.7, 150.5 (CO-2), 157.7, 161.6. 
19F NMR (282.38 MHz, CDCl3): δ = –112.4 (s, CHF2). 
MS (GC, 70 eV): m/z (%) = 378 ([M+H]+, 17), 377 ([M]+, 76), 336 (18), 335 (100), 307 
(17), 294 (21), 293 (100), 277 (26), 265 (15), 263 (23), 250 (14), 249 (18), 236 (12), 208 (14), 188 
(16). 
HRMS (EI): Calcd. for C19H21F3N3O3 [M]+: 377.15455, found: 377.15478. 
IR (ATR, cm–1): ṽ = 3356 (w), 3093 (w), 3004 (w), 2963 (w), 2936 (w), 2876 (w), 2834 (w), 
1703 (m), 1655 (s), 1622 (m), 1589 (s), 1572 (s), 1505 (w), 1457 (m), 1442 (s), 1423 (w), 1411 (s), 
1396 (s), 1370 (m), 1348 (w), 1322 (m), 1302 (w), 1282 (w), 1271 (m), 1253 (w), 1226 (s), 1187 
(w), 1175 (w), 1142 (m), 1112 (m), 1049 (m), 1031 (w), 1015 (s), 966 (w), 920 (w), 903 (w), 872 
(w), 837 (s), 807 (m), 772 (w), 759 (w), 749 (m), 729 (w), 707 (m), 696 (w), 674 (m), 622 (w), 570 
(m), 560 (m), 530 (m). 
 
7-Methoxy-5-(pentafluoroethyl)-1,3-dipropylpyrimido[4,5-b]quinoline-2,4(1H,3H)-
dione (88t) 
 
The product was prepared according to the general procedure, 
starting from 0.342 g of 87t and 1.7 mL of H2SO4. 
Yield 0.265 (81%), yellow solid, mp 115 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 0.98 (t, 3H, 3J = 7.55 Hz, 
CH3(Pr)), 1.03 (t, 3H, 3J = 7.36 Hz, CH3(Pr)), 1.66-1.89 (m, 4H, CH2(Pr-1), CH2(Pr-3)), 3.93 (s, 3H, 
MeO), 4.05 (t, 2H, 3J = 7.55 Hz, NCH2-3), 4.40 (t, 2H, 3J = 7.55 Hz, NCH2-1), 7.44-7.53 (m, 2H, 
H-6, H-8), 7.91 (d, 1H, 3J = 9.07 Hz, H-9). 
13C NMR (62.90 MHz, CDCl3): δ = 11.58 (CH3(Pr)), 11.64 (CH3(Pr)), 21.37 (CH2(Pr)), 21.43 
(CH2(Pr)), 44.4 (CH2(Pr)), 45.0 (CH2(Pr)), 55.8 (MeO), 103.6 (CH-6), 111.5 (C-4a), 123.7, 127.0 
(CHAr), 130.7 (CHAr), 137.7 (t, 2J(C-F) = 23.8 Hz, C-5), 146.7, 146.9, 150.7 (CO-2), 158.0 (C-7), 
159.4 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –92.6 (s, CF2), –74.9 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 446 ([M–F]+, 18), 445 (80), 404 (20), 403 (100), 375 (12), 361 
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(18), 346 (11), 345 (28), 334 (38), 333 (26), 331 (38), 319 (18), 318 (64), 317 (33), 304 (16), 277 
(12), 274 (10), 206 (10), 41 (14). 
HRMS (EI): Calcd. for C20H20F5N3O3 [M]+: 455.14193, found: 455.14179. 
IR (ATR, cm–1): ṽ = 3371 (w), 2969 (w), 2940 (w), 2882 (w), 2833 (w), 1712 (m), 1668 (s), 
1622 (m), 1565 (m), 1504 (m), 1449 (s), 1442 (s), 1407 (m), 1390 (s), 1368 (m), 1325 (m), 1301 
(m), 1272 (w), 1255 (w), 1226 (s), 1181 (s), 1157 (s), 1140 (s), 1120 (s), 1047 (s), 1030 (m), 1011 
(s), 975 (m), 959 (m), 902 (w), 895 (w), 872 (w), 845 (s), 828 (m), 802 (m), 755 (m), 742 (m), 724 
(s), 691 (m), 685 (m), 676 (m), 642 (w), 635 (w), 600 (m), 564 (s), 529 (m). 
 
1,1',3,3'-Tetramethyl-5,5'-bis(trifluoromethyl)-7,7'-bipyrimido[4,5-b]quinoline-
2,2',4,4'(1H,1'H,3H,3'H)-tetrone (88u) 
 
The product was prepared according to the general 
procedure, starting from 0.329 g of 87u and 1.6 mL of H2SO4. 
Yield 0.143 (46%), yellow solid, mp ˃ 375 °C. 
1H NMR (300.13 MHz, 12% TFA-d in CDCl3): δ = 3.60 
(s, 6H, CH3-3, CH3-3'), 3.96 (s, 6H, CH3-1, CH3-1'), 8,30 (s, 4H, H-8, H-9, H-8', H-9'), 8.66 (s, 2H, 
H-6, H-6'). 
13C NMR (75.47 MHz, TFA-d): δ = 31.5 (CH3), 33.0 (CH3), 114.3 (C-4a, C-4a'), 124.0, 
124.1 (q, 1J(C-F) = 278.9 Hz, CF3), 127.1 (CH), 127.8 (q, 4J(C-F) = 5.7 Hz, CH-6, CH-6'), 138.1 (CH), 
142.0, 145.5, 147.1 (q, 2J(C-F) = 35.4 Hz), 150.0, 152.6 (CO-2, CO-2'), 160.9 (CO-4, CO-4'). 
19F NMR (282.38 MHz, 12% TFA-d in CDCl3): δ = –52.7 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 617 ([M+H]+, 26), 616 ([M]+, 100), 504 (39), 406 (10), 196 (22), 
69 (11). 
HRMS (EI): Calcd. for C28H18F6N6O4 [M]+: 616.12882, found: 616.12925. 
IR (ATR, cm–1): ṽ = 3070 (w), 2960 (w), 1716 (s), 1680 (s), 1619 (w), 1567 (s), 1499 (w), 
1468 (m), 1434 (s), 1399 (m), 1384 (m), 1370 (m), 1357 (m), 1331 (s), 1288 (m), 1271 (m), 1205 
(m), 1168 (s), 1145 (s), 1106 (s), 1062 (m), 1044 (w), 986 (m), 926 (w), 868 (w), 835 (s), 808 (m), 
788 (w), 771 (w), 760 (w), 747 (s), 727 (w), 712 (w), 699 (m), 677 (w), 643 (m), 602 (m), 555 (m), 
535 (w). 
 
7,7'-Methylenebis[1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-
2,4(1H,3H)-dione] (88v) 
 
The product was prepared according to the general procedure, starting from 0.46 g of 87v 
and 2.3 mL of H2SO4. 
NN
N
O
O
FF
F
N
N
N
F F
F
O
O
Experimental	Part	
124 
Yield 0.224 (51%), yellow solid, mp 368-370 °C. 
1H NMR (300.13 MHz, 12% TFA-d in CDCl3): δ = 3.60 
(s, 6H, CH3-3, CH3-3'), 3.96 (s, 6H, CH3-1, CH3-1'), 4.46 (s, 
2H, CH2), 7.80 (d, 2H, 3J = 8.87 Hz, H-8, H-8'), 8.14 (d, 2H, 3J 
= 8.87 Hz, H-9, H-9'), 8.24 (s, 2H, H-6, H-6'). 
13C NMR (62.90 MHz, 12% TFA-d in CDCl3): δ = 30.1 (CH3), 31.3 (CH3), 42.8 (CH2), 
110.2, 122.4, 123.0 (q, 1J(C-F) = 278.4 Hz, CF3), 125.6 (q, 4J(C-F) = 5.9 Hz, CH-6, CH-6'), 129.4 
(CH), 136.0 (CH), 139.5 (q, 2J(C-F) = 35.7 Hz), 139.8, 147.7, 149.2, 152.2 (CO-2, CO-2'), 160.2 
(CO-4, CO-4'). 
19F NMR (282.38 MHz, 12% TFA-d in CDCl3): δ = –52.8 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 631 ([M+H]+, 30), 630 ([M]+, 100), 561 (13), 518 (19), 498 (32), 
429 (16), 203 (30), 69 (29), 44 (16), 40 (21). 
HRMS (EI): Calcd. for C29H20F6N6O4 [M]+: 630.14447, found: 630.14403. 
IR (ATR, cm–1): ṽ = 3372 (w), 3078 (w), 2952 (w), 1719 (m), 1667 (s), 1621 (w), 1580 (s), 
1564 (m), 1495 (w), 1470 (s), 1462 (s), 1456 (s), 1414 (m), 1292 (m), 1272 (m), 1215 (m), 1192 
(m), 1163 (s), 1127 (s), 1108 (s), 1064 (m), 987 (m), 920 (w), 897 (w), 860 (w), 847 (w), 837 (m), 
820 (w), 811 (m), 770 (w), 747 (s), 721 (w), 708 (m), 696 (m), 677 (w), 667 (w), 638 (m), 574 (m), 
564 (w), 542 (w). 
 
9,11-Dimethyl-7-(pentafluoroethyl)benzo[h]pyrimido[4,5-b]quinoline-8,10(9H,11H)-
dione (88w) 
 
The product was prepared according to the general procedure, starting 
from 0.393 g of 87w and 2 mL of H2SO4. 
Yield 0.307 (54%), yellow solid, mp 313-315 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.55 (s, 3H, CH3-9), 3.98 (s, 3H, 
CH3-11), 7.73-7.86 (m, 3H, CHAr), 7.91 (d, 1H, 3J = 7.55 Hz, CHAr), 8.02-8.11 (m, 1H, CHAr), 9.20 
(d, 1H, 3J = 7.74 Hz, CHAr). 
13C NMR (62.90 MHz, 12% TFA-d in CDCl3): δ = 30.1 (CH3), 31.2 (CH3), 109.4 (C-7a), 
122.0 (CH-6), 122.2, 126.5 (CH), 128.2 (CH), 128.5 (CH), 129.7 (CH), 130.1, 131.7 (CH), 134.7, 
139.4 (t, 2J(C-F) = 24.2 Hz), 147.6, 150.6, 152.5, 160.3 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –90.9 (s, CF2), –74.9 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 410 ([M+H]+, 23), 409 ([M]+, 100), 352 (11), 311 (12), 298 
(12), 297 (72). 
HRMS (EI): Calcd. for C19H12F5N3O2 [M]+: 409.08442, found: 409.08417. 
IR (ATR, cm–1): ṽ = 3377 (w), 3056 (w), 2959 (w), 1719 (m), 1673 (s), 1620 (w), 1573 (m), 
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1562 (s), 1513 (w), 1503 (m), 1470 (m), 1450 (m), 1435 (w), 1422 (m), 1387 (w), 1367 (s), 1336 
(m), 1295 (m), 1239 (w), 1226 (m), 1189 (s), 1159 (m), 1138 (s), 1113 (m), 1101 (m), 1074 (w), 
1047 (m), 1028 (m), 997 (m), 969 (s), 934 (w), 885 (w), 878 (w), 834 (w), 810 (m), 796 (w), 787 
(m), 761 (m), 747 (m), 735 (s), 726 (m), 708 (m), 682 (m), 663 (w), 628 (w), 594 (w), 566 (w), 558 
(w), 543 (w). 
 
3,6,8-Trimethyl-1-phenyl-4-(trifluoromethyl)-1H-pyrazolo[4',3':5,6]pyrido[2,3-
d]pyrimidine-5,7(6H,8H)-dione (88x) 
 
The product was prepared according to the general procedure for the 
synthesis of compounds 87 (!) from 0.477 g of 70d, 0.136 g of pyridine and 
0.603 g of trifluoroacetic anhydride in 4.5 mL of dry dioxane. 
Yield 0.42 g (75%, calculated on 1,3-dimethyl-6-[(3-methyl-1-phenyl-
1H-pyrazol-5-yl)amino]pyrimidine-2,4(1H,3H)-dione 70d, which cyclizes immediately while 
acylated by TFAA; non-cyclized intermediate product hasn’t been obtained), yellow solid, mp 254 
°C. 
1H NMR (300.13 MHz, CDCl3): δ = 2.73 (q, 3H, 6J(H-F) = 3.07 Hz, CH3-3) 3.51 (s, 3H, CH3-
6), 3.78 (s, 3H, CH3-8), 7.36 (t, 1H, 3J = 7.46 Hz, CHPh), 7.50-7.59 (m, 2H, CHPh), 8.12-8.20 (m, 
2H, CHPh). 
13C NMR (62.90 MHz, CDCl3): δ = 17.5 (q, 5J(C-F) = 7.4 Hz, CH3-3), 29.3 (CH3-6), 31.1 
(CH3-8), 104.5, 111.8, 121.3 (CHPh), 122.3 (q, 1J(C-F) = 278.8 Hz, CF3), 127.0 (CHPh), 129.4 (CHPh), 
136.7 (q, 2J(C-F) = 37.3 Hz, C-4), 138.4, 144.5, 151.00, 151.04, 151.06, 159.1 (CO-5). 
19F NMR (282.38 MHz, CDCl3): δ = –54.6 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 390 ([M+H]+, 20), 389 ([M]+, 100), 277 (33), 276 (17), 77 (21). 
HRMS (EI): Calcd. for C18H14F3N5O2 [M]+: 389.10941, found: 389.10929. 
IR (ATR, cm–1): ṽ = 3114 (w), 2996 (w), 2956 (w), 1715 (s), 1669 (s), 1593 (m), 1575 (s), 
1532 (m), 1504 (m), 1489 (s), 1470 (m), 1462 (m), 1456 (m), 1421 (s), 1411 (s), 1385 (m), 1367 (s), 
1336 (s), 1272 (m), 1227 (s), 1210 (m), 1179 (m), 1152 (s), 1135 (s), 1117 (s), 1062 (m), 1043 (m), 
1025 (m), 1000 (w), 987 (m), 970 (w), 911 (w), 864 (m), 845 (w), 805 (m), 774 (w), 763 (s), 754 
(m), 746 (s), 700 (m), 691 (s), 661 (m), 645 (w), 632 (w), 601 (m), 539 (w). 
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4.2.7 Synthesis of 5-hydroxy-1,3-dimethyl-5-perfluoroalkyl-5,10-dihydro-5-deazaallox-
azines 
 
General procedure for the synthesis of 5-hydroxy-1,3-dimethyl-5-perfluoroalkyl-5,10-
dihydro-1H-pyrimido[4,5-b]quinoline-2,4-diones 91a-c. 
Initial 5-(perfluoroacyl)-6-amino-1,3-dimethylrimidine-2,4(1H,3H)-dione 90 (1 g) was 
dissolved in concentrated H2SO4 (5 mL) and allowed to stand at r.t. for 2 hours. Then the solution 
was poured into ice water and extracted with chloroform, extracts were died over Na2SO4 and 
evaporated by rotovap. The crude product was purified via short-part column chromatography 
(silica gel / CHCl3), followed by recrystallization from methanol to give pure product. 
 
5-Hydroxy-1,3,10-trimethyl-5-(trifluoromethyl)-5,10-dihydropyrimido[4,5-b]quinoline-
2,4(1H,3H)-dione (91c) 
 
The product was prepared following the general procedure, starting from 
0.25 g of 90c and 1.3 mL of H2SO4. 
Yield 0.18 g (72%), white solid, mp 216-218 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.26 (s, 3H, CH3), 3.48 (s, 3H, CH3), 3.51 (s, 3H, 
CH3), 7.32 (dd, 1H, 3J1 = 7.74 Hz, 3J2 = 7.17 Hz, H-7), 7.46 (d, 1H, 3J = 8.31 Hz, H-9), 7.55 (dd, 
1H, 3J1 = 8.31 Hz, 3J2 = 7.17 Hz, H-8), 7.67 (d, 1H, 3J = 7.74 Hz, H-6), 8.45 (br s, 1H, OH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.5 (CH3), 37.3 (CH3), 41.8 (CH3), 71.8 (q, 2J(C-F) = 
30.5 Hz), 88.1 (C-4a), 119.3 (CH), 125.2 (CH), 126.2 (q, 1J(C-F) = 290.5 Hz, CF3), 126.7 (CH), 
130.8 (CH), 141.7, 152.4, 153.3, 165.0. 
19F NMR (282.38 MHz, DMSO-d6): δ = –83.1 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 273 (41), 272 (100), 257 (10). 
HRMS (ESI): Calcd. for C15H15F3N3O3 [M+H]+: 342.10600, found: 342.10635. 
IR (ATR, cm–1): ṽ = 3271 (w), 3190 (w), 2980 (w), 1703 (s), 1687 (m), 1622 (s), 1608 (s), 
1574 (m), 1504 (s), 1487 (s), 1470 (s), 1464 (s), 1456 (s), 1423 (s), 1396 (m), 1381 (m), 1323 (m), 
1254 (s), 1207 (m), 1161 (s), 1119 (s), 1090 (m), 1070 (s), 1049 (s), 972 (m), 955 (w), 937 (m), 922 
(s), 866 (w), 833 (m), 779 (s), 768 (s), 760 (s), 746 (s), 710 (s), 662 (s), 642 (s), 602 (m), 565 (m), 
550 (m), 538 (m). 
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6-Hydroxy-8,10-dimethyl-6-(trifluoromethyl)-1,2-dihydro-6H-pyrimido[4,5-
b]pyrrolo[3,2,1-ij]quinoline-7,9(8H,10H)-dione (91a) 
 
The product was prepared following the general procedure, starting from 
0.336 g of 90a and 1.7 mL of H2SO4. 
Yield 0.299 g (89%), white solid, mp 253-255 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.25 (s, 3H, CH3), 3.26-3.49 (m, 2H, CH2-2), 3.67 
(s, 3H, CH3), 4.22-4.35 (m, 1H, CH2-1a), 4.80-4.92 (m, 1H, CH2-1b), 7.25 (dd, 1H, 3J1 = 7.74 Hz, 
3J2 = 7.36 Hz, H-4), 7.39 (d, 1H, 3J = 7.36 Hz, CHAr), 7.45 (d, 1H, 3J = 7.74 Hz, CHAr), 8.69 (s, 1H, 
OH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.5 (CH3), 29.1 (CH2), 37.7 (CH3), 54.1 (CH2), 
72.7 (q, 2J(C-F) = 30.7 Hz, C-6), 80.6 (C-6a), 116.7 125.0 (CHAr), 125.9 (CHAr), 126.3 (CHAr), 126.7 
(q, 1J(C-F) = 291.2 Hz, CF3), 130.3, 140.8, 152.0, 152.7, 164.7. 
19F NMR (282.38 MHz, DMSO-d6): δ = –82.5 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 285 ([M+H–CF3]+, 17), 284 ([M–CF3]+, 100), . 
HRMS (ESI): Calcd. for C16H14F3N3NaO3 [M+Na]+: 376.08795, found: 376.08866. 
Anal. Calcd for C16H14F3N3O3: C, 54.39; H, 3.99; N, 11.89. Found: C, 54.30; H, 4.05; N, 
11.52. 
IR (ATR, cm–1): ṽ = 3029 (m), 2967 (m), 1695 (s), 1639 (w), 1606 (m), 1544 (m), 1494 (s), 
1462 (s), 1455 (s), 1443 (s), 1430 (s), 1401 (m), 1379 (m), 1360 (m), 1344 (m), 1301 (w), 1259 (m), 
1242 (s), 1233 (s), 1220 (m), 1184 (w), 1156 (s), 1129 (s), 1157 (s), 1035 (m), 1005 (w), 991 (m), 
964 (s), 936 (m), 866 (m), 832 (w), 783 (s), 773 (m), 764 (m), 753 (s), 745 (m), 716 (m), 704 (s), 
679 (m), 616 (w), 574 (w), 534 (w). 
 
7-(Heptafluoropropyl)-7-hydroxy-9,11-dimethyl-2,3-dihydro-1H,7H-pyrido[3,2,1-
ij]pyrimido[4,5-b]quinoline-8,10(9H,11H)-dione (91b) 
 
The product was prepared following the general procedure, starting from 
0.2 g of 90b and 1 mL of H2SO4. 
Yield 0.188 g (94%), white solid, mp 177 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 2.09-2.23 (m, 1H, CH2-2a), 2.24-
2.43 (m, 1H, CH2-2b), 2.94-3.05 (m, 2H, CH2-3), 3.25-3.35 (m, 1H, CH2-1a), 3.35 (s, 3H, CH3), 
3.50 (s, 3H, CH3),3.92-4.02 (m, 1H, CH2-1b), 7.12-7.21 (m, 2H, CHAr), 7.60-7.67 (m, 1H, CHAr), 
8.41 (s, 1H, OH). 
13C NMR (75.48 MHz, CDCl3): δ = 22.8 (CH2), 25.4 (CH2), 28.3 (CH3), 37.5 (CH3), 47.3 
(CH2-1), 74.4 (t, 2J(C-F) = 25.2 Hz, C-7), 88.9 (C-7a), 123.1, 124.6 (CHAr), 125.3 (CHAr), 126.7, 
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129.7, 136.5 (CHAr), 150.5, 152.8, 165.1. 
19F NMR (282.38 MHz, CDCl3): δ = –125.3 (dd, 2J = 289.17 Hz, 3J = 9.19 Hz, CF2-1a), –
123.6 (dd, 2J = 289.17 Hz, 3J = 7,16 Hz, CF2-1b), 121.6 (m, CF2-2), –80.8 (t, J = 12.27 Hz, CF3). 
IR (ATR, cm–1): ṽ = 3216 (m), 2956 (w), 2849 (w), 1693 (m), 1622 (m), 1601 (m), 1575 
(m), 1504 (m), 1462 (s), 1455 (s), 1428 (s), 1407 (m), 1389 (w), 1371 (m), 1345 (m), 1286 (w), 
1250 (w), 1206 (s), 1184 (s), 1116 (s), 1091 (m), 1061 (m), 1045 (m), 1032 (m), 1003 (w), 984 (w), 
942 (w), 907 (w), 878 (w), 856 (m), 827 (w), 807 (w), 782 (m), 769 (m), 746 (s), 733 (w), 701 (m), 
676 (w), 667 (m), 646 (s), 589 (w), 575 (w), 568 (w), 550 (w), 530 (w). 
 
4.2.8 Synthesis of 9-(ω-chloroalkyl)-1,3-dimethyl-5-trifluoromethyl-5-deazaalloxazines 
 
Synthesis of 9-(2-Chloroethyl)-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-
b]quinoline-2,4(1H,3H)-dione 92a and 9-(3-Chloropropyl)-5-(heptafluoropropyl)-1,3-
dimethylpyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 92b. General procedure. 
A starting material (6-hydroxy-8,10-dimethyl-6-(trifluoromethyl)-1,2-dihydro-6H-pyrimido-
[4,5-b]pyrrolo[3,2,1-ij]quinoline-7,9(8H,10H)-dione 91a or 7-(heptafluoropropyl)-7-hydroxy-9,11-
dimethyl-2,3-dihydro-1H,7H-pyrido[3,2,1-ij]pyrimido[4,5-b]quinoline-8,10(9H,11H)-dione 91b) 
was dissolved in chloroform and then refluxed with thionyl chloride (2 eq) for 3 hours till the solid 
phase disappeared. Afterwards the solvent was evaporated and the crude product was purified via 
short-part column chromatography (silica gel / CHCl3), followed by recrystallization from 
methanol. 
 
9-(2-Chloroethyl)-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-
2,4(1H,3H)-dione (92a) 
 
The product was prepared following the general procedure, starting from 
0.4 g of 91a, 0.269 g of thionyl chloride and 8 mL of chloroform. 
Yield 100%, yellow solid, mp 151-153 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.52 (s, 3H, CH3-3), 3.67 (t, 2H, 3J 
= 7.55 Hz, Ar-CH2-), 3.83 (s, 3H, CH3-1), 3.94 (t, 2H, 3J = 7.55 Hz, CH2Cl), 7.55 (dd, 1H, 3J1 = 
8.97 Hz, 3J2 = 6.99 Hz, H-7), 7.78 (d, 1H, 3J = 6.99 Hz, H-8), 8.23-8.30 (dm, 1H, 3J = 8.97 Hz, H-
6). 
13C NMR (75.48 MHz, CDCl3): δ = 29.5 (CH3-3), 30.7 (CH3-1), 36.1 (Ar-CH2-), 44.2 
(CH2Cl), 110.4 (C-4a), 122.1, 123.2 (q, 1J(C-F) = 278.3 Hz, CF3), 125.4 (q, 4J(C-F) = 6.0 Hz, CH-6), 
126.9 (CHAr), 134.4 (CHAr), 136.1, 139.3 (q, 2J(C-F) = 33.5 Hz, C-5), 147.6, 148.6, 151.2 (CO-2), 
159.3 (CO-4). 
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19F NMR (282.38 MHz, CDCl3): δ = –52.4 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 371 ([M]+, 35Cl, 7.9), 337 ([M+H–Cl]+, 20), 336 ([M–Cl]+, 
100), 279 (29). 
HRMS (ESI): Calcd. for C16H13F3N3O2 [M-Cl]+: 336.09544, found: 336.09572. 
Anal. Calcd for C16H13ClF3N3O2: C, 51.69; H, 3.52; N, 11.30. Found: C, 47.85; H, 3.52; N, 
10.05. 
IR (ATR, cm–1): ṽ = 2953 (w), 1718 (m), 1669 (s), 1607 (w), 1574 (s), 1494 (w), 1479 (m), 
1464 (m), 1467 (m), 1445 (m), 1421 (m), 1391 (m), 1375 (m), 1352 (m), 1327 (m), 1290 (m), 1277 
(m), 1224 (s), 1195 (m), 1158 (s), 1134 (s), 1116 (s), 1079 (m), 1032 (m), 977 (m), 928 (w), 875 
(m), 845 (w), 828 (w), 794 (m), 780 (m), 770 (s), 746 (s), 723 (m), 711 (m), 700 (s), 682 (m), 605 
(w), 579 (m), 564 (m), 551 (m), 541 (m). 
 
9-(3-Chloropropyl)-5-(heptafluoropropyl)-1,3-dimethylpyrimido[4,5-b]quinoline-
2,4(1H,3H)-dione (92b) 
 
The product was prepared following the general procedure, starting 
from 1.2 g of 91a, 0.611 g of thionyl chloride and 24 mL of chloroform. 
Yield 1.121 g (90%), yellow solid, mp 113-114 °C. 
1H NMR (250.13 MHz, CDCl3): δ = 2.19-2.34 (m, 2H, CH2), 3.40 (t, 
2H, 3J = 7.41 Hz, Ar-CH2-), 3.51 (s, 3H, CH3-3), 3.60 (t, 2H, 3J = 6.31 Hz, 
CH2Cl), 3.85 (s, 3H, CH3-1), 7.52 (dd, 1H, 3J1 = 8.99 Hz, 3J2 = 6.94 Hz, H-7), 7.76 (d, 1H, 3J = 6.94 
Hz, H-8), 8.22 (d, 1H, 3J = 8.99 Hz, H-5). 
13C NMR (62.90 MHz, CDCl3): δ = 29.7 (CH3-3), 30.0 (CH2), 30.9 (CH3-1), 33.1 (CH2), 
45.0 (CH2), 111.5 (C-4a), 123.1 (C-5a), 125.5 (m, CH-6), 127.1 (CH), 133.4 (CH), 139.4, 140.4 (t, 
2J(C-F) = 24.0 Hz, C-5), 147.7, 148.7, 151.1 (CO-2), 159.1 (CO-4). 
19F NMR (235.33 MHz, CDCl3): δ = –116.5 (s, CF2), –90.4 (br s, CF2), –80.0 (t, J = 9.54 
Hz, CF3). 
MS (GC, 70 eV): m/z (%) = 485 ([M]+, 35Cl, 15), 451 (21), 450 (100), 436 (36), 423 (28), 
393 (16), 311 (10). 
HRMS (ESI): Calcd. for C19H16ClF7N3O2 [M+H, 35Cl]+: 486.08138, found: 486.08130. 
IR (ATR, cm–1): ṽ = 2958 (w), 2929 (w), 1722 (s), 1678 (s), 1612 (w), 1568 (s), 1504 (m), 
1479 (m), 1462 (m), 1423 (s), 1392 (m), 1371 (m), 1344 (m), 1319 (m), 1311 (m), 1288 (m), 1269 
(m), 1255 (m), 1227 (s), 1211 (s), 1188 (s), 1171 (s), 1132 (s), 1113 (s), 1078 (s), 1047 (m), 1020 
(m), 980 (m), 949 (m), 910 (s), 878 (m), 825 (m), 798 (m), 785 (s), 777 (s), 760 (s), 743 (s), 731 (s), 
721 (s), 700 (s), 692 (s), 623 (s), 617 (s), 590 (m), 565 (m), 550 (s), 536 (m). 
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4.2.9 Suzuki–Miyaura cross-coupling with 7-bromo-1,3-dimethyl-5-(trifluoromethyl)-5-
deazaalloxazine 
 
1,3-Dimethyl-7-phenyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 
(96) 
 
A sealed ACE pressure tube was charged with 0.05 g of 7-bromo-
1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-
dione 88p (0.13 mmol, 1 eq), 0.019 g of phenylboronic acid (0.15 mmol, 
1.2 eq), 0.053 g of K2CO3 (0.039 mmol, 3 eq), 0.003 g of Pd(PPh3)4 
(0.0026 mmol, 0.02 eq), 2.5 mL of dioxane and 0.5 mL of water. The reaction mixture was stirred 
under argon at 100 °C for half an hour. After cooling to r.t. formed precipitate was filtered off by 
suction, washed twice with methanol and dried in high vacuum to give the pure product. 
Yield 0.047 g (95%), green solid, mp 230 °C. 
1H NMR (300.13 MHz, 12% TFA-d in CDCl3): δ = 3.58 (s, 3H, CH3-3), 3.94 (s, 3H, CH3-
1), 7.44-7.59 (m, 3H, CHPh), 7.68-7.74 (m, 2H, CHPh), 8.23 (s, 2H, H-8, H-9), 8.53 (s, 1H, H-6). 
13C NMR (62.90 MHz, 12% TFA-d in CDCl3): δ = 30.1 (CH3-3), 31.3 (CH3-1), 110.3 (C-
4a), 122.6, 122.7 (q, 1J(C-F) = 278.4 Hz, CF3), 123.8 (q, 4J(C-F) = 6.0 Hz, CH-6), 128.1 (CHAr), 129.0 
(CHAr), 129.1 (CHAr), 129.7 (CHAr), 134.9 (CHAr), 139.5, 140.1 (q, 2J(C-F) = 33.8 Hz, C-5), 141.4, 
147.4, 149.2, 152.2 (CO-2), 160.3 (CO-4). 
19F NMR (282.38 MHz, 12% TFA-d in CDCl3): δ = –52.8 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 386 ([M+H]+, 23), 385 ([M]+, 100), 316 (10), 287 (16), 274 
(14), 273 (78), 259 (13). 
HRMS (EI): Calcd. for C20H14F3N3O2 [M]+: 385.10326, found: 385.10314. 
IR (ATR, cm–1): ṽ = 3379 (w), 3054 (w), 2958 (w), 1720 (m), 1668 (s), 1651 (m), 1621 (w), 
1574 (s), 1516 (w), 1469 (s), 1433 (s), 1328 (m), 1293 (m), 1281 (m), 1212 (m), 1165 (s), 1152 (s), 
1131 (s), 1074 (m), 1027 (w), 994 (m), 942 (w), 918 (w), 894 (w), 883 (w), 860 (w), 843 (m), 807 
(m), 765 (m), 756 (s), 744 (s), 706 (m), 694 (s), 674 (m), 639 (m), 617 (w), 607 (w), 594 (w), 557 
(m), 540 (w). 
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4.2.10 Sonogashira cross-coupling with 7-bromo-1,3-dimethyl-5-(trifluoromethyl)-5-
deazaalloxazine 
 
Sonogashira coupling with 7-bromo-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-
b]quinoline-2,4(1H,3H)-dione 88p. General procedure. 
 
Into a flask were placed 7-bromo-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-
2,4(1H,3H)-dione 88p (1 eq), terminal acetylene (1.2 eq), Pd(PPh3)2Cl2 (0.02 eq), CuI (0.01 eq), 
diisopropylamine (10 eq) and THF (1 mL per 0.05 g of starting aryl bromide). The mixture was 
stirred for 3 hours and then allowed to stay at r.t. for two days. After that the reaction mixture was 
diluted with water, the formed precipitate was filtered off by suction, washed with methanol and 
heptane and dried in high vacuum. 
 
1,3-Dimethyl-7-(phenylethynyl)-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-
2,4(1H,3H)-dione (97a) 
 
The product was prepared following the general procedure, 
starting from 0.05 g of 8-bromo derivative 88p, 0.016 g of 
phenylacetylene, 0.9 mg of Pd(PPh3)2Cl2, 0.12 mg of CuI, 0.13 g of 
diisopropylamine and 1 mL of THF. 
Yield 0.047 g (89%), yellow solid, mp 269 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.51 (s, 3H, CH3-3), 3.82 (s, 3H, CH3-1), 7.35-7.44 (m, 
3H, CHPh), 7.55-7.62 (m, 2H, CHPh), 7.90 (d, 1H, 3J = 8.88 Hz, H-8), 7.99 (d, 1H, 3J = 8.88 Hz, H-
9), 8.46 (s, 1H, H-6). 
13C NMR (75.48 MHz, CDCl3): δ = 29.6 (CH3-3), 30.8 (CH3-1), 88.8 (C-sp), 92.4 (C-sp), 
111.0 (C-4a), 121.6, 122.7, 122.8, 123.2 (q, 1J(C-F) = 278.4 Hz, CF3), 128.8 (CHAr), 129.19 (q, 4J(C-F) 
= 6.1 Hz, CH-6), 129.26 (CHPh), 129.29 (CHPh), 132.1 (CHPh), 136.0 (CHAr), 138.2 (q, 2J(C-F) = 33.6 
Hz, C-5), 148.7, 149.7, 151.1 (CO-2), 159.2 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –52.6 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 410 ([M+H]+, 25), 409 ([M]+, 100), 311 (15), 298 (11), 297 
(54), 283 (16). 
HRMS (ESI): Calcd. for C22H15F3N3O2 [M+H]+: 410.11109, found: 410.11143. 
Anal. Calcd for C22H14F3N3O2: C, 50.22; H, 3.58; N, 11.71. Found: C, 49.43; H, 3.21; N, 
10.13. 
IR (ATR, cm–1): ṽ = 3375 (w), 3061 (w), 2952 (w), 2213 (w), 1714 (s), 1674 (s), 1652 (m), 
1616 (w), 1574 (s), 1558 (m), 1512 (w), 1505 (w), 1490 (w), 1470 (m), 1440 (s), 1418 (m), 1405 
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(m), 1386 (m), 1373 (s), 1324 (m), 1303 (m), 1290 (m), 1275 (m), 1207 (m), 1162 (s), 1143 (s), 
1128 (s), 1070 (m), 1027 (w), 996 (m), 985 (m), 919 (w), 884 (w), 864 (w), 835 (s), 807 (w), 783 
(w), 755 (m), 744 (s), 704 (m), 689 (s), 674 (w), 662 (m), 641 (w), 578 (m), 538 (w), 529 (m). 
 
7-Hex-1-yn-1-yl-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-
dione (97b) 
 
The product was prepared following the general procedure, 
starting from 0.25 g of 8-bromo derivative 88p, 0.063 g of 
phenylacetylene, 4.52 mg of Pd(PPh3)2Cl2, 0.61 mg of CuI, 0.652 g 
of diisopropylamine and 5 mL of THF. 
Yield 0.234 (89%), yellow solid, mp 180 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 0.97 (t, 3H, 3J = 7.27 Hz, Bu), 1.43-1.70 (m, 4H, Bu), 
2.47 (t, 2H, Bu, 3J = 7.08 Hz), 3.49 (s, 3H, CH3-3), 3.78 (s, 3H, CH3-1), 7.74 (d, 1H, 3J = 8.87 Hz, 
H-8), 7.87 (d, 1H, 3J = 8.87 Hz, H-9), 8.28 (s, 1H, H-6). 
13C NMR (75.48 MHz, CDCl3): δ = 13.9 (CH3(Bu)), 19.5 (CH2(Bu)), 22.4 (CH2(Bu)), 29.5 
(CH3-3), 30.7 (CH3-1), 30.9 (CH2(Bu)), 80.1 (C-sp), 94.0 (C-sp), 110.8 (C-4a), 121.5, 123.1 (q, 1J(C-F) 
= 278.5 Hz, CF3), 123.4, 128.7 (q, 4J(C-F) = 6.1 Hz, CH-6), 128.9 (CHAr), 136.3 (CHAr), 137.8 (q, 
2J(C-F) = 33.5 Hz, C-5), 148.3, 149.2, 151.0 (CO-2), 159.2 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –52.7 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 390 ([M+H]+, 21), 389 ([M]+, 100), 388 (12), 360 (23), 346 
(30), 317 (14), 289 (21), 277 (27), 261 (10), 234 (23), 220 (15). 
HRMS (ESI): Calcd. for C20H19F3N3O2 [M+H]+: 390.14239, found: 390.14253. 
IR (ATR, cm–1): ṽ = 3379 (w), 3089 (w), 2960 (w), 2934 (w), 2862 (w), 2228 (w), 1726 (m), 
1671 (s), 1614 (w), 1581 (s), 1468 (s), 1451 (s), 1411 (m), 1386 (m), 1370 (s), 1322 (w), 1287 (m), 
1240 (w), 1205 (m), 1173 (s), 1159 (s), 1145 (s), 1132 (s), 1108 (s), 1071 (m), 1019 (w), 989 (m), 
956 (w), 933 (w), 887 (m), 858 (w), 854 (s), 807 (m), 775 (w), 761 (w), 748 (s), 728 (w), 704 (s), 
689 (w), 672 (m), 659 (w), 641 (m), 589 (w), 575 (m), 538 (w). 
 
4.2.11 Reduction of 5-(trifluoromethyl)-5-deazaalloxazines 
 
Reduction of 5-polyfluoroalkyl-pyrimido[4,5-b]quinoline-2,4-diones 88. General 
procedure. 
Method A 
Into a 50-mL flask were placed 5-polyfluoroalkyl-pyrimido[4,5-b]quinoline-2,4-dione 88 
(1.48 mmol, 1 eq), sodium cyanoborohydride (5.93 mmol, 4 eq) and THF (10 mL). Then the 
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mixture was cooled to 0 °C and acetic acid (11.9 mmol, 8 eq) was added. Afterwards the reaction 
mixture was allowed to warm to r.t.. Three days later the reaction was monitored by TLC and 
stirred 8 hours at 45 °C, if the starting material still was detected. After that mixture was diluted 
with water. Precipitate was filtered off to give a pure product. 
Method B 
A sealed ACE pressure tube was charged with 0.1 g of 1,3,7,9-tetramethyl-5-
(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 88c (0.30 mmol, 1 eq), 0.451 g of 
diethyl 1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate (1.78 mmol, 6 eq), 0.0056 g of TsOH 
(0.03 mmol, 0.1 eq) and 3 mL of xylene. The reaction mixture was stirred under argon at 155 °C for 
5 hours. Then the solution was cooled to r.t. and formed precipitate was filtered off, washed twice 
with xylene and dried in high vacuum to give the desired product. 
 
1,3,7,9-Tetramethyl-5-(trifluoromethyl)-5,10-dihydropyrimido[4,5-b]quinoline-
2,4(1H,3H)-dione (98a) 
 
Yield 99% (Method A; starting from 0.5 g of 88c, 0.373 g of sodium 
cyanoborohydride, 0.712 g of acetic acid and 10 mL of THF) and 41% 
(Method B), white solid, mp 263-265 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 2.32 (s, 6H, CH3-7, CH3-9), 3.40 
(s, 3H, CH3), 3.60 (s, 3H, CH3), 4.88 (q, 1H, 3J(H-F) = 8.22 Hz, CH-5), 6.40 (br s, 1H, NH), 7.01 (s, 
1H, CHAr), 7.04 (s, 1H, CHAr). 
13C NMR (75.47 MHz, DMSO-d6): δ = 17.9 (Ar-CH3), 21.1 (Ar-CH3), 28.7 (N-CH3), 30.4 
(N-CH3), 40.2 (q, 2J(C-F) = 29.2 Hz, CH-5), 79.6, 117.5, 126.4, 129.0 (CH), 127.4 (q, 1J(C-F) = 284.3 
Hz, CF3), 132.3 (CH), 133.6, 134.1, 148.7, 151.8, 161.7. 
19F NMR (282.38 MHz, CDCl3): δ = –73.7 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 339 ([M]+, 5.0), 271 (17), 270 ([M–CF3]+, 100), 213 (11). 
HRMS (ESI): Calcd. for C16H17F3N3O2 [M+H]+: 340.12674, found: 340.12665. 
Anal. Calcd for C16H16F3N3O2: C, 56.64; H, 4.75; N, 12.38. Found: C, 56.72; H, 4.73; N, 
12.10. 
IR (ATR, cm–1): ṽ = 3457 (m), 3322 (w), 2914 (w), 1693 (m), 1633 (s), 1611 (m), 1520 (s), 
1489 (m), 1475 (s), 1445 (m), 1418 (w), 1382 (w), 1354 (w), 1336 (m), 1326 (m), 1275 (w), 1240 
(s), 1218 (m), 1180 (w), 1146 (s), 1107 (s), 1057 (w), 1042 (w), 991 (w), 968 (w), 951 (w), 936 (w), 
900 (w), 870 (w), 844 (m), 820 (w), 777 (w), 768 (m), 751 (s), 710 (w), 696 (w), 681 (w), 667 (m), 
580 (w), 568 (w). 
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7-Ethyl-1,3-dimethyl-5-(trifluoromethyl)-5,10-dihydropyrimido[4,5-b]quinoline-
2,4(1H,3H)-dione (98b) 
 
The product was prepared according to the Method A, starting from 
0.15 g of 88f, 0.112 g of sodium cyanoborohydride, 0.214 g of acetic acid 
and 3 mL of THF. 
Yield 0.144 g (95%), white solid, mp 241 °C. 
1H NMR (250.13 MHz, DMSO-d6): δ = 1.20 (t, 3H, 3J = 7.57 Hz, Et), 2.61 (q, 2H, 3J = 7.57 
Hz, Et), 3.24 (s, 3H, CH3), 3.51 (s, 3H, CH3), 4.91 (q, 1H, 3J(H-F) = 8.51 Hz, CH-5), 7.23 (dd, 1H, 3J 
= 8.20 Hz, 4J = 1.82 Hz, H-8), 7.28 (s, 1H, H-6), 7.35 (d, 1H, 3J = 8.20 Hz, H-9), 9.57 (br s, 1H, 
NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 16.5 (CH3), 28.4 (CH2), 28.7 (CH3), 30.9 (CH3), 
40.0 (q, 2J(C-F) = 28.9 Hz, CH-5), 77.3 (C-4a), 115.6, 117.6 (CHAr), 127.4 (q, 1J(C-F) = 284.3 Hz, 
CF3), 129.3 (CHAr), 130.0 (CHAr), 136.4, 140.0, 148.5, 151.6, 161.6. 
19F NMR (282.38 MHz, DMSO-d6): δ = –72.7 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 339 ([M]+, 3.7), 271 (18), 270 ([M–CF3]+, 100), 213 (13). 
HRMS (EI): Calcd. for C16H16F3N3O2 [M]+: 339.11891, found: 339.11894. 
IR (ATR, cm–1): ṽ = 3275 (m), 3206 (w), 3139 (w), 2973 (w), 2893 (w), 1701 (s), 1633 (m), 
1607 (s), 1557 (s), 1497 (s), 1476 (s), 1460 (m), 1429 (m), 1394 (w), 1368 (w), 1328 (m), 1312 (m), 
1292 (w), 1282 (w), 1258 (m), 1237 (s), 1217 (m), 1189 (m), 1157 (s), 1148 (m), 1141 (m), 1121 
(m), 1113 (s), 1049 (w), 981 (m), 952 (w), 929 (w), 895 (w), 846 (m), 833 (m), 813 (w), 803n (w), 
773 (m), 750 (m), 727 (w), 713 (m), 676 (m), 667 (m), 642 (m), 577 (w), 555 (w), 545 (w). 
 
4.2.12 Alkylation of 1,3,7,9-tetramethyl-5-(trifluoromethyl)-5,10-dihydro-5-
deazaalloxazine 
 
(4aR,5R)- and (4aS,5S)-4a-Benzyl-1,3,7,9-tetramethyl-5-(trifluoromethyl)-4a,5-
dihydropyrimido[4,5-b]quinoline-2,4(1H,3H)-dione (100), racemic mixture of enantiomers. 
 
A mixture of 1,3,7,9-tetramethyl-5-(trifluoromethyl)-5,10-
dihydropyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 98a (0.1 g, 0.29 mmol, 1 
eq), benzyl bromide (0.055 g, 0.32 mmol, 1.1 eq), K2CO3 (0.081 g, 0.59 
mmol, 2 eq) and DMF (2 mL) was stirred overnight under argon. The next 
day the reaction mixture was diluted with water and heptane. The formed precipitate was filtered off 
by suction, washed twice with water and heptanes and dried in high vacuum to give the pure 
product. 
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Yield 104 g (82%), white solid, mp 159-161 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 2.39 (s, 3H, Ar-CH3), 2.51 (s, 3H, Ar-CH3), 3.00 (d, 
1H, 2J = 12.56 Hz, CH2-a), 3.09 (d, 1H, 2J = 12.56 Hz, CH2-b), 3.15 (s, 3H, N-CH3), 3.28 (s, 3H, N-
CH3), 4.00 (q, 1H, 3J(H-F) = 8.25 Hz, H-5), 6.82-6.91 (m, 2H, CHo-Ph), 6.99 (s, 1H, H-6), 7.17 (s, 1H, 
H-8), 7.20-7.32 (m, 3H, CHPh). 
13C NMR (62.90 MHz, CDCl3): δ = 17.9 (CH3), 21.4 (CH3), 28.4 (CH3), 29.8 (CH3), 42.9 
(CH2), 47.8 (C-4a), 48.8 (q, 2J(C-F) = 26.8 Hz, CH), 118.7, 125.4 (q, 1J(C-F) = 283.4 Hz, CF3), 128.7 
(CH), 128.7 (CH), 128.7 (CH), 129.4 (CH), 133.0 (CH), 133.5, 134.4, 136.0, 139.2, 150.2, 151.6, 
168.8. 
19F NMR (282.38 MHz, DMSO-d6): δ = –65.5 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 430 ([M+H]+, 14), 429 ([M]+, 51), 91 (100). 
HRMS (EI): Calcd. for C23H22O2N3F3 [M]+: 429.16586, found: 429.16570. 
IR (ATR, cm–1): ṽ = 2933 (w), 2920 (w), 1726 (m), 1682 (s), 1622 (s), 1597 (s), 1471 (m), 
1443 (s), 1427 (s), 1381 (s), 1344 (m), 1325 (s), 1315 (s), 1294 (s), 1273 (s), 1255 (s), 1238 (s), 
1215 (m), 1196 (m), 1151 (s), 1119 (s), 1068 (m), 1051 (m), 1032 (m), 995 (m), 982 (m), 959 (m), 
939 (m), 916 (m), 893 (m), 870 (w), 858 (m), 851 (m), 831 (m), 804 (m), 791 (m), 770 (m), 764 
(m), 743 (s), 702 (s), 671 (m), 648 (m), 582 (m), 571 (m), 548 (m). 
 
4.2.13 Nucleophilic additions to position 5 of 5-polyfluoroalkyl-5-deazaalloxazines 
4.2.13.1 Addition of acetophenone 
 
Addition of acetophenone to 1,3-dialkyl-5-polyfluoroalkyl-pyrimido[4,5-b]quinoline-
2,4-diones. General procedure. 
Into a flask were placed 1,3-dialkyl-5-polyfluoroalkyl-pyrimido[4,5-b]quinoline-2,4-dione 
(1 eq), acetophenone (1.5 eq), dry THF (20 mL per 1 g of starting material) and sodium hydride 
(60% in mineral oil, 2 eq). The reaction mixture was stirred for half an hour at r.t. and then allowed 
to stay overnight. Afterwards 2.5 eq of acetic acid was added and the mixture was diluted with 
water. The formed precipitate was filtered off by suction, washed with heptane and recrystallized 
from methanol/water giving the pure product. 
 
7-Ethyl-1,3-dimethyl-5-(2-oxo-2-phenylethyl)-5-(trifluoromethyl)-5,10-
dihydropyrimido[4,5-b]quinoline-2,4(1H,3H)-dione (101a) 
 
The product was prepared according to the general method, starting from 0.2 g of 88f, 0.107 
g of acetophenone, 0.047 g of sodium hydride (60% in mineral oil) and 4 mL of THF. 
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Yield 0.219 g (81%), white solid, mp 233 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.09 (t, 3H, 3J = 7.55 Hz, 
Et), 2.53 (q, 2H, 3J = 7.55 Hz, Et), 3.09 (s, 3H, CH3), 3.59 (s, 3H, CH3), 4.33 
(d, 1H, 2J = 18.70 Hz, CH2CO-a), 5.50 (d, 1H, 2J = 18.70 Hz, CH2CO-b), 
7.18 (d, 1H, 3J = 8.12 Hz, H-8), 7.36 (d, 1H, 3J = 8.12 Hz, H-9), 7.41 (s, 1H, 
H-6), 7.50-7.60 (m, 2H, CHm-Ph), 7.62-7.70 (m, 1H, CHp-Ph), 7.95-8.04 (m, 2H, CHo-Ph) 9.38 (br s, 
1H, NH). 
13C NMR (75.48 MHz, DMSO-d6): δ = 16.6 (CH3), 28.5 (CH2), 28.6 (CH3), 31.2 (CH3), 
38.5 (CH2CO), 47.5 (q, 2J(C-F) = 25.7 Hz, C-5), 79.9 (C-4a), 117.6 (CHAr), 119.9, 127.0 (CHAr), 
128.6 (q, 1J(C-F) = 287.3 Hz, CF3), 128.7 (CHAr), 128.9 (CHAr), 129.5 (CHAr), 133.9 (CHAr), 135.0, 
137.6, 139.6, 148.1, 151.1, 161.6, 195.8. 
19F NMR (282.38 MHz, DMSO-d6): δ = –75.8 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 457 ([M]+, 1.7), 338 ([M–CF3]+, 42), 337 (28), 225 (35), 105 
(100), 77 (33). 
HRMS (ESI): Calcd. for C24H23F3N3O3 [M+H]+: 458.16860, found: 458.16921. 
IR (ATR, cm–1): ṽ = 3375 (w), 3340 (m), 2959 (w), 2873 (w), 1707 (w), 1694 (m), 1681 (s), 
1634 (s), 1615 (m), 1598 (s), 1531 (s), 1504 (s), 1477 (m), 1447 (m), 1404 (m), 1387 (m), 1367 (m), 
1319 (w), 1261 (m), 1234 (s), 1218 (s), 1184 (m), 1157 (s), 1144 (s), 1094 (w), 1056 (w), 1043 (w), 
1030 (w), 1003 (m), 963 (w), 948 (w), 928 (w), 896 (w), 879 (w), 828 (m), 795 (w), 772 (m), 752 
(s), 730 (w), 706 (w), 687 (m), 675 (m), 643 (w), 628 (w), 599 (w), 576 (m), 551 (m), 534 (m). 
 
8,10-Dimethyl-6-(2-oxo-2-phenylethyl)-6-(trifluoromethyl)-1,2-dihydro-6H-
pyrimido[4,5-b]pyrrolo[3,2,1-ij]quinoline-7,9(8H,10H)-dione (102a) 
 
The product was prepared according to the general method, starting from 
0.15 g of 92b, 0.073 g of acetophenone, 0.032 g of sodium hydride (60% in 
mineral oil) and 3 mL of THF. 
Yield 0.171 g (93%), white solid, mp 304-305 °C. 
1H NMR (250.13 MHz, CDCl3): δ = 3.18 (s, 3H, CH3), 3.20-3.44 (m, 
2H, CH2-2), 3.64 (s, 3H, CH3), 3.85 (d, 1H, 2J = 18.36 Hz, CH2CO-a), 4.00-4.14 (m, 1H, CH2-1a), 
4.54-4.65 (m, 1H, CH2-1b), 5.63 (d, 1H, 2J = 18.36 Hz, CH2CO-b), 7.00 (dd, 1H, 3J1 = 7.18 Hz, 3J2 
= 8.12 Hz, H-4), 7.11-7.19 (m, 2H, CHAr), 7.39-7.49 (m, 2H, CHAr), 7.54 (t, 1H, 3J = 7.25 Hz, CHp-
Ph), 7.91-7.98 (m, 2H, CHAr). 
13C NMR (62.90 MHz, CDCl3): δ = 28.5 (CH3), 28.9 (CH2), 38.4 (CH2), 38.6 (CH3), 47.8 
(q, 2J(C-F) = 26.7 Hz), 53.4 (CH2), 84.7 (C-6a), 117.6, 124.4 (CH), 124.8 (CH), 125.0 (CH), 127.5 
(q, 1J(C-F) = 286.6 Hz, CF3), 128.2 (CH), 128.8, 128.9 (CH), 133.3, 137.2, 141.8, 152.9, 152.9, 
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162.0, 195.7. 
19F NMR (235.33 MHz, CDCl3): δ = –76.8 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 455 ([M]+, 5.8), 387 (26), 386 (100), 336 (15), 105 (38), 77 
(14). 
HRMS (ESI): Calcd. for C24H21F3N3O3 [M+H]+: 456.15295, found: 456.15399. 
IR (ATR, cm–1): ṽ = 3043 (w), 3016 (w), 2929 (w), 1691 (s), 1633 (s), 1626 (s), 1539 (s), 
1498 (s), 1464 (s), 1446 (s), 1435 (s), 1408 (s), 1375 (s), 1360 (s), 1342 (m), 1302 (m), 1242 (s), 
1227 (s), 1201 (m), 1186 (m), 1176 (m), 1155 (s), 1120 (s), 1078 (m), 1057 (m), 1041 (m), 1028 
(m), 1001 (m), 976 (m), 964 (m), 939 (m), 912 (m), 897 (w), 860 (w), 847 (w), 779 (s), 770 (m), 
756 (s), 748 (s), 737 (s), 714 (m), 694 (s), 658 (m), 617 (s), 581 (m), 569 (m), 528 (m). 
 
4.2.13.2 Addition of nitromethane 
 
Addition of nitromethane to 1,3-dialkyl-5-polyfluoroalkyl-pyrimido[4,5-b]quinoline-
2,4-diones. General procedure. 
Into a flask were placed 1,3-dialkyl-5-polyfluoroalkyl-pyrimido[4,5-b]quinoline-2,4-dione 
(1 eq), nitromethane (10 eq), dry THF (20 mL per 1 g of starting material), dry methanol (20 mL 
per 1 g of starting material) and sodium methylate (2 eq). The reaction mixture was allowed to stay 
at r.t. overnight. Afterwards 2.5 eq of acetic acid was added and the mixture was diluted with water. 
The formed precipitate was filtered off by suction and recrystallized from methanol/water giving 
the pure product. 
 
7-Ethyl-1,3-dimethyl-5-(nitromethyl)-5-(trifluoromethyl)-5,10-dihydropyrimido[4,5-
b]quinoline-2,4(1H,3H)-dione (101b) 
 
The product was prepared according to the general method, starting 
from 0.45 g of 88f, 0.814 g of nitromethane, 0.144 g of sodium methylate, 9 
mL of methanol and 9 mL of THF. 
Yield 0.457 g (86%), white solid, mp 351-353 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.19 (t, 3H, 3J = 7.55 Hz, Et), 2.62 (q, 2H, 3J = 7.55 
Hz, Et), 3.22 (s, 3H, CH3), 3.57 (s, 3H, CH3), 5.93 (d, 1H, 2J = 14.78 Hz, CH2NO2-a), 6.90 (d, 1H, 
2J = 14.78 Hz, CH2NO2-b), 7.27 (d, 1H, 3J = 8.31 Hz, H-8), 7.41 (d, 1H, 3J = 8.31 Hz, H-9), 7.62 (s, 
1H, H-6), 9.54 (br s, 1H, NH). 
13C NMR (75.48 MHz, DMSO-d6): δ = 16.5 (CH3), 28.6 (CH2), 28.7 (CH3), 31.4 (CH3), 
49.8 (q, 2J(C-F) = 26.6 Hz, C-5), 72.8 (CH2NO2), 77.4 (C-4a), 116.3, 118.2 (CHAr), 127.0 (q, 1J(C-F) = 
288.9 Hz, CF3), 127.3 (CHAr), 130.1 (CHAr), 134.9, 140.1, 148.6, 151.0, 162.0. 
N
+
N
N
O
O
F
F
F
N
H
O O
Experimental	Part	
138 
19F NMR (282.38 MHz, DMSO-d6): δ = –73.8 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 398 ([M]+, 8.6), 338 (22), 337 ([M–CH3NO2]+, 77), 329 (60), 
322 (18), 284 (30), 283 (100), 282 (37), 268 (15), 265 (12), 225 (77), 224 (11), 210 (11). 
HRMS (ESI): Calcd. for C17H18F3N4O4 [M+H]+: 399.12747, found: 399.12780. 
IR (ATR, cm–1): ṽ = 3362 (m), 3034 (w), 2967 (w), 2879 (w), 1688 (m), 1614 (s), 1552 (s), 
1530 (s), 1511 (s), 1479 (s), 1435 (s), 1438 (m), 1392 (m), 1375 (s), 1338 (w), 1318 (m), 1302 (w), 
1289 (w), 1264 (m), 1229 (s), 1208 (m), 1183 (s), 1170 (s), 1163 (s), 1147 (s), 1103 (m), 1062 (w), 
1017 (m), 986 (w), 969 (m), 949 (w), 900 (w), 831 (s), 787 (w), 773 (m), 752 (m), 738 (w), 692 
(w), 668 (s), 592 (m), 568 (m), 538 (w). 
 
8,10-Dimethyl-6-(nitromethyl)-6-(trifluoromethyl)-1,2-dihydro-6H-pyrimido[4,5-
b]pyrrolo[3,2,1-ij]quinoline-7,9(8H,10H)-dione (102b) 
 
The product was prepared according to the general method, starting from 
0.05 g of 92a, 0.082 g of nitromethane, 0.015 g of sodium methylate, 1 mL of 
methanol and 1 mL of THF. 
Yield 0.049 g (92%), white solid, mp 285-286 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.19-3.45 (m, 2H, CH2-2), 3.32 (s, 3H, CH3), 3.64 (s, 
3H, CH3), 3.95-4.70 (m, 1H, CH2-1a), 4.55-4.65 (m, 1H, CH2-1b), 5.22 (d, 1H, 2J = 14.17 Hz, 
CH2NO2-a), 7.11 (dd, 1H, 3J1 = 7.36 Hz, 3J2 = 8.12 Hz, H-4), 7.16 (d, 1H, 2J = 14.17 Hz, CH2NO2-
b), 7.22 (d, 1H, 3J = 7.36 Hz, H-3), 7.29 (d, 1H, 3J = 8.12 Hz, H-5). 
13C NMR (125.77 MHz, CDCl3): δ = 28.7 (CH3), 28.8 (CH2), 38.6 (CH3), 50.2 (q, 2J(C-F) = 
27.8 Hz), 53.6 (CH2), 72.1 (CH2), 82.5 (C-6a), 113.6, 124.8 (CH), 125.5 (CH), 125.9 (q, 1J(C-F) = 
288.0 Hz, CF3), 126.0 (CH), 129.5, 141.7, 152.6, 153.0, 162.3. 
19F NMR (282.38 MHz, CDCl3): δ = –74.4 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 396 ([M]+, 8.2), 327 (33), 282 (18), 281 (100),  
HRMS (ESI): Calcd. for C17H16F3N4O4 [M+H]+: 397.11182, found: 397.11096. 
IR (ATR, cm–1): ṽ = 3034 (w), 2974 (w), 1697 (s), 1626 (s), 1545 (s), 1497 (s), 1471 (s), 
1446 (s), 1417 (s), 1404 (s), 1381 (s), 1371 (s), 1304 (m), 1267 (m), 1255 (s), 1227 (s), 1184 (s), 
1159 (s), 1134 (s), 1124 (s), 1078 (m), 1065 (m), 1047 (m), 1030 (m), 1011 (s), 968 (s), 943 (m), 
933 (m), 864 (m), 849 (m), 779 (s), 768 (s), 748 (s), 731 (s), 714 (m), 677 (s), 654 (m), 606 (m), 
581 (m), 571 (m), 546 (m), 532 (m). 
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4.2.13.3 Addition of hydrogen cyanide 
 
Addition of hydrogen cyanide to 1,3-dialkyl-5-polyfluoroalkyl-pyrimido[4,5-
b]quinoline-2,4-diones. General procedure. 
Initial 1,3-dialkyl-5-polyfluoroalkyl-pyrimido[4,5-b]quinoline-2,4-dione (1 eq) was 
suspended in DMSO. Then KCN (2 eq) was added. Reaction mixture was stirred overnight and 
afterwards acetic acid (2 eq) was carefully added under fume hood. Then mixture was diluted with 
water. The formed precipitate was filtered off by suction and recrystallized from methanol/water 
giving the pure product. 
 
7-Ethyl-1,3-dimethyl-2,4-dioxo-5-(trifluoromethyl)-1,2,3,4,5,10-
hexahydropyrimido[4,5-b]quinoline-5-carbonitrile (101c) 
 
The product was prepared according to the general method, starting 
from 0.2 g of 88f, 0.077 g of KCN and 4 mL of DMSO. 
Yield 0.203 g (94%), white solid, mp 179 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.22 (t, 3H, 3J = 7.56 Hz, Et), 2.70 (q, 2H, 3J = 7.56 
Hz, Et), 3.26 (s, 3H, CH3), 3.54 (s, 3H, CH3), 7.43 (dd, 1H, 3J = 8.39 Hz, 4J = 1.79 Hz, H-8), 7.51 
(d, 1H, 3J = 8.39 Hz, H-9), 7.53 (s, 1H, H-6), 9.96 (br s, 1H, NH). 
13C NMR (75.48 MHz, DMSO-d6): δ = 16.4 (CH3), 28.3 (CH2), 28.8 (CH3), 31.4 (CH3), 
46.3 (q, 2J(C-F) = 31.9 Hz, C-5), 74.5 (C-4a), 112.6, 115.9, 118.7 (CHAr), 124.8 (q, 1J(C-F) = 289.3 
Hz, CF3), 128.4 (CHAr), 131.7 (CHAr), 134.6, 141.0, 148.3, 151.0, 160.4. 
19F NMR (282.38 MHz, DMSO-d6): δ = –75.1 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 364 ([M]+, 1.03), 338 (17), 337 ([M–HCN]+, 97), 322 (27), 309 
(11), 296 (10), 295 (53), 280 (11), 268 (19), 265 (23), 239 (10), 238 (16), 237 (11), 226 (12), 225 
(100), 224 (13), 210 (17), 196 (11). 
HRMS (ESI): Calcd. for C17H16F3N4O2 [M+H]+: 365.12199, found: 365.12186. 
IR (ATR, cm–1): ṽ = 3526 (w), 3326 (m), 2977 (w), 1688 (m), 1633 (m), 1613 (s), 1601 (m), 
1531 (s), 1502 (s), 1472 (s), 1435 (s), 1414 (m), 1392 (w), 1368 (w), 1338 (w), 1300 (w), 1260 (w), 
1232 (w), 1218 (m), 1180 (s), 1159 (m), 1145 (m), 1101 (w), 1068 (w), 1035 (m), 1002 (w), 965 
(m), 940 (w), 894 (w), 866 (w), 835 (s), 771 (m), 759 (m), 733 (w), 706 (w), 692 (w), 661 (w), 577 
(m), 565 (m), 545 (m), 531 (w). 
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8,10-Dimethyl-7,9-dioxo-6-(trifluoromethyl)-1,2,7,8,9,10-hexahydro-6H-pyrimido[4,5-
b]pyrrolo[3,2,1-ij]quinoline-6-carbonitrile (102c) 
 
The product was prepared according to the general method, starting from 
0.2 g of 92a, 0.105 g of KCN and 4 mL of DMSO. 
Yield 0.136 g (70%), white solid, mp 242 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 3.26-3.54 (m, 2H, CH2-2), 3.34 (s, 
1H, CH3), 3.68 (s, 1H, CH3), 4.03-4.16 (m, 1H, CH2-1a), 4.65-4.77 (m, 1H, (m, 1H, CH2-1b), 7.23 
(dd, 1H, 3J1 = 7.74 Hz, 3J2 = 7.37 Hz, CH-4), 7.32 (d, 1H, 3J = 7.37 Hz, CHAr), 7.62 (d, 1H, 3J = 
7.74 Hz, CHAr). 
13C NMR (75.48 MHz, CDCl3): δ = 28.7 (CH3), 29.0 (CH2), 38.0 (CH3), 46.2 (q, 2J(C-F) = 
33.0 Hz, C-6), 53.8 (CH2), 79.5 (C-6a), 110.8, 115.0, 124.0 (q, 1J(C-F) = 288.7 Hz, CF3), 126.3 
(CHAr), 126.8 (CHAr), 127.3 (CHAr), 129.5, 140.9, 152.2, 152.2, 160.3. 
19F NMR (282.38 MHz, CDCl3): δ = –75.8 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 362 ([M]+, 2.0), 294 (18), 293 ([M–CF3]+, 100), 236 (23). 
HRMS (EI): Calcd. for C17H13F3N4O2 [M]+: 362.09851, found: 362,09826. 
IR (ATR, cm–1): ṽ = 3071 (w), 2951 (w), 2858 (w), 1716 (m), 1640 (m), 1633 (m), 1545 
(m), 1498 (m), 1449 (s), 1435 (s), 1403 (m), 1363 (m), 1342 (w), 1300 (w), 1285 (w), 1266 (w), 
1224 (w), 1208 (m), 1185 (s), 1174 (s), 1161 (s), 1107 (m), 1054 (w), 1025 (w), 1001 (w), 987 (m), 
964 (m), 939 (m), 867 (w), 826 (w), 796 (s), 768 (s), 746 (s), 712 (m), 679 (w), 666 (w), 611 (w), 
571 (w), 539 (w). 
 
4.2.13.4 Addition of indole 
 
7-Ethyl-5-(1H-indol-1-yl)-1,3-dimethyl-5-(trifluoromethyl)-5,10-dihydropyrimido[4,5-
b]quinoline-2,4(1H,3H)-dione (101d) 
 
Initial 7-ethyl-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-
b]quinoline-2,4(1H,3H)-dione 88f (0.25 g, 0.74 mmol, 1 eq) was added to a 
mixture of indole (0.13 g, 1.11 mmol, 1,5 eq) and sodium hydride (60% in 
mineral oil, 0.044g, 1.11 mmol, 1.5 eq) in dry THF (2.5 mL). The reaction 
mixture was stirred for 5 min at r.t., followed by addition of acetic acid (0.1 
g, 1.67 mmol, 2.25 eq) and dilution with water. The formed precipitate was filtered off by suction, 
washed with water, recrystallized from DMSO containing one drop of acetic acid (just to stabilize 
the product) and dried in high vacuum at 60 °C (avoid overheating!). 
Yield 0.194 g (58%), white solid, mp 212 °C (dec.). 
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1H NMR (300.13 MHz, DMSO-d6): δ = 0.89 (t, 3H, 3J = 7.56 Hz, Et), 2.33 (q, 2H, 3J = 7.56 
Hz, Et), 2.97 (s, 3H, CH3), 3.65 (s, 3H, CH3), 6.42 (s, 1H, CHAr), 6.61 (d, 1H, 3J = 3.21 Hz, CHAr), 
6.69 (d, 1H, 3J = 8.31 Hz, CHAr), 6.74-6.82 (m, 1H, CHAr), 6.89-6.98 (m, 1H, CHAr), 7.28 (d, 1H, 3J 
= 7.93 Hz, H-8), 7.55 (m, 2H, CHAr), 7.71 (s, 1H, H-5), 9.92 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 16.2 (CH3), 28.2 (CH2), 28.3 (CH3), 31.5 (CH3), 
65.3 (q, 2J(C-F) = 29.7 Hz), 78.7 (C-4a), 101.9 (CH), 112.9 (CH), 117.7, 117.8 (CH), 120.1 (CH), 
121.4 (CH), 121.7 (CH), 126.4 (q, 1J(C-F) = 290.5 Hz, CF3), 127.2 (CH), 129.6, 130.2 (CH), 130.7 
(CH), 134.1, 135.7, 139.8, 147.9, 151.2, 159.4. 
19F NMR (282.38 MHz, DMSO-d6): δ = –72.2 (s, CF3). 
MS (EI, 70 eV): m/z (%) = 338 (25), 337 (100), 322 (40), 309 (11), 280 (11), 268 (17), 265 
(23), 239 (10), 226 (14), 225 (95), 224 (13), 210 (15), 117 (92), 90 (30), 89 (18). 
HRMS (ESI): Calcd. for C24H22F3N4O2 [M+H]+: 455.16894, found: 455.16903. 
IR (ATR, cm–1): ṽ = 3273 (w), 3207 (w), 1713 (s), 1626 (s), 1614 (s), 1599 (m), 1527 (s), 
1504 (s), 1479 (s), 1456 (s), 1444 (m), 1390 (m), 1369 (w), 1315 (w), 1298 (m), 1259 (m), 1238 (s), 
1211 (m), 1203 (m), 1173 (s), 1161 (s), 1153 (s), 1140 (m), 1126 (w), 1059 (m), 1016 (w), 984 (m), 
939 (w), 916 (w), 891 (s), 879 (w), 847 (w), 827 (m), 770 (m), 739 (s), 708 (s), 692 (m), 679 (m), 
658 (m), 625 (w), 596 (w), 582 (m), 563 (m), 542 (w). 
 
7-Ethyl-5-(1H-indol-3-yl)-1,3-dimethyl-5-(trifluoromethyl)-5,10-dihydropyrimido[4,5-
b]quinoline-2,4(1H,3H)-dione (101e) 
 
Initial 7-ethyl-1,3-dimethyl-5-(trifluoromethyl)pyrimido[4,5-b]qui-
noline-2,4(1H,3H)-dione 88f (0.15 g, 0.44 mmol, 1 eq) was added to a 
mixture of indole (0.078 g, 0.67 mmol, 1,5 eq) and sodium hydride (60% in 
mineral oil, 0.036 g, 0.89 mmol, 2 eq) in dry DMF (3 mL). The reaction 
mixture was stirred for 5 hours at 60 °C under argon. After cooling to r.t. 
0.134 g of acetic acid (2.22 mmol, 3.75 eq) and water were added. The formed precipitate was 
filtered off by suction and recrystallized from methanol giving the pure product. 
Yield 0.115 g (57%), pinkish solid, mp 295-297 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 0.92 (t, 3H, 3J = 7.55 Hz, Et), 2.31 (q, 2H, 3J = 7.55 
Hz, Et), 2.96 (s, 3H, CH3), 3.63 (s, 3H, CH3), 6.64-6.72 (m, 2H, CHAr, NH-1'), 6.91-7.01 (m, 2H, 
CHAr), 7.13 (dd, 1H, 3J = 8.22 Hz, 4J = 2.00 Hz, CHAr), 7.33-7.42 (m, 3H, CHAr), 9.47 (s, 1H, H-2'), 
11.00 (s, 1H, NH-10). 
13C NMR (62.90 MHz, DMSO-d6): δ = 16.4 (CH3), 28.3 (CH2), 28.3 (CH3), 31.2 (CH3), 
49.1 (q, 2J(C-F) = 27.0 Hz), 81.1 (C-4a), 112.3 (CH), 114.4, 117.2 (CH), 118.9 (CH), 120.1 (CH), 
120.4, 121.4 (CH), 121.7 (q, 1J(C-F) = 288.4 Hz, CF3), 123.9 (CH), 126.8, 129.1 (CH), 130.1 (CH), 
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134.7, 137.0, 138.7, 148.0, 151.4, 159.7. 
MS (EI, 70 eV): m/z (%) = 454 ([M]+, 3.0), 385 (16), 338 (28), 337 (100), 322 (42.92), 309 
(12), 280 (13), 268 (20), 265 (26), 239 (11), 237 (10), 226 (16), 225 (96), 224 (14), 210 (15), 196 
(10), 117 (34), 90 (11), 60 (10). 
HRMS (EI): Calcd. for C24H21F3N4O2 [M]+: 454.16111, found: 454.16137. 
IR (ATR, cm–1): ṽ = 3271 (w), 3207 (w), 2914 (w), 1713 (s), 1626 (s), 1614 (s), 1599 (s), 
1525 (s), 1504 (s), 1479 (s), 1454 (s), 1444 (s), 1390 (m), 1369 (m), 1315 (m), 1298 (m), 1288 (m), 
1259 (m), 1238 (s), 1211 (m), 1173 (s), 1153 (s), 1126 (m), 1099 (m), 1057 (s), 1016 (m), 982 (m), 
941 (w), 916 (w), 891 (s), 879 (m), 847 (m), 827 (m), 770 (s), 739 (s), 708 (s), 692 (m), 679 (m), 
658 (m), 625 (m), 596 (m), 582 (m), 563 (m), 542 (m). 
 
4.2.14 Synthesis of 1,3-dimethyl-9-{2-[(4-methylphenyl)thio]ethyl}-5-(trifluoromethyl)-
5-deazaalloxazine 
 
1,3-Dimethyl-9-{2-[(4-methylphenyl)thio]ethyl}-5-(trifluoromethyl)pyrimido[4,5-
b]quinoline-2,4(1H,3H)-dione (104) 
 
Into a 10-mL flask were placed 0.5 g of 9-(2-chloroethyl)-1,3-dimethyl-
5-(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4(1H,3H)-dione 92a (0.13 
mmol, 1 eq), 0.33 g of 4-methylthiophenol (0.27 mmol, 2 eq), 0.013 g of 
sodium methylate (0.24 mmol, 1.8 eq) and 1 mL of DMF. The reaction mixture 
was stirred for 4 hours and then diluted with water. The formed precipitate was 
filtered off by suction, washed with water and recrystallized from methanol giving the pure product. 
Yield 0.059 g (95%), yellow solid, mp 142-143 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 2.31 (s, 3H, CH3), 3.28 (t, 2H, CH2-Ar), 3.45-3.55 (m, 
5H, CH3, CH2-S), 3.66 (s, 1H, CH3), 7.06 (d, 2H, 3J = 7.93 Hz, H-2', H-6'), 7.25 (d, 2H, 3J = 7.93 
Hz, H-3', H-5'), 7.50 (dd, 1H, 3J1 = 7.11 Hz, 3J2 = 8.62 Hz, H-7), 7.70 (d, 1H, 3J = 7.11 Hz, H-8), 
8.19 (d, 1H, 3J = 8.62 Hz, H-6). 
13C NMR (62.90 MHz, CDCl3): δ = 21.3 (Ar-CH3), 29.5 (CH3-3), 30.5 (CH3-1), 33.1 (CH2), 
35.4 (CH2), 110.1 (C-4a), 122.0, 123.6 (q, 1J(C-F) = 278.3 Hz, CF3), 124.9 (q, 4J(C-F) = 5.9 Hz, CH-
6), 127.0 (CH), 129.9 (CH), 131.3 (CH), 132.5, 133.8 (CH), 137.0, 138.4, 139.1 (q, 2J(C-F) = 33.2 
Hz, C-5), 147.4, 148.6, 151.2 (CO-2), 159.3 (CO-4). 
19F NMR (282.38 MHz, CDCl3): δ = –52.4 (s, CF3). 
MS (GC, 70 eV): m/z (%) = 459 ([M]+, 35), 337 (19), 336 (100), 279 (29), 137 (68). 
HRMS (EI): Calcd. for C23H20O2N3F3S [M+H]+: 459.12228, found: 459.122964. 
IR (ATR, cm–1): ṽ = 2955 (w), 2929 (w), 1728 (s), 1666 (s), 1608 (w), 1585 (s), 1574 (s), 
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1485 (s), 1470 (s), 1421 (s), 1394 (m), 1379 (s), 1356 (s), 1333 (m), 1286 (s), 1261 (m), 1227 (s), 
1198 (m), 1169 (s), 1134 (s), 1115 (s), 1082 (m), 1039 (m), 1014 (m), 982 (m), 930 (m), 883 (w), 
856 (w), 820 (m), 804 (s), 789 (s), 779 (s), 762 (s), 748 (s), 739 (m), 702 (s), 685 (m), 675 (m), 667 
(m), 590 (w), 555 (m), 542 (w). 
 
4.2.15 Cyclisation of 6-(benzylamino)-1,3-dimethyl-5-(trifluoroacetyl)pyrimidine-
2,4(1H,3H)-dione 
 
6,8-Dimethyl-2-phenyl-4-(trifluoromethyl)-4,8-dihydro-2H-pyrimido[4,5-
d][1,3]oxazine-5,7(1H,6H)-dione (108) 
 
A sealed ACE pressure tube was charged 
with 1 g of 6-(benzylamino)-1,3-dimethyl-5-
(trifluoroacetyl)pyrimidine-2,4(1H,3H)-dione 78c 
(2.93 mmol, 1 eq), 1.186 g of dry triethylamine 
(11.7 mmol, 4 eq) and 10 mL of dry DMF. The 
reaction mixture was stirred for 10 hours at 125 °C 
under argon. Then the solvent was evaporated and the crude product was purified via short-part 
column chromatography (silica gel / EtOAc), following by washing with ether. 
Yield 0.798 g (80%), white solid, mp 220-222 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.31 (s, 3H, CH3-6-a), 3.32 (s, 0.15H, CH3-6-b), 
3.32 (s, 0.15H, CH3-8-b), 3.36 (s, 3H, CH3-8-a), 5.27 (q, 1H, 4J(H-F) = 7.18 Hz, H-4-a), 5.49.(q, 
0.15H, 4J(H-F) = 5.29 Hz, H-4-b), 5.55 (d, 0.15H, J = 3.11 Hz, H-2-b), 5.91 (br s, 1H, H-2-a), 7.48-
7.64 (m, 5.75H, CHPh-a, CHPh-b), 8.11 (d, 0.15H, J = 3.11 Hz, NH-b), 8.15 (br s, 1H, NH-a). 
13C NMR (62.90 MHz, CDCl3): δ = 28.2 (CH3-6-a,b), 30.1 (CH3-8-b), 30.4 (CH3-8-a), 69.6 
(q, 2J(C-F) = 31.6 Hz, CH-4-a), 70.5 (q, 2J(C-F) = 31.9 Hz, CH-4-b), 77.2 (4a-a), 81.9 (CH-2-a), 82.2 
(4a-b), 83.0 (CH-2-b), 125.7 (q, 1J(C-F) = 287.6 Hz, CF3-a), 128.5 (CHo-Ph-b), 128.6 (CHo-Ph-a), 
129.3 (CHm-Ph-b), 129.4 (CHm-Ph-a), 130.4 (CHp-Ph-b), 130.8 (CHp-Ph-a), 137.0 (CPh-b), 137.6 (CPh-
a), 150.5 (C-8-a), 151.5 (CO-7-b), 151.6 (CO-7-a), 154.0 (C-8-b), 160.2 (CO-5-a), 160.4 (CO-5-b). 
19F NMR (282.38 MHz, DMSO-d6): δ = –75.5 (s, CF3-b), –71.3 (s, CF3-a). 
MS (EI, 70 eV): m/z (%) = 341 ([M]+, 16), 273 (32), 272 (100), 258 (17), 110 (11), 105 (15), 
82 (12), 77 (12). 
HRMS (ESI): Calcd. for C15H15F3N3O3 [M+H]+: 342.10600, found: 340.10654. 
Anal. Calcd for C15H14F3N3O3: C, 52.79; H, 4.13; N, 12.31. Found: C, 52.95; H, 3.87; N, 
11.79. 
IR (ATR, cm–1): ṽ = 3243 (s), 3097 (w), 3040 (w), 2952 (w), 1707 (s), 1616 (s), 1556 (s), 
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1482 (s), 1459 (m), 1439 (m), 1395 (w), 1383 (m), 1360 (m), 1335 (w), 1321 (m), 1307 (w), 1290 
(w), 1258 (s), 1248 (s), 1234 (m), 1167 (s), 1123 (s), 1076 (m), 1053 (m), 1028 (w), 1005 (m), 998 
(m), 982 (w), 967 (m), 670 (s), 650 (w), 634 (s), 617 (w), 582 (m), 531 (m). 
 
4.2.16 Detection of 5-deazaalloxazine-10-ium cation 
 
8,10-Dimethyl-7,9-dioxo-6-(trifluoromethyl)-1,2,7,8,9,10-hexahydropyrimido[4,5-
b]pyrrolo[3,2,1-ij]quinolin-11-ium trifluoromethanesulfonate (95a) 
 
The solution of title salt was prepared inside a NMR tube by 
addition of triflic anhydride to 6-hydroxy-8,10-dimethyl-6-(tri-
fluoromethyl)-1,2-dihydro-6H-pyrimido[4,5-b]pyrrolo[3,2,1-ij]quino-
line-7,9(8H,10H)-dione 91a dissolved in pure CDCl3 or 
CDCl3/CD2Cl2 mixture. 
1H NMR (300.13 MHz, CDCl3): δ = 3.42 (s, 3H, CH3-3), 3.80 (t, 2H, 3J = 7.27 Hz, Ar-CH2-
), 3.96 (s, 3H, CH3-1), 5.48 (t, 2H, 3J = 7.27 Hz, -CH2-NAr+), 7.89 (dd, 1H, 3J1 = 8.59 Hz, 3J2 = 7,27 
Hz, H-4), 8.03 (d, 1H, 3J = 7.27 Hz, H-3), 8.24-8.32 (dm, 1H, 3J = 8.59 Hz, H-5), 13.99 (s, 1.67H, 
TfOH). 
13C NMR (75.47 MHz, CD2Cl2/CDCl3): δ = 27.8 (CH2-2), 30.0 (CH3-8), 36.6 (CH3-10), 
60.0 (CH2-1), 115.6 (C-6a), 118.8 (q, 1J(C-F) = 317.6 Hz, TfOH/TfO–), 120.5, 121.6 (q, 1J(C-F) = 
279.6 Hz, CF3), 124.6 (q, 4J(C-F) = 5.9 Hz, CH-5), 131.9 (CHAr), 133.1 (CHAr), 134.5, 143.3, 145.2 
(q, 2J(C-F) = 35.9 Hz, C-6), 149.2, 149.3, 155.9. 
 
4.2.17 Synthesis of spiro[pyrimido[4,5-b]quinoline-3',5-indoline-2'-one]-3,10-dihydro-
2,4-diones 
 
General procedure for the synthesis of spiro[pyrimido[4,5-b]quinoline-3',5-indoline-2'-
one]-3,10-dihydro-2,4-diones 118/119 a-w. 
Into a 25-mL flask were placed barbituric acid (1.92 mmol, 1 eq), isatin (1.92 mmol, 1 eq), 
aromatic amine (1.92 mmol, 1 eq) and 6 ml of ethanol. After that 0.096 mmol (0.05 eq) of iodine 
was added and the mixture was stirred at r.t. overnight. The next day formed precipitate was filtered 
off, washed with ethanol and recrystallized from appropriate solvent (DMF or TFA/EtOH), if 
necessary. 
  
N
+
N
N
O
O
FF
F
TfO- + TfOH
Experimental	Part	
145 
4,6-Dimethoxy-1',3'-dipropyl-1'H-spiro[indole-3,5'-pyrimido[4,5-b]quinoline]-
2,2',4'(1H,3'H,10'H)-trione (119a) 
 
The product was prepared according to the general procedure, 
starting from 0.245 g of 1,3-dipropylbarbituric acid, 0.177 g of 3,5-
dimethoxyaniline, 0.170 g of isatin, 0.015 g of iodine and 4.9 mL of 
ethanol. 
Yield 0.436 (79%), white solid, mp 303-305 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 0.78 (t, 3H, 3J = 7.46 Hz, NCH2CH2CH3-3'), 0.97 (t, 
3H, 3J = 7.37 Hz, NCH2CH2CH3-1'), 1.36-1.52 (m, 2H, NCH2CH2CH3-3'), 1.64-1.78 (m, 2H, 
NCH2CH2CH3-1'), 3.49 (s, 3H, MeO-4), 3.66 (t, 2H, 3J = 7.37 Hz, NCH2CH2CH3-3'), 3.75 (s, 3H, 
MeO-6), 4.06-4.30 (m, 2H, NCH2CH2CH3-1'), 6.03 (d, 1H, 4J = 2.08 Hz, H-5), 6.11 (d, 1H, 4J = 
2.08 Hz, H-7), 6.71 (d, 1H, 3J = 7.94 Hz, H-9'), 6.85-6.93 (m, 1H, H-7'), 7.13-7.21 (m, 1H, H-8'), 
7.31 (d, 1H, 3J = 8.12 Hz, H-6'), 9,14 (br s, 1H, NH-10'), 10.32 (br s, 1H, NH-1). 
13C NMR (62.90 MHz, DMSO-d6): δ = 11.5 (CH3), 11.9 (CH3), 21.6 (CH2), 22.0 (CH2), 
42.6 (N-CH2), 43.8 (N-CH2), 51.0 (C-5',3), 56.1 (MeO-6), 56.4 (MeO-4), 85.1 (C-4a'), 90.1 (CH-7), 
92.9 (CH-5), 117.2 (CHAr), 118.0, 122.9, 124.2 (CHAr), 126.7 (CHAr), 128.5 (CHAr), 136.7, 143.8, 
146.2, 151.2, 156.7, 160.2, 161.5, 181.9 (CO-2). 
MS (EI, 70 eV): m/z (%) = 477 ([M+H]+, 10), 476 ([M]+, 27), 448 (34), 325 (20), 324 (100), 
282 (33), 240 (42), 217 (18), 169 (13), 43 (17), 41 (13). 
HRMS (ESI): Calcd. for C26H29N4O5 [M]+: 477.21325, found: 477.21398. 
IR (ATR, cm–1): ṽ = 3182 (m), 2955 (m), 2833 (w), 1707 (s), 1691 (s), 1626 (s), 1606 (s), 
1593 (s), 1531 (s), 1489 (s), 1460 (s), 1443 (s), 1394 (m), 1338 (m), 1325 (s), 1306 (m), 1277 (m), 
1254 (s), 1238 (m), 1215 (s), 1194 (s), 1144 (s), 1124 (s), 1113 (s), 1092 (s), 1041 (m), 1016 (m), 
991 (m), 947 (m), 935 (m), 914 (w), 887 (w), 862 (m), 816 (m), 789 (m), 775 (s), 744 (s), 725 (m), 
710 (s), 673 (s), 631 (m), 617 (s), 604 (m), 561 (m), 548 (m), 530 (m). 
 
4,5,6-Trimethoxy-1',3'-dipropyl-1'H-spiro[indole-3,5'-pyrimido[4,5-b]quinoline]-
2,2',4'(1H,3'H,10'H)-trione (119b) 
 
The product was prepared according to the general procedure, 
starting from 0.245 g of 1,3-dipropylbarbituric acid, 0.211 g of 3,4,5-
trimethoxyaniline, 0.170 g of isatin, 0.015 g of iodine and 4.9 mL of 
ethanol. 
Yield 0.153 g (26%), white solid, mp 300 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 0.78 (t, 3H, 3J = 7.46 Hz, NCH2CH2CH3-3'), 0.99 (t, 
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3H, 3J = 7.37 Hz, NCH2CH2CH3-1'), 1.33-1.54 (m, 2H, NCH2CH2CH3-3'), 1.63-1.78 (m, 2H, 
NCH2CH2CH3-1'), 3.29 (s, 1H, MeO), 3.59 (s, 1H, MeO), 3.61-3.73 (m, 2H, NCH2CH2CH3-3'), 
3.83 (s, 1H, MeO), 4.10-4.23 (m, 2H, NCH2CH2CH3-1'), 6.36 (s, 1H, H-7), 6.71 (d, 1H, 3J = 7.93 
Hz, H-9'), 6.88-6.96 (m, 1H, H-7'), 7.16-7.24 (m, 1H, H-8'), 7.36 (d, 1H, 3J = 8.12 Hz, H-6'), 9,19 
(br s, 1H, NH-10'), 10.31 (br s, 1H, NH-1). 
13C NMR (62.90 MHz, DMSO-d6): δ = 11.6 (CH3), 11.9 (CH3), 21.6 (CH2), 22.2 (CH2), 
42.6 (N-CH2), 44.0 (N-CH2), 51.7 (C-5',3), 56.8 (MeO), 60.8 (MeO), 61.3 (MeO), 85.5 (C-4a'), 
92.0 (CH-7), 117.5 (CHAr), 123.0, 123.5, 124.4 (CHAr), 126.8 (CHAr), 128.7 (CHAr), 136.4, 137.2, 
138.2, 146.1, 150.2, 151.1, 154.4, 160.3, 181.7 (CO-2). 
MS (EI, 70 eV): m/z (%) = 507 ([M+H]+, 11), 506 ([M]+, 55), 463 (10), 325 (22), 324 (100), 
282 (21), 240 (33), 169 (10), 43 (13). 
HRMS (EI): Calcd. for C27H30N4O6 [M]+: 506.21599, found: 506.216186. 
Anal. Calcd for C27H30N4O6: C, 64.02; H, 5.97; N, 11.06. Found: C, 62.77; H, 5.98; N, 
10.77. 
IR (ATR, cm–1): ṽ = 3271 (w), 2962 (m), 2933 (m), 2874 (w), 1689 (s), 1610 (s), 1591 (s), 
1533 (s), 1487 (s), 1471 (s), 1435 (s), 1421 (s), 1392 (s), 1325 (s), 1286 (m), 1254 (s), 1232 (s), 
1194 (m), 1138 (s), 1117 (s), 1095 (s), 1049 (s), 1011 (m), 995 (m), 974 (m), 943 (m), 922 (m), 895 
(m), 860 (m), 814 (m), 798 (m), 775 (m), 760 (s), 744 (s), 700 (s), 690 (s), 608 (s), 561 (s). 
 
1',3'-Dipropyl-1'H-spiro[naphtho[2,3-e]indole-1,5'-pyrimido[4,5-b]quinoline]-
2,2',4'(3H,3'H,10'H)-trione (119c) 
 
The product was prepared according to the general procedure, 
starting from 0.23 g of 1,3-dipropylbarbituric acid, 0.209 g of 2-
anthracenamine, 0.159 g of isatin, 0.014 g of iodine and 4.6 mL of 
ethanol. 
Yield 0.512 g (91%), dark goldish solid, mp 300-302 °C. 
1H NMR (500.13 MHz, DMSO-d6): δ = 0.66 (t, 3H, 3J = 7.46 Hz, NCH2CH2CH3-3'), 1.07 (t, 
3H, 3J = 7.56 Hz, NCH2CH2CH3-1'), 1.26-1.40 (m, 2H, NCH2CH2CH3-3'), 1.85-1.97 (m, 2H, 
NCH2CH2CH3-1'), 3.56 (t, 2H, 3J = 7.37 Hz, NCH2CH2CH3-3'), 4.25-4.43 (m, 2H, NCH2CH2CH3-
1'), 6.73 (d, 1H, 3J = 7.84 Hz, H-6'), 6.82 (m, 1H, H-7'), 7.18 (m, 1H, H-8'), 7.35-7.40 (m, 1H, H-8), 
7.41 (d, 1H, H-4), 7.41-7.45 (m, 1H, H-9), 7.50 (d, 1H, 3J = 8.03 Hz, H-9'), 7.66 (d, 1H, 3J = 8.31 
Hz, H-10), 7.90 (s, 1H, H-11), 7.98 (d, 1H, 3J = 8.31 Hz, H-7), 8.09 (d, 1H, 3J = 8.69 Hz, H-5), 8.57 
(s, 1H, H-6), 9.59 (br s, 1H, NH-10'), 10.68 (br s, 1H, NH-3). 
13C NMR (125.77 MHz, DMSO-d6): δ = 11.7 (NCH2CH2CH3-1'), 11.8 (NCH2CH2CH3-3'), 
21.5 (NCH2CH2CH3-3'), 22.2 (NCH2CH2CH3-1'), 42.7 (NCH2CH2CH3-3'), 44.1 (NCH2CH2CH3-1'), 
N
H
N
N
O
O
N
H
O
Experimental	Part	
147 
53.2 (C-5',1), 86.2 (C-4a'), 114.3 (CH-4), 117.9 (CH-9'), 118.5 (CH-11), 122.4, 124.8 (CH-7'), 
125.3 (CH-8), 127.0 (CH-6'), 127.0 (CH-9), 127.6, 128.1 (CH-10), 128.4, 129.1 (CH-8'), 129.2 
(CH-7), 129.3 (CH-6), 130.0, 130.0, 130.6 (CH-5), 132.4, 136.4, 139.6, 146.4, 151.2, 160.3, 182.9 
(CO-2), 19.5 and 57.0 – traces of EtOH. 
MS (EI, 70 eV): m/z (%) = 517 ([M+H]+, 36). 516 ([M]+, 100), 515 (10), 514 (16), 489 (14), 
488 (48), 487 (80), 474 (14), 388 (14), 360 (13), 346 (14), 324 (41), 318 (30), 316 (13). 
HRMS (ESI): Calcd. for C32H29N4O3 [M+H]+: 517.22342, found: 517.22319. 
IR (ATR, cm–1): ṽ = 3167 (m), 2960 (m), 2872 (m), 1689 (s), 1606 (s), 1583 (s), 1566 (s), 
1525 (s), 1504 (s), 1485 (s), 1429 (s), 1406 (s), 1369 (s), 1336 (s), 1319 (s), 1234 (s), 1205 (m), 
1182 (m), 1157 (m), 1130 (m), 1097 (m), 1065 (m), 1001 (m), 957 (m), 943 (m), 935 (m), 895 (m), 
879 (m), 864 (s), 827 (m), 802 (m), 775 (s), 744 (s), 716 (s), 689 (s), 673 (s), 644 (s), 617 (s), 600 
(s), 573 (s), 554 (s). 
 
4,6-Dimethoxy-1'H-spiro[indole-3,5'-pyrimido[4,5-b]quinoline]-2,2',4'(1H,3'H,10'H)-
trione (119d) 
 
The product was prepared according to the general procedure, starting 
from 0.3 g of barbituric acid, 0.359 g of 3,5-dimethoxyaniline, 0.345 g of 
isatin, 0.03 g of iodine and 6 mL of ethanol. 
Yield 0.469 g (51%), white solid, mp 357-359 °C. 
1H NMR (300.13 MHz, TFA-d): δ = 3.56 (s, 1H, MeO), 3.92 (s, 1H, MeO), 6.83 (d, 1H, 3J = 
2.08 Hz, H-9'), 6.95-7.03 (m, 1H, H-7'), 7.02 (d, 1H, 3J = 2.08 Hz, H-6'), 7.20-7.29 (m, 1H, H-8'). 
MS (EI, 70 eV): m/z (%) = 393 ([M+H]+, 13), 392 ([M]+, 52), 390 (16), 365 (13), 364 (60), 
363 (58), 348 (11), 347 (10), 333 (14), 240 (21), 169 (10), 153 (21), 78 (32), 45 (11), 44 (100), 43 
(19). 
HRMS (ESI): Calcd. for C20H17N4O5 [M+H]+: 393.11935, found: 393.11992. 
Anal. Calcd for C20H16N4O5: C, 61.22; H, 4.11; N, 14.28. Found: C, 62.03; H, 3.99; N, 
14.25. 
IR (ATR, cm–1): ṽ = 3267 (w), 3072 (w), 1722 (s), 1699 (s), 1626 (s), 1608 (s), 1549 (s), 
1504 (s), 1493 (s), 1475 (s), 1462 (s), 1446 (s), 1385 (s), 1342 (s), 1319 (s), 1261 (m), 1219 (s), 
1201 (m), 1167 (m), 1149 (s), 1109 (s), 1049 (m), 1036 (m), 993 (m), 959 (m), 951 (m), 933 (m), 
916 (m), 862 (m), 827 (s), 793 (s), 777 (s), 744 (s), 727 (s), 714 (m), 673 (s), 638 (s), 625 (s), 604 
(s), 588 (s), 555 (s), 532 (s). 
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4,6-Dimethoxy-1',3'-dimethyl-1'H-spiro[indole-3,5'-pyrimido[4,5-b]quinoline]-
2,2',4'(1H,3'H,10'H)-trione (119e) 
 
The product was prepared according to the general procedure, starting 
from 0.3 g of 1,3-dimethylbarbituric acid, 0.294 g of 3,5-dimethoxyaniline, 
0.283 g of isatin, 0.024 g of iodine and 6 mL of ethanol. 
Recrystallized from DMF. Yield 0.457 g (57%), white solid, mp 335 
°C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.08 (s, 3H, NCH3-3'), 3.50 (s, 3H, MeO-4), 3.57 (s, 
3H, NCH3-1'), 3.76 (s, 3H, MeO-6), 6.04 (d, 1H, 4J = 2.08 Hz, H-5), 6.12 (d, 1H, 4J = 2.08 Hz, H-
7), 6.69 (d, 1H, 3J = 7.93 Hz, H-9'), 6.85-6.93 (m, 1H, H-7'), 7.13-7.21 (m, 1H, H-8'), 7.29 (d, 1H, 
3J = 8.22 Hz, H-6'), 9,27 (br s, 1H, NH-10'), 10.34 (br s, 1H, NH-1). 
MS (GC, 70 eV): m/z (%) = 420 ([M]+, 3.6), 419 ([M–H]+, 22), 418 (85), 387 (33), 377 (10), 
376 (43), 281 (12), 254 (42), 209 (16), 208 (17), 207 (100), 191 (14). 
HRMS (ESI): Calcd. for C22H21N4O5 [M+H]+: 421.15065, found: 421.15040. 
Anal. Calcd for C22H20N4O5: C, 62.85; H, 4.79; N, 13.33. Found: C, 62.25; H, 4.86; N, 
13.30. 
IR (ATR, cm–1): ṽ = 3450 (w), 3184 (m), 2839 (w), 1707 (m), 1693 (s), 1674 (s), 1643 (s), 
1606 (s), 1593 (s), 1533 (s), 1512 (s), 1489 (s), 1464 (s), 1450 (s), 1425 (s), 1394 (m), 1373 (m), 
1342 (m), 1317 (s), 1257 (s), 1219 (s), 1201 (s), 1149 (s), 1126 (s), 1117 (s), 1086 (m), 1065 (m), 
1047 (m), 1001 (m), 989 (m), 939 (m), 932 (m), 916 (m), 868 (m), 818 (m), 797 (m), 777 (s), 750 
(s), 739 (s), 702 (s), 671 (s), 638 (s), 623 (s), 582 (s), 528 (s). 
 
7'-Chloro-4,6-dimethoxy-1',3'-dimethyl-1'H-spiro[indole-3,5'-pyrimido[4,5-
b]quinoline]-2,2',4'(1H,3'H,10'H)-trione (119f) 
 
The product was prepared according to the general procedure, starting 
from 0.3 g of 1,3-dimethylbarbituric acid, 0.294 g of 3,5-dimethoxyaniline, 
0.349 g of 5-chloroisatin, 0.024 g of iodine and 6 mL of ethanol. 
Yield 0.63 (72%), white solid, mp ˃320 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.08 (s, 3H, NCH3-3'), 3.53 (s, 3H, MeO-4), 3.56 (s, 
3H, NCH3-1'), 3.77 (s, 3H, MeO-6), 6.07 (d, 1H, 4J = 2.08 Hz, H-5), 6.14 (d, 1H, 4J = 2.08 Hz, H-
7), 6.59 (d, 1H, 4J = 2.45 Hz, H-6'), 7.26 (dd, 1H, 3J = 8.69 Hz, 4J = 2.45 Hz, H-8'), 7.34 (d, 1H, 3J 
= 8.69 Hz, H-9'), 9,45 (br s, 1H, NH-10'), 10.45 (br s, 1H, NH-1). 
13C NMR (75.48 MHz, DMSO-d6): δ = 28.3 (NCH3-3'), 31.0 (NCH3-1'), 51.0 (C-5',3), 56.2 
(MeO-6), 56.5 (MeO-4), 84.6 (C-4a'), 90.2 (CH-7), 93.1 (CH-5), 117.3, 119.4 (CH-9'), 125.0 (C-
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5a'), 125.9 (C H-6'), 127.5, 128.7 (C H-8'), 135.9 (C-9a'), 143.7, 146.7, 151.3, 156.8, 160.3, 161.8, 
181.3 (CO-2). 
MS (GC, 70 eV): m/z (%) = 454 ([M]+, 35Cl, 35), 453 (27), 452 (100), 423 (14), 421 (39), 
412 (21), 411 (15), 410 (57), 290 (19), 289 (10), 288 (51). 
HRMS (ESI): Calcd. for C22H2035ClN4O5 [M+H]+: 455.11167, found: 455.11218. 
IR (ATR, cm–1): ṽ = 3232 (m), 3001 (w), 1709 (s), 1687 (s), 1633 (s), 1622 (s), 1606 (s), 
1589 (s), 1525 (s), 1506 (s), 1479 (s), 1464 (s), 1456 (s), 1435 (s), 1402 (m), 1371 (m), 1333 (m), 
1321 (m), 1306 (m), 1292 (m), 1277 (m), 1254 (s), 1215 (s), 1196 (s), 1144 (s), 1128 (m), 1113 (s), 
1084 (s), 1066 (m), 1039 (m), 997 (m), 989 (m), 945 (m), 866 (m), 827 (s), 818 (s), 806 (m), 785 
(w), 771 (s), 754 (s), 698 (m), 675 (s), 665 (s), 625 (s), 588 (m), 557 (s), 552 (s), 542 (s). 
 
1-Ethyl-6',8'-dimethoxy-1',3'-dimethyl-1'H-spiro[indole-3,5'-pyrimido[4,5-
b]quinoline]-2,2',4'(1H,3'H,10'H)-trione (118g) 
 
The product was prepared according to the general procedure, starting 
from 0.3 g of 1,3-dimethylbarbituric acid, 0.294 g of 3,5-dimethoxyaniline, 
0.337 g of 1-ethylisatin, 0.024 g of iodine and 6 mL of ethanol. 
Yield 0.704 g (82%), white solid, mp ˃320 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.29 (t, 3H, 3J = 7.18 Hz, Et), 3.00 (s, 3H, NCH3-
3'), 3.32 (s, 3H, MeO-6'), 3.55 (s, 3H, NCH3-1'), 3.66-3.75 (m, 1H, CH2-a), 3.75-3.84 (m, 1H, CH2-
b), 3.77 (s, 3H, MeO-8'), 6.13 (d, 1H, 4J = 2.55 Hz, H-7'), 6.67 (d, 1H, 4J = 2.55 Hz, H-9'), 6.77-
6.84 (m, 1H, H-5), 6.85 (d, 1H, 3J = 7.27 Hz, H-4), 6.90 (d, 1H, 3J = 7.55 Hz, H-7), 7.11-7.19 (m, 
1H, H-6), 9,16 (br s, 1H, NH). 
13C NMR (125.77 MHz, TFA-d): δ = 13.1 (CH3(Et)), 30.5 (NCH3-3'), 31.8 (NCH3-1'), 38.8 
(CH2(Et)), 53.4 (C-5',3), 56.9 (MeO-6'), 57.4 (MeO-8'), 89.4 (C-4a'), 97.4 (CH-9'), 97.8 (CH-7'), 
104.5 (C-9a'), 111.4 (CH-7), 125.7 (CH-4), 127.2 (CH-5), 130.9, 137.9 (CH-6), 138.1, 143.9, 149.8, 
154.0, 161.1, 162.7, 165.0, 185.0 (CO-2). 
MS (EI, 70 eV): m/z (%) = 449 ([M+H]+, 28), 448 ([M]+, 100), 421 (13), 420 (48), 419 (29), 
405 (35), 390 (24), 389 (46), 362 (15), 328 (16), 327 (24), 312 (15), 310 (11), 303 (12), 302 (45), 
73 (11), 69 (11), 60 (16), 44 (28), 43 (14). 
HRMS (ESI): Calcd. for C24H25N4O5 [M+H]+: 449.18195, found: 449.18176. 
IR (ATR, cm–1): ṽ = 2972 (w), 1703 (s), 1682 (s), 1645 (s), 1601 (s), 1537 (s), 1487 (s), 
1462 (s), 1454 (s), 1441 (s), 1412 (m), 1392 (m), 1371 (s), 1352 (m), 1296 (m), 1279 (m), 1232 (s), 
1219 (s), 1174 (m), 1153 (s), 1132 (s), 1092 (m), 1078 (m), 1059 (m), 1045 (m), 1020 (m), 1007 
(m), 984 (m), 957 (m), 945 (m), 933 (m), 912 (m), 856 (w), 841 (w), 822 (s), 806 (s), 795 (m), 771 
(s), 752 (s), 725 (m), 712 (m), 694 (m), 683 (m), 669 (m), 654 (s), 621 (m), 602 (m), 582 (m), 563 
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(m), 534 (m). 
 
1-Ethyl-6',7',8'-trimethoxy-1',3'-dimethyl-1'H-spiro[indole-3,5'-pyrimido[4,5-
b]quinoline]-2,2',4'(1H,3'H,10'H)-trione (118h) 
 
The product was prepared according to the general procedure, starting 
from 0.3 g of 1,3-dimethylbarbituric acid, 0.352 g of 3,4,5-trimethoxyaniline, 
0.337 g of 1-ethylisatin, 0.024 g of iodine and 6 mL of ethanol. 
Yield 0.503 g (55%), white solid, mp ˃320 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.30 (t, 3H, 3J = 7.18 Hz, Et), 3.01 (s, 3H, NCH3-
3'), 3.03 (s, 1H, MeO-6'), 3.55 (s, 3H, NCH3-1'), 3.60 (s, 3H, MeO-7'), 3.78 (q, 2H, 3J = 7.18 Hz, 
Et), 3.83 (s, 3H, MeO-8'), 6.82-6.89 (m, 1H, H-5), 6.92 (d, 1H, 3J = 6.80 Hz, CHAr), 6.92 (s, 1H, H-
9'), 6.97 (d, 1H, 3J = 7.74 Hz, CHAr), 7.15-7.22 (m, 1H, H-6), 9,17 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 13.0 (CH3(Et)), 28.3 (NCH3-3'), 31.1 (NCH3-1'), 35.3 
(CH2(Et)), 50.1 (C-5',3), 56.6 (MeO-8'), 60.1 (MeO-6'), 61.1 (MeO-7'), 86.6 (C-4a'), 97.2 (CH-9'), 
107.9 (CHAr), 109.7, 122.1 (CHAr), 124.2 (CHAr), 128.4 (CHAr), 132.8, 137.5, 138.3, 144.7, 146.1, 
151.2, 152.0, 153.8, 160.1, 179.0 (CO-2). 
MS (EI, 70 eV): m/z (%) = 479 ([M+H]+, 26), 478 ([M]+, 100), 463 (11), 450 (16), 449 (16), 
435 (17), 420 (16), 419 (40), 358 (22), 332 (17), 147 (34), 82 (11), 79 (14), 78 (88), 77 (15), 75 
(70), 73 (32), 71 (11), 69 (26), 66 (60), 65 (31), 63 (98), 62 (13), 61 (21), 60 (40), 57 (18), 55 (19), 
48 (10), 47 (26), 46 (15), 45 (34), 44 (81), 43 (39), 41(20), 40 (29), 39 (25), 36 (11). 
HRMS (ESI): Calcd. for C25H27N4O6 [M+H]+: 479.19251, found: 479.19276. 
IR (ATR, cm–1): ṽ = 2972 (m), 2947 (w), 1703 (s), 1678 (s), 1639 (s), 1606 (s), 1539 (s), 
1489 (s), 1468 (s), 1450 (s), 1435 (s), 1383 (s), 1371 (s), 1354 (m), 1284 (m), 1271 (m), 1234 (s), 
1213 (m), 1180 (m), 1161 (m), 1136 (s), 1115 (m), 1092 (s), 1059 (s), 1026 (m), 1001 (m), 980 (m), 
959 (m), 941 (m), 920 (m), 874 (m), 852 (w), 827 (s), 793 (m), 777 (m), 752 (s), 741 (s), 714 (m), 
702 (m), 681 (s), 656 (m), 642 (m), 594 (m), 557 (m), 540 (m), 528 (m). 
 
7'-Fluoro-4,6-dimethoxy-1',3'-dimethyl-1'H-spiro[indole-3,5'-pyrimido[4,5-
b]quinoline]-2,2',4'(1H,3'H,10'H)-trione (119i) 
 
The product was prepared according to the general procedure, starting 
from 0.3 g of 1,3-dimethylbarbituric acid, 0.294 g of 3,5-dimethoxyaniline, 
0.317 g of 5-fluoroisatin, 0.024 g of iodine and 6 mL of ethanol. 
Yield 0.628 (75%), white solid, mp ˃320 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.08 (s, 3H, NCH3-3'), 3.52 (s, 
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3H, MeO-4), 3.56 (s, 3H, NCH3-1'), 3.77 (s, 3H, MeO-6), 6.07 (d, 1H, 4J = 2.08 Hz, H-5), 6.13 (d, 
1H, 4J = 2.08 Hz, H-7), 6.37 (dd, 1H, 3J(H-F) = 9.45 Hz, 4J = 2.83 Hz, H-6'), 7.03-7.12 (m, 1H, H-8'), 
7.35 (dd, 1H, 3J = 9.06 Hz, 4J(H-F) = 5.29 Hz, H-9'), 9,36 (br s, 1H, NH-10'), 10.42 (br s, 1H, NH-1). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.3 (NCH3-3'), 31.0 (NCH3-1'), 51.3 (C-5',3), 56.2 
(MeO-6), 56.5 (MeO-4), 84.0 (C-4a'), 90.2 (CH-7), 93.1 (CH-5), 112.5 (d, 2J(C-F) = 23.3 Hz, CHAr), 
115.9 (d, 2J(C-F) = 22.7 Hz, CHAr), 117.2, 119.2 (d, 3J(C-F) = 8.1 Hz, CH-9'), 124.7 (d, 3J(C-F) = 6.9 
Hz, C-5a'), 133.4 (d, 4J(C-F) = 2.0 Hz, C-9a'), 143.8, 146.9, 151.4, 156.8, 159.0 (d, 1J(C-F) = 239.0 Hz, 
C-7'), 160.4, 161.8, 181.3 (CO-2). 
19F NMR (282.38 MHz, CDCl3): δ = –120.2 (s, F-7'). 
MS (EI, 70 eV): m/z (%) = 439 ([M+H]+, 6.4), 438 ([M]+, 27), 437 (25), 436 (100), 410 (30), 
409 (20), 405 (29), 395 (15), 394 (67), 286 (48), 272 (58), 201 (15). 
HRMS (ESI): Calcd. for C22H20FN4O5 [M+H]+: 439.14122, found: 439.14209. 
IR (ATR, cm–1): ṽ = 3207 (m), 2841 (w), 1709 (s), 1687 (s), 1643 (s), 1622 (s), 1606 (s), 
1539 (s), 1495 (s), 1464 (s), 1441 (s), 1410 (s), 1392 (m), 1373 (m), 1335 (m), 1323 (m), 1296 (m), 
1277 (m), 1255 (s), 1217 (s), 1200 (s), 1146 (s), 1117 (s), 1090 (m), 1065 (m), 1041 (m), 999 (m), 
987 (m), 945 (m), 922 (w), 878 (m), 860 (s), 822 (s), 804 (m), 771 (s), 752 (s), 700 (m), 681 (s), 627 
(s), 592 (m), 557 (s). 
 
6',8'-Dimethoxy-1,1',3'-trimethyl-1'H-spiro[indole-3,5'-pyrimido[4,5-b]quinoline]-
2,2',4'(1H,3'H,10'H)-trione (118j) 
 
The product was prepared according to the general procedure, starting 
from 0.18 g of 1,3-dimethylbarbituric acid, 0.177 g of 3,5-dimethoxyaniline, 
0.186 g of 1-methylisatin, 0.015 g of iodine and 3.6 mL of ethanol. 
Yield 0.501 g (86%), white solid, mp ˃320 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.01 (s, 3H, NCH3-3'), 3.20 (s, 3H, NCH3-1), 3.36 
(s, 3H, MeO-6'), 3.55 (s, 3H, NCH3-1'), 3.77 (s, 3H, MeO-8'), 6.12 (d, 1H, 4J = 2.55 Hz, H-7'), 6.67 
(d, 1H, 4J = 2.55 Hz, H-9'), 6.77-6.85 (m, 1H, H-5), 6.85 (d, 1H, 3J = 7.18 Hz, H-4), 6.88 (d, 1H, 3J 
= 7.74 Hz, H-7), 7.13-7.20 (m, 1H, H-6), 9,17 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 27.1 (NCH3-1), 28.3 (NCH3-3'), 31.1 (NCH3-1'), 
49.6 (C-5',3), 56.1 (MeO-8'), 56.8 (MeO-6'), 87.2 (C-4a'), 95.0 (CH-9'), 95.5 (CH-7'), 105.2, 107.4 
(CHAr), 122.2 (CHAr), 123.7 (CHAr), 128.2 (CHAr), 136.8, 138.1, 145.6, 146.2, 151.2, 159.1, 160.1, 
160.6, 179.8 (CO-2). 
MS (EI, 70 eV): m/z (%) = 435 ([M+H]+, 14), 434 ([M]+, 59), 406 (18), 376 (34), 375 (100), 
318 (11), 44 (16). 
HRMS (EI): Calcd. for C23H22N4O5 [M]+: 434.15847, found: 434.15903. 
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IR (ATR, cm–1): ṽ = 2964 (w), 1695 (s), 1682 (s), 1633 (s), 1608 (s), 1537 (s), 1489 (s), 
1471 (s), 1441 (s), 1410 (s), 1379 (s), 1362 (s), 1298 (m), 1259 (m), 1238 (s), 1219 (s), 1201 (m), 
1192 (m), 1178 (m), 1153 (s), 1130 (s), 1092 (s), 1053 (s), 1041 (s), 1022 (m), 1005 (s), 980 (m), 
962 (m), 949 (m), 933 (m), 924 (m), 912 (m), 854 (m), 841 (m), 820 (s), 797 (m), 771 (s), 750 (s), 
741 (s), 727 (s), 696 (s), 687 (s), 656 (s), 640 (s), 602 (m), 582 (m), 569 (s), 544 (s), 536 (s). 
 
6',7',8'-Trimethoxy-1,1',3'-trimethyl-1'H-spiro[indole-3,5'-pyrimido[4,5-b]quinoline]-
2,2',4'(1H,3'H,10'H)-trione (118k) 
 
The product was prepared according to the general procedure, starting 
from 0.18 g of 1,3-dimethylbarbituric acid, 0.211 g of 3,4,5-
trimethoxyaniline, 0.186 g of 1-methylisatin, 0.015 g of iodine and 3.6 mL of 
ethanol. 
Yield 0.275 g (52%), white solid, mp ˃320 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 3.01 (s, 3H, NCH3-3'), 3.12 (s, 3H, MeO-6'), 3.22 
(s, 3H, NCH3-1), 3.55 (s, 3H, NCH3-1'), 3.60 (s, 3H, MeO-7'), 3.83 (s, 3H, MeO-8'), 6.82-6.89 (m, 
1H, H-5), 6.90 (d, 1H, 3J = 7.37 Hz, H-4), 6.93 (s, 1H, H-9'), 6.94 (d, 1H, 3J = 7.75 Hz, H-7), 7.16-
7.23 (m, 1H, H-6), 9,19 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 27.2 (NCH3-1), 28.3 (NCH3-3'), 31.1 (NCH3-1'), 
50.0 (C-5',3), 56.6 (MeO-8'), 60.4 (MeO-6'), 61.2 (MeO-7'), 86.6 (C-4a'), 97.2 (CH-9'), 107.9 (CH-
7), 109.7, 122.3 (CH-5), 124.0 (CH-4), 128.4 (CH-6), 132.8, 137.3, 138.3, 145.4, 146.1, 151.2, 
151.9, 153.8, 160.1, 179.7 (CO-2). 
MS (GC, 70 eV): m/z (%) = 465 ([M+H]+, 32), 464 ([M]+, 100), 449 (17), 433 (12), 406 
(31), 405 (89), 390 (18), 376 (12), 375 (30), 358 (25), 204 (16). 
HRMS (EI): Calcd. for C24H24N4O6 [M]+: 464.16904, found: 464.16820. 
IR (ATR, cm–1): ṽ = 2945 (m), 1703 (s), 1678 (s), 1645 (s), 1633 (s), 1606 (s), 1537 (s), 
1487 (s), 1470 (s), 1450 (s), 1435 (s), 1402 (s), 1379 (s), 1358 (s), 1304 (m), 1284 (m), 1269 (s), 
1230 (s), 1200 (m), 1153 (m), 1126 (s), 1090 (s), 1061 (s), 1032 (m), 1020 (m), 997 (s), 976 (s), 933 
(m), 920 (m), 872 (m), 851 (m), 827 (s), 791 (m), 777 (m), 764 (m), 750 (s), 704 (s), 681 (s), 662 
(s), 638 (m), 592 (m), 563 (m), 542 (s), 528 (s). 
 
6',7',8'-Trimethoxy-1',3'-dimethyl-5-nitro-1'H-spiro[indole-3,5'-pyrimido[4,5-
b]quinoline]-2,2',4'(1H,3'H,10'H)-trione (118l) 
 
The product was prepared according to the general procedure, starting from 0.3 g of 1,3-
dimethylbarbituric acid, 0.352 g of 3,4,5-dimethoxyaniline, 0.369 g of 5-nitroisatin, 0.024 g of 
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iodine and 6 mL of ethanol. 
Yield of the mixture of the both isomers: 0.636 g (67%). Yield of the 
pure major isomer obtained after recrystallization from TFA: 0.215 g (23%), 
yellowish solid, mp ˃320 °C. 
1H NMR (500.13 MHz, DMSO-d6): δ = 3.03 (s, 3H, NCH3-3'), 3.27 (s, 3H, MeO-6'), 3.56 
(s, 3H, NCH3-1'), 3.62 (s, 3H, MeO-7'), 3.85 (s, 3H, MeO-8'), 6.96 (s, 1H, H-9'), 6.99 (d, 1H, 3J = 
8.72 Hz, H-7), 7.73 (d, 1H, 4J = 2.42 Hz, H-4), 8.12 (dd, 1H, 3J = 8.72 Hz, 4J = 2.42 Hz, H-6), 9.29 
(br s, 1H, NH), ), 11.05 (br s, 1H, NH-1). 
13C NMR (62.90 MHz, DMSO-d6): δ = 28.4 (NCH3-3'), 31.2 (NCH3-1'), 50.6 (C-5',3), 56.7 
(MeO-8'), 60.4 (MeO-6'), 61.2 (MeO-7'), 85.7 (C-4a'), 97.3 (CH-9'), 108.5, 109.0 (CHAr), 119.6 
(CHAr), 126.1 (CHAr), 133.0, 138.2, 139.1, 142.5, 146.6, 151.1, 151.2, 151.9, 154.3, 160.5, 182.0 
(CO-2). 
MS (EI, 70 eV): m/z (%) = 495 ([M]+, 4.9), 494 (22), 493 (100), 467 (39), 450 (10), 434 
(17), 421 (24), 420 (28), 406 (21), 360 (13), 44 (12). 
HRMS (ESI): Calcd. for C23H22N5O8 [M+H]+: 496.14629, found: 496.14622. 
IR (ATR, cm–1): ṽ = 3294 (w), 2945 (w), 1786 (m), 1705 (m), 1693 (s), 1622 (s), 1591 (s), 
1539 (s), 1516 (s), 1481 (s), 1454 (s), 1435 (s), 1406 (s), 1392 (s), 1367 (m), 1335 (s), 1296 (m), 
1275 (m), 1228 (s), 1207 (s), 1157 (s), 1119 (s), 1092 (s), 1068 (s), 1034 (m), 997 (s), 982 (s), 939 
(m), 918 (m), 839 (s), 818 (s), 791 (m), 775 (m), 766 (s), 756 (s), 739 (m), 687 (s), 656 (m), 625 (s), 
555 (s), 530 (s). 
 
1',3'-Diethyl-4,6-dimethoxy-2'-thioxo-2',3'-dihydro-1'H-spiro[indole-3,5'-pyrimido[4,5-
b]quinoline]-2,4'(1H,10'H)-dione (119m) 
 
The product was prepared according to the general procedure, 
starting from 0.2 g of 1,3-diethylthiobarbituric acid, 0.153 g of 3,5-
dimethoxyaniline, 0.147 g of isatin, 0.016 g of iodine and 4 mL of ethanol. 
Yield 0.376 g (81%), beige solid, mp ˃320 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.10 (t, 3H, 3J = 6.80 Hz, 
CH3(Et)), 1.36 (t, 3H, 3J = 6.90 Hz, CH3(Et)), 3.51 (s, 3H, MeO-4), 3.76 (s, 3H, MeO-6), 4.25-4.43 
(m, 2H, NCH2-3'), 4.50-5.40 (br m, 2H, NCH2-1'), 6.05 (d, 1H, 4J = 1.89 Hz, H-5), 6.13 (d, 1H, 4J = 
1.89 Hz, H-7), 6.72 (d, 1H, 3J = 7.85 Hz, H-9'), 6.89-6.97 (m, 1H, H-7'), 7.16-7.24 (m, 1H, H-8'), 
7.40 (d, 1H, 3J = 8.22 Hz, H-6'), 9,38 (br s, 1H, NH-10'), 10.44 (br s, 1H, NH-1). 
13C NMR (62.90 MHz, DMSO-d6): δ = 12.5 (CH3(Et)-3'), 13.3 (CH3(Et)-1'), 43.6 (NCH2-3'), 
45.0 (NCH2-1'), 51.0 (C-5',3), 56.2 (MeO-6), 56.5 (MeO-4), 89.8 (C-4a'), 90.2 (CH-7), 93.1 (CH-5), 
117.5, 117.7 (CHAr), 122.7, 124.7 (CHAr), 126.6 (CHAr), 128.7 (CHAr), 136.4, 143.8, 146.3, 156.7, 
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157.6, 161.7, 175.7 (CS), 181.3 (CO-2). 
MS (GC, 70 eV): m/z (%) = 464 ([M]+, 7.6), 463 (22), 462 (81), 461 (27), 435 (10), 434 
(32), 433 (100), 429 (21), 403 (29), 402 (13), 401 (13), 375 (12), 374 (10), 364 (15), 346 (10), 343 
(15), 333 (11), 332 (38), 60 (15), 46 (14). 
HRMS (ESI): Calcd. for C24H25N4O4S [M+H]+: 465.15910, found: 465.15934. 
IR (ATR, cm–1): ṽ = 3296 (m), 2970 (w), 2929 (w), 1699 (s), 1614 (s), 1589 (s), 1531 (s), 
1504 (s), 1487 (s), 1456 (s), 1416 (s), 1394 (s), 1377 (s), 1360 (s), 1336 (s), 1308 (m), 1265 (s), 
1254 (s), 1228 (s), 1209 (s), 1198 (s), 1144 (s), 1126 (s), 1111 (s), 1039 (s), 1009 (m), 993 (m), 949 
(m), 935 (m), 914 (m), 864 (m), 816 (s), 795 (m), 773 (s), 743 (s), 712 (s), 694 (m), 683 (m), 667 
(s), 642 (s), 621 (s), 536 (s). 
 
1',3'-Diethyl-4,5,6-trimethoxy-2'-thioxo-2',3'-dihydro-1'H-spiro[indole-3,5'-
pyrimido[4,5-b]quinoline]-2,4'(1H,10'H)-dione (119n) 
 
The product was prepared according to the general procedure, 
starting from 0.2 g of 1,3-diethylthiobarbituric acid, 0.183 g of 3,4,5-
dimethoxyaniline, 0.147 g of isatin, 0.016 g of iodine and 4 mL of ethanol. 
Yield 0.262 g (53%) , white solid, mp 318-319 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.10 (t, 3H, 3J = 6.80 Hz, 
CH3(Et)), 1.38 (t, 3H, 3J = 6.89 Hz, CH3(Et)), 3.28 (s, 3H, MeO), 3.59 (s, 3H, MeO), 3.83 (s, 3H, 
MeO), 4.27-4.44 (m, 2H, NCH2-3'), 4.50-5.50 (br m, 2H, NCH2-1'), 6.38 (s, 1H, H-7), 6.74 (d, 1H, 
3J = 7.84 Hz, H-9'), 6.92-6.99 (m, 1H, H-7'), 7.19-7.27 (m, 1H, H-8'), 7.45 (d, 1H, 3J = 8.22 Hz, H-
6'), 9,42 (br s, 1H, NH-10'), 10.43 (br s, 1H, NH-1). 
13C NMR (62.90 MHz, DMSO-d6): δ = 12.5 (CH3(Et)-3'), 13.3 (CH3(Et)-1'), 43.6 (NCH2-3'), 
45.2 (NCH2-1'), 51.6 (C-5',3), 56.9 (MeO), 60.8 (MeO), 61.4 (MeO), 90.2 (C-4a'), 92.1 (CH-7), 
118.0 (CHAr), 122.7, 123.0, 124.9 (CHAr), 126.7 (CHAr), 129.0 (CHAr), 136.1, 137.3, 138.2, 146.2, 
150.2, 154.6, 157.7, 175.7 (CS), 181.1 (CO-2). 
MS (GC, 70 eV): m/z (%) = 494 ([M]+, 10), 493 (29), 492 (100), 491 (24), 464 (29), 463 
(92), 459 (21), 450 (13), 433 (29), 432 (12), 373 (17), 362 (31), 60 (14), 29 (17). 
HRMS (ESI): Calcd. for C25H27N4O5S [M+H]+: 495.16967, found: 495.16962. 
IR (ATR, cm–1): ṽ = 3311 (m), 2931 (m), 1699 (s), 1622 (s), 1589 (s), 1533 (s), 1495 (s), 
1479 (s), 1462 (s), 1416 (s), 1392 (s), 1360 (m), 1350 (s), 1325 (s), 1306 (m), 1288 (m), 1261 (s), 
1255 (s), 1236 (s), 1194 (s), 1176 (m), 1138 (s), 1105 (s), 1068 (s), 1047 (s), 1039 (s), 995 (s), 972 
(s), 957 (m), 924 (m), 856 (m), 810 (m), 793 (m), 781 (m), 766 (s), 744 (s), 710 (s), 694 (s), 671 (s), 
644 (s), 611 (s), 534 (m). 
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1,1',3'-Triethyl-6',8'-dimethoxy-2'-thioxo-2',3'-dihydro-1'H-spiro[indole-3,5'-
pyrimido[4,5-b]quinoline]-2,4'(1H,10'H)-dione (118o) 
 
The product was prepared according to the general procedure, 
starting from 0.2 g of 1,3-diethylthiobarbituric acid, 0.153 g of 3,5-
dimethoxyaniline, 0.175 g of 1-ethylisatin, 0.016 g of iodine and 4 mL of 
ethanol. 
Yield 0.354 (72%), white solid, mp ˃320 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.03 (t, 3H, 3J = 6.89 Hz, CH3(Et)), 1.30 (t, 3H, 3J = 
7.18 Hz, CH3(Et)-1), 1.38 (t, 3H, 3J = 6.99 Hz, CH3(Et)), 3.34 (s, 3H, MeO-6'), 3.64-3.88 (m, 2H, 
NCH2-1), 3.79 (s, 3H, MeO-8'), 4.17-4.34 (m, 2H, NCH2-3'), 4.40-5.40 (br m, 2H, NCH2-1'), 6.16 
(d, 1H, 4J = 2.46 Hz, H-7'), 6.80 (d, 1H, 4J = 2.46 Hz, H-9'), 6.83 (d, 1H, 3J = 7.37 Hz, H-4), 6.89-
6.95 (m, 1H, H-5, H-7), 7.14-7.21 (m, 1H, H-6), 9,20 (br s, 1H, NH). 
MS (EI, 70 eV): m/z (%) = 493 ([M+H]+, 17), 492 ([M]+, 65), 464 (17), 459 (13), 433 (16), 
362 (11), 346 (11), 129 (19), 101 (13), 87 (13), 85 (13), 84 (12), 78 (13), 73 (77), 71 (15), 69 (21), 
63 (15), 61 (12), 60 (100), 57 (21), 55 (28), 45 (14), 44 (35), 43 (32), 41 (33). 
HRMS (ESI): Calcd. for C26H29N4O4S [M+H]+: 493.19040, found: 493.19056. 
IR (ATR, cm–1): ṽ = 2980 (m), 1784 (m), 1684 (s), 1639 (m), 1614 (s), 1603 (s), 1585 (s), 
1539 (s), 1487 (s), 1464 (s), 1452 (s), 1431 (s), 1406 (s), 1373 (s), 1360 (s), 1319 (m), 1298 (m), 
1282 (m), 1267 (s), 1254 (s), 1232 (s), 1200 (s), 1176 (m), 1157 (s), 1130 (s), 1109 (s), 1097 (s), 
1057 (s), 1003 (m), 922 (m), 910 (m), 822 (s), 795 (m), 773 (s), 750 (s), 723 (m), 690 (s), 677 (s), 
669 (m), 656 (m), 646 (m), 636 (m), 581 (m), 559 (m), 538 (s). 
 
7'-Chloro-1',3'-diethyl-4,6-dimethoxy-2'-thioxo-2',3'-dihydro-1'H-spiro[indole-3,5'-
pyrimido[4,5-b]quinoline]-2,4'(1H,10'H)-dione (119p) 
 
The product was prepared according to the general procedure, 
starting from 0.2 g of 1,3-diethylthiobarbituric acid, 0.153 g of 3,5-
dimethoxyaniline, 0.181 g of 5-chloroisatin, 0.016 g of iodine and 4 mL of 
ethanol. 
Yield 0.337 (68%), white solid, mp ˃320 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.10 (t, 3H, 3J = 6.89 Hz, CH3(Et)), 1.36 (t, 3H, 3J = 
6.89 Hz, CH3(Et)), 3.54 (s, 3H, MeO-4), 3.77 (s, 3H, MeO-6), 4.24-4.43 (m, 2H, NCH2-3'), 4.50-5.50 
(br m, 2H, NCH2-1'), 6.09 (d, 1H, 4J = 1.89 Hz, H-5), 6.15 (d, 1H, 4J = 1.89 Hz, H-7), 6.63 (d, 1H, 
4J = 2.39 Hz, H-6'), 7.26 (dd, 1H, 3J = 8.82 Hz, 4J = 2.39 Hz, H-8'), 7.34 (d, 1H, 3J = 8.82 Hz, H-9'), 
9,53 (br s, 1H, NH-10'), 10.52 (br s, 1H, NH-1). 
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13C NMR (62.90 MHz, DMSO-d6): δ = 12.5 (CH3(Et)-3'), 13.2 (CH3(Et)-1'), 43.7 (NCH2-3'), 
45.1 (NCH2-1'), 50.9 (C-5',3), 56.2 (MeO-6), 56.6 (MeO-4), 89.5 (C-4a'), 90.3 (CH-7), 93.2 (CH-5), 
116.9, 119.7 (CHAr), 124.6, 125.7 (CHAr), 128.0, 128.9 (CHAr), 135.6, 143.6, 146.2, 156.8, 157.6, 
162.0, 175.7 (CS), 180.9 (CO-2). 
MS (GC, 70 eV): m/z (%) = 501 ([M+H]+, 37Cl, 7.8), 500 ([M]+, 37Cl, 36), 499 ([M+H]+, 
35Cl, 24), 498 ([M]+, 35Cl, 95), 472 (20), 471 (29), 480 (49), 469 (47), 443 (16), 442 (13), 441 (32), 
439 (13), 437 (14), 426 (11), 411 (18), 382 (13), 349 (10), 348 (41), 347 (19), 346 (100), 320 (24), 
319 (15), 318 (66), 292 (11), 290 (34), 274 (11), 219 (19), 204 (11), 203 (11), 175 (11), 162 (12), 
140 (10), 125 (18), 122 (11), 86 (20), 69 (14), 60 (14), 29 (22). 
HRMS (ESI): Calcd. for C24H2435ClN4O4S [M+H]+: 499.12013, found: 499.12035. 
IR (ATR, cm–1): ṽ = 3190 (w), 2966 (w), 1705 (s), 1645 (m), 1622 (s), 1587 (s), 1527 (s), 
1506 (s), 1481 (s), 1456 (s), 1444 (s), 1427 (s), 1387 (s), 1360 (m), 1338 (m), 1317 (m), 1290 (m), 
1259 (s), 1252 (s), 1217 (s), 1198 (s), 1178 (m), 1147 (s), 1109 (s), 1066 (m), 1041 (m), 1009 (m), 
991 (m), 964 (m), 945 (m), 872 (m), 827 (m), 812 (s), 771 (m), 744 (m), 690 (m), 669 (m), 638 (m), 
625 (m), 552 (m). 
 
1,1',3'-Triethyl-6',7',8'-trimethoxy-2'-thioxo-2',3'-dihydro-1'H-spiro[indole-3,5'-
pyrimido[4,5-b]quinoline]-2,4'(1H,10'H)-dione (118q) 
 
The product was prepared according to the general procedure, 
starting from 0.2 g of 1,3-diethylthiobarbituric acid, 0.183 g of 3,4,5-
dimethoxyaniline, 0.175 g of 1-ethylisatin, 0.016 g of iodine and 4 mL of 
ethanol. 
Yield 0.245 g (47%), white solid, mp ˃320 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.04 (t, 3H, 3J = 6.89 Hz, CH3(Et)), 1.30 (t, 3H, 3J = 
7.18 Hz, CH3(Et)-1), 1.38 (t, 3H, 3J = 6.90 Hz, CH3(Et)), 3.04 (s, 3H, MeO-6'), 3.61 (s, 3H, MeO-7'), 
3.80 (q, 2H, 3J = 7.18 Hz, NCH2-1), 3.85 (s, 3H, MeO-8'), 4.17-4.35 (m, 2H, NCH2-3'), 4.40-5.40 
(br m, 2H, NCH2-1'), 6.83-6.91 (m, 1H, H-5), 6.96-7.02 (m, 2H, H-4, H-7), 7.05 (s, 1H, H-9'), 7.17-
7.25 (m, 1H, H-6), 9,19 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 12.5 (CH3(Et)-3'), 13.0 (CH3(Et)-1), 13.3 (CH3(Et)-1'), 
35.3 (NCH2-1), 43.6 (NCH2-3'), 45.4 (NCH2-1'), 50.2 (C-5',3), 56.7 (MeO-8'), 60.2 (MeO-6'), 61.1 
(MeO-7'), 91.3 (C-4a'), 97.5 (CH-9'), 108.0 (CH-7), 109.4, 122.2 (CH-5), 124.3 (CH-4), 128.6 (CH-
6), 132.5, 136.9, 138.6, 144.7, 145.5, 151.9, 153.9, 157.3 (CO-4'), 175.6 (CS), 178.5 (CO-2). 
MS (EI, 70 eV): m/z (%) = 523 ([M+H]+, 31), 522 ([M]+, 100), 494 (21), 493 (17), 489 (26), 
479 (14), 465 (11), 464 (12), 463 (35), 450 (11), 402 (12), 392 (17), 391 (11), 376 (14), 364 (15). 
HRMS (ESI): Calcd. for C27H31N4O5S [M+H]+: 523.20097, found: 523.20090. 
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IR (ATR, cm–1): ṽ = 2972 (m), 2933 (m), 1678 (s), 1660 (s), 1622 (s), 1614 (s), 1593 (s), 
1537 (s), 1489 (s), 1464 (s), 1423 (s), 1387 (s), 1371 (s), 1358 (s), 1317 (m), 1269 (s), 1244 (s), 
1200 (s), 1176 (m), 1136 (s), 1109 (s), 1097 (s), 1065 (s), 1030 (m), 1001 (s), 964 (m), 928 (s), 874 
(w), 827 (s), 795 (m), 775 (m), 754 (s), 744 (s), 702 (m), 689 (m), 679 (m), 662 (m), 648 (m), 621 
(m), 598 (m), 559 (m), 536 (m). 
 
1',3'-Diethyl-7'-fluoro-4,6-dimethoxy-2'-thioxo-2',3'-dihydro-1'H-spiro[indole-3,5'-
pyrimido[4,5-b]quinoline]-2,4'(1H,10'H)-dione (119r) 
 
The product was prepared according to the general procedure, 
starting from 0.2 g of 1,3-diethylthiobarbituric acid, 0.153 g of 3,5-
dimethoxyaniline, 0.165 g of 5-fluoroisatin, 0.016 g of iodine and 4 mL of 
ethanol. 
Yield 0.286 g (59%), white solid, mp ˃320 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.10 (t, 3H, 3J = 6.90 Hz, CH3(Et)), 1.36 (t, 3H, 3J = 
6.89 Hz, CH3(Et)), 3.53 (s, 3H, MeO-4), 3.77 (s, 3H, MeO-6), 4.24-4.43 (m, 2H, NCH2-3'), 4.50-5.50 
(br m, 2H, NCH2-1'), 6.08 (d, 1H, 4J = 1.99 Hz, H-5), 6.15 (d, 1H, 4J = 1.99 Hz, H-7), 6.42 (dd, 1H, 
3J(H-F) = 9.35 Hz, 4J = 2.93 Hz, H-6'), 7.06-7.15 (m, 1H, H-8'), 7.46 (dd, 1H, 3J = 9.07 Hz, 4J(H-F) = 
5.10 Hz, H-9'), 9,45 (br s, 1H, NH-10'), 10.49 (br s, 1H, NH-1). 
13C NMR (125.77 MHz, DMSO-d6): δ = 12.5 (CH3(Et)-3'), 13.2 (CH3(Et)-1'), 43.6 (NCH2-3'), 
45.0 (NCH2-1'), 51.2 (C-5',3), 56.2 (MeO-6), 56.5 (MeO-4), 88.9 (C-4a'), 90.3 (CH-7), 93.2 (CH-5), 
112.3 (d, 2J(C-F) = 23.2 Hz, CHAr), 116.1 (d, 2J(C-F) = 22.8 Hz, CHAr), 116.8, 119.5 (d, 3J(C-F) = 7.9 
Hz, CH-9'), 124.4 (d, 3J(C-F) = 7.1 Hz, C-5a'), 133.1 (d, 4J(C-F) = 1.6 Hz, C-9a'), 143.6, 146.3, 156.8, 
157.6, 159.3 (d, 1J(C-F) = 239.5 Hz, CH-7'), 161.9 (CS), 175.7 (CS), 180.8 (CO-2). 
19F NMR (282.38 MHz, CDCl3): δ = –119.6 (s, F-7'). 
MS (GC, 70 eV): m/z (%) = 483 ([M+H]+, 19), 482 ([M]+, 76), 454 (38), 453 (24), 426 (12), 
425 (26), 421 (11), 366 (10), 331 (18), 330 (100), 303 (12), 302 (65), 274 (34), 203 (18), 187 (14), 
86 (11), 29 (19). 
HRMS (ESI): Calcd. for C24H24FN4O4S [M+H]+: 483.14968, found: 483.14980. 
IR (ATR, cm–1): ṽ = 3294 (m), 2972 (w), 2929 (w), 2839 (w), 1703 (s), 1622 (s), 1597 (s), 
1537 (s), 1497 (s), 1487 (s), 1464 (s), 1441 (s), 1425 (s), 1408 (m), 1392 (s), 1379 (s), 1362 (s), 
1336 (m), 1323 (s), 1288 (m), 1265 (s), 1254 (s), 1238 (s), 1209 (s), 1196 (s), 1180 (m), 1144 (s), 
1111 (s), 1041 (m), 1012 (m), 984 (m), 945 (s), 918 (m), 862 (s), 833 (m), 814 (s), 797 (m), 787 
(m), 771 (s), 743 (s), 716 (m), 698 (m), 683 (m), 667 (s), 644 (s), 627 (s), 586 (m), 569 (m), 555 
(m). 
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1',3'-Diethyl-7'-fluoro-4,5,6-trimethoxy-2'-thioxo-2',3'-dihydro-1'H-spiro[indole-3,5'-
pyrimido[4,5-b]quinoline]-2,4'(1H,10'H)-dione (119s) 
 
The product was prepared according to the general procedure, 
starting from 0.2 g of 1,3-diethylthiobarbituric acid, 0.183 g of 3,5-
trimethoxyaniline, 0.165 g of 5-fluoroisatin, 0.016 g of iodine and 4 mL of 
ethanol. 
Yield 0.182 g (36%), white solid, mp 310-312 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.09 (t, 3H, 3J = 6.99 Hz, CH3(Et)), 1.38 (t, 3H, 3J = 
6.90 Hz, CH3(Et)), 3.33 (s, 3H, MeO), 3.61 (s, 3H, MeO), 3.84 (s, 3H, MeO), 4.26-4.43 (m, 2H, 
NCH2-3'), 4.50-5.50 (br m, 2H, NCH2-1'), 6.40 (s, 1H, H-7), 6.44 (dd, 1H, 3J(H-F) = 9.45 Hz, 4J = 
2.84 Hz, H-6'), 7.10-7.18 (m, 1H, H-8'), 7.46 (dd, 1H, 3J = 8.98 Hz, 4J(H-F) = 5.20 Hz, H-9'), 9,49 (br 
s, 1H, NH-10'), 10.48 (br s, 1H, NH-1). 
13C NMR (125.77 MHz, DMSO-d6): δ = 12.5 (CH3(Et)-3'), 13.3 (CH3(Et)-1'), 43.6 (NCH2-3'), 
45.2 (NCH2-1'), 51.9 (C-5',3), 56.9 (MeO), 60.9 (MeO), 61.4 (MeO), 89.2 (C-4a'), 92.2 (CH-7), 
112.4 (d, 2J(C-F) = 23.42 Hz, CHAr), 116.3 (d, 2J(C-F) = 22.7 Hz, CHAr), 119.9 (d, 3J(C-F) = 8.0 Hz, CH-
9'), 122.2, 124.4 (d, 3J(C-F) = 7.1 Hz, C-5a'), 132.8 (d, 4J(C-F) = 1.5 Hz, C-9a'), 137.3, 138.0, 146.2, 
150.2, 154.9, 157.7, 159.3 (d, 1J(C-F) = 240.1 Hz, C-7'), 175.8 (CS), 180.6 (CO-2). 
19F NMR (282.38 MHz, CDCl3): δ = –119.2 (s, F-7'). 
MS (GC, 70 eV): m/z (%) = 513 ([M+H]+, 17), 512 ([M]+, 71), 331 (21), 330 (100), 303 
(12), 302 (43), 301 (13), 274 (25), 273 (10), 203 (14), 182 (23), 168 (11), 29 (13). 
HRMS (ESI): Calcd. for C25H26FN4O5S [M+H]+: 513.16025, found: 513.16026. 
IR (ATR, cm–1): ṽ = 3313 (m), 2978 (m), 2933 (m), 1699 (s), 1643 (s), 1622 (s), 1597 (s), 
1539 (s), 1497 (s), 1475 (s), 1444 (s), 1435 (s), 1394 (s), 1362 (s), 1327 (s), 1288 (s), 1267 (s), 1254 
(s), 1232 (s), 1211 (s), 1196 (s), 1178 (s), 1165 (s), 1130 (s), 1109 (s), 1095 (s), 1066 (s), 1041 (s), 
1012 (m), 993 (s), 974 (s), 920 (s), 885 (m), 868 (s), 824 (s), 814 (s), 791 (s), 773 (m), 754 (m), 735 
(m), 712 (s), 694 (s), 671 (s), 656 (s), 638 (s), 588 (s), 569 (s). 
 
1',3'-Diethyl-6',8'-dimethoxy-1-methyl-2'-thioxo-2',3'-dihydro-1'H-spiro[indole-3,5'-
pyrimido[4,5-b]quinoline]-2,4'(1H,10'H)-dione (118t) 
 
The product was prepared according to the general procedure, 
starting from 0.2 g of 1,3-diethylthiobarbituric acid, 0.153 g of 3,5-
dimethoxyaniline, 0.161 g of 1-methylisatin, 0.016 g of iodine and 4 mL of 
ethanol. 
Yield 0.269 g (56%), white solid, mp ˃320 °C. 
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1H NMR (300.13 MHz, DMSO-d6): δ = 1.04 (t, 3H, 3J = 6.89 Hz, CH3(Et)), 1.38 (t, 3H, 3J = 
6.90 Hz, CH3(Et)), 3.22 (s, 3H, NCH3-1), 3.38 (s, 3H, MeO-6'), 3.78 (s, 3H, MeO-8'), 4.18-4.34 (m, 
2H, NCH2-3'), 4.50-5.40 (br m, 2H, NCH2-1'), 6.15 (d, 1H, 4J = 2.46 Hz, H-7'), 6.79 (d, 1H, 4J = 
2.46 Hz, H-9'), 6.80-6.88 (m, 1H, H-5), 6.88-6.94 (m, 2H, H-4, H-7), 7.15-7.22 (m, 1H, H-6), 9,22 
(br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 12.5 (CH3(Et)-3'), 13.4 (CH3(Et)-1'), 27.2 (NCH3-1), 
43.7 (NCH2-3'), 45.4 (NCH2-1'), 49.6 (C-5',3), 56.2 (MeO-8'), 56.9 (MeO-6'), 92.0 (C-4a'), 95.2 
(CH-9'), 96.0 (CH-7'), 105.0, 107.5 (CH-7), 122.3 (CH-5), 123.9 (CH-4), 128.5 (CH-6), 136.1, 
137.8, 145.5, 145.8, 157.4, 159.0, 160.7, 175.6 (CS), 179.3 (CO-2). 
MS (EI, 70 eV): m/z (%) = 479 ([M+H]+, 26), 478 ([M]+, 97), 450 (11), 445 (21), 420 (22), 
419 (75), 391 (15), 378 (16), 348 (21), 332 (115), 320 (18), 292 (24), 291 (15), 78 (20), 73 (14), 69 
(16), 63 (22), 60 (18), 45 (17), 44 (100), 43 (19), 42 (10). 
HRMS (ESI): Calcd. for C27H31N4O5S [M+H]+: 479.17475, found: 479.17422. 
IR (ATR, cm–1): ṽ = 3267 (w), 2983 (w), 2679 (w), 1782 (m), 1687 (s), 1641 (m), 1614 (s), 
1605 (s), 1585 (s), 1537 (s), 1489 (s), 1454 (s), 1433 (s), 1408 (s), 1390 (s), 1373 (s), 1358 (s), 1321 
(m), 1300 (m), 1267 (m), 1252 (s), 1236 (m), 1201 (s), 1153 (s), 1132 (s), 1109 (s), 1084 (s), 1057 
(s), 1005 (s), 922 (s), 910 (m), 822 (s), 812 (s), 793 (m), 773 (s), 756 (s), 725 (m), 690 (s), 681 (s), 
667 (s), 656 (s), 646 (s), 636 (s), 579 (s), 538 (s). 
 
1',3'-Diethyl-6',7',8'-trimethoxy-1-methyl-2'-thioxo-2',3'-dihydro-1'H-spiro[indole-3,5'-
pyrimido[4,5-b]quinoline]-2,4'(1H,10'H)-dione (118u) 
 
The product was prepared according to the general procedure, 
starting from 0.2 g of 1,3-diethylthiobarbituric acid, 0.183 g of 3,4,5-
trimethoxyaniline, 0.161 g of 1-methylisatin, 0.016 g of iodine and 4 mL of 
ethanol. 
Yield 0.232 g (47%), white solid, mp ˃320 °C. 
1H NMR (500.13 MHz, DMSO-d6): δ = 1.04 (t, 3H, 3J = 6.94 Hz, CH3(Et)-3'), 1.38 (t, 3H, 3J 
= 6.94 Hz, CH3(Et)-1'), 3.14 (s, 3H, MeO-6'), 3.24 (s, 3H, NCH3-1), 3.61 (s, 3H, MeO-7'), 3.85 (s, 
3H, MeO-8'), 4.19-4.33 (m, 2H, NCH2-3'), 4.50-5.40 (br m, 2H, NCH2-1'), 6.85-6.90 (m, 1H, H-5), 
6.95 (d, 1H, H-4), 6.97 (d, 1H, H-7), 7.05 (s, 1H, H-9'), 7.19-7.24 (m, 1H, H-6), 9,22 (br s, 1H, 
NH). 
13C NMR (125.77 MHz, DMSO-d6): δ = 12.4 (CH3(Et)-3'), 13.3 (CH3(Et)-1'), 27.3 (NCH3-1), 
43.6 (NCH2-3'), 45.4 (NCH2-1'), 50.0 (C-5',3), 56.7 (MeO-8'), 60.4 (MeO-6'), 61.2 (MeO-7'), 91.3 
(C-4a'), 97.5 (CH-9'), 108.0 (CH-7), 109.4 (C-5a'), 122.4 (CH-5), 124.1 (CH-4), 128.7 (CH-6), 
132.4 (C-9a'), 136.6 (C-3a), 138.6 (C-7'), 145.4, 145.6, 151.7 (C-6'), 153.9 (C-8'), 157.3 (CO-4'), 
N
H
N
N
O
S
N
O
O
O
O
Experimental	Part	
160 
175.6 (CS), 179.2 (CO-2). 
MS (EI, 70 eV): m/z (%) = 509 ([M+H]+, 25), 508 ([M]+, 100), 480 (11), 475 (22), 450 (13), 
449 (43), 378 (15), 350 (15), 322 (15). 
HRMS (ESI): Calcd. for C26H29N4O5S [M+H]+: 509.18532, found: 509.18526. 
IR (ATR, cm–1): ṽ = 3248 (w), 3196 (w), 2933 (w), 1680 (s), 1651 (s), 1626 (s), 1606 (s), 
1593 (s), 1537 (s), 1493 (s), 1471 (s), 1456 (s), 1423 (s), 1387 (s), 1358 (s), 1338 (s), 1315 (m), 
1269 (s), 1240 (s), 1203 (s), 1186 (m), 1174 (m), 1132 (s), 1105 (s), 1088 (s), 1066 (s), 1028 (s), 
997 (s), 957 (m), 926 (s), 912 (m), 878 (m), 852 (m), 825 (s), 791 (m), 777 (m), 768 (m), 756 (s), 
744 (s), 702 (m), 679 (s), 665 (m), 640 (s), 621 (m), 596 (m), 575 (m), 557 (m), 534 (m). 
 
1',3'-Diethyl-4,6-dimethoxy-7'-nitro-2'-thioxo-2',3'-dihydro-1'H-spiro[indole-3,5'-
pyrimido[4,5-b]quinoline]-2,4'(1H,10'H)-dione (119v) 
 
The product was prepared according to the general procedure, 
starting from 0.2 g of 1,3-diethylthiobarbituric acid, 0.153 g of 3,5-
dimethoxyaniline, 0.192 g of 5-nitroisatin, 0.016 g of iodine and 4 mL of 
ethanol. 
Yield of the mixture of the both isomers: 0.32 g (63%). Yield of the 
pure major isomer obtained after recrystallization from TFA/EtOH: 0.098 g (19%), yellow solid, 
mp ˃320 °C. 
1H NMR (500.13 MHz, DMSO-d6): δ = 1.12 (t, 3H, 3J = 6.94 Hz, CH3(Et)), 1.38 (t, 3H, 3J = 
7.09 Hz, CH3(Et)), 3.54 (s, 3H, MeO-4), 3.78 (s, 3H, MeO-6), 4.27-4.43 (m, 2H, NCH2-3'), 4.50-5.50 
(br m, 2H, NCH2-1'), 6.10 (d, 1H, 4J = 1.89 Hz, H-5), 6.20 (d, 1H, 4J = 1.89 Hz, H-7), 7.53 (d, 1H, 
4J = 2.63 Hz, H-6'), 7.67 (d, 1H, 3J = 8.93 Hz, H-9'), 8.14 (dd, 1H, 3J = 8.93 Hz, 4J = 2.63 Hz, H-8'), 
9,98 (br s, 1H, NH-10'), 10.67 (br s, 1H, NH-1). 
13C NMR (62.90 MHz, DMSO-d6): δ = 12.4 (CH3(Et)-3'), 13.4 (CH3(Et)-1'), 43.8 (NCH2-3'), 
45.4 (NCH2-1'), 50.7 (C-5',3), 56.2 (MeO-6), 56.6 (MeO-4), 90.4 (CH-7), 90.5 (C-4a'), 93.3 (CH-5), 
117.2, 118.6 (CHAr), 122.2 (CHAr), 123.5, 124.9 (CHAr), 142.4, 143.4, 143.7, 145.9, 156.9, 157.6, 
162.2, 175.8 (CS), 180.6 (CO-2). 
MS (EI, 70 eV): m/z (%) = 509 ([M]+, 18), 508 (30), 507 (100), 506 (31), 491 (11), 481 (11), 
480 (16), 479 (28), 478 (73), 474 (23), 449 (12), 448 (33), 447 (19), 409 (13), 377 (21). 
HRMS (ESI): Calcd. for C24H24N5O6S [M+H]+: 510.14418, found: 510.14363. 
IR (ATR, cm–1): ṽ = 3400 (w), 3203 (w), 2972 (w), 2935 (w), 1716 (m), 1703 (m), 1651 (s), 
1633 (s), 1622 (s), 1591 (m), 1547 (s), 1506 (s), 1485 (s), 1446 (s), 1429 (s), 1392 (s), 1363 (m), 
1329 (s), 1257 (s), 1217 (s), 1198 (s), 1171 (m), 1151 (s), 1107 (s), 1066 (m), 1041 (m), 1012 (m), 
974 (m), 941 (m), 922 (m), 897 (m), 879 (m), 839 (m), 831 (m), 814 (s), 800 (m), 771 (m), 743 (s), 
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687 (m), 669 (s), 638 (s), 623 (m), 606 (m), 563 (m), 538 (s). 
 
1,2',4'-Triethyl-3'-thioxo-3',4'-dihydro-2'H-spiro[indole-3,14'-naphtho[2,3-
f]pyrimido[4,5-b]quinoline]-1',2(1H,5'H)-dione (118w) 
 
The product was prepared according to the general procedure, 
starting from 0.2 g of 1,3-diethylthiobarbituric acid, 0.193 g of 2-
anthracenamine, 0.175 g of 1-ethylisatin, 0.016 g of iodine and 4 mL of 
ethanol. 
Recrystallized from TFA. Yield 0.388 g (73%), yellow solid, mp 
˃320 °C. 
1H NMR (300.13 MHz, CDCl3): δ = 0.93 (t, 3H, 3J = 6.89 Hz, CH3(Et)), 1.33 (t, 3H, 3J = 6.90 
Hz, CH3(Et)), 1.63 (t, 3H, 3J = 7.27 Hz, CH3(Et)), 2.55-3.00 (br m, 1H, NCH2-4'a), 3.10-3.5 (br m, 
1H, NCH2-4'b), 3.99-4.14 (m, 1H, NCH2), 4.25-4.60 (m, 3H, NCH2), 6.90-6.97 (m, 1H, CHAr), 7.06 
(d, 1H, 3J = 7.46 Hz, CHAr), 7.21 (d, 1H, 3J = 7.74 Hz, CHAr), 7.25-7.50 (m, 5H, CHAr), 7.01 (s, 1H, 
CHAr), 7.92 (d, 1H, 3J = 7.27 Hz, CHAr), 8.23 (s, 1H, CHAr), 9.17 (NH-5'). 
13C NMR (62.90 MHz, CDCl3): δ = 11.8 (CH3), 12.3 (CH3), 13.0 (CH3), 36.3 (NCH2-1), 
43.5 (NCH2-4'), 44.2 (NCH2-2'), 54.0 (C-14',3), 92.3 (C-14a'), 108.4 (CH-7), 109.2, 118.2 (CHAr), 
121.4 (CHAr), 124.3 (CHAr), 125.0 (CHAr), 125.8 (CHAr), 126.5 (CHAr), 128.1 (CHAr), 128.4 (CHAr), 
129.2 (CHAr), 129.2 (CHAr), 129.2, 129.6, 130.3, 130.9 (CHAr), 132.7, 134.6, 135.9, 144.0, 144.3, 
158.3, 174.9 (CS), 180.4 (CO-2). 
MS (EI, 70 eV): m/z (%) = 533 ([M+H]+, 33), 532 ([M]+, 100), 530 (22), 516 (10), 504 (21), 
503 (13), 499 (15), 489 (26), 475 (10), 473 (12), 472 (13), 461 (11), 402 (17), 386 (19), 374 (20), 
346 (10), 345 (12), 344 (12), 326 (10), 318 (16), 316 (11), 315 (10). 
HRMS (ESI): Calcd. for C32H27N4O2S [M−H]−: 531.18602, found: 531.18696. 
IR (ATR, cm–1): ṽ = 3252 (w), 2968 (m), 1790 (m), 1682 (s), 1659 (s), 1651 (s), 1608 (s), 
1593 (s), 1574 (s), 1552 (m), 1520 (s), 1479 (s), 1464 (s), 1431 (s), 1417 (s), 1396 (s), 1371 (s), 
1362 (s), 1350 (s), 1306 (m), 1269 (s), 1250 (s), 1232 (s), 1207 (s), 1169 (s), 1155 (s), 1132 (s), 
1111 (s), 1092 (s), 1053 (m), 1007 (m), 959 (m), 941 (m), 924 (m), 883 (s), 858 (s), 797 (m), 777 
(m), 754 (s), 737 (s), 692 (s), 681 (s), 667 (m), 652 (m), 633 (m), 621 (m), 592 (s), 538 (m). 
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4.2.18 Synthesis of 5,10-dihydropyrimido[4,5-b]quinoline-2,4(1H,3H)-diones via 
Hantzsch-like reaction 
 
10-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-6,8-dimethoxy-1,3-
dimethyl-2,4-dioxo-1,2,3,4,5,10-hexahydropyrimido[4,5-b]quinoline-5-carboxylic acid (123) 
 
Into a 25-mL flask were placed 1,3-dimethylbarbituric acid (0.6 g, 
3.84 mmol, 2 eq), chloral hydrate (0.35 g, 2.11 mmol, 1.1 eq), 3,5-
dimethylaniline (0.353 g, 2.31 mmol, 1.2 eq) and 6 ml of ethanol. After that 
0.024 g of iodine (0.096 mmol, 0.05 eq) was added and the mixture was 
stirred at r.t. overnight. After 5 days the formed precipitate was filtered off, 
washed with ethanol and dried in a high vacuum to give 0.155 g of pinkish solid. 
Yield 17%, white solid, mp 302-304 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 2.88 (s, 3H, NCH3), 3.22 (s, 3H, N-CH3), 3.29 (s, 
3H, N-CH3), 3.31 (s, 3H, N-CH3), 3.66 (s, 3H, MeO), 3.79 (s, 3H, MeO), 4.99 (s, 1H, H-5'), 5.60 (s, 
1H, H-5), 6.34 (d, 1H, 4J = 1.89 Hz, H-7), 6.94 (d, 1H, 4J = 1.89 Hz, H-9), 13.00 (br s, 1H, COOH). 
MS (EI, 70 eV): m/z (%) = 486 ([M+H]+, 11), 485 ([M]+, 47), 397 (24), 331 (39), 330 (100), 
156 (10), 78 (11), 63 (12), 42 (10). 
HRMS (ESI): Calcd. for C22H24N5O8 [M+H]+: 486.16194, found: 486.16123. 
Anal. Calcd for C22H23N5O8: C, 54.43; H, 4.78; N, 14.43. Found: C, 52.76; H, 4.88; N, 
13.68. 
IR (ATR, cm–1): ṽ = 3186 (w), 2962 (w), 2843 (w), 1699 (s), 1672 (s), 1622 (s), 1614 (s), 
1545 (s), 1504 (s), 1444 (s), 1417 (s), 1379 (s), 1363 (s), 1336 (s), 1286 (s), 1267 (s), 1230 (m), 
1207 (s), 1169 (m), 1140 (s), 1122 (s), 1095 (s), 1047 (s), 1024 (s), 964 (m), 943 (m), 852 (m), 839 
(m), 812 (s), 795 (s), 783 (s), 756 (s), 727 (s), 704 (m), 694 (m), 671 (m), 662 (s), 644 (m), 600 (m), 
552 (m). 
 
Ethyl 6,8-dimethoxy-1,3,5-trimethyl-2,4-dioxo-1,2,3,4,5,10-hexahydropyrimido[4,5-
b]quinoline-5-carboxylate (125) 
 
Into a 25-mL flask were placed barbituric acid (0.3 g, 1.92 mmol, 1 
eq), ethyl pyruvate (0.669 g, 5.76 mmol, 3 eq), aromatic amine (0.294 g, 
1.92 mmol, 1 eq) and 6 ml of ethanol. After that 0.024 g of iodine (0.096 
mmol, 0.05 eq) was added and the mixture was stirred at r.t. overnight. The 
next day formed precipitate was filtered off, washed with ethanol and dried in a high vacuum. The 
product should be stored in hermetic package at low temperature preferably in presence of drying 
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agent (CaCl2, etc.). 
Yield 0.187 g (25%), white solid, mp 248-249 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.18 (t, 3H, 3J = 7.18 Hz, Et), 1.47 (s, 3H, CH3-5), 
3.15 (s, 3H, NCH3-3), 3.50 (s, 3H, NCH3-1), 3.70 (s, 3H, MeO), 3.78 (s, 3H, MeO), 4.05 (q, 2H, 3J 
= 7.18 Hz, Et), 6.25 (d, 1H, 4J = 2.37 Hz, H-7), 6.55 (d, 1H, 4J = 2.37 Hz, H-9), 8.99 (br s, 1H, 
NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 15.0 (CH3(Et)), 25.8 (CH3-5), 28.4 (N-CH3), 30.9 (N-
CH3), 44.4, 56.1 (MeO), 56.3 (MeO), 60.5 (CH2(Et)), 90.1 (C-4a), 94.7 (CHAr), 95.1 (CHAr), 108.2, 
137.2, 145.3, 151.3, 158.8, 160.2, 160.9, 175.1. 
MS (EI, 70 eV): m/z (%) = 389 ([M]+, 23), 374 (13), 328 (20), 318 (60), 317 (100), 316 (80), 
315 (72), 302 (15), 301 (56), 300 (67), 287 (23), 286 (26), 260 (21), 259 (89), 258 (12), 216 (11), 
215 (14), 206 (61), 205 (13), 203 (40), 202 (50), 201 (25), 189 (29), 188 (10), 187 (25), 186 (15), 
174 (12), 173 (20), 172 (17), 171 (11), 158 (35), 156 (10), 146 (15), 130 (10), 122 (15), 42 (15). 
HRMS (ESI): Calcd. for C19H24N3O6 [M+H]+: 390.16596, found: 390.16679. 
Anal. Calcd for C19H23N3O6: C, 58.60; H, 5.95; N, 10.79. Found: C, 56.37; H, 5.58; N, 
11.15. 
IR (ATR, cm–1): ṽ = 3190 (w), 2945 (w), 1745 (w), 1699 (s), 1660 (s), 1633 (s), 1539 (s), 
1495 (s), 1470 (s), 1441 (s), 1423 (s), 1373 (s), 1342 (s), 1304 (m), 1290 (s), 1271 (s), 1257 (s), 
1234 (m), 1221 (s), 1196 (m), 1186 (m), 1176 (m), 1146 (s), 1122 (s), 1099 (s), 1022 (m), 986 (s), 
947 (m), 912 (m), 870 (m), 814 (s), 787 (m), 771 (s), 760 (s), 750 (s), 727 (m), 694 (m), 646 (m), 
635 (m), 571 (m), 554 (m), 538 (m). 
 
4.2.19 Formation of 5-(4,6-dimethoxy-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl)-1,3-
dimethylpyrimidine-2,4,6(1H,3H,5H)-trione 
 
5-(4,6-Dimethoxy-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl)-1,3-dimethylpyrimidine-
2,4,6(1H,3H,5H)-trione (126) 
 
This substance was formed from compound 125, during the storage 
at r.t. in untight package for 6 month. 
Yield 100%, white solid, mp 243-244 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.33 (s, 3H, CH3), 2.76 (s, 
3H, N-CH3), 3.22 (s, 3H, N-CH3), 3.66 (s, 3H, MeO), 3.76 (s, 3H, MeO), 3.80 (s, 1H, H-5), 6.05 (d, 
1H, 4J = 2.08 Hz, H-5'), 6.14 (d, 1H, 4J = 2.08 Hz, H-7'), 10.53 (br s, 1H, NH). 
13C NMR (62.90 MHz, DMSO-d6): δ = 21.1 (CH3), 28.5 (N-CH3), 29.0 (N-CH3), 51.5, 54.4 
(CH-5), 56.3 (MeO), 56.7 (MeO), 90.3 (CHAr), 92.3 (CHAr), 108.9, 144.6, 152.6, 157.3, 162.4, 
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167.2, 167.7, 180.3. 
MS (EI, 70 eV): m/z (%) = 361 ([M]+, 15), 316 (13), 207 (36), 206 (100), 205 (38), 176 (17), 
156 (21), 42 (14). 
HRMS (EI): Calcd. for C17H18N3O6 [M−H]−: 360.11956, found: 360.12922. 
IR (ATR, cm–1): ṽ = 3192 (w), 2943 (w), 1745 (w), 1699 (s), 1682 (s), 1660 (s), 1633 (s), 
1608 (s), 1539 (m), 1510 (s), 1495 (m), 1470 (s), 1454 (s), 1435 (s), 1423 (s), 1373 (s), 1342 (s), 
1325 (m), 1304 (m), 1290 (s), 1269 (s), 1221 (s), 1196 (m), 1186 (s), 1176 (m), 1146 (s), 1120 (s), 
1097 (s), 1028 (s), 986 (s), 947 (m), 912 (m), 870 (m), 816 (s), 787 (m), 771 (m), 760 (s), 750 (s), 
727 (s), 692 (s), 671 (m), 646 (s), 635 (s), 615 (m), 600 (m), 571 (m). 
 
4.2.20 Synthesis of 2-benzyl-4,4-dimethyl-4,5-dihydropyrrolo[2,3,4-kl]acridin-1(2H)-
one 
 
2-Benzyl-4,4-dimethyl-4,5-dihydropyrrolo[2,3,4-kl]acridin-1(2H)-one (128) 
 
Into a 25-mL flask were placed 0.188 g of isatin (0.128 mmol, 1 eq), 
0.293 g of 3-(benzylamino)-5,5-dimethylcyclohex-2-en-1-one and 6 ml of 
ethanol. After that 0.016 g of iodine (0.064 mmol, 0.05 eq) was added and 
the mixture was stirred at r.t. overnight. The next day the solvent was evaporated and the residue 
purified with short path column chromatography using chloroform as eluent. 
Yield 0.187 g (43%), brownish solid, mp 136-138 °C. 
1H NMR (300.13 MHz, DMSO-d6): δ = 1.26 (s, 3H, CH3), 3.13 (s, 2H, H-5), 5.01 (s, 2H, 
CH2(Bn)), 5.43 (s, 1H, H-3), 7.23-7.36 (m, 5H, Ph), 7.60-7.67 (m, 1H, CHAr), 7.69-7.76 (m, 1H, 
CHAr), 8.14 (d, 1H, 3J = 8.41 Hz, CHAr), 7.80 (d, 1H, 3J = 8.12 Hz, CHAr). 
13C NMR (62.90 MHz, DMSO-d6): δ = 31.2 (CH3), 37.4, 44.1 (CH2), 44.5 (CH2), 118.0 
(CH-3), 122.9, 124.5 (CHAr), 125.8, 126.9, 127.7 (CHAr), 127.9 (CHAr), 127.9 (CHAr), 129.0 
(CHAr), 129.7 (CHAr), 129.7 (CHAr), 133.2, 137.1, 150.0, 154.7, 167.9. 
MS (EI, 70 eV): m/z (%) = 340 ([M]+, 17), 326 (26), 325 (100), 247 (14), 91 (65). 
HRMS (EI): Calcd. for C23H20N2O [M]+: 340.15701, found: 340.15714. 
IR (ATR, cm–1): ṽ = 2953 (m), 2924 (w), 2862 (w), 1697 (s), 1660 (s), 1585 (w), 1524 (m), 
1495 (m), 1464 (m), 1456 (m), 1441 (m), 1417 (m), 1406 (m), 1379 (m), 1358 (m), 1338 (s), 1296 
(m), 1261 (m), 1252 (m), 1221 (w), 1205 (m), 1192 (m), 1144 (m), 1124 (m), 1101 (m), 1076 (m), 
1049 (w), 1030 (m), 1016 (m), 968 (m), 959 (m), 949 (m), 914 (m), 899 (m), 885 (w), 876 (w), 827 
(s), 820 (m), 798 (m), 770 (s), 746 (s), 729 (m), 696 (s), 631 (s), 586 (m), 575 (s), 550 (m). 
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4.3 Crystal data and structure refinement 
 
Crystal data and structure refinement for 16a 
 
Identification code sd217 
Empirical formula C10H11F3N2O4∙CHCl3 
Formula weight 399.58 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group (H.-M.) P21 
Space group (Hall) P 2yb 
Unit cell dimensions a = 10.5112(5) Å α = 90° 
 b = 6.1932(3) Å β = 101.793(2)° 
 c = 12.5665(6) Å γ = 90° 
Volume 800.79(7) Å3 
Z 2 
Calculated density 1.657 Mg/m3 
Absorption coefficient 0.622 mm-1 
F(000) 404 
Crystal size 0.33 × 0.07 × 0.05 mm 
Θ range for data collection 2.83 to 30.00° 
Index ranges −14 ≤ h ≤ 11, −8 ≤ k ≤ 8, −16 ≤ l ≤ 17 
Reflections collected 9501 
Independent reflections 4419 [R(int) = 0.0327] 
Completeness to Θ = 30.00° 99.8 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9696 and 0.8210 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3051 / 1 / 220 
Goodness-of-fit on F2 1.018 
Final R indices [I>2sigma(I)] R1 = 0.0494, wR2 = 0.0821 
R indices (all data) R1 = 0.0883, wR2 = 0.0914 
Largest diff. peak and hole 0.314 and −0.357 e.Å-3 
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Crystal data and structure refinement for 74a 
 
Identification code sd084 
Empirical formula C11H4ClF3O3 
Formula weight 276.59 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group (H.-M.) P21/c 
Space group (Hall) -P 2ybc 
Unit cell dimensions a = 11.1587(6) Å α = 90° 
 b = 5.2079(2) Å β = 102.836(2)° 
 c = 18.8468(9) Å γ = 90° 
Volume 1067.88(9) Å3 
Z 4 
Calculated density 1.720 Mg/m3 
Absorption coefficient 0.397mm-1 
F(000) 522 
Crystal size 0.54 × 0.15 × 0.07 mm 
Θ range for data collection 2.56 to 32.50° 
Index ranges −16 ≤ h ≤ 16, −7 ≤ k ≤ 7, −27 ≤ l ≤ 28 
Reflections collected 14509 
Independent reflections 3774 [R(int) = 0.0239] 
Completeness to Θ = 32.50° 97.8 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9728 and 0.8143 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2930 / 0 / 163 
Goodness-of-fit on F2 1.073 
Final R indices [I>2sigma(I)] R1 = 0.0365, wR2 = 0.0943 
R indices (all data) R1 = 0.0514, wR2 = 0.1013 
Largest diff. peak and hole 0.389 and −0.310 e.Å-3 
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Crystal data and structure refinement for 88n 
 
Identification code sd184 
Empirical formula C16H14F3N3O3 
Formula weight 353.30 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Triclinic 
Space group (H.-M.)  
Space group (Hall) -P 1 
Unit cell dimensions a = 7.6951(3) Å α = 65.724(2)° 
 b = 10.1134(5) Å β = 82.426(2)° 
 c = 10.1134(5) Å γ = 71.772(2)° 
Volume 734.82(6) Å3 
Z 2 
Calculated density 1.597 Mg/m3 
Absorption coefficient 0.137 mm-1 
F(000) 364 
Crystal size 0.48 × 0.35 × 0.10 mm 
Θ range for data collection 2.31 to 29.99° 
Index ranges −10 ≤ h ≤ 10, −13 ≤ k ≤ 13, −14 ≤ l ≤ 14 
Reflections collected 15164 
Independent reflections 3881 [R(int) = 0.0317] 
Completeness to Θ = 29.99° 99.2 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9864 and 0.9371 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3116 / 0 / 229 
Goodness-of-fit on F2 1.041 
Final R indices [I>2sigma(I)] R1 = 0.0380, wR2 = 0.1056 
R indices (all data) R1 = 0.0503, wR2 = 0.1129 
Largest diff. peak and hole 0.363 and −0.265 e.Å-3 
1P
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Crystal data and structure refinement for 88j 
 
Identification code sd194 
Empirical formula C15H12ClF2N3O3 
Formula weight 355.73 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Triclinic 
Space group (H.-M.)  
Space group (Hall) -P 1 
Unit cell dimensions a = 8.6849(7) Å α = 115.546(2)° 
 b = 9.3993(4) Å β = 101.079(2)° 
 c = 10.0441(4) Å γ = 98.711(3)° 
Volume 700.09(7) Å3 
Z 2 
Calculated density 1.687 Mg/m3 
Absorption coefficient 0.319 mm-1 
F(000) 364 
Crystal size 0.41 × 0.22 × 0.21 mm 
Θ range for data collection 2.35 to 30.99° 
Index ranges −12 ≤ h ≤ 12, −13 ≤ k ≤ 13, −14 ≤ l ≤ 14 
Reflections collected 15923 
Independent reflections 4451 [R(int) = 0.0355] 
Completeness to Θ = 30.99° 99.8 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9360 and 0.8803 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3595 / 0 / 220 
Goodness-of-fit on F2 1.052 
Final R indices [I>2sigma(I)] R1 = 0.0363, wR2 = 0.0995 
R indices (all data) R1 = 0.0487, wR2 = 0.1062 
Largest diff. peak and hole 0.397 and −0.325 e.Å-3 
1P
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Crystal data and structure refinement for 88m 
 
Identification code sd206 
Empirical formula C17H12F7N3O3∙CHCl3 
Formula weight 558.66 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group (H.-M.) P21/m 
Space group (Hall) -P 2yb 
Unit cell dimensions a = 12.2256(8) Å α = 90° 
 b = 6.8967(4) Å β = 95.776(3)° 
 c = 12.7724(8) Å γ = 90° 
Volume 1071.45(12) Å3 
Z 2 
Calculated density 1.732 Mg/m3 
Absorption coefficient 0.516 mm-1 
F(000) 560 
Crystal size 0.85 × 0.33 × 0.08 mm 
Θ range for data collection 3.21 to 28.00° 
Index ranges −16 ≤ h ≤ 16, −9 ≤ k ≤ 9, −16 ≤ l ≤ 16 
Reflections collected 10034 
Independent reflections 2781 [R(int) = 0.0223] 
Completeness to Θ = 28.00° 99.7 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9599 and 0.6680 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2118 / 0 / 260 
Goodness-of-fit on F2 1.060 
Final R indices [I>2sigma(I)] R1 = 0.0478, wR2 = 0.1365 
R indices (all data) R1 = 0.0658, wR2 = 0.1491 
Largest diff. peak and hole 0.532 and −0.311 e.Å-3 
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Crystal data and structure refinement for 91a 
 
Identification code sd283 
Empirical formula C16H14F3N3O3 
Formula weight 353.30 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Triclinic 
Space group (H.-M.)  
Space group (Hall) -P 1 
Unit cell dimensions a = 7.4835(3) Å α = 92.445(2)° 
 b = 8.5920(3) Å β = 104.160(2)° 
 c = 11.4002(4) Å γ = 93.761(2)° 
Volume 707.90(5) Å3 
Z 2 
Calculated density 1.657 Mg/m3 
Absorption coefficient 0.142 mm-1 
F(000) 364 
Crystal size 0.48 × 0.17 × 0.10 mm 
Θ range for data collection 2.92 to 30.00° 
Index ranges −10 ≤ h ≤ 10, −12 ≤ k ≤ 12, −16 ≤ l ≤ 15 
Reflections collected 15295 
Independent reflections 4101 [R(int) = 0.0186] 
Completeness to Θ = 30.00° 99.5 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9859 and 0.9349 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3515 / 0 / 232 
Goodness-of-fit on F2 1.026 
Final R indices [I>2sigma(I)] R1 = 0.0390, wR2 = 0.1002 
R indices (all data) R1 = 0.0472, wR2 = 0.1053 
Largest diff. peak and hole 0.419 and −0.278 e.Å-3 
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Crystal data and structure refinement for 92a 
 
Identification code sd284 
Empirical formula C16H13ClF3N3O2 
Formula weight 371.74 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group (H.-M.) P21/c 
Space group (Hall) -P 2ybc 
Unit cell dimensions a = 19.9679(8) Å α = 90° 
 b = 20.1167(8) Å β = 111.103(2)° 
 c = 16.4722(7) Å γ = 90° 
Volume 6172.9(4) Å3 
Z 16 
Calculated density 1.600 Mg/m3 
Absorption coefficient 0.298 mm-1 
F(000) 3040 
Crystal size 0.72 × 0.31 × 0.09 mm 
Θ range for data collection 1.49 to 26.99° 
Index ranges −19 ≤ h ≤ 25, −25 ≤ k ≤ 25, −20 ≤ l ≤ 16 
Reflections collected 55556 
Independent reflections 13379 [R(int) = 0.0341] 
Completeness to Θ = 26.99° 99.5 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9737 and 0.8142 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10025 / 0 / 909 
Goodness-of-fit on F2 1.035 
Final R indices [I>2sigma(I)] R1 = 0.0418, wR2 = 0.1005 
R indices (all data) R1 = 0.0643, wR2 = 0.1095 
Largest diff. peak and hole 0.346 and −0.396 e.Å-3 
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Crystal data and structure refinement for 98a 
 
Identification code sd228 
Empirical formula C16H16F3N3O2 
Formula weight 339.32 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group (H.-M.) P21/c 
Space group (Hall) -P 2ybc 
Unit cell dimensions a = 8.5186(3) Å α = 90° 
 b = 9.1302(3) Å β = 96.8670(10)° 
 c = 19.1613(6) Å γ = 90° 
Volume 1479.61(9) Å3 
Z 4 
Calculated density 1.523 Mg/m3 
Absorption coefficient 0.128 mm-1 
F(000) 704 
Crystal size 0.50 × 0.39 × 0.30 mm 
Θ range for data collection 2.47 to 31.03° 
Index ranges −6 ≤ h ≤ 12, −12 ≤ k ≤ 13, −27 ≤ l ≤ 27 
Reflections collected 16967 
Independent reflections 4698 [R(int) = 0.0164] 
Completeness to Θ = 30.50° 99.2 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9627 and 0.9389 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4099 / 0 / 225 
Goodness-of-fit on F2 1.064 
Final R indices [I>2sigma(I)] R1 = 0.0368, wR2 = 0.1077 
R indices (all data) R1 = 0.0428, wR2 = 0.1119 
Largest diff. peak and hole 0.461 and −0.256 e.Å-3 
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Crystal data and structure refinement for 100 
 
Identification code sd402 
Empirical formula C23H22F3N3O2 
Formula weight 429.44 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Triclinic 
Space group (H.-M.)  
Space group (Hall) -P 1 
Unit cell dimensions a = 8.6107(7) Å α = 102.613(5)° 
 b = 11.0873(10) Å β = 91.556(6)° 
 c = 11.3982(10) Å γ = 106.607(5)° 
Volume 1012.95(15) Å3 
Z 2 
Calculated density 1.408 Mg/m3 
Absorption coefficient 0.110 mm-1 
F(000) 448 
Crystal size 0.33 × 0.13 × 0.10 mm 
Θ range for data collection 2.94 to 32.50° 
Index ranges −13 ≤ h ≤ 13, −16 ≤ k ≤ 16, −17 ≤ l ≤ 16 
Reflections collected 28093 
Independent reflections 7309 [R(int) = 0.0327] 
Completeness to Θ = 32.50° 99.9 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9891 and 0.9646 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4879 / 0 / 284 
Goodness-of-fit on F2 1.012 
Final R indices [I>2sigma(I)] R1 = 0.0495, wR2 = 0.1179 
R indices (all data) R1 = 0.0856, wR2 = 0.1380 
Largest diff. peak and hole 0.377 and −0.258 e.Å-3 
1P
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Crystal data and structure refinement for 108 
 
Identification code sd341 
Empirical formula C15H14F3N3O3 
Formula weight 341.29 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group (H.-M.) P21/c 
Space group (Hall) -P 2ybc 
Unit cell dimensions a = 17.9524(3) (6) Å α = 90° 
 b = 6.20460(10) Å β = 109.1480(10)° 
 c = 14.3442(2) Å γ = 90° 
Volume 1509.37(4) Å3 
Z 4 
Calculated density 1.502 Mg/m3 
Absorption coefficient 0.130 mm-1 
F(000) 704 
Crystal size 0.30 × 0.17 × 0.16 mm 
Θ range for data collection 2.85 to 29.99° 
Index ranges −25 ≤ h ≤ 25, −7 ≤ k ≤ 8, −20 ≤ l ≤ 19 
Reflections collected 17011 
Independent reflections 4381 [R(int) = 0.0229] 
Completeness to Θ = 29.99° 99.7 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9794 and 0.9619 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3462 / 0 / 223 
Goodness-of-fit on F2 1.036 
Final R indices [I>2sigma(I)] R1 = 0.0510, wR2 = 0.1278 
R indices (all data) R1 = 0.0663, wR2 = 0.1387 
Largest diff. peak and hole 0.890 and –0.364 e.Å-3 
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Crystal data and structure refinement for 119e 
 
Identification code sd209 
Empirical formula C22H20N4O5∙3C2HF3O2 
Formula weight 762.50 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Triclinic 
Space group (H.-M.)  
Space group (Hall) -P 1 
Unit cell dimensions a = 9.6401(6) Å α = 78.929(3)° 
 b = 12.6637(8) Å β = 71.301(3)° 
 c = 14.1111(9) Å γ = 83.218(3)° 
Volume 1598.41(17) Å3 
Z 2 
Calculated density 1.584 Mg/m3 
Absorption coefficient 0.155 mm-1 
F(000) 776 
Crystal size 0.63 × 0.48 × 0.35 mm 
Θ range for data collection 2.23 to 28.00° 
Index ranges −12 ≤ h ≤ 12, −16 ≤ k ≤ 16, −18 ≤ l ≤ 18 
Reflections collected 30889 
Independent reflections 7716 [R(int) = 0.0283] 
Completeness to Θ = 28.00° 99.9 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9479 and 0.9089 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6188 / 19 / 577 
Goodness-of-fit on F2 1.085 
Final R indices [I>2sigma(I)] R1 = 0.0493, wR2 = 0.1368 
R indices (all data) R1 = 0.0623, wR2 = 0.1448 
Largest diff. peak and hole 0.609 and −0.397 e.Å-3 
1P
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Crystal data and structure refinement for 119b 
 
Identification code sd222 
Empirical formula C27H30N4O6∙CH4O 
Formula weight 538.59 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group (H.-M.) P21/n 
Space group (Hall) -P 2yn 
Unit cell dimensions a = 13.2916(3) Å α = 90° 
 b = 13.4393(3) Å β = 109.5340(10)° 
 c = 16.4546(4) Å γ = 90° 
Volume 2770.11(11) Å3 
Z 4 
Calculated density 1.291 Mg/m3 
Absorption coefficient 0.094 mm-1 
F(000) 1144 
Crystal size 0.36 × 0.33 × 0.30 mm 
Θ range for data collection 1.71 to 30.50° 
Index ranges −18 ≤ h ≤ 17, −18 ≤ k ≤ 19, −21 ≤ l ≤ 23 
Reflections collected 33513 
Independent reflections 8447 [R(int) = 0.0386] 
Completeness to Θ = 30.50° 100.0 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9724 and 0.9670 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5909 / 2 / 423 
Goodness-of-fit on F2 1.091 
Final R indices [I>2sigma(I)] R1 = 0.0465, wR2 = 0.1274 
R indices (all data) R1 = 0.0723, wR2 = 0.1391 
Largest diff. peak and hole 0.289 and −0.258 e.Å-3 
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Crystal data and structure refinement for 126 
 
Identification code sd303 
Empirical formula C17H19N3O6 
Formula weight 361.35 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group (H.-M.) P21/c 
Space group (Hall) -P 2ybc 
Unit cell dimensions a = 8.4358(8) Å α = 90° 
 b = 8.6118(9) Å β = 97.003(3)° 
 c = 23.023(2) Å γ = 90° 
Volume 1660.1(3) Å3 
Z 4 
Calculated density 1.446 Mg/m3 
Absorption coefficient 0.111 mm-1 
F(000) 760 
Crystal size 0.89 × 0.39 × 0.03 mm 
Θ range for data collection 1.78 to 29.99° 
Index ranges −11 ≤ h ≤ 11, −12 ≤ k ≤ 11, −32 ≤ l ≤ 32 
Reflections collected 17062 
Independent reflections 4819 [R(int) = 0.0381] 
Completeness to Θ = 29.99° 99.8 % 
Absorption correction Multi-scan 
Max. and min. transmission 0.9967 and 0.9076 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2996 / 0 / 244 
Goodness-of-fit on F2 1.021 
Final R indices [I>2sigma(I)] R1 = 0.0469, wR2 = 0.1020 
R indices (all data) R1 = 0.0963, wR2 = 0.1145 
Largest diff. peak and hole 0.271 and −0.277 e.Å-3 
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List of Symbols and Abbreviations 
 
 –ʺ– symbol indicating the repetition 
 (m) medium 
 (s) strong 
 (w) weak 
 Ac Acetyl group 
 AID Activation-induced cytidine deaminase 
 APOBEC Apolipoprotein B mRNA editing enzyme 
 Ar Aryl group 
 ART Attenuated total reflection 
 br broad signal 
 cat. catalyst 
 CDA Cytidine deaminase 
 Compd Compound 
 conc. concentrated 
 COSY Correlation spectroscopy 
 d doublet 
 DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
 DCM Dichloromethane 
 DEPT Distortionless enhancement by polarization transfer 
 DHP 1,4-Dihydropyridine 
 dioxane 1,4-dioxane 
 DIPA Diisopropylamine 
 DMAP 4-Dimethylaminopyridine 
 DMF N,N-Dimethylformamide 
 DMFDMA N,N-Dimethylformamide dimethyl acetal 
 DMSO Dimethyl sulfoxide 
 DNA Deoxyribonucleic acid 
 EA Elemental analysis 
 EI Electron ionization 
 eq chemical equivalent 
 ESI Electrospray ionization 
 Et Ethyl group 
 EWG Electron-withdrawing group 
 FAD Flavin adenine dinucleotide 
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 GC Gas chromatography 
 h hour 
 Het Hetaryl group 
 HMBC Heteronuclear multiple-bond correlation 
 HMQC Heteronuclear multiple-quantum correlation 
 HPTLC High-performance TLC 
 HRMS High-resolution mass spectrometry 
 HSQC Heteronuclear single quantum coherence 
 IMP Inosine-5'-monophosphate 
 IMPDH IMP dehydrogenase 
 IR Infrared (spectroscopy) 
 IUPAC International Union of Pure and Applied Chemistry 
 J Coupling constant, Hz 
 l cuvette length 
 LC Liquid chromatography 
 LCD Liquid crystals displays 
 m multiplet 
 Me Methyl group 
 Me Methyl group 
 MRC Multicomponent reaction 
 mRNA Messenger RNA 
 MS Mass spectrometry 
 N Normality (concentration) 
 n-BuLi n-Butyllithium 
 NMP N-Methyl-2-pyrrolidone 
 NMR Nuclear magnetic resonance 
 NOE Nuclear Overhauser effect 
 NOESY NOE spectroscopy 
 Nu Nucleophile 
 OLED Organic light-emitting diode 
 Ph Phenyl group 
 Py Pyridil group 
 q quartet 
 Rf Chromatographic retention factor 
 Rf or RF Polyfluoroalkyl group 
 RNA Ribonucleic acid 
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 s singlet 
 t triplet 
 Tf Triflic group 
 TFA Trifluoroacetic acid 
 TFAA Trifluoroacetic anhydride 
 THF Tetrahydrofuran 
 TLC Thin layer chromatography 
 TMS Trimethylsilyl group 
 TsOH p-Toluenesulfonic acid 
 UV Ultraviolet 
 ṽ wavenumber, cm−1 
 Vis Visible 
 w cuvette width 
 wt. % weight percent 
 Z number of formula units in unit cell 
 δ chemical shift, ppm 
 ΔνSt Stokes shift, cm-1 
 ε molar absorption coefficient, M-1∙cm-1 
 λ wavelength, Å 
 λa absorption maximum, nm 
 λf fluorescence band maxima, nm 
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